0001628280-22-013673.txt : 20220510 0001628280-22-013673.hdr.sgml : 20220510 20220510172336 ACCESSION NUMBER: 0001628280-22-013673 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220510 DATE AS OF CHANGE: 20220510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Convey Health Solutions Holdings, Inc. CENTRAL INDEX KEY: 0001787640 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 842099378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40506 FILM NUMBER: 22911132 BUSINESS ADDRESS: STREET 1: 100 SE 3RD AVENUE STREET 2: 26TH FLOOR CITY: FT. LAUDERDALE STATE: FL ZIP: 33394 BUSINESS PHONE: 800-559-9358 MAIL ADDRESS: STREET 1: 100 SE 3RD AVENUE STREET 2: 26TH FLOOR CITY: FT. LAUDERDALE STATE: FL ZIP: 33394 FORMER COMPANY: FORMER CONFORMED NAME: Convey Holding Parent, Inc. DATE OF NAME CHANGE: 20210504 FORMER COMPANY: FORMER CONFORMED NAME: Cannes Holding Parent, Inc. DATE OF NAME CHANGE: 20190909 10-Q 1 cnvy-20220331.htm 10-Q cnvy-20220331
000178764012/312022Q1FALSEone yearone yearone yearone yearone yearP10YP10Yhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet00017876402022-01-012022-03-3100017876402022-04-29xbrli:shares00017876402022-03-31iso4217:USD00017876402021-12-31iso4217:USDxbrli:shares0001787640us-gaap:ServiceMember2022-01-012022-03-310001787640us-gaap:ServiceMember2021-01-012021-03-310001787640us-gaap:ProductMember2022-01-012022-03-310001787640us-gaap:ProductMember2021-01-012021-03-3100017876402021-01-012021-03-310001787640us-gaap:CommonStockMember2021-12-310001787640us-gaap:AdditionalPaidInCapitalMember2021-12-310001787640us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001787640us-gaap:RetainedEarningsMember2021-12-310001787640us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001787640us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001787640us-gaap:RetainedEarningsMember2022-01-012022-03-310001787640us-gaap:CommonStockMember2022-03-310001787640us-gaap:AdditionalPaidInCapitalMember2022-03-310001787640us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001787640us-gaap:RetainedEarningsMember2022-03-310001787640us-gaap:CommonStockMember2020-12-310001787640us-gaap:AdditionalPaidInCapitalMember2020-12-310001787640us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001787640us-gaap:RetainedEarningsMember2020-12-3100017876402020-12-310001787640us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001787640us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001787640us-gaap:RetainedEarningsMember2021-01-012021-03-310001787640us-gaap:CommonStockMember2021-03-310001787640us-gaap:AdditionalPaidInCapitalMember2021-03-310001787640us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001787640us-gaap:RetainedEarningsMember2021-03-3100017876402021-03-3100017876402021-06-042021-06-04xbrli:pure00017876402021-06-040001787640cnvy:VotingCommonStockMember2021-06-040001787640us-gaap:NonvotingCommonStockMember2021-06-040001787640us-gaap:IPOMember2021-06-182021-06-180001787640us-gaap:IPOMember2021-06-180001787640cnvy:IPOCompanySharesMember2021-06-182021-06-180001787640cnvy:IPOSharesFromExistingShareholdersMember2021-06-182021-06-1800017876402021-06-180001787640us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercnvy:CustomerAMember2022-01-012022-03-310001787640us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercnvy:CustomerAMember2021-01-012021-03-310001787640us-gaap:CustomerConcentrationRiskMembercnvy:CustomerBMemberus-gaap:SalesRevenueNetMember2022-01-012022-03-310001787640us-gaap:CustomerConcentrationRiskMembercnvy:CustomerBMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001787640us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercnvy:CustomerAMember2022-03-310001787640us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercnvy:CustomerAMember2021-12-310001787640us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercnvy:CustomerAMember2022-01-012022-03-310001787640us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercnvy:CustomerAMember2021-01-012021-12-310001787640us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercnvy:CustomerBMember2022-03-310001787640us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercnvy:CustomerBMember2021-12-310001787640us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercnvy:CustomerBMember2022-01-012022-03-310001787640us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercnvy:CustomerBMember2021-01-012021-12-310001787640us-gaap:FairValueInputsLevel3Member2021-12-310001787640us-gaap:FairValueInputsLevel3Membercnvy:EarnOutLiabilitiesMember2022-01-012022-03-310001787640us-gaap:FairValueInputsLevel3Membercnvy:HoldbackLiabilitiesMember2022-01-012022-03-310001787640us-gaap:FairValueInputsLevel3Member2022-03-310001787640us-gaap:FairValueInputsLevel3Member2020-12-310001787640us-gaap:FairValueInputsLevel3Membercnvy:HoldbackLiabilitiesMember2021-01-012021-03-310001787640us-gaap:FairValueInputsLevel3Membercnvy:EarnOutLiabilitiesMember2021-01-012021-03-310001787640us-gaap:FairValueInputsLevel3Member2021-03-3100017876402022-01-01cnvy:segment0001787640cnvy:TechnologyEnabledSolutionsMemberus-gaap:ProductMember2022-01-012022-03-310001787640cnvy:AdvisoryServicesMemberus-gaap:ProductMember2022-01-012022-03-310001787640cnvy:TechnologyEnabledSolutionsMemberus-gaap:HealthCareMember2022-01-012022-03-310001787640us-gaap:HealthCareMembercnvy:AdvisoryServicesMember2022-01-012022-03-310001787640us-gaap:HealthCareMember2022-01-012022-03-310001787640cnvy:TechnologyEnabledSolutionsMembercnvy:ConsultingMember2022-01-012022-03-310001787640cnvy:ConsultingMembercnvy:AdvisoryServicesMember2022-01-012022-03-310001787640cnvy:ConsultingMember2022-01-012022-03-310001787640cnvy:TechnologyEnabledSolutionsMemberus-gaap:TechnologyServiceMember2022-01-012022-03-310001787640us-gaap:TechnologyServiceMembercnvy:AdvisoryServicesMember2022-01-012022-03-310001787640us-gaap:TechnologyServiceMember2022-01-012022-03-310001787640cnvy:TechnologyEnabledSolutionsMembercnvy:DataAnalyticsMember2022-01-012022-03-310001787640cnvy:AdvisoryServicesMembercnvy:DataAnalyticsMember2022-01-012022-03-310001787640cnvy:DataAnalyticsMember2022-01-012022-03-310001787640cnvy:TechnologyEnabledSolutionsMember2022-01-012022-03-310001787640cnvy:AdvisoryServicesMember2022-01-012022-03-310001787640cnvy:TechnologyEnabledSolutionsMemberus-gaap:ProductMember2021-01-012021-03-310001787640cnvy:AdvisoryServicesMemberus-gaap:ProductMember2021-01-012021-03-310001787640cnvy:TechnologyEnabledSolutionsMemberus-gaap:HealthCareMember2021-01-012021-03-310001787640us-gaap:HealthCareMembercnvy:AdvisoryServicesMember2021-01-012021-03-310001787640us-gaap:HealthCareMember2021-01-012021-03-310001787640cnvy:TechnologyEnabledSolutionsMembercnvy:ConsultingMember2021-01-012021-03-310001787640cnvy:ConsultingMembercnvy:AdvisoryServicesMember2021-01-012021-03-310001787640cnvy:ConsultingMember2021-01-012021-03-310001787640cnvy:TechnologyEnabledSolutionsMemberus-gaap:TechnologyServiceMember2021-01-012021-03-310001787640us-gaap:TechnologyServiceMembercnvy:AdvisoryServicesMember2021-01-012021-03-310001787640us-gaap:TechnologyServiceMember2021-01-012021-03-310001787640cnvy:TechnologyEnabledSolutionsMembercnvy:DataAnalyticsMember2021-01-012021-03-310001787640cnvy:AdvisoryServicesMembercnvy:DataAnalyticsMember2021-01-012021-03-310001787640cnvy:DataAnalyticsMember2021-01-012021-03-310001787640cnvy:TechnologyEnabledSolutionsMember2021-01-012021-03-310001787640cnvy:AdvisoryServicesMember2021-01-012021-03-310001787640us-gaap:TransferredAtPointInTimeMembercnvy:DataAnalyticsMember2022-01-012022-03-310001787640us-gaap:TransferredAtPointInTimeMembercnvy:DataAnalyticsMember2021-01-012021-03-3100017876402022-04-012022-03-3100017876402023-01-012022-03-3100017876402024-01-012022-03-3100017876402025-01-012022-03-3100017876402026-01-012022-03-3100017876402027-01-012022-03-310001787640cnvy:PurchaseAgreementMember2022-01-090001787640cnvy:A2022IncrementalTermLoansMember2022-02-010001787640cnvy:DMSHoldingsIncMember2022-02-010001787640us-gaap:TradeNamesMembercnvy:DMSHoldingsIncMember2022-02-010001787640cnvy:DMSHoldingsIncMemberus-gaap:CustomerRelationshipsMember2022-02-010001787640cnvy:DMSHoldingsIncMember2022-02-012022-02-010001787640us-gaap:TradeNamesMember2022-01-012022-03-310001787640us-gaap:CustomerRelationshipsMember2022-01-012022-03-310001787640cnvy:DMSHoldingsIncMember2022-01-012022-03-310001787640cnvy:DMSHoldingsIncMember2022-03-310001787640srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2022-01-012022-03-310001787640srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2022-01-012022-03-310001787640us-gaap:MachineryAndEquipmentMember2022-03-310001787640us-gaap:MachineryAndEquipmentMember2021-12-310001787640srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2022-01-012022-03-310001787640us-gaap:LeaseholdImprovementsMember2022-03-310001787640us-gaap:LeaseholdImprovementsMember2021-12-310001787640us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2022-01-012022-03-310001787640us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2022-01-012022-03-310001787640us-gaap:FurnitureAndFixturesMember2022-03-310001787640us-gaap:FurnitureAndFixturesMember2021-12-310001787640srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2022-01-012022-03-310001787640us-gaap:SoftwareDevelopmentMembersrt:MaximumMember2022-01-012022-03-310001787640us-gaap:SoftwareDevelopmentMember2022-03-310001787640us-gaap:SoftwareDevelopmentMember2021-12-310001787640cnvy:AdvancedPlanAdministrationMember2022-03-310001787640cnvy:SupplementalBenefitsAdministrationMember2022-03-310001787640cnvy:ValueBasedAnalyticsMember2022-03-310001787640cnvy:AdvisoryServicesMember2022-03-310001787640cnvy:HealthSmartMember2022-03-310001787640cnvy:TechnologyEnabledSolutionsMember2022-03-310001787640srt:MinimumMember2022-03-310001787640srt:MaximumMember2022-03-310001787640us-gaap:TradeNamesMember2022-03-310001787640us-gaap:CustomerRelationshipsMember2022-03-310001787640us-gaap:TechnologyBasedIntangibleAssetsMember2022-03-310001787640us-gaap:SoftwareDevelopmentMember2022-03-310001787640us-gaap:TradeNamesMember2021-12-310001787640us-gaap:CustomerRelationshipsMember2021-12-310001787640us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310001787640us-gaap:SoftwareDevelopmentMember2021-12-310001787640cnvy:TradenamesCustomerRelationshipsAndTechnologyMember2022-01-012022-03-310001787640cnvy:TradenamesCustomerRelationshipsAndTechnologyMember2021-01-012021-03-310001787640us-gaap:SoftwareDevelopmentMember2022-01-012022-03-310001787640us-gaap:SoftwareDevelopmentMember2021-01-012021-03-310001787640cnvy:TermLoansMemberus-gaap:SecuredDebtMember2019-09-040001787640us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-09-040001787640cnvy:TermLoansMemberus-gaap:SecuredDebtMember2019-09-042019-09-040001787640us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-09-042019-09-0400017876402019-09-042019-09-040001787640us-gaap:SecuredDebtMember2019-09-042019-09-040001787640us-gaap:LineOfCreditMemberus-gaap:BridgeLoanMember2019-09-040001787640cnvy:A2020IncrementalTermLoanMemberus-gaap:SecuredDebtMember2020-04-080001787640cnvy:A2021IncrementalTermLoanMemberus-gaap:SecuredDebtMember2021-02-120001787640cnvy:A2022IncrementalTermLoansMemberus-gaap:SecuredDebtMember2022-02-010001787640us-gaap:LondonInterbankOfferedRateLIBORMember2022-01-012022-03-310001787640srt:MinimumMember2022-01-012022-03-310001787640srt:MaximumMember2022-01-012022-03-310001787640cnvy:CreditAgreementMembersrt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-01-012022-03-310001787640cnvy:CreditAgreementMembersrt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-01-012022-03-310001787640cnvy:CreditAgreementMembersrt:MinimumMemberus-gaap:BaseRateMember2022-01-012022-03-310001787640cnvy:CreditAgreementMembersrt:MaximumMemberus-gaap:BaseRateMember2022-01-012022-03-310001787640cnvy:CreditAgreementMembersrt:MinimumMemberus-gaap:EurodollarMember2022-01-012022-03-310001787640cnvy:CreditAgreementMembersrt:MaximumMemberus-gaap:EurodollarMember2022-01-012022-03-310001787640cnvy:UndrawnLetterOfCreditMember2022-03-310001787640cnvy:TermLoansMember2022-01-012022-03-310001787640cnvy:TermLoansMember2022-03-310001787640cnvy:TermLoansMember2021-12-310001787640cnvy:TermLoansMember2021-01-012021-03-310001787640us-gaap:RevolvingCreditFacilityMember2022-03-310001787640us-gaap:RevolvingCreditFacilityMember2021-12-310001787640us-gaap:RevolvingCreditFacilityMember2022-01-012022-03-310001787640us-gaap:RevolvingCreditFacilityMember2021-01-012021-03-310001787640us-gaap:SecuredDebtMember2022-01-012022-03-310001787640us-gaap:SecuredDebtMember2021-01-012021-03-310001787640us-gaap:SecuredDebtMember2021-12-310001787640us-gaap:SecuredDebtMember2022-03-310001787640cnvy:A2020IncrementalTermLoanMember2022-01-012022-03-310001787640cnvy:A2022IncrementalTermLoansMember2022-03-3100017876402020-01-230001787640cnvy:TermLoansMember2022-03-3100017876402021-02-280001787640cnvy:DividendsPaidOutstandingAndVestedOptionHoldersMember2021-02-012021-02-280001787640cnvy:DividendsPaidExistingShareholdersMember2021-02-012021-02-280001787640cnvy:A2021OmnibusIncentiveCompensationPlanMember2021-06-032021-06-030001787640cnvy:A2019EquityPlanMemberus-gaap:EmployeeStockOptionMember2021-03-012021-03-310001787640cnvy:A2019EquityPlanMemberus-gaap:EmployeeStockOptionMember2021-12-310001787640us-gaap:EmployeeStockOptionMember2021-03-012021-03-310001787640cnvy:A2021OmnibusIncentiveCompensationPlanMemberus-gaap:EmployeeStockOptionMember2021-06-012021-06-300001787640cnvy:A2021OmnibusIncentiveCompensationPlanMemberus-gaap:EmployeeStockOptionMember2021-06-300001787640cnvy:A2019EquityPlanMemberus-gaap:EmployeeStockOptionMember2021-06-012021-06-3000017876402021-06-012021-06-300001787640us-gaap:RestrictedStockUnitsRSUMember2021-06-300001787640us-gaap:EmployeeStockOptionMember2021-06-012021-06-300001787640us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001787640cnvy:A2021OmnibusIncentiveCompensationPlanMemberus-gaap:EmployeeStockOptionMember2021-08-012021-08-310001787640cnvy:A2021OmnibusIncentiveCompensationPlanMemberus-gaap:EmployeeStockOptionMember2021-08-3100017876402021-08-012021-08-310001787640us-gaap:RestrictedStockUnitsRSUMember2021-08-310001787640cnvy:A2021EquityPlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-03-012022-03-310001787640us-gaap:PerformanceSharesMembercnvy:A2021EquityPlanMember2022-03-012022-03-310001787640cnvy:A2021EquityPlanMemberus-gaap:EmployeeStockOptionMember2021-03-310001787640us-gaap:PerformanceSharesMember2021-06-012021-06-300001787640us-gaap:RestrictedStockUnitsRSUMember2021-06-012021-06-30cnvy:installment0001787640us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001787640us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-3100017876402021-02-1500017876402021-01-012021-12-310001787640us-gaap:EmployeeStockOptionMember2022-03-310001787640us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001787640us-gaap:RestrictedStockUnitsRSUMember2021-12-310001787640us-gaap:RestrictedStockUnitsRSUMember2022-03-3100017876402020-03-012020-03-31cnvy:award0001787640cnvy:LongTermIncentiveAwardsMember2020-09-300001787640cnvy:LongTermIncentiveAwardsMember2022-01-012022-03-310001787640cnvy:LongTermIncentiveAwardsMember2021-12-310001787640cnvy:LongTermIncentiveAwardsMember2022-03-310001787640srt:AffiliatedEntityMember2022-03-310001787640srt:AffiliatedEntityMembercnvy:TPGManagementAndConsultingFeesMember2022-01-012022-03-310001787640srt:AffiliatedEntityMembercnvy:TPGManagementAndConsultingFeesMember2021-01-012021-03-310001787640cnvy:TPGTermLoanFeesMembersrt:AffiliatedEntityMember2022-01-012022-03-310001787640cnvy:TPGTermLoanFeesMembersrt:AffiliatedEntityMember2021-01-012021-03-310001787640cnvy:TPGTermLoanFeesMembersrt:AffiliatedEntityMember2021-06-012021-06-300001787640cnvy:TPGTermLoanFeesMembersrt:AffiliatedEntityMember2021-12-310001787640srt:AffiliatedEntityMembercnvy:EIRPartnersMonthlyConsultingAgreementMember2022-01-012022-03-310001787640cnvy:EIRPartnersConsultingAgreementMembersrt:AffiliatedEntityMember2022-01-012022-03-310001787640cnvy:EIRPartnersConsultingAgreementMembersrt:AffiliatedEntityMember2021-01-012021-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from  _ to _
Commission file number 001-40506
Convey Health Solutions Holdings, Inc.
(Exact name of registrant as specified in its charter)
Delaware84-2099378
(State or other jurisdiction of
 incorporation or organization)
(I.R.S. Employer Identification No.)
100 SE 3rd Avenue, 26th Floor, Fort Lauderdale, Florida
33394
(Address of Principal Executive Offices)(Zip Code)
(800) 559-9358
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareCNVYNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒   No  ☐ 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filer  Smaller reporting company
Emerging growth company



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes   ☐     No  
As of April 29, 2022, the registrant had 73,194,171 shares of common stock, $0.01 par value per share, outstanding.


TABLE OF CONTENTS
3

PART I-FINANCIAL INFORMATION
Item 1. Financial Statements.
CONVEY HEALTH SOLUTIONS HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data) (unaudited)
March 31,
2022
December 31,
2021
ASSETS
Current assets
Cash and cash equivalents$20,866 $38,811 
Accounts receivable, net of allowance for doubtful accounts of $69 as of March 31, 2022, and December 31, 2021
72,707 62,813 
Inventories, net36,408 14,060 
Prepaid expenses and other current assets10,809 16,569 
Total current assets140,790 132,253 
Property and equipment, net20,952 20,400 
Intangible assets, net247,993 220,014 
Goodwill482,558 455,206 
Operating lease right-of-use assets18,574  
Other assets5,667 2,030 
Total assets$916,534 $829,903 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Accounts payable$11,156 $13,868 
Accrued expenses30,038 48,558 
Operating lease liabilities, current portion5,605  
Finance lease obligations, current portion501 498 
Deferred revenue, current portion9,494 7,472 
Term loans, current portion780  
Total current liabilities57,574 70,396 
Operating lease liabilities, net of current portion18,623  
Finance leases obligations, net of current portion440 528 
Deferred taxes, net35,094 25,992 
Term loans, net of current portion264,483 189,643 
Other long-term liabilities2,475 5,595 
Total liabilities378,689 292,154 
Commitments and contingencies (Note 15)
Shareholders’ equity
Preferred stock, $0.01 par value; 25,000,000 shares authorized and no shares issued or outstanding as of March 31, 2022 and no shares authorized, issued or outstanding as of December 31, 2021
  
Common stock, $0.01 par value; 500,000,000 shares authorized as of March 31, 2022, and December 31, 2021; 73,194,171 shares issued and outstanding as of March 31, 2022, and December 31, 2021
732 732 
Additional paid-in capital571,516 570,252 
Accumulated other comprehensive income17 31 
Accumulated deficit(34,420)(33,266)
Total shareholders’ equity537,845 537,749 
Total liabilities and shareholders’ equity$916,534 $829,903 
See accompanying notes to unaudited condensed consolidated financial statements
4

CONVEY HEALTH SOLUTIONS HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(in thousands, except per share amounts)
(unaudited)
For the Three Months Ended March 31,
20222021
Net revenues:
Services$46,480 $43,527 
Products50,228 39,104 
Net revenues96,708 82,631 
Operating expenses:
Cost of services(1)
25,477 24,021 
Cost of products(1)
37,236 26,527 
Selling, general and administrative23,214 20,099 
Depreciation and amortization8,252 7,372 
Transaction related costs640 1,086 
Total operating expenses94,819 79,105 
Operating income (loss)1,889 3,526 
Other income (expense):
Interest expense(3,719)(5,467)
Total other expense, net(3,719)(5,467)
Income (loss) before income taxes(1,830)(1,941)
Income tax (expense) benefit676 1,007 
Net income (loss)$(1,154)$(934)
Income (loss) per common share – Basic and diluted
Net income (loss) per common share$(0.02)$(0.02)
Net income (loss)$(1,154)$(934)
Foreign currency translation adjustments(14)(7)
Comprehensive income (loss)$(1,168)$(941)
________________________
(1)    Excludes amortization of intangible assets and depreciation, which are separately stated below.
See accompanying notes to unaudited condensed consolidated financial statements
5

CONVEY HEALTH SOLUTIONS HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in thousands, except for number of shares)
(unaudited)
Common stock
Additional
Paid-in Capital
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
Shareholders’
Equity
SharesAmount
For the Three Months Ended March 31, 2022
December 31, 202173,194,171 $732 $570,252 $31 $(33,266)$537,749 
Share-based compensation— — 1,264 — — 1,264 
Foreign currency translation adjustments— — — (14)— (14)
Net loss— — — — (1,154)(1,154)
March 31, 202273,194,171 $732 $571,516 $17 $(34,420)$537,845 
Common stock
Additional
Paid-in Capital
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
Shareholders’
Equity
SharesAmount
For the Three Months Ended March 31, 2021
December 31, 202061,321,424 $613 $492,747 $78 $(23,288)$470,150 
Share-based compensation— — 990 — — 990 
Foreign currency translation adjustments— — — (7)— (7)
Dividend— — (74,500)— — (74,500)
Net loss— — — — (934)(934)
March 31, 202161,321,424 $613 $419,237 $71 $24,222 $395,699 
See accompanying notes to unaudited condensed consolidated financial statements
6

CONVEY HEALTH SOLUTIONS HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
For the Three Months Ended March 31,
20222021
Cash flows from operating activities
Net loss$(1,154)$(934)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation expense1,550 1,386 
Amortization expense6,702 5,986 
Write off capitalized software costs253  
Provision for bad debt 342 
Provision for inventory reserve90 399 
(Gain) loss from disposal of assets10  
Deferred income taxes(1,120)(963)
Amortization of debt issuance costs309 328 
Share-based compensation1,264 990 
Non-cash lease expense1,246  
Inventory step-up1,892  
Changes in operating assets and liabilities:
Accounts receivable(3,414)4,662 
Inventory(1,450)(3,207)
Prepaid expenses and other assets3,903 843 
Accounts payable and other accrued liabilities(26,222)(22,100)
Deferred revenue2,022 (358)
Operating lease liabilities(1,541) 
Net cash (used in) provided by operating activities(15,660)(12,626)
Cash flows from investing activities
Acquisition, net of cash received(74,613) 
Purchases of property and equipment, net(1,836)(3,063)
Capitalized software development costs(1,105)(1,287)
Net cash used in investing activities(77,554)(4,350)
Cash flows from financing activities
Proceeds from issuance of debt78,000 78,000 
Payment of debt issuance cost(2,631)(2,133)
Principal payment on term loan (821)
Payment on finance leases(86)(31)
Dividend (74,500)
Net cash provided by financing activities75,283 515 
Effect of exchange rate changes on cash(14)(7)
Net (decrease) increase in cash and cash equivalents and restricted cash(17,945)(16,468)
Cash, cash equivalents and restricted cash at beginning of period38,811 49,086 
Cash, cash equivalents and restricted cash at end of period$20,866 $32,618 
Cash, cash equivalents and restricted cash as of the end of the period
Cash and cash equivalents$20,866 $28,938 
Restricted cash 3,560 
Restricted cash, non-current 120 
Cash, cash equivalents and restricted cash$20,866 $32,618 


See accompanying notes to unaudited condensed consolidated financial statements
7

CONVEY HEALTH SOLUTIONS HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
(in thousands)
(unaudited)
For the Three Months Ended March 31,
20222021
Supplemental disclosures of cash flow information:
Cash paid for taxes$250 $216 
Cash paid for interest$3,986 $4,961 
Non-cash investing and financing activities:
Capitalized software and property and equipment, net included in accounts payable$672 $471 

See accompanying notes to unaudited condensed consolidated financial statements
8

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
NOTE 1. BUSINESS AND BASIS OF PRESENTATION
Business
Convey Health Solutions Holdings, Inc. (collectively with its subsidiaries, which includes our main operating subsidiary, Convey Health Solutions, Inc., “we”, “us”, “our”, “Convey” or the “Company”) provides technology enabled solutions to payors within the large and growing government sponsored health plan market. Our platform combines proprietary modular technology and end-to-end solutions to serve as an extension of our clients’ operations and core systems. Our clients are primarily Medicare Advantage, Medicare Part D and Employer Group Waiver Plans, as well as Pharmacy Benefit Managers. Convey is a United States (“U.S.”) based holding company incorporated in Delaware. Our principal executive offices are located in Fort Lauderdale, Florida.
Acquisition
On February 1, 2022, Convey’s indirect wholly-owned subsidiary, D-M-S Holdings Parent, LLC (f/k/a Dragon Holdings Parent, LLC), a Delaware limited liability company, acquired all of the issued and outstanding capital stock of D-M-S Holdings, Inc. d/b/a HealthSmart International, a Delaware corporation (“HealthSmart”). HealthSmart provides a diverse portfolio of health, wellness and diagnostic products centered on home based care outcomes. See Note 4. Acquisitions for additional information.
Stock Split
Prior to the IPO (as defined below), in June 2021, Convey’s Board of Directors (the “Board”) and stockholders approved a forward split of shares of Convey’s common stock, par value $0.01 per share, on a 126-for-1 basis (the “Stock Split”), which became effective as of June 4, 2021. Prior to the Stock Split, we were authorized to issue 1,000,000 shares of common stock of which (i) 915,000 shares were designated as voting common stock and (ii) 85,000 shares were designated as non-voting common stock. In connection with the Stock Split, the total number of authorized shares of common stock was proportionately increased and the par value of the common stock was not adjusted as a result of the Stock Split. In addition, all authorized shares of common stock were designated voting common stock. All references to common stock, options to purchase common stock, per share data and related information contained in our condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Stock Split.
Initial Public Offering
On June 18, 2021, we closed our initial public offering (“IPO”) of our common stock through an underwritten sale of 13,333,334 shares of our common stock at a price of $14.00 per share. In the offering, we sold 11,666,667 shares and a selling stockholder sold 1,666,667 shares. The aggregate net proceeds to us from the offering after deducting underwriting discounts and commissions and other offering expenses payable by us, were approximately $146.1 million. We used approximately $131.5 million of the net proceeds from the IPO to repay outstanding indebtedness under our credit agreement. We did not receive any of the proceeds from the sale by the selling stockholder.
Prior to the closing of the IPO, on June 17, 2021, our Second Amended and Restated Certificate of Incorporation (the “Charter”) and our Second Amended and Restated Bylaws, became effective. The Charter, among other things, provides that our authorized capital stock consists of 500,000,000 shares of common stock, par value $0.01 per share and 25,000,000 shares of preferred stock, par value $0.01 per share.
Basis of Presentation and Consolidation
The accompanying condensed consolidated financial statements are unaudited and include the accounts of Convey and our wholly-owned subsidiaries. They have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our condensed consolidated statements of operations and comprehensive income (loss), shareholders’ equity, and cash flows for the three months ended March 31, 2022, and 2021, and the condensed consolidated balance sheet as of March 31, 2022, reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results for the periods shown.
9

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Our condensed consolidated balance sheet as of December 31, 2021, has been derived from our audited consolidated financial statements as of that date. Our condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2021, which include a complete set of footnote disclosures, including our significant accounting policies, and are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 23, 2022 (“Form 10-K”). The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. All significant intercompany balances and transactions have been eliminated in consolidation.
COVID-19 Pandemic
During the first quarter ended March 31, 2020, concerns related to the spread of novel coronavirus (“COVID-19”) began to create global business disruptions as well as disruptions in our operations. COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. Governments at the national, state and local level in the U.S., and globally, have implemented varying measures in an effort to contain the virus, including social distancing, travel restrictions, border closures, limitations on public gatherings of people, work from home and supply chain logistical changes. While some of these actions have eased, escalating transmission rates (including of the Delta and Omicron variants of COVID-19), uneven vaccination and vaccination booster rates and further governmental guidance and orders may result in having to reimplement certain of these measures or implementing new and additional ones. The spread of COVID-19 has also caused significant volatility in the U.S. and international markets and has had and continues to have widespread, rapidly evolving and unpredictable impacts on global society, economics, financial markets and business practices. The impact of COVID-19 on our business has resulted in elongated sales cycles, postponement of customer contract renewals, and slower implementation of software solutions for our clients, as well as a reduction in billable hours in one of our reportable segments, the Advisory Services segment.
The full extent to which the COVID-19 pandemic and the various responses to the COVID-19 pandemic continues to impact our business, operations or financial condition will depend on numerous evolving factors that we may not be able to accurately predict, including, but not limited to, the duration, severity and scope of the COVID-19 pandemic (including due to new variants, such as Delta and Omicron); actions by governmental entities, businesses and individuals that have been and continue to be taken in response to the pandemic; the effect on our clients and demand by clients, clients and our clients’ members for and ability to pay for our solutions and services; and disruptions or restrictions on our employees’ ability to work and travel. The impact of these factors and others on our suppliers and clients could persist for some time after governments ease their restrictions and after the overall number of COVID-19 cases in the United States decreases.
We have assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context with the unknown future impacts of COVID-19 using information that is reasonably available to us at this time. While our current assessment of our estimates did not have a material impact on our condensed consolidated financial statements as of and for the three months ended March 31, 2022, as additional information becomes available to us, our future assessment of our estimates, including our expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact our consolidated financial statements in future reporting periods.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information currently available to us and based on various other assumptions that we conclude to be reasonable under the circumstances. While management concludes that such estimates are reasonable when considered in conjunction with our condensed consolidated balance sheets and statements of operations and comprehensive income (loss) taken as a whole, actual results could differ materially from those estimates.
Acquisitions
We allocate the purchase consideration to the identifiable net assets acquired, including intangible assets and liabilities assumed, based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, is recorded as goodwill. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition
10

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to the condensed consolidated statements of operations and comprehensive income (loss).
Determining the fair value of assets acquired and liabilities assumed requires significant judgment, including the selection of valuation methodologies which techniques include the royalty method, the multi-period excess earnings method, the cost approach, the market approach, and the probability weighted assessment method as considered necessary. Significant assumptions used in those methodologies include, but are not limited to, growth rates, discount rates, customer attrition rates, expected levels of revenues, earnings, cash flows and tax rates. The use of different valuation methodologies and assumptions is highly subjective and inherently uncertain and, as a result, actual results may differ materially from estimates.
Customer Concentrations
Revenue and Accounts receivable from our major customers are as follows:
Revenues
For the Three Months Ended
March 31,
(in thousands, except percentages)
20222021
Customer A
$27,108 $19,626 
    % of total revenue
28.0 %23.8 %
Customer B
$16,712 $16,766 
    % of total revenue
17.3 %20.3 %
Accounts Receivable
(in thousands, except percentages)
March 31, 2022December 31, 2021
Customer A$8,119 $13,161 
    % of total accounts receivable11.2 %21.0 %
Customer B$11,688 $15,174 
    % of total accounts receivable16.1 %24.2 %
Our customer base is highly concentrated. Revenue may significantly decline if we were to lose one or more of our major customers. However, our risk is reduced due to our significant customers having multiple product delivery solutions under separate contracts.
Contingent Consideration
We recognized an earn-out liability in connection with the November 2018 acquisition of HealthScape Advisors, LLC (“HealthScape Advisors”) and Pareto Intelligence LLC (“Pareto Intelligence”), which represented contingent consideration.
The initial fair value of the earn-out liability was determined by employing a Monte-Carlo simulation model. The underlying simulated variable was adjusted revenue discounted by the market price of risk embedded in the revenue metrics. The revenue volatility estimate was based on a study of historical asset volatility and implied volatility for a set of comparable public companies, adjusted by our operating leverage. The earn-out payments were calculated based on simulated revenue metrics and payment thresholds as set forth in the HealthScape Advisors and Pareto Intelligence purchase agreement. The calculated payments were further discounted back to present value using cost of debt reflecting our credit risk. The fair value of the earn-out liability at each reporting date subsequent to the acquisition was measured using a probability weighted approach. Any change in fair value was recognized in the condensed consolidated statements of operations and comprehensive income (loss).
On September 4, 2019, Cannes Parent, Inc. (“Cannes”), a direct subsidiary of Convey, entered into an agreement to acquire all of the outstanding stock of Convey Health Solutions, Inc. through the merger of Cannes Merger Sub, Inc. (“Merger Sub”) and Convey Health Parent, Inc. (“Parent”) (the “Merger”) with Parent surviving as a direct subsidiary of Cannes. The Merger principally occurred through an investment from TPG Cannes Aggregation, L.P., which is primarily funded by partners of TPG Partners VIII, L.P. and TPG Healthcare Partners, L.P. or any parallel fund or their alternative investment vehicles (collectively, “TPG”). In connection with the Merger, we recognized a holdback liability, which represented contingent consideration. The
11

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
initial fair value of the holdback liabilities and at each subsequent reporting date was measured using a probability weighted approach. Any change in fair value was recognized in the consolidated statements of operations and comprehensive income (loss).
In connection with the acquisition of HealthSmart in February 2022, we recognized an earn-out liability which represented contingent consideration. The initial fair value of the earn-out liability was determined by employing a Black-Scholes Merton model. The earn-out payments were calculated based on projected revenue metrics and payment thresholds as set forth in the HealthSmart purchase agreement. The calculated payments were further discounted back to present value using the cost of debt reflecting our credit risk.
The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2022:
(in thousands)
Balance at December 31, 2021$ 
Fair value of contingent consideration in connection with the HealthSmart acquisition2,254 
Payments  
Change in fair value 
Balance at March 31, 2022$2,254 
The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2021:
(in thousands)
Balance at December 31, 2020$20,538 
Payments 
Change in fair value 
Balance at March 31, 2021$20,538 
Net Income (Loss) Per Common Share
Basic income (loss) per share is computed by dividing net income (loss) attributable to common shareholders (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted net income (loss) per common share attributable to common shareholders is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period adjusted for the dilutive effects of common stock equivalents. In periods when losses from operations are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.
For the Three Months Ended
March 31,
(in thousands, except per share data)20222021
Net income (loss) attributable to common shareholders
Net income (loss)$(1,154)$(934)
Net income (loss) attributable to common shareholders$(1,154)$(934)
Weighted-average common shares outstanding:
Basic and diluted73,194,171 61,321,424 
Net income (loss) per share:
Basic and diluted$(0.02)$(0.02)
For the three months ended March 31, 2022, and 2021, 9,534,119 and 5,690,664 of potentially dilutive share-based awards outstanding, respectively, were excluded from the computation of diluted net income (loss) per share related to common shareholders as their effect was anti-dilutive. See Note 11. Share-Based Compensation.
12

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which supersedes the previous guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for virtually all of their leases except those which meet the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or financing. Classification is based on criteria that are similar to those applied in previous lease accounting, but without explicit bright lines. The recognition of these lease assets and lease liabilities represents a change from previous U.S. GAAP requirements, which did not require lease assets and lease liabilities to be recognized for most leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee, have not significantly changed from previous U.S. GAAP requirements. The Company adopted the provisions of Topic 842 on January 1, 2022, using the modified retrospective approach. All comparative periods prior to January 1, 2022 are not adjusted and continue to be reported in accordance with Topic 840.
The Company elected to utilize the package of practical expedients permitted within the new standard, which among other things, allowed the Company not to reassess prior conclusions about lease identification, classification and initial direct costs of existing leases as of the date of adoption. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the Company’s condensed consolidated balance sheet which resulted in recognizing those lease payments in the condensed consolidated statements of operations on a straight-line basis over the lease term.
Adoption of the new standard resulted in the recording of right-of-use assets and corresponding lease liabilities of $14.7 million and $20.7 million, respectively, as of January 1, 2022. The difference between the right-of-use assets and the lease liabilities was recorded to eliminate existing deferred rent balances and remaining balances of lease incentives recorded under Topic 840. The adoption of the new standard did not materially impact the Company's condensed consolidated statements of operations and had no impact on the Company's condensed consolidated statements of cash flows. See Note 18. Leases for further information.
Accounting Pronouncements Issued Not Yet Adopted
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Entities will be required to use a model that will result in the earlier recognition of allowances for losses for trade and other receivables, held-to-maturity debt securities, loans, and other instruments. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. ASU 2016-13, as subsequently amended for various technical issues, is effective for emerging growth companies following private company adoption dates for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”), subsequently clarified in January 2021 by ASU 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The main provisions of this update provide optional expedients and exceptions for contracts, hedging relationships, and other transactions that reference the London Inter-bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and, once adopted, may be applied prospectively to contract modifications and hedging relationships through December 31, 2022. We are currently evaluating the new guidance to determine the impact ASU 2020-04 and ASU 2021-01 will have on our consolidated financial statements.
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) (“ASU 2021-08”). The new guidance creates an exception to the general recognition and measurement principle for contract assets and contract liabilities from contracts with customers acquired in a business combination. Under this exception, an acquirer applies Topic 606 to recognize and measure contract assets and contract liabilities on the acquisition date. Topic 805 generally requires the acquirer in a business combination to recognize and measure the assets it acquires and liabilities it assumes at fair value on the acquisition date. This generally will result in companies recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date. This new guidance is effective for emerging growth companies following private business adoption dates, for the fiscal years beginning after December 15, 2023, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.
13

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
NOTE 3. REVENUE FROM CONTRACTS WITH CUSTOMERS
We provide technology enabled solutions and advisory services to assist our clients with workflows across product developments, sales, member experience, clinical management, core operations and business intelligence and analytics. We generate our revenues through our two reporting segments: (i) Technology Enabled Solutions and (ii) Advisory Services.
Technology Enabled Solutions
We help health plans grow membership and revenue as well as operate more effectively and efficiently. We also assist our clients in managing the compliance and administrative requirements imposed under government sponsored health plans. Our technology solutions are primarily delivered through a web-based customizable application. This application is used to identify, track, and administer contractual services, or benefits provided under a client’s plan to its Medicare and Medicaid beneficiaries. We also provide analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. With our technology enabled solutions, we offer the following services:
Health Plan Management provides technology-enabled plan administration services for government-sponsored health plans. Our service encompasses eligibility and enrollment processing, member services, premium billing, payment processing, reconciliation and other related services. In addition, we provide technology enabled services to manage supplemental benefits provided to members through their Medicare Advantage plans. Our services include benefit design and administration, member eligibility and engagement, analytics and reporting.
Software Services provide additional services to our clients for ad hoc enhancements on their existing software solutions.
Data Analytics provide payment tools and data analytics to improve revenue accuracy and identify gaps in quality, clinical care and compliance. Increasingly we are combining these analytics capabilities with our Health Plan Management offerings.
Supplemental Benefit Services include product fulfillment, as well as catalog development and product distribution. Many of these services are provided through our technology enabled solutions.
Advisory Services
We provide Advisory Services that complement our technology enabled solutions, including sales and marketing strategies, provider network strategies, compliance, Star ratings, quality, clinical, pharmacy, analytics and risk adjustment.
Revenue Recognition
We recognize revenue under ASC Topic 606, Revenue from Contracts with Customers. We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for contracts that are within the scope of the standard, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Disaggregation of revenue
The following tables present disaggregated revenue by reporting segment:
(in thousands)For the Three Months Ended
March 31, 2022
Technology
Enabled
Solutions
Advisory
Services
Total
Supplemental Benefit Services$50,228 $ $50,228 
Health Plan Management25,862  25,862 
Consulting Services2,327 13,457 15,784 
Software Services2,191 85 2,276 
Data Analytics2,558  2,558 
Total$83,166 $13,542 $96,708 
14

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
(in thousands)For the Three Months Ended
March 31, 2021
Technology
Enabled
Solutions
Advisory
Services
Total
Supplemental Benefit Services$39,104 $ $39,104 
Health Plan Management23,942  23,942 
Consulting Services1,038 13,049 14,087 
Software Services2,730  2,730 
Data Analytics2,768  2,768 
Total$69,582 $13,049 $82,631 
The revenue recognition pattern, point in time or over time, is consistent within all revenue categories with the exception of Data Analytics which includes revenue recognized on both a point in time and over time basis. The amount of point in time revenue within Data Analytics was $0.6 million and $1.4 million during the three months ended March 31, 2022, and 2021, respectively.
Contract Balances
The timing of our revenue recognition, invoicing, and cash collections results in billed accounts receivable, unbilled receivables, and deferred revenue. Accounts receivable includes unbilled receivable balances of $17.4 million and $7.0 million as of March 31, 2022, and December 31, 2021, respectively.
Deferred revenue represents payments received from our customers in advance of recognition of revenue. Deferred revenue that will be recognized during the succeeding 12 months is recognized as current deferred revenue and the remaining portion is recognized as non-current deferred revenue within Other long-term liabilities. Revenue recognized during the three months ended March 31, 2022, and 2021 that was included in the deferred revenue balance at the beginning of the period was $4.4 million and $3.9 million, respectively.
Remaining Performance Obligations
Transaction price allocated to remaining performance obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes contract liabilities and non-cancelable amounts that will be invoiced and recognized as revenue in future periods.
The timing and amount of revenue recognition for our remaining performance obligations are influenced by several factors and therefore the amount of remaining obligations may not be a meaningful indicator of future results. Total RPO equaled $8.4 million as of March 31, 2022, of which we expect to recognize approximately $4.2 million over the next 12 months. The remaining $4.2 million is expected to be recognized in fiscal years 2023, 2024, 2025, 2026 and 2027 by $3.0 million, $1.1 million, $0.1 million, $7.5 thousand and $7.5 thousand, respectively.
NOTE 4. ACQUISITIONS
On January 9, 2022, Convey’s indirect wholly-owned subsidiary, D-M-S Holdings Parent, LLC (f/k/a Dragon Holdings Parent, LLC), a Delaware limited liability company (“Buyer”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Briggs Medical Service Company, a Delaware corporation (“Seller”), and D-M-S Holdings, Inc. d/b/a HealthSmart International, a Delaware corporation (“Target”), pursuant to which, on the terms and subject to the conditions set forth in the Purchase Agreement, Buyer agreed to acquire from Seller all of the issued and outstanding capital stock of Target (the acquisition of such capital stock, the “Acquisition”). Target provides a diverse portfolio of health, wellness and diagnostic products centered on home based care outcomes, and the Company intends to leverage the Target’s supply chain and logistics expertise to get high quality products to members faster and at a lower cost.
On February 1, 2022, Buyer completed its acquisition of all of the issued and outstanding capital stock of the Target. The Acquisition was consummated pursuant to the Purchase Agreement.
Pursuant to the terms set forth in the Purchase Agreement, at closing Buyer paid to Seller cash in an amount equal to $74.7 million, subject to certain adjustments for, among other things, Target’s cash, indebtedness and net working capital (the “Closing Purchase Price”). If the Target achieves certain amounts of net revenue in calendar year 2022, Buyer will pay to Seller cash up to an additional $15 million. A portion of the Closing Purchase Price was deposited into an escrow account held by an
15

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
escrow agent and will be released to Buyer or Seller, as applicable, following the final determination of any purchase price adjustment.
In connection with the Purchase Agreement, CHS obtained a first lien incremental term loan facility under CHS’s existing First Lien Credit Agreement in an aggregate principal amount of $78 million, for the purpose of financing the Acquisition and paying fees and expenses related thereto. See Note 9. Credit Facility for additional information related to the incremental term loan facility.
The Acquisition was accounted for using the acquisition method of accounting under which assets and liabilities of the Target were recorded at their respective fair values including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. A deferred tax liability has been recorded for the excess of financial statement basis over tax basis of the acquired assets and assumed liabilities with a corresponding increase to goodwill. The goodwill attributable to the Acquisition has been recorded as a non-current asset and is not amortized, but is subject to an annual review for impairment. Such goodwill, which is non-deductible for income tax purposes, is part of the Technology Enabled Solutions segment.
The Acquisition price was allocated to the tangible and identified intangible assets acquired and liabilities assumed as of the closing date. The fair values assigned to tangible and identifiable intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions. The estimated fair values of assets acquired and liabilities assumed are considered preliminary and are based on the most recent information available. The Company believes that the information provides a reasonable basis for assigning the fair values of assets acquired and liabilities assumed. Thus, the provisional measurements of fair value set forth below are subject to change. The Company expects to finalize the valuation as soon as practicable, but not later than one year from the acquisition date.
The following table summarizes the Acquisition date fair value of the allocation of the purchase consideration assigned to each major class of assets acquired and liabilities assumed as of February 1, 2022, the acquisition date:
Estimated Fair Value
(in thousands)
ASSETS ACQUIRED
Cash $112 
Accounts receivable 6,481 
Inventories22,879 
Prepaid expenses and other current assets 1,840 
Property and equipment1,269 
Operating lease right-of-use-assets4,908 
Total identifiable assets acquired 37,489 
Fair value of intangible assets
Trade names 8,600 
Customer relationships 25,500 
Total fair value of intangible assets acquired 34,100 
Total assets acquired $71,589 
LIABILITIES ASSUMED
Accounts payable $2,937 
Accrued expenses 3,895 
Operating lease liabilities, current portion1,003 
Deferred taxes10,222 
Operating lease liabilities, net of current portion3,905 
Total liabilities assumed 21,962 
Net identifiable assets49,627 
Goodwill27,352 
Total consideration$76,979 
16

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Indications of fair value of the intangible assets acquired in connection with the Acquisition were determined using either the income, market or replacement cost methodologies. The intangible assets are being amortized over periods which reflect the pattern in which economic benefits of the assets are expected to be realized. The trade names and customer relationships are being amortized on a straight-line basis over an estimated useful life of twenty years and seventeen years, respectively. The goodwill recognized is primarily attributable to synergies of the business and the acquisition of workforce knowledgeable of product development and supply chain expertise in the healthcare industry.
The following table summarizes the purchase consideration transferred in connection with the Acquisition and consists of the following:
(in thousands)March 31, 2022
Initial purchase price$74,725 
Earn-out (contingent consideration)2,254 
Total consideration$76,979 
Included in the condensed consolidated statement of operations and comprehensive income (loss) for the three months ended March 31, 2022, are net sales of $7.2 million and net loss of $1.6 million, related to the Target’s operations since the acquisition date of February 1, 2022.
Unaudited Supplemental Pro Forma Information
The following table presents the unaudited pro forma combined results of operations of the Company and Target for the three months ended March 31, 2022 and 2021, as if the acquisition had occurred on January 1, 2021. The pro forma information presented is for informational purposes only and is not indicative of results of operations that would have been achieved had the Acquisition taken place at the beginning of the period.
For the Three Months Ended
March 31
(in thousands)20222021
Net revenue101,174 97,567 
Net income (loss)205 (299)
NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid expenses and other current assets consist of the following:
(in thousands)March 31, 2022December 31, 2021
Prepaid expenses and other advances$5,896 $6,904 
Software licenses828 2,547 
Insurance527 1,271 
Inventory purchase advances1,390 23 
Cloud computing subscription & implementation costs822 4,841 
Other current assets1,346 983 
Total prepaid expenses and other current assets$10,809 $16,569 
17

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
NOTE 6. PROPERTY AND EQUIPMENT
Property and equipment consist of the following:
(in thousands)
Estimated Life
(in years)
March 31, 2022December 31, 2021
Office and computer equipment
3 – 7 years
$16,399 $14,442 
Leasehold improvements
Up to 10 years
10,542 10,503 
Furniture and fixtures
3 – 7 years
4,064 4,054 
Software
35 years
2,366 2,277 
33,371 31,276 
Less: accumulated depreciation(12,419)(10,876)
Property and equipment, net$20,952 $20,400 
Depreciation expense for the three months ended March 31, 2022, and 2021 totaled $1.5 million and $1.4 million, respectively.
We lease various equipment and software under finance leases. The depreciation expense associated with the assets under finance leases for the three months ended March 31, 2022, and 2021, totaled $89 thousand and $0.1 million, respectively. Assets held under finance leases are included in property and equipment as follows:
(in thousands)March 31, 2022December 31, 2021
Office and computer equipment$1,682 $1,682 
Less: accumulated depreciation(742)(656)
Total financing leases included in property and equipment$940 $1,026 
NOTE 7. INTANGIBLE ASSETS AND GOODWILL
The activity for goodwill as of March 31, 2022 is as follows:
(in thousands)
Balance at December 31, 2021$455,206 
Measurement period adjustments  
Acquisitions (see Note 4)27,352 
Impairment  
Balance at March 31, 2022$482,558 
The carrying amount of goodwill by reporting unit as of March 31, 2022 is $88.9 million for Advanced Plan Administration (“APA”), $190.2 million for Supplemental Benefits Administration (“SBA”), $138.2 million for Value Based Payment Assurance (“VBPA”), $37.9 million for Advisory Services (“Advisory”) and $27.4 million for HealthSmart acquisition, respectively.
The goodwill allocated to the Technology Enabled Solutions and Advisory Services reportable segments is $444.7 million and $37.9 million, respectively as of March 31, 2022. Goodwill is assessed for impairment on an annual basis (on October 1 of each year) and on an interim basis when indicators of impairment exist.
As a result of the decline in our stock price since December 31, 2021, we performed an interim impairment test for goodwill for APA, SBA, VBPA and Advisory reporting units using the quantitative approach as of March 31, 2022. Since HealthSmart was recently acquired, no impairment test was performed on that reporting unit. Based on our evaluation performed, we determined the fair value of each of the reporting units exceeded its respective carrying amount, and therefore, we determined that goodwill was not impaired at any of our reporting units as of March 31, 2022. We define “headroom” as the percentage difference between the fair value of a reporting unit and its carrying value. For the interim impairment test, the headroom for the reporting units ranged between eight percent to sixty-five percent. Our SBA reporting unit and our VBPA reporting unit have headroom at the low-end of that range (8.4% for SBA and 12.5% for VBPA) and could experience
18

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
impairment in the future if we do not achieve our profitability projections, there is a change in key assumptions underlying the valuation or if we continue to experience a substantial decrease in our stock price.
Evaluation of goodwill for impairment requires judgment, including the identification of reporting units, assignment of assets, liabilities and goodwill to reporting units and determination of the fair value of each reporting unit. We estimate the fair value of our reporting units using a combination of an income approach, utilizing a discounted cash flow analysis, and a market approach, using market multiples. Under the income approach, we estimate projected future cash flows, the timing of such cash flows and long-term growth rates, and determine the appropriate discount rate that reflects the risk inherent in the projected future cash flows. The discount rate used is based on a market participant weighted-average cost of capital and may be adjusted for the relevant risk associated with business-specific characteristics and the uncertainty related to the reporting unit’s ability to execute on the projected future cash flows. Under the market approach, we estimate fair value based on market multiples of revenues and earnings derived from comparable publicly-traded companies with characteristics similar to the reporting unit. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions and other factors. The assumptions and estimates used in determining the fair values of the reporting units contain uncertainties, and any changes to these assumptions and estimates could have a negative impact and result in a future impairment.
The carrying value of identifiable intangible assets consisted of the following as of March 31, 2022:
(in thousands)
Gross
Carrying
Amount
Accumulated
Amortization
Net Carrying
Amount
Amortized intangible assets
Trade names$35,900 $(3,830)$32,070 
Customer relationships214,500 (44,636)169,864 
Technology47,800 (12,348)35,452 
Capitalized software development costs13,026 (2,419)10,607 
Total intangible assets$311,226 $(63,233)$247,993 
The carrying value of identifiable intangible assets consisted of the following as of December 31, 2021:
(in thousands)
Gross
Carrying
Amount
Accumulated
Amortization
Net Carrying
Amount
Amortized intangible assets
Trade names$27,300 $(3,395)$23,905 
Customer relationships189,000 (40,091)148,909 
Technology47,800 (11,153)36,647 
Capitalized software development costs12,454 (1,901)10,553 
Total intangible assets$276,554 $(56,540)$220,014 
Amortization expense for Trade names, Customer relationships and Technology for the three months ended March 31, 2022, and 2021, totaled $6.2 million and $5.9 million, respectively.
Amortization expense for Capitalized software development costs for the three months ended March 31, 2022, and 2021, totaled $0.5 million and $0.1 million, respectively.
19

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
NOTE 8. ACCRUED EXPENSES
Accrued expenses and other current liabilities consist of the following:
(in thousands)March 31, 2022December 31, 2021
Incentive bonus$257 $15,214 
Employee related7,784 11,154 
Sales and use tax6,365 6,865 
Rebates2,372 4,276 
Accrued interest83 637 
Accrued professional fees5,538 7,046 
Refundable deposits4,626  
Other3,013 3,366 
Total accrued expenses$30,038 $48,558 
NOTE 9. CREDIT FACILITY
On September 4, 2019, we entered into the First Lien Credit Agreement (the “Credit Agreement”). The Credit Agreement provides for senior secured credit facilities consisting of (i) a $225.0 million closing date term loan (the “Term Facility”) and loans thereunder (the “Term Loans”) and (ii) a $40.0 million revolving credit facility (the “Revolving Facility”) (collectively, the “Credit Facility”). The Term Facility has a seven-year term which expires on September 4, 2026 and the Revolving Facility has a five-year term which expires on September 4, 2024. We paid debt issuance costs of approximately $6.1 million on the closing date of the Credit Facility, $5.2 million is being amortized over the life of the Term Facility (84 months) and $0.9 million is being amortized over the term of the Revolving Facility (60 months) on a straight-line method. The Revolving Facility includes a letter of credit sub-facility (subject to a sublimit not to exceed $10.0 million) and a swing line loan sub-facility (subject to a sublimit not to exceed $10.0 million).
On April 8, 2020, we amended the Credit Agreement to establish an incremental loan facility in an aggregate principal amount equal to $25.0 million for an incremental term loan request (the “2020 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $1.1 million on the closing date of the 2020 Incremental Term Loan.
On February 12, 2021, we amended the Credit Agreement to establish an incremental term loan in an aggregate principal amount equal to $78.0 million (the “2021 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $2.4 million on the closing date of the 2021 Incremental Term Loan.
On February 1, 2022, we further amended the Credit Agreement to establish an incremental term loan in an aggregate principal amount equal to $78.0 million (the “2022 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $2.6 million on the closing date of the 2022 Incremental Term Loan, which is being amortized over the life of the 2022 Incremental Term Loan. The proceeds of the term loans borrowed under the 2022 Incremental Term Loan were used to finance the HealthSmart acquisition (see Note 4) and pay fees and expenses related thereto. The 2022 Incremental Term Loan was accounted for as a debt modification.
The Credit Agreement includes an uncommitted incremental facility, which provides that we have the right at any time to request term loan increases, additional term loan facilities, revolving commitment increases and/or additional revolving credit facilities, in an aggregate principal amount, together with the aggregate principal amount of permitted incremental equivalent debt under the Credit Agreement, not to exceed (a) the sum of the greater of (i) $46.9 million and (ii) 100.0% of Consolidated EBITDA (as defined in the Credit Agreement) of CHS and its restricted subsidiaries for the most recently ended period of four consecutive fiscal quarters of CHS (calculated on a pro forma basis), plus (b) certain additional amounts, including an unlimited amount subject to pro forma compliance with a leverage ratio test.
20

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Interest Rate and Fees
Borrowings under the Credit Agreement (other than borrowings of swing line loans) bear interest at a rate per annum equal to, at our election, either (i) the LIBOR for the relevant interest period (subject to a floor of 1.00% per annum) plus an applicable margin, as defined in the Credit Agreement, or (ii) a base rate plus an applicable margin, as defined in the Credit Agreement. We elected to use the LIBOR rate for the Term Loans and the Revolving Facility. The Credit Agreement provides for the replacement of LIBOR with a successor or alternative index rate in the event LIBOR is phased-out.
In addition to paying interest on the outstanding principal of the Credit Facility, we are required to pay a commitment fee in respect of any unused commitments under the Revolving Facility at a rate that is subject to adjustment based upon the First Lien Net Leverage Ratio, as defined in the Credit Agreement (maximum debt to Earnings Before Interest, Income Tax, Depreciation and Amortization (“EBITDA”), as defined in the Credit Agreement) at such time and ranges from 0.375% to 0.500% per annum. We are also required to pay customary letter of credit fees and certain other agency fees.
On July 12, 2021, CHS entered into Amendment No. 4 to the Credit Agreement (“Amendment No. 4”). Amendment No. 4 amends the Credit Agreement to provide for, among other things, (i) the reduction of the Applicable Rate (as defined in the Credit Agreement) for Eurodollar Rate Loans (as defined in the Credit Agreement) from 5.25% to 4.75% and, for Base Rate Loans (as defined in the Credit Agreement), from 4.25% to 3.75%, and (ii) the reduction of the floor for the Eurodollar Rate (as defined in the Credit Agreement) from 1.00% to 0.75% for the Closing Date Term Loans (as defined in the Credit Agreement). Amendment No. 4 was accounted for as a debt modification.
Covenants
The Credit Facility contains a financial covenant that requires us to maintain as of the last day of each period of four consecutive quarters of the Company, a First Lien Net Leverage Ratio not to exceed 7.4 to 1.0 if, as of the last day of any fiscal quarter of the Company, there are outstanding revolving loans and letters of credit (excluding (i) undrawn letters of credit in an aggregate face amount up to $10.0 million and (ii) letters of credit (whether drawn or undrawn) to the extent reimbursed, cash collateralized or backstopped on terms reasonably acceptable to the applicable issuing bank on or prior to the date that is three business days following the end of the applicable period of four consecutive fiscal quarters of CHS in an aggregate principal amount exceeding 35% of the aggregate principal amount of the Revolving Facility at such time. We were in compliance with our debt covenants at March 31, 2022.
Prepayments and Mandatory Prepayment
Under the terms of the Credit Agreement, we are permitted to voluntarily prepay outstanding loans or commitments in whole or part without premium or penalty other than certain exceptions described in the Credit Agreement; however, the Credit Agreement requires us to prepay outstanding term loans, subject to certain exceptions and limitations with (i) 50% of our annual excess cash flow, subject to certain step-downs based upon the First Lien Net Leverage Ratio; (ii) 100% of the net cash proceeds of certain asset sales or casualty events; and (iii) 100% of the net cash proceeds of certain incurrences or issuances of indebtedness. We were not required to prepay outstanding term loans based on our 2021 results.
Scheduled Repayments
In connection with the prepayment noted under the “Extinguishment of Debt” below, no additional scheduled installments of principal are required on the Term Facility.
We are required to make scheduled quarterly payments on the 2022 Incremental Term Loan. We are required to make quarterly payments commencing with the quarter ending June 30, 2022, in an amount equal to 0.25% of the aggregate principal amount of the 2022 Incremental Term Loan outstanding on February 1, 2022 with the balance due upon maturity date.
Guarantees and Collateral
All obligations under the Credit Agreement are unconditionally guaranteed by Parent and certain subsidiaries. All obligations under the Credit Agreement are secured, subject to permitted liens and other exceptions and limitations, by first priority security interests in substantially all the assets of the Company and each guarantor (including all the equity interests of CHS).
21

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Extinguishment of Debt
On June 18, 2021, $131.5 million from the IPO proceeds (see Note 1) were used to repay the principal balance, accrued but unpaid interest, and prepayment premium under the Credit Agreement. The 2020 Incremental Term Loan and the 2021 Incremental Term Loan were repaid in full and the remainder of the proceeds were used to repay a portion of the Term Facility. The prepayment for the Term Facility was applied to the remaining scheduled installments of principal.
Other Information
As of March 31, 2022, and December 31, 2021, unamortized deferred financing costs for the Term Loans totaled $5.4 million and $3.0 million, respectively. Amortization of deferred financing costs for the three months ended March 31, 2022, and 2021, totaled $0.3 million and $0.9 million, respectively.
As of March 31, 2022, and December 31, 2021, unamortized deferred financing costs associated with the Revolving Facility totaled $0.5 million for each period, and were included in Other assets in the condensed consolidated balance sheets. Amortization of deferred financing costs was approximately $50 thousand for each of the three months ended March 31, 2022, and 2021.
Amortization of deferred financing costs is included within Interest expense in the condensed consolidated statement of operations and comprehensive income (loss).
For the three months ended March 31, 2022, and 2021, the average interest rate for the Term Facility was 5.5% and 6.3%, respectively. As of March 31, 2022, and December 31, 2021, the aggregate principal balance was $192.6 million for each period.
For the three months ended March 31, 2022, the average interest rate for the 2022 Incremental Term Loan was 5.5%. As of March 31, 2022, the aggregate principal balance was $78.0 million.
For the three months ended March 31, 2022, and 2021, the average interest rate for the Revolving Facility was 2.75% for each period. As of March 31, 2022, and December 31, 2021, the available balance was $39.4 million. On January 23, 2020, we established an irrevocable transferable letter of credit (“LOC”) in the favor of a lessor totaling $0.5 million. The LOC expired on January 31, 2021, however, per the terms of the agreement, the LOC automatically extends for a one year period upon the expiration date and each anniversary thereafter, unless at least 60 days prior to such expiration date or anniversary written notice is provided that we elect not to extend the LOC. The LOC was automatically extended for a one year period on January 31, 2022.
Debt consists of the following as of March 31, 2022, and December 31, 2021:
(in thousands)March 31, 2022December 31, 2021
Term loans$270,631 $192,631 
Less: deferred financing costs(5,368)(2,988)
Term loans, net of deferred financing costs265,263 189,643 
Less: current portion(780) 
$264,483 $189,643 
22

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Debt Maturities Schedule
The required principal payments for Term Loans for each of the five years and thereafter following the balance sheet date are as follows:
(in thousands)
For the nine months ending December 31, 2022$585 
2023780 
2024780 
2025780 
2026267,706 
Total $270,631 
NOTE 10. SHAREHOLDERS’ EQUITY
As of March 31, 2022, we are authorized to issue 500,000,000 shares of common stock, par value $0.01 per share and 25,000,000 shares of preferred stock, par value $0.01 per share. See Note 1 for additional information related to the Stock Split and IPO.
In February 2021, our Board, through a unanimous written consent, adopted a written resolution declaring a special dividend of $1.18 per share of common stock totaling $74.5 million in cash (“Special Dividend”) ultimately to be distributed to the shareholders of Convey. Of the Special Dividend, $72.2 million was paid to existing shareholders and $2.3 million was paid to outstanding and vested stock option holders. The Special Dividend was paid out during the three months ended March 31, 2021.
NOTE 11. SHARE-BASED COMPENSATION
On September 4, 2019, our Board adopted the Cannes Holding Parent, Inc. 2019 Equity Incentive Plan (the “2019 Equity Plan”). The 2019 Equity Plan was terminated and replaced and superseded by the 2021 Plan (as defined below) on the effective date of the 2021 Plan and no further grant of awards under the 2019 Equity Plan have been made since such effective date. Outstanding awards granted under the 2019 Equity Plan remain in effect pursuant to their terms.
On June 4, 2021, in connection with the IPO, the Company adopted the Convey Holding Parent, Inc. 2021 Omnibus Incentive Compensation Plan (the “2021 Plan”). The 2021 Plan has a term of ten years.
In March 2021, pursuant to the 2019 Equity Plan, Convey issued option awards to acquire 69,300 shares of Convey’s common stock with an exercise price of $9.92 per share and a term of ten (10) years. The awards were comprised of time-vesting options which vest 25% on each anniversary date from the vesting commencement date.
In June 2021, in connection with the IPO and pursuant to the 2021 Plan, Convey issued option awards to acquire 497,321 shares of Convey’s common stock with an exercise price of $14.00 per share and a term of ten (10) years. In addition, Convey issued 198,929 restricted stock units (“RSUs”) with a grant date fair value of $13.00 per unit. The option awards and RSUs are time-vesting awards which vest 25% on the first anniversary of the commencement date, and the remainder will vest in 12 equal 3-month installments over the following three years.
In August 2021, pursuant to the 2021 Plan, Convey issued option awards to acquire 20,380 shares of Convey’s common stock with an exercise price of $9.20 per share and a term of five (5) years. In addition, Convey issued 8,152 RSUs with a grant date fair value of $9.20 per unit. The option awards and RSUs were fully vested as of the date of the grant.
In March 2022, pursuant to the 2021 Plan, the Company issued 2,500,459 RSUs and 1,243,220 performance restricted stock units (“PSUs”) with a grant date fair value of $6.70 per unit. The grants are time-vesting awards which vest 25% on the first anniversary of the commencement date, and the remainder will vest in 12 equal 3-month installments over the following three years. The PSUs have a performance condition that affects vesting and is subject to the Company meeting certain annual Adjusted Earnings Before Interest, Income Tax, Depreciation and Amortization (“Adjusted EBITDA”) target.
23

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
The following table summarizes the total share-based compensation expense included in the condensed consolidated statements of operations and comprehensive income (loss):
For the Three Months Ended
March 31,
(in thousands)20222021
Selling, general and administrative$1,264 $990 
Total stock-based compensation expense$1,264 $990 
Stock Option Modification
On February 15, 2021, our Board approved a stock option award modification (the “Modification”) whereby the exercise price of certain previously granted and still outstanding unvested stock option awards held by current employees and certain executives were reduced by $1.18 per award, which represented the cash payment made for the vested awards as part of the Special Dividend. No other terms of the repriced stock options were modified, and the modified stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the Modification, 3,653,837 unvested stock options outstanding with an original exercise price of $7.94 were modified.
There was no incremental stock-based compensation expense as there was no incremental fair value generated as a result of the Modification.
Stock Option Grants
Stock option activity and information about stock options outstanding are summarized in the following table:
Stock Option Awards
Weighted Average Exercise Price
Weighted Average Remaining Contractual Life (Years)
Outstanding at December 31, 20215,636,154 $7.68 8.29
Granted  — 
Exercised  — 
Forfeited  — 
Outstanding at March 31, 20225,636,154 7.68 7.99
Vested or expect to vest as of March 31, 20225,636,154 7.68 7.99
Vested and Exercisable as of March 31, 20222,876,085 7.53 7.88
The stock options are equity-based awards and their aggregate intrinsic value outstanding and exercisable at March 31, 2022, is $0.
As of March 31, 2022, there was approximately $9.4 million total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted average period of 2.11 years.
We estimate the fair value of the time-vesting stock option awards on the date of grant using the Black-Scholes Merton model. The time-vesting options have a service condition. Option valuation models, including the Black-Scholes Merton model, require the input of certain assumptions that involve judgment. Changes in the input assumptions can materially affect the fair value estimates and, ultimately, how much we recognize as stock-based compensation expense.
24

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Restricted Stock Units
Activity and information about non-vested RSUs outstanding are summarized in the following table:
Restricted Stock Units
Weighted Average Grant Date Fair Value (in thousands)
Outstanding at December 31, 2021154,286 $2,006 
Granted3,743,679 25,083 
Vested  
Forfeited  
Outstanding at March 31, 20223,897,965 $27,089 
One RSU gives the right to one share of the Company’s common stock. RSUs that vest based on service are measured based on the fair value of the underlying stock on the date of grant. Compensation with respect to RSU awards is expensed on a straight-line basis over the vesting period.
As of March 31, 2022, there was approximately $26.6 million total unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted average period of 3.88 years.
Long-Term Incentive Awards
In March 2020, Convey issued fifty-six (56) Long-Term Incentive (LTI) awards with a total grant-date fair value of $1.1 million to employees. These awards vest upon satisfaction of the performance condition as determined by our Board at its sole discretion, subject to the participants continued employment or service. The performance condition is satisfied by TPG meeting a certain multiple-of-money return, on a scale, prior to or upon (i) TPG in the aggregate beneficially owning less than 20% of the voting equity securities of the Company or (ii) the date on which a change in control occurs. The awards contain a market condition with an implicit performance condition. No awards have vested as of March 31, 2022, as such events did not occur during the three months ended March 31, 2022. No awards have been granted or cancelled during the three months ended March 31, 2022. The awards do not expire. On the date the performance condition is met, any unvested awards will be forfeited.
LTI Awards
Outstanding as of December 31, 202143
Forfeited(4)
Outstanding as of March 31, 202239
Settlement of the award can be made, as determined by our Board at its sole discretion, (i) in cash, (ii) common stock, or (iii) in other property acceptable to our Board. The LTIs are treated as liability-based awards under Accounting Standards Codification (“ASC”) Topic 718, Compensation — Stock Compensation, (“ASC 718”) and the Company shall recognize compensation expense for the LTIs upon the liquidity event occurring.
NOTE 12. EMPLOYEE SAVINGS PLAN
We offer our employees a savings plan pursuant to Section 401(k) of the Internal Revenue Code (the “Code”), whereby employees may contribute a percentage of their compensation, not to exceed the maximum amount allowable under the Code. At the discretion of our Board, we may elect to make matching or other contributions into the savings plan. We made matching contributions of $0.9 million and $0.7 million for the three months ended March 31, 2022, and 2021, respectively, to our employee savings plan, which is included within Selling, general and administrative expenses, Cost of services and Cost of products in the condensed consolidated statement of operations and comprehensive income (loss).
NOTE 13. TAXES
Our tax provision or benefit from income taxes for interim periods is determined using an estimate of our global annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment.
25

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Our quarterly tax provision, and our quarterly estimate of our annual effective tax rate, is subject to change resulting from several factors, including variability in forecasting our pre-tax and taxable income and loss due to external changes in market conditions, changes in statutes, regulations and administrative practices, principles, and interpretations related to tax. Our effective tax rate can be more or less volatile based on the amount of pre-tax income or loss. For example, the impact of discrete items and non-deductible expenses on our effective tax rate is greater when our pre-tax income is lower.
Our income tax (expense) benefit for the three months ended March 31, 2022, and 2021, was $0.7 million and $1.0 million, respectively. For the three months ended March 31, 2022, our effective tax rate of 37.0%, before discrete items, was above the U.S. statutory rate of 21.0% primarily due to foreign taxes, state taxes and non-deductible compensation for covered employees. For the three months ended March 31, 2021, our effective tax rate of 22.5%, before discrete items, was slightly above the U.S. statutory rate of 21.0% primarily due to foreign taxes, state taxes, tax on Global Intangible Low-Taxed Income, disallowed wage expense and fringe benefits and certain other non-deductible items. We did not have any unrecognized tax benefits as a result of tax positions taken during a prior period or during the current period. No interest or penalties were recorded as a result of tax uncertainties.
NOTE 14. TRANSACTION RELATED COSTS
The following table represents the components of Transaction related costs as reported in the condensed consolidated statements of operations and comprehensive income (loss):
For the Three Months Ended
March 31,
(in thousands)20222021
Mergers and acquisitions related costs$640 $30 
Public company readiness costs 1,056 
Total$640 $1,086 
NOTE 15. COMMITMENTS AND CONTINGENCIES
Employment Agreements
We have employment agreements with various executives. The agreements have open-ended terms providing that employment shall continue until terminated by either party in accordance with the agreement. In addition to salary, bonuses, and benefits, the agreements also provide for termination benefits if the agreements are terminated by us for reasons other than cause or by the executives for good reason.
Inventory Purchases
As of March 31, 2022 and December 31, 2021, we have contractual commitments to purchase inventory from certain manufacturers totaling $3.1 million and $5.2 million, respectively.
Legal Proceedings
We are involved in various lawsuits, claims, inquiries, and other regulatory and compliance matters, most of which are routine to the nature of our business. When it is probable that a loss will be incurred and where a range of the loss can be reasonably estimated, the best estimate within the range is accrued. When the best estimate within the range cannot be determined, the low end of the range is accrued. The ultimate resolution of these claims could affect future results of operations should our exposure be materially different from our estimates or should liabilities be incurred that were not previously accrued. Potential insurance reimbursements are not offset against potential liabilities.
Because of the uncertainties associated with claims resolution and litigation, future losses to resolve these matters could be higher than the liabilities we have accrued; however, we are unable to reasonably estimate a range of potential losses. If new information were to become available that allowed us to reasonably estimate a range of potential losses in an amount higher or lower than what we have accrued, we would adjust our accrued liabilities accordingly. Based upon current information, we concluded that the impact of the resolution of these matters would not be, individually or in the aggregate, material to our financial position, results of operations or cash flows. Additional lawsuits, claims, inquiries, and other regulatory and compliance matters could arise in the future. The range of losses for resolving any future matters would be assessed as they arise.
26

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Sales Tax Accrual
ASC Topic 450, Contingencies, (“ASC 450”) requires an estimated loss to be accrued by a charge to income if it is probable that a liability has been incurred at the date of the financial statements and the amount of the liability can be reasonably estimated. We recognized liabilities for contingencies related to state sales and use tax deemed probable and estimable totaling $6.4 million and $6.9 million at March 31, 2022, and December 31, 2021, respectively. These are included in accrued liabilities in our condensed consolidated balance sheets.
NOTE 16. RELATED PARTY TRANSACTIONS
TPG Management Service Agreement
On September 4, 2019, in connection with the Merger, we had entered into a management services agreement (“MSA”) with TPG. Under the MSA, TPG agreed to provide certain financial, strategic advisory services, and consulting services in exchange for (i) reimbursement of certain expenses incurred by TPG and (ii) an aggregate annual retainer fee of 1% based on our previous year’s consolidated EBITDA determined by our Board. Additional services may be provided in exchange for the fees structured within the MSA. During the three months ended March 31, 2022, and 2021, we paid management and consulting fees of $0 and $0.2 million, respectively. Also, during the three months ended March 31, 2022, and 2021, we paid TPG a fee of $1.0 million and $1.0 million for services provided in connection with establishing: (i) the 2022 Incremental Term Loan and (ii) the 2021 Incremental Term Loan, respectively.
In the event the MSA was terminated by an IPO or business combination and TPG continues to hold at least 10% of equity of the Company upon closing of such transaction, we were required to pay TPG the net present value of the remaining portion of management and consulting fees that would have been incurred until three years after the date of such termination, as well as certain other expenses of TPG. In connection with the IPO completed in June 2021, the MSA was terminated and we paid TPG a $2.3 million termination fee. The termination fee is included within Selling, general and administrative expenses in the condensed consolidated statement of operations and comprehensive income (loss). There were no amounts payable to TPG as of March 31, 2022, or December 31, 2021.
EIR Partners Consulting Agreement
We have a Consulting Agreement with EIR Partners, LLC (“EIR”), a former member of our Board, and a current shareholder. Under the terms of the Consulting Agreement, EIR provides consulting services for the purpose of analyzing and reviewing potential sellers in the marketplace for the benefit of the Company as agreed to from time-to-time. As compensation for service, the Company remits to EIR $10 thousand monthly, plus reasonable out-of-pocket expenses incurred in the performance of the duties under the Consulting Agreement. The Consulting Agreement may be terminated by either party upon providing 10 days advance written notice and unless terminated, automatically renews for additional terms of one year. For the three months ended March 31, 2022, and 2021, $20 thousand and $30 thousand were paid for services rendered, respectively. The Consulting Agreement is still active with the Company.
NOTE 17. SEGMENT INFORMATION
ASC 280 establishes the standards for reporting information about segments in financial statements. In applying the criteria set forth in ASC 280, we have determined that we have two reportable segments: Technology Enabled Solutions and Advisory Services. These reportable segments reflect the manner in which the Chief Operating Decision Maker (“CODM”) group assesses information for decision-making purposes. The CODM group consists of our Chief Executive Officer and Chief Financial Officer.
The key factors used to identify these reportable segments are the organization and alignment of our internal operations and the nature of our products and services. This reflects how the CODM group monitors performance, allocates resources, and makes strategic and operational decisions.
In addition to the reportable segments, we have the “Unallocated” classification which includes those profit and loss items not allocated to either reportable segment. Unallocated includes corporate costs, primarily relating to group wide functions, including but not limited to, finance, tax and legal.
We present reportable segment revenue and Segment Adjusted EBITDA. Segment Adjusted EBITDA is the financial measure by which management and the CODM group allocate resources and analyze the performance of the reportable segments.
27

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
Segment Adjusted EBITDA represents each segment’s earnings before interest, tax, depreciation and amortization and is further adjusted to exclude certain items of a significant or unusual nature, including but not limited to, COVID-19 cost impacts, sales and use tax, non-cash stock compensation expense, transaction related costs, acquisition bonus expense, inventory step-up and other costs. Other includes costs such as management and board of directors fees and fees associated with obtaining the incremental term loans.
We do not report assets by reportable segment, as this metric is not used by the CODM group to allocate resources to the segments.
Presented in the tables below is revenue and Segment Adjusted EBITDA by reportable segment:
For the Three Months Ended
March 31, 2022
(in thousands)
Technology Enabled
Solutions
Advisory
Services
Revenue$83,166 $13,542 
Segment Adjusted EBITDA$12,370 $5,323 
For the Three Months Ended
March 31, 2021
(in thousands)
Technology Enabled
Solutions
Advisory
Services
Revenue$69,582 $13,049 
Segment Adjusted EBITDA$16,307 $3,338 
The following table presents a reconciliation of Segment Adjusted EBITDA to the condensed consolidated U.S. GAAP net income (loss) from operations:
(in thousands)For the Three Months Ended
March 31,
20222021
Technology Enabled Solutions Segment Adjusted EBITDA$12,370 $16,307 
Advisory Services Segment Adjusted EBITDA5,323 3,338 
Total$17,693 $19,645 
Unallocated(1)
$(2,377)$(2,048)
Adjustments to reconcile to U.S. GAAP net income (loss)
Depreciation and amortization(8,252)(7,372)
Interest, net(3,719)(5,467)
Income tax provision676 1,007 
Cost of COVID-19(2)
(274)(1,185)
Sales and use tax (1,498)
Non-cash stock compensation expense(1,264)(990)
Transaction related costs(640)(1,086)
Acquisition bonus expense(58)(192)
Inventory step-up(3)
(1,892) 
Other(4)
(1,047)(1,748)
Net income (loss)$(1,154)$(934)
________________________
(1)Represents certain corporate costs associated with the executive compensation, legal, accounting, finance and other costs not specifically attributable to the segments.
(2)Expenses incurred due to the COVID-19 pandemic are primarily related to higher pricing from vendors due to supply chain disruptions and product shortages and higher employee costs due to hazard pay for our employees. While we had
28

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
previously expected that these costs would not be an adjustment in the calculation of Segment Adjusted EBITDA after 2021, the COVID-19 pandemic has not subsided and during 2022, to a lesser extent, we have continued to incur higher product costs due to higher pricing from vendors for certain items (e.g., masks and other similar high demand products). We now expect that these expenses will not be an adjustment in the calculation of Segment Adjusted EBITDA after 2022.
(3)Incremental cost of products associated with the step-up of inventory recognized in purchase accounting for the HealthSmart acquisition.
(4)These adjustments include individual adjustments related to management and board of directors fees and fees associated with obtaining the incremental term loans.
NOTE 18. LEASES
We lease office space, warehouse and distribution space, and equipment under non-cancelable operating and finance leases expiring at various dates through 2029.
We determine whether an arrangement is a lease at inception, based on the (1) conveyed rights to obtain substantially all economic benefits from using the asset and (2) the right to direct the uses to which the asset is put.
Our lease population does not include any residual value guarantees, and therefore none were considered in the calculation of the lease balances. We have leases with variable payments, most commonly in the form of common area maintenance charges which are based on actual costs incurred. These variable payments were excluded from the right-of-use asset and lease liability balances since they are not fixed or in-substance fixed payments. We have lease agreements with lease and non-lease components. We elected the practical expedient to account for lease and non-lease components as a single lease component.
For leases with terms greater than 12 months, right-of-use assets and lease liabilities are recognized at the implementation date of Topic 842 or lease commencement date based on the present value of the future lease payments over the lease term. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, we utilize our incremental borrowing rate. Our lease agreements generally do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at either the implementation date of Topic 842 or at lease commencement for leases entered into thereafter in determining the present value of future payments. Lease expense for net present value of payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less with purchase options or extension options that are not reasonably certain to be exercised are not recorded on the condensed consolidated financial statements.
The components of lease expense were as follows:
(in thousands)Three Months Ended March 31, 2022
Operating lease costs$1,246 
Variable lease costs760 
Short-term lease costs326 
Finance lease cost
Amortization of right-of-use assets89
Interest on lease liabilities6
Total lease expense$2,427 
29

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:
(in thousands) Operating LeasesFinance Leases
For the nine months ending December 31, 2022$4,852 $397 
20236,469 368 
20245,694 139 
20254,150 89 
20262,316  
Thereafter 3,297  
Total $26,778 $993 
Less: amounts representing interest $(2,550)$(52)
Net present value of lease obligations $24,228 $941 
The following table presents the balances for operating and finance right-of-use assets and lease liabilities:
(in thousands) ClassificationMarch 31, 2022
Assets
Operating lease assetsRight-of-use assets$18,574 
Finance lease assetsProperty and equipment940 
Total lease assets$19,514 
Liabilities
Current liabilities
Operating lease liabilitiesOperating lease liabilities$5,605 
Finance lease liabilitiesFinance lease obligations501
Non-current liabilities
Operating lease liabilitiesOperating lease liabilities18,623 
Finance lease liabilitiesFinance lease obligations440 
Total lease liabilities$25,169 
The table below presents additional information related to our leases as of March 31, 2022:
(in thousands)
Three Months Ended March 31, 2022
Supplemental cash flow information and non-cash activity:
Cash paid for amounts related to lease liabilities:
Operating cash flows from finance leases (interest)$6 
Operating cash flows from operating leases$1,541 
Financing cash flows from finance leases (principal payments)$86 
Weighted Average Remaining Lease Term (in years):
Operating leases4.7
Finance leases2.3
Weighted Average Discount Rate:
Operating leases4.1 %
Finance leases3.9 %
30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) and the Form 10-K.
The following discussion and analysis also includes discussion of certain non-GAAP financial measures. For a description and reconciliation of the non-GAAP measures discussed in this section, see “Non-GAAP Financial Measures” below.
This Form 10-Q contains “forward-looking statements”. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies and other future conditions. Such forward-looking statements may include, without limitation, statements about future opportunities for us and our products and services, our future operations, financial or operating results, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions and other expectations and targets for future periods. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “predict,” “project,” “target,” “potential,” “seek,” “will,” “would,” “could,” “should,” continue,” contemplate,” “plan” and other words and terms of similar meaning. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition and cash flows, and the development of the markets in which we operate, are consistent with the forward-looking statements contained in this Form 10-Q, those results or developments may not be indicative of results or developments in subsequent periods. New factors emerge from time to time that may cause our business not to develop as we expect, and it is not possible for us to predict all of them. Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, among others, the following: our ability to retain our existing clients or attract new clients, and sell additional solutions and services to our clients; our dependence on a small number of clients for a substantial portion of our total revenue; limitations of our clients’ growth prospects, and the failure of the size of the total addressable markets in which we compete or expect that we may compete in the future to grow at rates currently expected; our ability to achieve or maintain profitability; Federal reductions in Medicare Advantage funding; significant consolidation in the healthcare industry, and decisions by clients to perform internally some of the same solutions or services we offer; the limited operating history we have with certain of our solutions; a failure to deliver high-quality member management services to our clients’ members; the competition we face from healthcare services and technology companies; risks related to acquisitions of other businesses or technologies and other significant transactions; increases in labor costs, including due to changing minimum wage laws, and an overall tightening of the labor market; the long and unpredictable sales and integration cycles for our solutions; an economic downturn or volatility, including as a result of the ongoing COVID-19 pandemic; our ability to achieve market acceptance of new or updated solutions and services; our reliance on third parties for certain components of our business; significant fluctuations in our quarterly results of operations due to seasonality; our ability to achieve or maintain adequate utilization and suitable billing rates for our consultants, and our ability to deliver our services to our clients; recent and future developments in the Medicare Advantage market or the healthcare industry generally, including with respect to changing laws and regulations; our ability to comply with applicable laws, regulations and standards relating to data privacy and security; security breaches or incidents, failures and other disruptions of the information technology systems used in our business operations and of the sensitive information we collect, process, transmit, use and store; disruptions in service, and other software and systems failures, affecting us and our vendors; our ability to obtain, maintain, protect and enforce our intellectual property and proprietary rights; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties; our substantial indebtedness, and the restrictions imposed by our indebtedness on our subsidiaries; identified material weaknesses in our internal control over financial reporting and a failure to remediate these material weaknesses, and the effectiveness of our internal control over financial reporting; and the significant influence our principal stockholder, TPG, has over us.
For a further discussion of these and other factors that could impact our future results, performance or transactions, see Part I, Item 1A "Risk Factors" of our Form 10-K and our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information
31

available to us as of the date of this Form 10-Q, and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. We qualify all of the forward-looking statements in this Form 10-Q by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Overview
The Company is a leading healthcare platform that utilizes technology and processes to improve government-sponsored health plans, including Medicare Advantage (“MA”) plans. We help health plans to grow membership and revenue as well as operate more effectively and efficiently. We are a trusted solutions-oriented partner to payors and deliver purpose-built technology and services to enhance our clients’ mission-critical workflows. Our solutions address health plan needs, including product development and sales, member experience management, clinical management, core operations, business intelligence and analytics. Leveraging our technology and expert advisory services, we serve as a unified and integrated extension of our clients’ core health plan operations. Our proprietary, modular technology and end-to-end solutions replace or supplement our clients’ existing systems and processes, enabling us to help health plans attract and retain members, improve revenue accuracy, drive cost savings, facilitate regulatory compliance, and enhance operational effectiveness.
On February 1, 2022, Convey’s indirect wholly-owned subsidiary, D-M-S Holdings Parent, LLC (f/k/a Dragon Holdings Parent, LLC), a Delaware limited liability company, acquired all of the issued and outstanding capital stock of D-M-S Holdings, Inc. d/b/a HealthSmart International, a Delaware corporation (“HealthSmart”). HealthSmart provides a diverse portfolio of health, wellness and diagnostic products centered on home based care outcomes. The acquisition of HealthSmart supports Convey's vision to empower health plans to excel by delivering a more diverse healthcare product portfolio to their members while streamlining logistics, resulting in a better healthcare consumer experience. The acquisition will combine Convey's best-in-class supplemental benefits administration technology and services solution with HealthSmart's market leading abilities as a trusted supplier of quality consumer healthcare products. Convey will extend the solutions serving the MA supplemental benefits business through a broader set of consumer healthcare products and expertise that serves many of the top health plans in the U.S.
Since our inception, we have created and continuously refined our technology solutions to best serve government-sponsored health plans. Our clients are primarily MA plans, Medicare Part D plans, including Employer Group Waiver plans, and pharmacy benefit managers.
We foster long-term collaborative partnerships as evidenced by our average relationship with our top 10 clients of over eight years, and we serve as a partner to nine of the nation’s top 10 MA payors by lives covered, in each case as of December 31, 2021. We believe that we have significant opportunity to grow within our existing client base as the majority of our clients currently subscribe to only a subset of our overall solutions and services. Moreover, we believe we have significant opportunity to grow by winning new clients in the MA market, by selling more products to our existing clients, by expanding into adjacent markets such as Medicaid and commercial insurance, and through complementary strategic acquisitions.
Our clients face significant and constantly evolving challenges managing their Medicare health plans:
Increasingly Competitive Environment for Medicare Plans: Effective benefit design and sales are critical to retaining and growing members during the Medicare annual enrollment period. Once members are enrolled in a plan, effective member engagement and supplemental benefits administration are paramount to ensuring strong satisfaction and retention. Moreover, the proliferation of value-based reimbursement models such as MA requires effective member management and broad ecosystem coordination, which fall outside the core competencies of many health plans.
Compliance with Centers for Medicare and Medicaid Services (“CMS”) Requirements: Constantly evolving CMS and client requirements result in hundreds of modifications per year that inhibit the operational effectiveness and capabilities of health plans. Our purpose-built government sector technology platform addresses these constantly evolving requirements.
Complex and Highly Regulated Medicare Market: Many health plans enter the government plan market by simply adapting their existing systems designed for the commercial insurance market. As a result, the technology they employ often lacks the sophistication and design needed to effectively maintain and administer benefits tailored for the complex and highly regulated Medicare market.
32

Health plans increasingly recognize the need for specialized solutions like ours to help them overcome these challenges and drive superior performance. We believe our proprietary technology and processes facilitate member engagement, health plan growth, and operational efficiencies.
We operate in two segments: Technology Enabled Solutions (“TES”) in which we provide technology and support solutions to our clients, and Advisory Services (“Advisory”) in which we provide project-based consulting services led by our long-tenured subject matter experts. We believe that our combination of technology and advisory solutions gives us a competitive advantage in the government-sponsored health plan market. Our Technology Enabled Solutions and Advisory teams collaborate effectively to combine a strong technology platform with deep domain expertise to deliver best-in-class solutions to our clients. Furthermore, we leverage the Advisory team’s industry expertise to identify new opportunities as well as cross-sell our solutions within existing clients.
We have a highly predictable and recurring revenue model with strong cash flow from operations. We typically charge a recurring subscription or per-member fee or a re-occurring utilization-based fee, which, coupled with our long-term contracts and strong client retention, has historically provided us with strong revenue visibility into estimated future revenue. Our Technology Enabled Solutions business historically has been highly predictable as most of our revenue in any given year is under contract or otherwise visible by the beginning of that year due to the contract structures we employ.
Initial Public Offering
On June 18, 2021, we closed the initial public offering (“IPO”) of our common stock through an underwritten sale of 13,333,334 shares of our common stock at a price of $14.00 per share. In the offering, we sold 11,666,667 shares and a selling stockholder sold 1,666,667 shares. The aggregate net proceeds to us from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by us, were approximately $146.1 million. We used approximately $131.5 million of the net proceeds from the IPO to repay outstanding indebtedness under our First Lien Credit Agreement (as amended, the “Credit Agreement”). We did not receive any of the proceeds from the sale by the selling stockholder.
COVID-19 Pandemic
COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. Governments at the national, state, and local level in the U.S., and globally, have implemented varying measures in an effort to contain the virus, including social distancing, travel restrictions, border closures, limitations on public gatherings of people, work from home and supply chain logistical changes. While some of these actions have eased, escalating transmission rates (including of the Delta and Omicron variants of COVID-19), uneven vaccination and vaccination booster rates and further governmental guidance and orders may result in having to reimplement certain of these measures or implementing new and additional ones. The spread of COVID-19 has also caused significant volatility in United States and international markets and has had and continues to have widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices.
Our operations have been impacted by COVID-19 since March 2020. During March and April 2020, we obtained approval from our clients for a work-at-home model, though not all required our approval, and transitioned most of our employees to the home environment so that they could work more safely. COVID-19 created a hardship for many of our employees. We worked during 2020 to care for our employees by periodically implementing temporary premium pay and temporary paid sick leave programs which provided additional financial resources for our employees, as well as partial pay for those employees who contracted the virus or had to care for a family member who was affected. We also had provided compensation to employees who worked with us for more than six months so that they can take time off to be vaccinated. In addition, we increased cleaning protocols throughout our facilities. Certain of these measures have resulted in increased costs.
Due to significant volatility to the markets, as well as business and supply chain disruptions, we incurred several additional expenses due to the COVID-19 pandemic, including the following:
Higher Pricing from Vendors and Higher Shipping Costs:   We experienced higher costs to procure certain products included in the formulary available to Medicare members. The price increases were due to supply chain disruptions and product shortages caused by the COVID-19 pandemic. We quantified the pricing increase by comparing the pre-pandemic prices for high demand products directly attributable to the COVID-19 pandemic (e.g., masks and other similar high demand products) to the prices to procure such products during the pandemic. Further, we incurred additional costs due to expedited shipping fees as a result of new inventory management practices put into place due to supply chain disruptions and delays caused by COVID-19 in order to fulfill product demand.
Sick Pay, Premium Pay and Hazard Pay:   Temporary sick leave was paid to employees if specific criteria related to the COVID-19 pandemic were met. Incremental premium pay and hazard pay were paid to distribution and shipping
33

employees who worked their normal scheduled shifts. In addition, we paid a one-time bonus to supervisors for working additional hours to support the transition of our employees to a work-at-home model.
Work-at-Home Training:   In response to the COVID-19 pandemic, we held work-at-home remote training. To accomplish this transition, hourly new hire employees were required to receive training regarding at-home information technology (“IT”) and telephony equipment setup. We paid the hourly new hire employees four hours for these efforts at their regular hourly wage rate and applicable fringe benefit rate.
IT Expenses:   Additional temporary IT resources were retained, and overtime hours were incurred, for existing IT resources, in order to implement the remote working environment designed in response to the COVID-19 pandemic.
Janitorial Costs:   Due to the onset of the COVID-19 pandemic, we implemented an enhanced sanitation policy. The enhanced sanitation policy included special deep cleaning sessions in areas contacted by employees who had tested positive for COVID-19 and enhanced sanitation sessions through our facilities compared to the sanitation methods used prior to the COVID-19 pandemic.
See “Non-GAAP Financial Measures” for amounts related to the additional expenses due to the COVID-19 pandemic (Cost of COVID-19). While we had previously expected that these costs would not be an adjustment in the calculation of Adjusted EBITDA after 2021, the COVID-19 pandemic has not subsided and during 2022, to a lesser extent, we have continued to incur higher product costs due to higher pricing from vendors for certain items (e.g., masks and other similar high demand products). We now expect that these expenses will not be an adjustment in the calculation of Adjusted EBITDA after 2022.
The full extent to which the COVID-19 pandemic and the various responses to the COVID-19 pandemic will impact our business, operations or financial condition continues to depend on numerous evolving factors that we may not be able to accurately predict, including, but not limited to, the duration, severity and scope of the COVID-19 pandemic (including due to new variants such as Delta and Omicron); actions by governmental entities, businesses and individuals that have been and continue to be taken in response to the pandemic; the effect on our clients and demand by clients, clients and our clients’ members for and ability to pay for our solutions and services; and disruptions or restrictions on our employees’ ability to work and travel. The impact of these factors and others on our suppliers and clients could persist for some time after governments ease their restrictions and after the overall number of COVID-19 cases in the United States decreases. We may continue to experience higher than usual costs as a result of COVID-19 for the foreseeable future. 
Non-GAAP Financial Measures
We present our financial results in accordance with GAAP. However, we use certain non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide investors with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. In particular, we use EBITDA and Adjusted EBITDA to assess our financial performance and also for internal planning and forecasting purposes. We believe EBITDA and Adjusted EBITDA provide investors with useful information because such metrics offer a consistent and comparable overview of our operations across historical financial periods. In evaluating EBITDA and Adjusted EBITDA, you should be aware that in the future we may incur expenses similar to those eliminated in the presentation. Non-GAAP measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. There are limitations to the use of the non-GAAP financial measures presented in this Form 10-Q. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.
The non-GAAP financial measures we present are not meant to be considered as indicators of performance in isolation from or as a substitute for measures prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA and Adjusted EBITDA to the most directly comparable GAAP financial measure, net income (loss), are presented below. We encourage you to review our financial information in its entirety, not to rely on any single financial measure and to view the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude such items, may incur income and expenses similar to these excluded items, and include other expenses, costs, and non-recurring items. The tables below provide reconciliations of EBITDA and Adjusted EBITDA to net income (loss) on a consolidated basis for the periods indicated.
34

We define EBITDA as net income (loss) adjusted for interest, net, income tax expense (benefit), and depreciation and amortization expense. We define Adjusted EBITDA as EBITDA further adjusted for certain items of a significant or unusual nature, including but not limited to, COVID-19 cost impacts, non-cash stock compensation expense, transaction related costs, acquisition bonus expense, inventory step-up and other costs. Other includes costs such as management fees and fees associated with obtaining the incremental term loans.
In addition, we measure the performance of our individual segments using Segment Adjusted EBITDA. Segment Adjusted EBITDA is the financial measure by which management allocates resources and analyzes the performance of the reportable segments. The main difference between Segment Adjusted EBITDA and Adjusted EBITDA is that Segment Adjusted EBITDA includes add backs for sales and use tax and board of directors fees.
The following table presents a reconciliation of net income (loss) to EBITDA and Adjusted EBITDA for the periods presented:
(in thousands)Three Months Ended March 31, 2022Three Months Ended March 31, 2021
Net income (loss)$(1,154)$(934)
Interest, net3,719 5,467 
Income tax expense (benefit)(676)(1,007)
Depreciation and amortization expense8,252 7,372 
EBITDA10,141 10,898 
Cost of COVID-19(1)
274 1,185 
Non-cash stock compensation expense(2)
1,264 990 
Transaction related costs(3)
640 1,086 
Acquisition bonus expense
58 192 
Inventory step-up(4)
1,892 — 
Other(5)
1,047 1,517 
Adjusted EBITDA$15,316 $15,868 
________________________
(1)Due to significant volatility to the markets, as well as business and supply chain disruptions, we incurred several additional expenses due to the COVID-19 pandemic, including: (i) higher pricing from vendors due to supply chain disruptions, product shortages and increases in shipping costs, (ii) higher employee costs due to premium pay and hazard pay for our employees and enhanced sick pay due to illness and quarantine protocols, (iii) COVID-19 training costs, (iv) overtime costs for IT personnel to setup eligible employees to work from home and temporary resources and (v) janitorial costs due to enhanced COVID-19 protocols. The expenses are included in cost of services and cost of products on our statements of operations and comprehensive income (loss). See “COVID-19 Pandemic” above for additional information related to these expenses. While we had previously expected that these costs would not be an adjustment in the calculation of Adjusted EBITDA after 2021, the COVID-19 pandemic has not subsided and during 2022, to a lesser extent, we have continued to incur higher product costs due to higher pricing from vendors for certain items (e.g., masks and other similar high demand products). We now expect that these expenses will not be an adjustment in the calculation of Adjusted EBITDA after 2022.
(2)Represents non-cash stock-based compensation expense in connection with the stock awards that have been granted to employees and non-employees. The expense is included in selling, general and administrative expenses on our statements of operations and comprehensive income (loss).
(3)Transaction related costs primarily consist of public company readiness costs, expenses for corporate development, such as mergers and acquisitions activity, and due diligence costs.
(4)Incremental cost of products associated with the step-up of inventory recognized in purchase accounting for the HealthSmart acquisition.
35

(5)Other includes other individual adjustments related to management fees and fees associated with obtaining the incremental term loans. All costs are included in selling, general and administrative expenses on our statements of operations and comprehensive income (loss).
Components of Results of Operations
Revenue
We generate revenue from contracts with our clients within our two operating segments: Technology Enabled Solutions and Advisory Services.
Through our Technology Enabled Solutions segment, we primarily provide technology solutions and services to assist our clients with workflows across product development, member experience, clinical management, core operations, business intelligence, and analytics. Through our Advisory Services segment, we provide fixed or variable fee arrangements to assist clients in the design and management of government and commercial health plans. Our revenue includes both product revenue and service arrangements.
Products revenue consists of technology enabled solutions for supplemental benefits to members through their Medicare Advantage plans. These include supplemental benefit products, administration, fulfillment, and shipment of eligible product, as well as catalog development and distribution. Revenue is derived from supplemental benefit membership, supplemental benefit dollars, member utilization of the benefits and, as a result of the HealthSmart acquisition, health, wellness and diagnostic products sold through the retail channel.
Services revenue consists of:
Technology-based Medicare plan administration services including eligibility and enrollment processing, member services, premium billing and payment processing, reconciliation and other related services. Our solutions are primarily priced on recurring per member per month fees, annual software license fees, and transaction-based fees.
Value based payment assurance solutions, including payment tools and data analytics, that improve revenue accuracy and gaps in quality, clinical care, and compliance. Our value-based solutions are primarily priced on an annual subscription fee, shared savings or fee-based engagement. Advisory (consulting) services that support health plan operations and drive business model evolution. Our Advisory services are priced on a fixed-fee or time and materials basis.
Operating Expenses
Costs of products consist of the value of supplemental benefit products, the value of health, wellness and diagnostic products, shipping and handling costs to acquire and to deliver the product to our clients; personnel costs including salaries, wages, overtime, benefits; facility costs and overhead allocation covering information technology, telecommunications costs, and other costs specifically identified to the shipment of our products.
Costs of services consist of all costs directly attributable to service revenue generation activities as outlined in contracts with our clients. Our largest components in costs of services are personnel costs, including salaries, wages, overtime, benefits, and discretionary bonus; facility costs and overhead allocation covering information technology, telecommunications costs, and other costs needed in the delivery of our services.
Selling, general and administrative expenses (“SG&A”) include corporate management and governance functions comprised of general management, legal, accounting, financial reporting, human resource, sales, marketing, and other costs not directly associated with revenue generation activities, including those involved with developing new service offerings. SG&A includes salaries, bonuses, and related benefits. SG&A also includes all general operating expenses, including, but not limited to, rent and occupancy costs for non-revenue generating activities, telecommunications costs, information technology infrastructure, and operations costs, including software licensing costs, advertising and marketing expenses, insurance expenses, professional services and consulting expenses.
Depreciation and amortization includes depreciation expense of property and equipment, including leasehold improvements, computer equipment, furniture and fixtures and software and amortization expense of capitalized internal-use software and software development costs, customer relationships, acquired software and certain trade names.
Transaction related costs primarily consist of professional services incurred in connection with public company readiness costs, expenses for corporate development such as mergers and acquisitions activity and due diligence costs.
36

Other Income (Expense)
Other Income (expense) is primarily composed of:
Interest income. Interest income consists of interest on cash and cash equivalents.
Interest expense. Interest expense consists of accrued interest and related payments on our outstanding term loans and revolving loans, as well as the amortization of debt issuance costs associated with our debt. Interest expense also includes interest on our sales tax accrual.
Results of Operations
Comparison of the Three Months Ended March 31, 2022, and 2021
The following table sets forth our results of operations for the periods indicated:

For the Three Months Ended March 31,Change
(in thousands, except for percentages)20222021$%
Net revenues:
Services$46,480 $43,527 $2,953 %
Products50,228 39,104 11,124 28 %
Net revenues96,708 82,631 14,077 17 %
Operating expenses:
Cost of services
25,477 24,021 1,456 %
Cost of products
37,236 26,527 10,709 40 %
Selling, general and administrative23,214 20,099 3,115 15 %
Depreciation and amortization8,252 7,372 880 12 %
Transaction related costs640 1,086 (446)(41)%
Total operating expenses94,819 79,105 15,714 20 %
Operating income1,889 3,526 (1,637)(46)%
Other income (expense):
Interest expense(3,719)(5,467)1,748 (32)%
Total other expense, net(3,719)(5,467)1,748 (32)%
Income (loss) before income taxes(1,830)(1,941)111 (6)%
Income tax (expense) benefit676 1,007 (331)(33)%
Net income (loss)$(1,154)$(934)$(220)24 %
Net Revenues
Services Revenue
Services revenue was $46.5 million and $43.5 million for the three months ended March 31, 2022, and March 31, 2021, respectively. The $3.0 million increase is driven by $1.9 million attributable to customer membership base increase and $1.7 million by net new consulting projects. This is offset by a decrease of $0.4 million in implementation related fees and $0.2 million in lower data analytics contracts.
Products Revenue
Products revenue was $50.2 million and $39.1 million for the three months ended March 31, 2022, and March 31, 2021, respectively. The increase of $11.1 million is driven by $7.2 million attributable to the acquisition of HealthSmart and $3.9 million for net new clients and existing client growth of memberships.
37

Operating Expenses
Cost of Services
Cost of services was $25.5 million and $24.0 million for the three months ended March 31, 2022, and March 31, 2021, respectively. The increase of $1.5 million is primarily attributable to higher staffing levels to handle increased support to our existing clients, wage increases and incentives paid to agents to handle increased call volumes.
Cost of Products
Cost of products was $37.2 million and $26.5 million for the three months ended March 31, 2022, and March 31, 2021, respectively. The increase of $10.7 million is driven by $5.2 million attributable to product costs associated with HealthSmart, $1.9 million of purchase accounting inventory step-up for HealthSmart, $2.1 million due to higher volume and $1.5 million due to higher rates and shipping costs due to supply chain constraints.
Selling, General and Administrative
Selling, general and administrative was $23.2 million and $20.1 million for the three months ended March 31, 2022, and March 31, 2021, respectively. The increase of $3.1 million is driven by $1.0 million attributable to the acquisition of HealthSmart and $2.1 million driven by higher IT, accounting, HR and operational costs, offset by lower expected management incentive bonus.
Depreciation and Amortization
Depreciation and amortization was $8.3 million and $7.4 million for the three months ended March 31, 2022, and March 31, 2021, respectively. The increase of $0.9 million in depreciation and amortization expense is due to the addition of property and equipment and capitalization of software development costs.
Transaction Related Costs
Transaction related costs were $0.6 million and $1.1 million for the three months ended March 31, 2022, and March 31, 2021, respectively. The decrease of $0.4 million in transaction related costs is due to the costs associated with readiness for last year’s IPO, offset by costs incurred in 2022 related to the acquisition of HealthSmart.
Other Income (Expense)
Interest Expense
Interest expense was $3.7 million and $5.5 million for the three months ended March 31, 2022, and March 31, 2021, respectively. The decrease of $1.7 million is mainly attributable to lower outstanding balances due to the pay down of the term loan from IPO proceeds; offset by the incremental term loan entered into to finance the HealthSmart acquisition. Furthermore, lower interest rates for both the term loan and the incremental term loan were also a factor.
Segment Information
Our reportable segments have been determined in accordance with Accounting Standards Codification Topic 280, Segment Reporting. We have two reportable segments: Technology Enabled Solutions and Advisory Services. We evaluate the performance of each of our two operating segments based on segment revenue and Segment Adjusted EBITDA.
Segment Adjusted EBITDA represents each segment’s earnings before interest, tax, depreciation and amortization and is further adjusted to exclude certain items of a significant or unusual nature, including but not limited to, COVID-19 cost impacts, sales and use tax, non-cash stock compensation expense, transaction related costs, acquisition bonus expense, inventory step-up and other costs. Other includes costs such as management and board of directors fees and fees associated with obtaining the incremental term loans.
See Note 17. Segment Information, to the notes accompanying our financial statements.
The segment measurements provided to and evaluated by the chief operating decision maker group are described in the notes to our financial statements. These results should be considered in addition to, and not as a substitute for, results reported in accordance with GAAP.
38

For the Three Months Ended March 31,Change
(in thousands, except for percentages)20222021$%
Revenue
Technology Enabled Solutions$83,166 $69,582 $13,584 20 %
Advisory Services13,542 13,049 493 %
Total$96,708 $82,631 $14,077 17 %
Segment Adjusted EBITDA
Technology Enabled Solutions$12,370 $16,307 $(3,937)(24)%
Advisory Services5,323 3,338 1,985 59 %
Total$17,693 $19,645 $(1,952)(10)%
Segment Revenues
Technology Enabled Solutions revenue was $83.2 million and $69.6 million for the three months ended March 31, 2022, and 2021, respectively. The increase of $13.6 million was mainly attributable to: (i) revenue from the acquisition of HealthSmart, and (ii) existing client growth of membership base accounts.
Advisory revenue was $13.5 million and $13.0 million for the three months ended March 31, 2022 and 2021, respectively. The increase of $0.5 million was primarily driven by new projects within our existing client base.
Segment Adjusted EBITDA
Technology Enabled Solutions Segment Adjusted EBITDA was $12.4 million and $16.3 million for the three months ended March 31, 2022, and 2021, respectively. The decrease of $3.9 million was primarily attributable to higher staffing levels to handle increased support to our existing clients, wage increases, higher incentives paid to agents to handle increased call volumes and higher shipping costs due to supply chain constraints. The decrease is offset by the contribution from the HealthSmart acquisition, higher volume and projected lower bonus payments.
Advisory Segment Adjusted EBITDA was $5.3 million and $3.3 million for the three months ended March 31, 2022, and 2021, respectively. The increase of $2.0 million was attributable to flow through of consulting services demand, higher utilization of our consultants and lower projected bonus payments.
Liquidity and Capital Resources
Overview
Our primary sources of liquidity are our existing cash and cash equivalents, cash provided by operating activities and borrowings available under our Credit Agreement. As of March 31, 2022, we had unrestricted cash and cash equivalents of $20.9 million, and as of March 31, 2022, our total indebtedness was $270.6 million.
We are a holding company that transacts substantially all of our business through our operating subsidiaries. Consequently, our ability to pay dividends to stockholders, meet debt payment obligations, and pay taxes and operating expenses is largely dependent on dividends or other distributions from our subsidiaries, whose ability to pay such distributions to us is restricted, subject to certain exceptions, pursuant to the terms of the Credit Agreement. Covenants contained in the Credit Agreement may restrict our operating subsidiaries from issuing dividends and other distributions to us.
Our principal liquidity needs have been, and we expect them to continue to be, working capital and general corporate needs, debt service, capital expenditures and potential acquisitions. Our capital expenditures for property and equipment to support growth in the business were $1.8 million and $3.1 million for the three months ended March 31, 2022, and 2021, respectively. Additional expenditures for software development were $1.1 million and $1.3 million for the three months ended March 31, 2022, and 2021, respectively.
We believe that our primary sources of liquidity, including our cash and cash equivalents, cash provided by operating activities and borrowing capacity under our Credit Agreement, will be sufficient to meet our liquidity needs for at least the next 12 months. We anticipate that to the extent that we require additional liquidity, it will be funded through the incurrence of additional indebtedness, the issuance of additional equity, or a combination thereof. We cannot assure you that we will be able to obtain this additional liquidity on reasonable terms, or at all. Additionally, our liquidity and our ability to meet our
39

obligations and fund our capital requirements are also dependent on our future financial performance, which is subject to general economic, financial, and other factors that are beyond our control.
Cash Flows Information
The following table presents a summary of cash flows for the periods presented:
(in thousands)Three Months Ended March 31, 2022Three Months Ended March 31, 2021
Net cash (used in) provided by operating activities$(15,660)$(12,626)
Net cash used in investing activities$(77,554)$(4,350)
Net cash provided by financing activities$75,283 $515 
Operating Activities
Net cash used in operating activities for the three months ended March 31, 2022, was $15.7 million compared to $12.6 million of net cash used in operating activities for the three months ended March 31, 2021.
Net loss was $1.2 million for the three months ended March 31, 2022, as compared to $0.9 million net loss for the three months ended March 31, 2021. The net loss for the three months ended March 31, 2022 is attributable to costs incurred for the HealthSmart acquisition including a $1.9 million purchase accounting inventory step-up and $0.6 million of additional transaction related costs, higher labor costs and higher freight costs driven by supply chain constraints. Non-cash items were $12.2 million for the three months ended March 31, 2022, as compared to $8.5 million for the three months ended March 31, 2021.
The effect of changes in operating assets and liabilities was a cash decrease of $26.7 million for the three months ended March 31, 2022, as compared to a cash decrease of $20.2 million for the three months ended March 31, 2021. The most significant drivers contributing to this net decrease of $6.5 million relate to the following:
Decrease of accrued expenses mainly driven by higher incentive bonus accrued for as of December 31, 2021;
An increase in accounts receivable when compared to the prior period; and
Lower cash used on inventory purchases when compared to the prior period.
Investing Activities
Net cash used in investing activities for the three months ended March 31, 2022, was $77.6 million compared to $4.3 million for the three months ended March 31, 2021. During the three months ended March 31, 2022, net cash used in investing activities was primarily attributable to the HealthSmart acquisition.
Financing Activities
Net cash provided by financing activities for the three months ended March 31, 2022, was $75.3 million compared to $0.5 million for the three months ended March 31, 2021. During the three months ended March 31, 2022, net cash provided by financing activities was primarily attributable to net proceeds from the incremental loan established in February 2022 to finance the HealthSmart acquisition and pay fees and expenses related thereto.
Contractual Obligations and Commitments
The following table summarizes our contractual obligations as of March 31, 2022. The principal commitments consisted of obligations under outstanding operating leases for office facilities, capital leases related to copy machines, our long-term debt, and purchase commitments. The amount of the obligations presented in the following table summarizes as of March 31, 2022, the commitments to settle contractual obligations in cash for the periods presented.
40

Payments Due by Period
(in thousands)Total
Less than 1
year
1-3 Years4-5 Years
More than
5 years
Operating leases for facilities26,512 4,735 16,168 3,602 2,007 
Finance leases993 397 596 — — 
Long-term debt obligations(1)
270,631 585 2,340 267,706 — 
Purchase commitments6,910 6,910 — — — 
Total contractual obligations$305,046 $12,627 $19,104 $271,308 $2,007 
________________________
(1)Includes the term loan under our Credit Agreement.
Off-Balance Sheet Arrangements
During the periods presented, we did not have any off-balance sheet arrangements, as defined in Regulation S-K promulgated by the SEC.
Critical Accounting Policies and Use of Estimates
The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, income, and expenses and related disclosures of contingent assets and liabilities. We base these estimates on our historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results experienced may vary materially and adversely from our estimates. Revisions to estimates are recognized prospectively.
During the three months ended March 31, 2022, there were no material changes to our critical accounting policies and use of estimates from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies and Use of Estimates” included in our Form 10-K for the year ended December 31, 2021. The following discussion supplements our Critical Accounting Policies and Use of Estimates Policy for Goodwill as it relates to the interim goodwill impairment test performed as of March 31, 2022.
As a result of the decline in our stock price since December 31, 2021, we performed an interim impairment test for goodwill for APA, SBA, VBPA and Advisory reporting units using the quantitative approach as of March 31, 2022. Since HealthSmart was recently acquired, no impairment test was performed on that reporting unit. Based on our evaluation performed, we determined the fair value of each of the reporting units exceeded its respective carrying amount, and therefore, we determined that goodwill was not impaired at any of our reporting units as of March 31, 2022. We define “headroom” as the percentage difference between the fair value of a reporting unit and its carrying value. For the interim impairment test, the headroom for the reporting units ranged between eight percent to 65 percent. Our SBA reporting unit and our VBPA reporting unit have headroom at the low-end of that range (8.4% for SBA and 12.5% for VBPA) and could experience impairment in the future if we do not achieve our profitability projections, there is a change in key assumptions underlying the valuation or if we continue to experience a substantial decrease in our stock price.
Evaluation of goodwill for impairment requires judgment, including the identification of reporting units, assignment of assets, liabilities and goodwill to reporting units and determination of the fair value of each reporting unit. We estimate the fair value of our reporting units using a combination of an income approach, utilizing a discounted cash flow analysis, and a market approach, using market multiples. Under the income approach, we estimate projected future cash flows, the timing of such cash flows and long-term growth rates, and determine the appropriate discount rate that reflects the risk inherent in the projected future cash flows. The discount rate used is based on a market participant weighted-average cost of capital and may be adjusted for the relevant risk associated with business-specific characteristics and the uncertainty related to the reporting unit’s ability to execute on the projected future cash flows. Under the market approach, we estimate fair value based on market multiples of revenues and earnings derived from comparable publicly-traded companies with characteristics similar to the reporting unit. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions and other factors. The assumptions and estimates used in determining the fair values of the reporting units contain uncertainties, and any changes to these assumptions and estimates could have a negative impact and result in a future impairment.
41

Recent Accounting Pronouncements
See Note 2 to our unaudited interim condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.
Emerging Growth Company Status
Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption for complying with new or revised accounting standards within the same time periods as private companies. Accordingly, the information contained herein may be different than the information you receive from other public companies.
We also intend to take advantage of some of the reduced regulatory and reporting requirements of emerging growth companies pursuant to the JOBS Act so long as we qualify as an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding non-binding advisory votes on executive compensation and golden parachute payments.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
In the normal course of business, we are subject to market risks. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Financial instruments that are exposed to concentrations of credit risk primarily consist of accounts receivable. We do not require collateral or other security for receivables, but believe the potential for collection issues with any clients was minimal as of March 31, 2022, based on the lack of collection issues in the past and the high financial standards we require of clients. As of March 31, 2022, two clients accounted for 11.2% and 16.1% of total accounts receivable.
Interest Rate Risk
As of March 31, 2022, we had cash of $20.9 million deposited in non-interest bearing accounts at a major bank with limited to no interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage interest rate risk exposure.
The current administrator of LIBOR will cease to publish the overnight and 1, 3, 6 and 12 months USD LIBOR settings immediately following the LIBOR publication on June 30, 2023 and has ceased to publish all other LIBOR settings, including the 1 week and 2 months USD LIBOR settings, since December 31, 2021. The discontinuation, reform, or replacement of LIBOR may result in fluctuating interest rates, or higher interest rates, which could have a material adverse effect on our interest expense.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.
Based on the evaluation of our disclosure controls and procedures as of March 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of the material weaknesses in our internal control over financial reporting described below, our disclosure controls and procedures were not effective as of March 31, 2022.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
42

Previously Disclosed Material Weaknesses
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. As previously disclosed in our Form 10-K for the year ended December 31, 2021, we identified the following material weaknesses in our internal control over financial reporting:
We did not design and maintain an effective control environment commensurate with the financial reporting requirements of an SEC registrant. Additionally, we did not design control activities to adequately address identified risks or operate at a sufficient level of precision that would identify material misstatements to our financial statements and did not design and maintain formal documentation of accounting policies and procedures nor did we maintain sufficient evidence to support the operation of key control procedures. Specifically, we did not design and maintain controls to ensure (i) the appropriate segregation of duties within our financial reporting function, including the preparation and review of journal entries and (ii) account reconciliations and balance sheet and income statement fluctuation analyses were reviewed at the appropriate level of precision.
We also did not design and maintain effective controls over IT general controls for information systems that are relevant to the preparation of our financial statements. Specifically, we did not design and maintain: (i) program change management controls to ensure that information technology program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately; and (ii) user access controls to ensure appropriate segregation of duties and that adequately restrict user and privilege access to financial applications, programs, and data to appropriate Company personnel.
These IT deficiencies did not result in a material misstatement to the financial statements, however, the deficiencies, when aggregated, could impact maintaining effective segregation of duties, as well as the effectiveness of IT-dependent controls (such as automated controls that address the risk of material misstatement to one or more assertions, along with the IT controls and underlying data that support the effectiveness of system-generated data and reports) that could result in misstatements potentially impacting all financial statement accounts and disclosures that would not be prevented or detected on a timely basis. Accordingly, management has determined these deficiencies in the aggregate constitute material weaknesses.
These material weaknesses resulted in adjustments in our 2019 and 2020 financial statements primarily related to revenues recognized from contracts with customers that were recognized in the improper periods, the accrual of certain compensation related costs, and the misstatement of income tax benefit related to the treatment of certain deferred tax positions. The material weaknesses described above could result in misstatements of our account balances or disclosures that would result in a material misstatement of our annual or interim financial statements that would not be prevented or detected on a timely basis.
Remediation Efforts to Address Material Weaknesses
With the oversight of the Audit Committee of our Board of Directors, we have designed and are implementing a remediation plan to remediate the material weaknesses described above. Accordingly, our remediation activities include the following measures:
We implemented in the first quarter of 2022 a new Enterprise Resource Planning (“ERP”) system, Workday, to replace legacy and decentralized financial reporting systems. We have also standardized our account reconciliation and analysis process and will leverage our ERP implementation to centralize our controls over journal entries. In addition, we are in the process of refining appropriate segregation of duties and system access within our ERP and other relevant supporting systems.
We have formalized several of our financial reporting policies and procedures and will continue to reflect evolution of business and the impact of the new ERP.
Provide ongoing training for individuals involved with internal control over financial reporting.
We continue to monitor the effectiveness of our remediation efforts and will refine our remediation plan as appropriate. In addition, we report the progress and status of the above remediation efforts to the Audit Committee on a periodic basis. While we believe these efforts will improve our internal control over financial reporting and address the underlying causes of the material weaknesses, such material weaknesses will not be remediated until our remediation plan has been fully implemented, and we have concluded that our controls are operating effectively for a sufficient period of time.
43

Changes in Internal Control Over Financial Reporting
Other than the updates noted above under Remediation Efforts to Address Material Weaknesses, there were no changes to our internal control over financial reporting during the quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
44

PART II-OTHER INFORMATION
Item 1. Legal Proceedings
From time to time we are a party to various legal proceedings incidental to the conduct of our business. The results of legal proceedings are inherently unpredictable and uncertain. We are not presently party to any legal proceedings that we believe would have a material adverse effect on our business, prospects, financial condition, liquidity, results of operation, cash flows or capital levels. We periodically reexamine our estimates of probable liabilities and any associated expenses and receivables and make appropriate adjustments to such estimates based on experience and developments in litigation. As a result, the current estimates of the potential impact on our business, prospects, financial condition, liquidity, results of operation, cash flows or capital levels for the proceedings and claims described in the notes to our condensed consolidated financial statements could change in the future.
Regardless of the outcome, legal proceedings have the potential to have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Item 1A. Risk Factors
There have been no material changes in our risk factors from those disclosed in Part I, Item 1A, Risk Factors, in our Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 23, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
None.
45

Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.
Exhibit
Number
Exhibit Description
Amendment No. 5 to First Lien Credit Agreement, dated as of February 1, 2022, by and among Convey Health Solutions, Inc., as borrower, Ares Capital Corporation, as administrative agent and collateral agent, and the term lenders party thereto (Incorporated by reference to Exhibit 10.1 of Form 8-K, filed by Convey Health Solutions Holdings, Inc. on February 1, 2022 (File No. 001-40506)).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101).
________________________
*    Filed herewith
**    Furnished herewith.

46

Signatures
Pursuant to the requirements of the Securities Act of 1934, as amended, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
Convey Health Solutions Holdings, Inc.
Date:May 10, 2022
By:
/s/ Stephen C. Farrell
Name: Stephen C. Farrell
Title:   Chief Executive Officer and Director
(Principal Executive Officer)
Convey Health Solutions Holdings, Inc.
Date:May 10, 2022
By:
/s/ Timothy Fairbanks
Name: Timothy Fairbanks
Title:   Chief Financial Officer & Executive Vice President
(Principal Financial Officer)

47
EX-31.1 2 q12022exhibit311.htm EX-31.1 Document

Exhibit 31.1

Certification of Principal Executive Officer Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Stephen C. Farrell, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Convey Health Solutions Holdings, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)[paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ STEPHEN C. FARRELL
Stephen C. Farrell
Chief Executive Officer
(Principal Executive Officer)
Date: May 10, 2022


EX-31.2 3 q12022exhibit312.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Timothy Fairbanks, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Convey Health Solutions Holdings, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)[paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ TIMOTHY FAIRBANKS
Timothy Fairbanks
Chief Financial Officer
(Principal Financial Officer)
Date: May 10, 2022



EX-32.1 4 q12022exhibit321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q (the “Form 10-Q”) of Convey Health Solutions Holdings, Inc. (the “Company”) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ STEPHEN C. FARRELL
Stephen C. Farrell
Chief Executive Officer
(Principal Executive Officer)
Date: May 10, 2022

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished in accordance with Securities and Exchange Commission Release No. 34-47551 and shall not be considered filed as part of the Form 10-Q.


EX-32.2 5 q12022exhibit322.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q (the “Form 10-Q”) of Convey Health Solutions Holdings, Inc. (the “Company”) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ TIMOTHY FAIRBANKS
Timothy Fairbanks
Chief Financial Officer
(Principal Financial Officer)
Date: May 10, 2022

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished in accordance with Securities and Exchange Commission Release No. 34-47551 and shall not be considered filed as part of the Form 10-Q.

EX-101.SCH 6 cnvy-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - BUSINESS AND BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earn-Out and Holdback Liabilities Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss (income) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2110103 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2114104 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - ACQUISITIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - ACQUISITIONS - Assets and Liabilities Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2418410 - Disclosure - ACQUISITIONS - Purchase Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2419411 - Disclosure - ACQUISITIONS - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2120105 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 2123106 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2427415 - Disclosure - PROPERTY AND EQUIPMENT - Assets Held Under Capital Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2128107 - Disclosure - INTANGIBLE ASSETS AND GOODWILL link:presentationLink link:calculationLink link:definitionLink 2329306 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables) link:presentationLink link:calculationLink link:definitionLink 2430416 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Goodwill Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2431417 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2432418 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Carrying Value of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2133108 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 2334307 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 2435419 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 2136109 - Disclosure - CREDIT FACILITY link:presentationLink link:calculationLink link:definitionLink 2337308 - Disclosure - CREDIT FACILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2438420 - Disclosure - CREDIT FACILITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - CREDIT FACILITY - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - CREDIT FACILITY - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2440422 - Disclosure - CREDIT FACILITY - Debt Maturities Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2141110 - Disclosure - SHAREHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 2442423 - Disclosure - SHAREHOLDERS’ EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 2143111 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2344309 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2445424 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2446425 - Disclosure - SHARE-BASED COMPENSATION - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2447426 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2448427 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2449428 - Disclosure - SHARE-BASED COMPENSATION - Long Term Incentive Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2150112 - Disclosure - EMPLOYEE SAVINGS PLAN link:presentationLink link:calculationLink link:definitionLink 2451429 - Disclosure - EMPLOYEE SAVINGS PLAN (Details) link:presentationLink link:calculationLink link:definitionLink 2152113 - Disclosure - TAXES link:presentationLink link:calculationLink link:definitionLink 2453430 - Disclosure - TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2154114 - Disclosure - TRANSACTION RELATED COSTS link:presentationLink link:calculationLink link:definitionLink 2355310 - Disclosure - TRANSACTION RELATED COSTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2456431 - Disclosure - TRANSACTION RELATED COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 2157115 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2458432 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2159116 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2460433 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2161117 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 2362311 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2463434 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2464435 - Disclosure - SEGMENT INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 2165118 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2366312 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2467436 - Disclosure - LEASES - Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2468437 - Disclosure - LEASES - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2468437 - Disclosure - LEASES - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2469438 - Disclosure - LEASES - Lease Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2470439 - Disclosure - LEASES - Additional Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cnvy-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 cnvy-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 cnvy-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Dividends [Axis] Dividends [Axis] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Net Income (Loss) Per Common Share Earnings Per Share, Policy [Policy Text Block] TRANSACTION RELATED COSTS Acquisition Related and Deferred Offering Costs [Text Block] Acquisition Related and Deferred Offering Costs Exercised (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Leasehold improvements Leasehold Improvements [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income (loss) Net loss Net Income (Loss) Attributable to Parent Number of long term incentive awards Number Of Long Term Incentive Awards Number Of Long Term Incentive Awards Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Preferred stock shares outstanding Preferred Stock, Shares Outstanding Income Statement Location [Axis] Income Statement Location [Axis] Mergers and acquisitions related costs Business Combination, Acquisition Related Costs Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Sales and use tax Excise and Sales Taxes Sales and use tax Sales and Excise Tax Payable, Current Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Operating leases Operating Lease, Weighted Average Remaining Lease Term Other assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Segments [Axis] Segments [Axis] Retirement Benefits [Abstract] Net (decrease) increase in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Adjustments to reconcile to U.S. GAAP net income (loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract] Entity File Number Entity File Number 2024 Long-Term Debt, Maturity, Year Two Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Weighted Average Remaining Lease Term (in years): Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Change in fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Measurement period adjustments Goodwill, Purchase Accounting Adjustments 2020 Incremental Term Loan 2020 Incremental Term Loan [Member] 2020 Incremental Term Loan (Gain) loss from disposal of assets Gain (Loss) on Disposition of Assets 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Schedule of Finance Leased Assets Schedule of Finance Leased Assets [Table Text Block] Schedule of Finance Leased Assets Incentive bonus Accrued Bonuses, Current Deferred taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of intangible assets Amortization of Intangible Assets Total fair value of intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Variable lease costs Variable Lease, Cost Operating leases Operating Lease, Weighted Average Discount Rate, Percent Antidilutive securities excluded from computation of earnings per share, amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Contract with customer, liability, revenue recognized Contract with Customer, Liability, Revenue Recognized Sale of Stock [Axis] Sale of Stock [Axis] Liability Class [Axis] Liability Class [Axis] Dividends payable, current Dividends Payable, Current Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Amount Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Amount Operating lease liabilities, net of current portion Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liability, Non-Current Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liability, Non-Current Business Combination and Asset Acquisition [Abstract] Stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Business Acquisition [Axis] Business Acquisition [Axis] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Office and computer equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Award Type [Domain] Award Type [Domain] Software Services Technology Service [Member] Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Related Party Transactions [Abstract] Subsegments [Axis] Subsegments [Axis] Weighted Average Remaining Contractual Life (Years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] 2025 Long-Term Debt, Maturity, Year Three Acquisition bonus expense Business Combination, Acquisition Related Costs, Bonus Expense Business Combination, Acquisition Related Costs, Bonus Expense Vested or expect to vest at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period INTANGIBLE ASSETS AND GOODWILL Goodwill and Intangible Assets Disclosure [Text Block] Concentration risk, percentage Concentration Risk, Percentage Preferred stock, $0.01 par value; 25,000,000 shares authorized and no shares issued or outstanding as of March 31, 2022 and no shares authorized, issued or outstanding as of December 31, 2021 Preferred Stock, Value, Issued Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period Trade names Trade Names [Member] Accumulated Deficit Retained Earnings [Member] IPO IPO [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Non-current liabilities Liabilities, Noncurrent [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Long-term debt, weighted average interest rate, over time Long-term Debt, Weighted Average Interest Rate, over Time Related Party [Axis] Related Party [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Purchase agreement, revenue threshold Purchase Agreement, Revenue Threshold Purchase Agreement, Revenue Threshold Secured Debt Secured Debt [Member] Accounts receivable Increase (Decrease) in Accounts Receivable Capitalized software and property and equipment, net included in accounts payable Capital Expenditures Incurred but Not yet Paid Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Nonvoting Common Stock Nonvoting Common Stock [Member] Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Non-cash investing and financial activities: Other Noncash Investing and Financing Items [Abstract] Installment period Share-based Compensation Arrangement by Share-based Payment Award, Installment Period Share-based Compensation Arrangement by Share-based Payment Award, Installment Period Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Award vesting rights, percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Payment on finance leases Financing cash flows from finance leases (principal payments) Finance Lease, Principal Payments EIR Partners Monthly Consulting Agreement EIR Partners Monthly Consulting Agreement [Member] EIR Partners Monthly Consulting Agreement Net income (loss) per common share - basic (in usd per share) Earnings Per Share, Basic PREPAID EXPENSES AND OTHER CURRENT ASSETS Other Assets Disclosure [Text Block] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Operating lease right-of-use-assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Right-Of-Use Asset Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Right-Of-Use Asset REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue from Contract with Customer [Text Block] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Voting Common Stock Voting Common Stock [Member] Voting Common Stock 2023 Long-Term Debt, Maturity, Year One Unamortized debt issuance expense Unamortized Debt Issuance Expense Contingent Consideration Commitments and Contingencies, Policy [Policy Text Block] Net identifiable assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Defined contribution plan, cost Defined Contribution Plan, Cost Consulting Services Consulting [Member] Consulting Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Loss on contract termination Gain (Loss) on Contract Termination Related party transaction, renewal term Related Party Transaction, Renewal Term Related Party Transaction, Renewal Term Office and computer equipment Machinery and Equipment [Member] Operating cash flows from operating leases Operating Lease, Payments Fair value of contingent consideration in connection with the HealthSmart acquisition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Payments Total consideration Business Combination, Consideration Transferred Provision for bad debt Accounts Receivable, Credit Loss Expense (Reversal) Long-term debt, gross Term loans, net of deferred financing costs Long-term Debt, Gross Goodwill [Roll Forward] Goodwill [Roll Forward] Total lease liabilities Lease Liability Lease Liability Plan Name [Axis] Plan Name [Axis] Finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Term loans, net of deferred financing costs Long-term Debt Debt Instrument Redemption [Table] Debt Instrument Redemption [Table] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Impairment Goodwill, Impairment Loss Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Income Tax Disclosure [Abstract] Data Analytics Data Analytics [Member] Data Analytics Software Capitalized software development costs Software Development [Member] Entity Small Business Entity Small Business Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Acquisition Related and Deferred Offering Costs [Abstract] Acquisition Related and Deferred Offering Costs Long-term debt, irrevocable letter of credit threshold Long-term Debt, Irrevocable Letter Of Credit Threshold Long-term Debt, Irrevocable Letter Of Credit Threshold Software licenses Software Licenses, Current Software Licenses, Current Base Rate Base Rate [Member] 2022 Incremental Term Loans 2022 Incremental Term Loans [Member] 2022 Incremental Term Loans Public company readiness costs Public Company Readiness Costs Public Company Readiness Costs Supplemental Benefits Administration Supplemental Benefits Administration [Member] Supplemental Benefits Administration Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and shareholders’ equity Liabilities and Equity Other Other Accrued Liabilities, Current Other income (expense): Other Income and Expenses [Abstract] Deferred revenue, current portion Contract with Customer, Liability, Current Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Services Service [Member] Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Long-term debt, irrevocable letter of credit, extension period Long-term Debt, Irrevocable Letter Of Credit, Extension Period Long-term Debt, Irrevocable Letter Of Credit, Extension Period Cash and cash equivalents Cash Equivalents, at Carrying Value Concentration Risk [Line Items] Concentration Risk [Line Items] LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] D-M-S Holdings, Inc. D-M-S Holdings, Inc. [Member] D-M-S Holdings, Inc. Cash paid for amounts related to lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Entity Interactive Data Current Entity Interactive Data Current Term Loans Term Loans [Member] Term Loans Minimum Minimum [Member] BUSINESS AND BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Affiliated Entity Affiliated Entity [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Customer B Customer B [Member] Customer B Selling, general and administrative Selling, General and Administrative Expense Preferred stock shares authorized Preferred Stock, Shares Authorized Thereafter Finance Lease, Liability, to be Paid, after Year Four Finance Lease, Liability, to be Paid, after Year Four Amortization expense Amortization of Other Deferred Charges Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province LEASES Lessee, Finance Leases [Text Block] Current liabilities Liabilities, Current [Abstract] Capitalized software development costs Payments to Develop Software 2026 Long-Term Debt, Maturity, Year Four Operating lease liabilities Increase (Decrease) in Operating Lease Liability Tradenames, Customer Relationships and Technology Tradenames, Customer Relationships and Technology [Member] Tradenames, Customer Relationships and Technology Acquisition, net of cash received Payments to Acquire Businesses, Net of Cash Acquired CREDIT FACILITY Debt Disclosure [Text Block] Beginning Balance (in shares) Ending Balance (in shares) Shares, Outstanding Vested or expect to vest at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Line of Credit Line of Credit [Member] SHARE-BASED COMPENSATION Share-based Payment Arrangement [Text Block] 2021 Incremental Term Loan 2021 Incremental Term Loan [Member] 2021 Incremental Term Loan Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Less: accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Accounting Policies [Abstract] Consolidated EBITDA, percentage Consolidated EBITDA, Threshold Percentage Consolidated EBITDA, Threshold Percentage Technology Enabled Solutions Technology Enabled Solutions [Member] Technology Enabled Solutions Contractual obligation Contractual Obligation Weighted Average Remaining Contractual Life (Years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Number of reportable segments Number of Reportable Segments Accrued professional fees Accrued Professional Fees, Current Net present value of lease obligations Operating Lease, Liability Document Transition Report Document Transition Report IPO - Shares From Existing Shareholders IPO - Shares From Existing Shareholders [Member] IPO - Shares From Existing Shareholders Net income (loss) Net income (loss) Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent #REF! Common Stock, Value, Issued Finance leases Finance Lease, Weighted Average Discount Rate, Percent Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total other expense, net Nonoperating Income (Expense) Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Acquisitions Goodwill, Acquired During Period Basis of Presentation and Consolidation Basis of Accounting, Policy [Policy Text Block] Performance Shares Performance Shares [Member] Commitments and contingencies (Note 15) Commitments and Contingencies Weighted Average Discount Rate: Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate LEASES Lessee, Operating Leases [Text Block] Advisory Services Advisory Services [Member] Advisory Services Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Dividends payable, amount per share (in usd per share) Dividends Payable, Amount Per Share Entity Emerging Growth Company Entity Emerging Growth Company Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Assets And Liabilities, Lessee Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Provision for inventory reserve Inventory Write-down For the nine months ending December 31, 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year ACQUISITIONS Business Combination Disclosure [Text Block] Payment of debt issuance cost Payment of debt issuance cost Payments of Debt Issuance Costs Total lease expense Finance Lease Cost Finance Lease Cost Cover [Abstract] Due from related parties, current Due from Related Parties, Current Class of Stock [Axis] Class of Stock [Axis] Net loss Net income (loss) Business Acquisition, Pro Forma Net Income (Loss) Interest expense Interest Income (Expense), Net Less: amounts representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Dividends [Domain] Dividends [Domain] Unallocated Segment Adjusted Earnings Before Interest, Unallocated Segment Adjusted Earnings Before Interest, Unallocated Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Unbilled receivables, current Unbilled Receivables, Current Cloud computing subscription & implementation costs Cloud Computing Subscription And Implementation Costs Cloud Computing Subscription And Implementation Costs Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Selling, general and administrative Selling, General and Administrative Expenses [Member] Accrued expenses Total accrued expenses Accrued Liabilities, Current Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Less: amounts representing interest Finance Lease, Liability, Undiscounted Excess Amount ASSETS ACQUIRED Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Dividend Payments of dividends Payments of Dividends Net income (loss) attributable to common shareholders Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Purchase Agreement Purchase Agreement [Member] Purchase Agreement Transaction related costs Total Transaction related costs Business Combination, Acquisition Related and Deferred Offering Costs Business Combination, Acquisition Related and Deferred Offering Costs Share-based Payment Arrangement, Option Share-based Payment Arrangement, Option [Member] 2019 Equity Plan 2019 Equity Plan [Member] 2019 Equity Plan Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Common stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Finance leases Finance Lease, Weighted Average Remaining Lease Term SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Operating income (loss) Operating Income (Loss) 2021 Omnibus Incentive Compensation Plan 2021 Omnibus Incentive Compensation Plan [Member] 2021 Omnibus Incentive Compensation Plan Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Segment Adjusted EBITDA Segment Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization Segment Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization Operating lease liabilities, current portion Operating Lease, Liability, Current Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Share-based compensation Non-cash stock compensation expense Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Additional Paid-in Capital Additional Paid-in Capital [Member] Depreciation expense Depreciation Technology Technology-Based Intangible Assets [Member] Annual retainer fee Related Party Transaction, Annual Retainer Fee Related Party Transaction, Annual Retainer Fee Related party transaction, amounts of transaction Related Party Transaction, Amounts of Transaction Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Share-based Payment Arrangement, Restricted Stock Unit, Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Cash paid for taxes Income Taxes Paid Insurance Prepaid Insurance Purchases of property and equipment, net Payments to Acquire Property, Plant, and Equipment EIR Partners Consulting Agreement EIR Partners Consulting Agreement [Member] EIR Partners Consulting Agreement Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Prepayment premium on early repayment of term loan Payment for Debt Extinguishment or Debt Prepayment Cost Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Options, outstanding, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total shareholders’ equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent Non-cash lease expense Non-Cash Lease Expense Non-Cash Lease Expense Common stock shares issued Common Stock, Shares, Issued Preferred stock shares issued Preferred Stock, Shares Issued City Area Code City Area Code Accounts payable and other accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Options, exercisable, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Dividends Paid, Outstanding and Vested Option Holders Dividends Paid, Outstanding and Vested Option Holders [Member] Dividends Paid, Outstanding and Vested Option Holders Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Dividends Paid, Existing Shareholders Dividends Paid, Existing Shareholders [Member] Dividends Paid, Existing Shareholders Debt Instrument, Redemption [Line Items] Debt Instrument, Redemption [Line Items] Estimated Life (in years) Property, Plant and Equipment, Useful Life Eurodollar Eurodollar [Member] Earn-Out Liabilities Earn-Out Liabilities [Member] Earn-Out Liabilities Shareholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Debt instrument, repurchase amount Debt Instrument, Repurchase Amount Customer Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Total Finance Lease, Liability, Payment, Due Total lease assets Lease, Right-of-Use Asset Lease, Right-of-Use Asset Debt instrument, face amount Debt Instrument, Face Amount Interest expense Interest Expense 2023 Finance Lease, Liability, to be Paid, Year One Accumulated deficit Retained Earnings (Accumulated Deficit) Share-based payment award expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Value Based Analytics Value Based Analytics [Member] Value Based Analytics Restricted Stock Units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Entity Filer Category Entity Filer Category Net present value of lease obligations Finance Lease, Liability Employee related Other Employee-related Liabilities, Current Business Acquisition [Line Items] Business Acquisition [Line Items] Cash, cash equivalents and restricted cash as of the end of the period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Income Statement [Abstract] Credit Agreement Credit Agreement [Member] Credit Agreement Concentration Risk [Table] Concentration Risk [Table] Entity Registrant Name Entity Registrant Name Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables 2025 Finance Lease, Liability, to be Paid, Year Three Debt instrument, leverage ratio Debt Instrument, Leverage Ratio Debt Instrument, Leverage Ratio 2026 Finance Lease, Liability, to be Paid, Year Four 2024 Finance Lease, Liability, to be Paid, Year Two Related Party Transaction [Axis] Related Party Transaction [Axis] Forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax (expense) benefit Income tax provision Income Tax Expense (Benefit) IPO - Company Shares IPO - Company Shares [Member] IPO - Company Shares Accounts receivable, net of allowance for doubtful accounts of $69 as of March 31, 2022, and December 31, 2021 Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] Options nonvested, number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Dividends Payable [Table] Dividends Payable [Table] Entity Tax Identification Number Entity Tax Identification Number Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Total Lessee, Operating Lease, Liability, to be Paid Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Accounts Receivable Accounts Receivable [Member] Sale of Stock [Domain] Sale of Stock [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Inventories, net Inventory, Net Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Sale of stock, net proceeds Sale Of Stock, Net Proceeds Sale Of Stock, Net Proceeds Net cash proceeds of certain asset sales or casualty events, percentage Net Cash Proceeds Of Certain Asset Sales Or Casualty Events, Percentage Net Cash Proceeds Of Certain Asset Sales Or Casualty Events, Percentage Statement of Financial Position [Abstract] Equity instruments other than options, aggregate intrinsic value, nonvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Term loans, current portion Term loans, current portion Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Preferred stock par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Revenue Benchmark Revenue Benchmark [Member] Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Short-term lease costs Short-term Lease, Cost Option, nonvested, weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Share-based payment award, shares issued in period Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Debt issuance costs, gross Debt Issuance Costs, Gross Statement [Line Items] Statement [Line Items] Options, nonvested, weighted average grant date fair value, reduction (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value, Reduction Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value, Reduction Number of installments Share-Based Payment Arrangement, Number Of Installments Share-Based Payment Arrangement, Number Of Installments Total financing leases included in property and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restricted cash, non-current Restricted Cash, Noncurrent Dividends Payable [Line Items] Dividends Payable [Line Items] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Liabilities Liabilities [Abstract] Percentage of fair value in excess of carrying amount Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Cost of COVID-19 Other Expenses, CARES Act Other Expenses, CARES Act 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Disclosure of Share-based Compensation Arrangements by Share-based Payment Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Finance lease liabilities Finance Lease, Liability, Current Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Segment Reporting [Abstract] Number of awards Number Of Awards Number Of Awards Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Customer [Axis] Customer [Axis] Interest on lease liabilities Finance Lease, Interest Expense EMPLOYEE SAVINGS PLAN Retirement Benefits [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value, Amount Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value, Amount Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of Earnings per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Finance Leases Finance Lease, Liability, Payment, Due [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Entity Ex Transition Period Entity Ex Transition Period Title of 12(b) Security Title of 12(b) Security Inventory purchase advances Advances on Inventory Purchases Total assets Assets Deferred income taxes Deferred Income Taxes and Tax Credits Plan Name [Domain] Plan Name [Domain] Common stock shares authorized Common Stock, Shares Authorized Weighted average remaining contractual life vested or expect to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Consolidated EBITDA, maximum amount Consolidated EBITDA, Threshold Maximum Amount Consolidated EBITDA, Threshold Maximum Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Health Plan Management Health Care [Member] Document Type Document Type Product and Service [Domain] Product and Service [Domain] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction HealthSmart HealthSmart [Member] HealthSmart Earn-out (contingent consideration) Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Line of Credit Facilities Schedule of Line of Credit Facilities [Table Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Refundable deposits Contract with Customer, Refund Liability, Current SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Furniture and fixtures Furniture and Fixtures [Member] Customer A Customer A [Member] Customer A Lease, Cost Lease, Cost [Table Text Block] Inventory step-up Inventory step-up Inventory Step-Up Inventory Step-Up Weighted-average common shares outstanding: basic Weighted Average Number of Shares Outstanding, Basic Net income (loss) per common share - diluted (in usd per share) Earnings Per Share, Diluted Segments [Domain] Segments [Domain] Sale of stock, price per share (in usd per share) Sale of Stock, Price Per Share Products Supplemental Benefit Services Product [Member] Contractual Obligation, Fiscal Year Maturity Contractual Obligation, Fiscal Year Maturity [Table Text Block] Total identifiable assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Finance lease cost Lease, Cost [Abstract] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Deferred taxes, net Deferred Income Tax Liabilities, Net Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Other Other Cost and Expense, Operating Finance Lease, Liability, Fiscal Year Maturity Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Subsegments [Domain] Subsegments [Domain] Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] Depreciation and amortization Depreciation, Depletion and Amortization Capital lease, depreciation expense Capital Lease, Income Statement, Depreciation Expense Capital Lease, Income Statement, Depreciation Expense Accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities Debt instrument, aggregate principal amount, payment, percentage Debt Instrument, Aggregate Principal Amount, Payment, Percentage Debt Instrument, Aggregate Principal Amount, Payment, Percentage Acquisitions Business Combinations Policy [Policy Text Block] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Inventory Increase (Decrease) in Inventories Common stock shares outstanding Common Stock, Shares, Outstanding Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Net revenues: Revenues [Abstract] Operating lease liabilities, current portion Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liability, Current Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liability, Current Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Stock Option Awards Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Debt instrument, term Debt Instrument, Term Bridge Loan Bridge Loan [Member] Customer relationships Customer Relationships [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Prepaid expenses and other advances Other Prepaid Expense, Current Total operating expenses Operating Expenses Other long-term liabilities Other Liabilities, Noncurrent Principal payment on term loan Repayments of Long-term Debt Trading Symbol Trading Symbol Net revenue Business Acquisition, Pro Forma Revenue Property, plant and equipment, gross Property, Plant and Equipment, Gross ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Related Party Transaction [Domain] Related Party Transaction [Domain] Vested or expect to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Line of Credit Facility [Table] Line of Credit Facility [Table] Loss contingency accrual Loss Contingency Accrual Undrawn Letter Of Credit Undrawn Letter Of Credit [Member] Undrawn Letter Of Credit Options outstanding, weighted average exercise price (in usd per share) Beginning balance (in usd per share) Ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Debt issuance costs, amortization period Debt Issuance Costs, Amortization Period Debt Issuance Costs, Amortization Period Operating expenses: Costs and Expenses [Abstract] Term loans, net of current portion Long-term Debt, Excluding Current Maturities Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Total stock-based compensation expense Share-based Payment Arrangement, Expense Entity Current Reporting Status Entity Current Reporting Status Holdback Liabilities Holdback Liabilities [Member] Holdback Liabilities Income (loss) per common share – Basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent Exercised (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value, Amount Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value, Amount Restricted cash Restricted Cash, Current Amortization of debt issuance costs Amortization of Debt Issuance Costs Payables and Accruals [Abstract] Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Dividend Dividends TPG Management Service Agreement TPG Term Loan Fees [Member] TPG Term Loan Fees Sale of stock, number of shares issued in transaction Sale of Stock, Number of Shares Issued in Transaction Common stock par value (in usd per share) Common Stock, Par or Stated Value Per Share Schedules of Concentration of Risk, by Risk Factor Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Current assets Assets, Current [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Advanced Plan Administration Advanced Plan Administration [Member] Advanced Plan Administration Leases [Abstract] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Annual excess cash flow, percentage Annual Excess Cash Flow, Percentage Annual Excess Cash Flow, Percentage Entity Address, Postal Zip Code Entity Address, Postal Zip Code Rebates Customer Refund Liability, Current Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Weighted-average common shares outstanding: diluted Weighted Average Number of Shares Outstanding, Diluted Related party, equity held, percent Related Party Transaction, Equity Held, Percent Related Party Transaction, Equity Held, Percent LIABILITIES ASSUMED Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] TAXES Income Tax Disclosure [Text Block] Accrued interest Interest Payable, Current Related Party [Domain] Related Party [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Share-based Payment Arrangement, Option, Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Finance lease, right-of-use asset, statement of financial position Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Transferred at Point in Time Transferred at Point in Time [Member] SHAREHOLDERS’ EQUITY Stockholders' Equity Note Disclosure [Text Block] Statement of Cash Flows [Abstract] Vested or expect to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Class of Stock [Line Items] Class of Stock [Line Items] Net cash proceeds of debt, percentage Net Cash Proceeds Of Debt, Percentage Net Cash Proceeds Of Debt, Percentage Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Write off capitalized software costs Capitalized Computer Software, Impairments Less: deferred financing costs Debt Issuance Costs, Line of Credit Arrangements, Net Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company LTI Awards Long Term Incentive Awards [Member] Long Term Incentive Awards Total current liabilities Liabilities, Current Class of Stock [Domain] Class of Stock [Domain] Initial purchase price Payments to Acquire Businesses, Gross Operating cash flows from finance leases (interest) Finance Lease, Interest Payment on Liability Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] 2021 Equity Plan 2021 Equity Plan [Member] 2021 Equity Plan Current Fiscal Year End Date Current Fiscal Year End Date Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] For the nine months ending December 31, 2022 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Outstanding at beginning of period (in usd per share) Outstanding at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Amount Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Amount Other current assets Other Assets, Current Statement [Table] Statement [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cost of services and products, excluding depreciation, depletion, and amortization Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Statistical Measurement [Axis] Statistical Measurement [Axis] Finance leases obligations, net of current portion Finance Lease, Liability, Noncurrent Net Carrying Amount Finite-Lived Intangible Assets, Net Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Related party, payment, term Related Party Transaction, Payment, Term Related Party Transaction, Payment, Term Schedule of Goodwill Schedule of Goodwill [Table Text Block] Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Operating lease costs Operating Lease, Cost Schedule of Acquisition Related and Deferred Offering Costs Schedule Of Acquisition Related and Deferred Offering Costs [Table Text Block] Schedule Of Acquisition Related and Deferred Offering Costs TPG Management and Consulting Fees TPG Management and Consulting Fees [Member] TPG Management and Consulting Fees RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Weighted average remaining contractual life vested or expect to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term EX-101.PRE 10 cnvy-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
3 Months Ended
Mar. 31, 2022
Apr. 29, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-40506  
Entity Registrant Name Convey Health Solutions Holdings, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 84-2099378  
Entity Address, Address Line One 100 SE 3rd Avenue, 26th Floor  
Entity Address, City or Town Fort Lauderdale  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33394  
City Area Code 800  
Local Phone Number 559-9358  
Title of 12(b) Security Common Stock, $0.01 par value per share  
Trading Symbol CNVY  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   73,194,171
Entity Central Index Key 0001787640  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 20,866 $ 38,811
Accounts receivable, net of allowance for doubtful accounts of $69 as of March 31, 2022, and December 31, 2021 72,707 62,813
Inventories, net 36,408 14,060
Prepaid expenses and other current assets 10,809 16,569
Total current assets 140,790 132,253
Property and equipment, net 20,952 20,400
Intangible assets, net 247,993 220,014
Goodwill 482,558 455,206
Operating lease right-of-use assets 18,574 0
Other assets 5,667 2,030
Total assets 916,534 829,903
Current liabilities    
Accounts payable 11,156 13,868
Accrued expenses 30,038 48,558
Operating lease liabilities, current portion 5,605 0
Finance lease liabilities 501 498
Deferred revenue, current portion 9,494 7,472
Term loans, current portion 780 0
Total current liabilities 57,574 70,396
Operating lease liabilities, net of current portion 18,623 0
Finance leases obligations, net of current portion 440 528
Deferred taxes, net 35,094 25,992
Term loans, net of current portion 264,483 189,643
Other long-term liabilities 2,475 5,595
Total liabilities 378,689 292,154
Commitments and contingencies (Note 15)
Shareholders’ equity    
Preferred stock, $0.01 par value; 25,000,000 shares authorized and no shares issued or outstanding as of March 31, 2022 and no shares authorized, issued or outstanding as of December 31, 2021 0 0
#REF! 732 732
Additional paid-in capital 571,516 570,252
Accumulated other comprehensive income 17 31
Accumulated deficit (34,420) (33,266)
Total shareholders’ equity 537,845 537,749
Total liabilities and shareholders’ equity $ 916,534 $ 829,903
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 69 $ 69
Preferred stock par value (in usd per share) $ 0.01 $ 0.01
Preferred stock shares authorized 25,000,000 0
Preferred stock shares issued 0 0
Preferred stock shares outstanding 0 0
Common stock par value (in usd per share) $ 0.01 $ 0.01
Common stock shares authorized 500,000,000 500,000,000
Common stock shares issued 73,194,171 73,194,171
Common stock shares outstanding 73,194,171 73,194,171
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Net revenues:    
Net revenues $ 96,708 $ 82,631
Operating expenses:    
Selling, general and administrative 23,214 20,099
Depreciation and amortization 8,252 7,372
Transaction related costs 640 1,086
Total operating expenses 94,819 79,105
Operating income (loss) 1,889 3,526
Other income (expense):    
Interest expense (3,719) (5,467)
Total other expense, net (3,719) (5,467)
Income (loss) before income taxes (1,830) (1,941)
Income tax (expense) benefit 676 1,007
Net income (loss) $ (1,154) $ (934)
Income (loss) per common share – Basic and diluted    
Net income (loss) per common share - diluted (in usd per share) $ (0.02) $ (0.02)
Net income (loss) per common share - basic (in usd per share) $ (0.02) $ (0.02)
Foreign currency translation adjustments $ (14) $ (7)
Comprehensive income (loss) (1,168) (941)
Services    
Net revenues:    
Net revenues 46,480 43,527
Operating expenses:    
Cost of services and products, excluding depreciation, depletion, and amortization [1] 25,477 24,021
Products    
Net revenues:    
Net revenues 50,228 39,104
Operating expenses:    
Cost of services and products, excluding depreciation, depletion, and amortization [1] $ 37,236 $ 26,527
[1] Excludes amortization of intangible assets and depreciation, which are separately stated below.
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2020   61,321,424      
Beginning Balance at Dec. 31, 2020 $ 470,150 $ 613 $ 492,747 $ 78 $ (23,288)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation 990   990    
Foreign currency translation adjustments (7)     (7)  
Dividend (74,500)   (74,500)    
Net loss (934)       (934)
Ending Balance (in shares) at Mar. 31, 2021   61,321,424,000      
Ending Balance at Mar. 31, 2021 395,699 $ 613 419,237 71 24,222
Beginning Balance (in shares) at Dec. 31, 2021   73,194,171      
Beginning Balance at Dec. 31, 2021 537,749 $ 732 570,252 31 (33,266)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation 1,264   1,264    
Foreign currency translation adjustments (14)     (14)  
Net loss (1,154)       (1,154)
Ending Balance (in shares) at Mar. 31, 2022   73,194,171      
Ending Balance at Mar. 31, 2022 $ 537,845 $ 732 $ 571,516 $ 17 $ (34,420)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Cash Flows [Abstract]    
Net loss $ (1,154) $ (934)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation expense 1,550 1,386
Amortization expense 6,702 5,986
Write off capitalized software costs 253 0
Provision for bad debt 0 342
Provision for inventory reserve 90 399
(Gain) loss from disposal of assets 10 0
Deferred income taxes (1,120) (963)
Amortization of debt issuance costs 309 328
Share-based compensation 1,264 990
Non-cash lease expense 1,246 0
Inventory step-up 1,892 0
Changes in operating assets and liabilities:    
Accounts receivable (3,414) 4,662
Inventory (1,450) (3,207)
Prepaid expenses and other assets 3,903 843
Accounts payable and other accrued liabilities (26,222) (22,100)
Deferred revenue 2,022 (358)
Operating lease liabilities (1,541) 0
Net cash (used in) provided by operating activities (15,660) (12,626)
Cash flows from investing activities    
Acquisition, net of cash received (74,613) 0
Purchases of property and equipment, net (1,836) (3,063)
Capitalized software development costs (1,105) (1,287)
Net cash used in investing activities (77,554) (4,350)
Cash flows from financing activities    
Proceeds from issuance of debt 78,000 78,000
Payment of debt issuance cost (2,631) (2,133)
Principal payment on term loan 0 (821)
Payment on finance leases (86) (31)
Dividend 0 (74,500)
Net cash provided by financing activities 75,283 515
Effect of exchange rate changes on cash (14) (7)
Net (decrease) increase in cash and cash equivalents and restricted cash (17,945) (16,468)
Cash, cash equivalents and restricted cash at beginning of period 38,811 49,086
Cash, cash equivalents and restricted cash at end of period 20,866 32,618
Cash, cash equivalents and restricted cash as of the end of the period    
Cash and cash equivalents 20,866 28,938
Restricted cash 0 3,560
Restricted cash, non-current 0 120
Cash, cash equivalents and restricted cash 20,866 32,618
Supplemental disclosures of cash flow information:    
Cash paid for taxes 250 216
Cash paid for interest 3,986 4,961
Non-cash investing and financial activities:    
Capitalized software and property and equipment, net included in accounts payable $ 672 $ 471
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS AND BASIS OF PRESENTATION
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS AND BASIS OF PRESENTATION BUSINESS AND BASIS OF PRESENTATION
Business
Convey Health Solutions Holdings, Inc. (collectively with its subsidiaries, which includes our main operating subsidiary, Convey Health Solutions, Inc., “we”, “us”, “our”, “Convey” or the “Company”) provides technology enabled solutions to payors within the large and growing government sponsored health plan market. Our platform combines proprietary modular technology and end-to-end solutions to serve as an extension of our clients’ operations and core systems. Our clients are primarily Medicare Advantage, Medicare Part D and Employer Group Waiver Plans, as well as Pharmacy Benefit Managers. Convey is a United States (“U.S.”) based holding company incorporated in Delaware. Our principal executive offices are located in Fort Lauderdale, Florida.
Acquisition
On February 1, 2022, Convey’s indirect wholly-owned subsidiary, D-M-S Holdings Parent, LLC (f/k/a Dragon Holdings Parent, LLC), a Delaware limited liability company, acquired all of the issued and outstanding capital stock of D-M-S Holdings, Inc. d/b/a HealthSmart International, a Delaware corporation (“HealthSmart”). HealthSmart provides a diverse portfolio of health, wellness and diagnostic products centered on home based care outcomes. See Note 4. Acquisitions for additional information.
Stock Split
Prior to the IPO (as defined below), in June 2021, Convey’s Board of Directors (the “Board”) and stockholders approved a forward split of shares of Convey’s common stock, par value $0.01 per share, on a 126-for-1 basis (the “Stock Split”), which became effective as of June 4, 2021. Prior to the Stock Split, we were authorized to issue 1,000,000 shares of common stock of which (i) 915,000 shares were designated as voting common stock and (ii) 85,000 shares were designated as non-voting common stock. In connection with the Stock Split, the total number of authorized shares of common stock was proportionately increased and the par value of the common stock was not adjusted as a result of the Stock Split. In addition, all authorized shares of common stock were designated voting common stock. All references to common stock, options to purchase common stock, per share data and related information contained in our condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Stock Split.
Initial Public Offering
On June 18, 2021, we closed our initial public offering (“IPO”) of our common stock through an underwritten sale of 13,333,334 shares of our common stock at a price of $14.00 per share. In the offering, we sold 11,666,667 shares and a selling stockholder sold 1,666,667 shares. The aggregate net proceeds to us from the offering after deducting underwriting discounts and commissions and other offering expenses payable by us, were approximately $146.1 million. We used approximately $131.5 million of the net proceeds from the IPO to repay outstanding indebtedness under our credit agreement. We did not receive any of the proceeds from the sale by the selling stockholder.
Prior to the closing of the IPO, on June 17, 2021, our Second Amended and Restated Certificate of Incorporation (the “Charter”) and our Second Amended and Restated Bylaws, became effective. The Charter, among other things, provides that our authorized capital stock consists of 500,000,000 shares of common stock, par value $0.01 per share and 25,000,000 shares of preferred stock, par value $0.01 per share.
Basis of Presentation and Consolidation
The accompanying condensed consolidated financial statements are unaudited and include the accounts of Convey and our wholly-owned subsidiaries. They have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our condensed consolidated statements of operations and comprehensive income (loss), shareholders’ equity, and cash flows for the three months ended March 31, 2022, and 2021, and the condensed consolidated balance sheet as of March 31, 2022, reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results for the periods shown.
Our condensed consolidated balance sheet as of December 31, 2021, has been derived from our audited consolidated financial statements as of that date. Our condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2021, which include a complete set of footnote disclosures, including our significant accounting policies, and are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 23, 2022 (“Form 10-K”). The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. All significant intercompany balances and transactions have been eliminated in consolidation.
COVID-19 Pandemic
During the first quarter ended March 31, 2020, concerns related to the spread of novel coronavirus (“COVID-19”) began to create global business disruptions as well as disruptions in our operations. COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. Governments at the national, state and local level in the U.S., and globally, have implemented varying measures in an effort to contain the virus, including social distancing, travel restrictions, border closures, limitations on public gatherings of people, work from home and supply chain logistical changes. While some of these actions have eased, escalating transmission rates (including of the Delta and Omicron variants of COVID-19), uneven vaccination and vaccination booster rates and further governmental guidance and orders may result in having to reimplement certain of these measures or implementing new and additional ones. The spread of COVID-19 has also caused significant volatility in the U.S. and international markets and has had and continues to have widespread, rapidly evolving and unpredictable impacts on global society, economics, financial markets and business practices. The impact of COVID-19 on our business has resulted in elongated sales cycles, postponement of customer contract renewals, and slower implementation of software solutions for our clients, as well as a reduction in billable hours in one of our reportable segments, the Advisory Services segment.
The full extent to which the COVID-19 pandemic and the various responses to the COVID-19 pandemic continues to impact our business, operations or financial condition will depend on numerous evolving factors that we may not be able to accurately predict, including, but not limited to, the duration, severity and scope of the COVID-19 pandemic (including due to new variants, such as Delta and Omicron); actions by governmental entities, businesses and individuals that have been and continue to be taken in response to the pandemic; the effect on our clients and demand by clients, clients and our clients’ members for and ability to pay for our solutions and services; and disruptions or restrictions on our employees’ ability to work and travel. The impact of these factors and others on our suppliers and clients could persist for some time after governments ease their restrictions and after the overall number of COVID-19 cases in the United States decreases.
We have assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context with the unknown future impacts of COVID-19 using information that is reasonably available to us at this time. While our current assessment of our estimates did not have a material impact on our condensed consolidated financial statements as of and for the three months ended March 31, 2022, as additional information becomes available to us, our future assessment of our estimates, including our expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact our consolidated financial statements in future reporting periods.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information currently available to us and based on various other assumptions that we conclude to be reasonable under the circumstances. While management concludes that such estimates are reasonable when considered in conjunction with our condensed consolidated balance sheets and statements of operations and comprehensive income (loss) taken as a whole, actual results could differ materially from those estimates.
Acquisitions
We allocate the purchase consideration to the identifiable net assets acquired, including intangible assets and liabilities assumed, based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, is recorded as goodwill. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition
date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to the condensed consolidated statements of operations and comprehensive income (loss).
Determining the fair value of assets acquired and liabilities assumed requires significant judgment, including the selection of valuation methodologies which techniques include the royalty method, the multi-period excess earnings method, the cost approach, the market approach, and the probability weighted assessment method as considered necessary. Significant assumptions used in those methodologies include, but are not limited to, growth rates, discount rates, customer attrition rates, expected levels of revenues, earnings, cash flows and tax rates. The use of different valuation methodologies and assumptions is highly subjective and inherently uncertain and, as a result, actual results may differ materially from estimates.
Customer Concentrations
Revenue and Accounts receivable from our major customers are as follows:
Revenues
For the Three Months Ended
March 31,
(in thousands, except percentages)
20222021
Customer A
$27,108 $19,626 
    % of total revenue
28.0 %23.8 %
Customer B
$16,712 $16,766 
    % of total revenue
17.3 %20.3 %
Accounts Receivable
(in thousands, except percentages)
March 31, 2022December 31, 2021
Customer A$8,119 $13,161 
    % of total accounts receivable11.2 %21.0 %
Customer B$11,688 $15,174 
    % of total accounts receivable16.1 %24.2 %
Our customer base is highly concentrated. Revenue may significantly decline if we were to lose one or more of our major customers. However, our risk is reduced due to our significant customers having multiple product delivery solutions under separate contracts.
Contingent Consideration
We recognized an earn-out liability in connection with the November 2018 acquisition of HealthScape Advisors, LLC (“HealthScape Advisors”) and Pareto Intelligence LLC (“Pareto Intelligence”), which represented contingent consideration.
The initial fair value of the earn-out liability was determined by employing a Monte-Carlo simulation model. The underlying simulated variable was adjusted revenue discounted by the market price of risk embedded in the revenue metrics. The revenue volatility estimate was based on a study of historical asset volatility and implied volatility for a set of comparable public companies, adjusted by our operating leverage. The earn-out payments were calculated based on simulated revenue metrics and payment thresholds as set forth in the HealthScape Advisors and Pareto Intelligence purchase agreement. The calculated payments were further discounted back to present value using cost of debt reflecting our credit risk. The fair value of the earn-out liability at each reporting date subsequent to the acquisition was measured using a probability weighted approach. Any change in fair value was recognized in the condensed consolidated statements of operations and comprehensive income (loss).
On September 4, 2019, Cannes Parent, Inc. (“Cannes”), a direct subsidiary of Convey, entered into an agreement to acquire all of the outstanding stock of Convey Health Solutions, Inc. through the merger of Cannes Merger Sub, Inc. (“Merger Sub”) and Convey Health Parent, Inc. (“Parent”) (the “Merger”) with Parent surviving as a direct subsidiary of Cannes. The Merger principally occurred through an investment from TPG Cannes Aggregation, L.P., which is primarily funded by partners of TPG Partners VIII, L.P. and TPG Healthcare Partners, L.P. or any parallel fund or their alternative investment vehicles (collectively, “TPG”). In connection with the Merger, we recognized a holdback liability, which represented contingent consideration. The
initial fair value of the holdback liabilities and at each subsequent reporting date was measured using a probability weighted approach. Any change in fair value was recognized in the consolidated statements of operations and comprehensive income (loss).
In connection with the acquisition of HealthSmart in February 2022, we recognized an earn-out liability which represented contingent consideration. The initial fair value of the earn-out liability was determined by employing a Black-Scholes Merton model. The earn-out payments were calculated based on projected revenue metrics and payment thresholds as set forth in the HealthSmart purchase agreement. The calculated payments were further discounted back to present value using the cost of debt reflecting our credit risk.
The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2022:
(in thousands)
Balance at December 31, 2021$— 
Fair value of contingent consideration in connection with the HealthSmart acquisition2,254 
Payments — 
Change in fair value— 
Balance at March 31, 2022$2,254 
The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2021:
(in thousands)
Balance at December 31, 2020$20,538 
Payments— 
Change in fair value— 
Balance at March 31, 2021$20,538 
Net Income (Loss) Per Common Share
Basic income (loss) per share is computed by dividing net income (loss) attributable to common shareholders (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted net income (loss) per common share attributable to common shareholders is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period adjusted for the dilutive effects of common stock equivalents. In periods when losses from operations are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.
For the Three Months Ended
March 31,
(in thousands, except per share data)20222021
Net income (loss) attributable to common shareholders
Net income (loss)$(1,154)$(934)
Net income (loss) attributable to common shareholders$(1,154)$(934)
Weighted-average common shares outstanding:
Basic and diluted73,194,171 61,321,424 
Net income (loss) per share:
Basic and diluted$(0.02)$(0.02)
For the three months ended March 31, 2022, and 2021, 9,534,119 and 5,690,664 of potentially dilutive share-based awards outstanding, respectively, were excluded from the computation of diluted net income (loss) per share related to common shareholders as their effect was anti-dilutive. See Note 11. Share-Based Compensation.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which supersedes the previous guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for virtually all of their leases except those which meet the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or financing. Classification is based on criteria that are similar to those applied in previous lease accounting, but without explicit bright lines. The recognition of these lease assets and lease liabilities represents a change from previous U.S. GAAP requirements, which did not require lease assets and lease liabilities to be recognized for most leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee, have not significantly changed from previous U.S. GAAP requirements. The Company adopted the provisions of Topic 842 on January 1, 2022, using the modified retrospective approach. All comparative periods prior to January 1, 2022 are not adjusted and continue to be reported in accordance with Topic 840.
The Company elected to utilize the package of practical expedients permitted within the new standard, which among other things, allowed the Company not to reassess prior conclusions about lease identification, classification and initial direct costs of existing leases as of the date of adoption. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the Company’s condensed consolidated balance sheet which resulted in recognizing those lease payments in the condensed consolidated statements of operations on a straight-line basis over the lease term.
Adoption of the new standard resulted in the recording of right-of-use assets and corresponding lease liabilities of $14.7 million and $20.7 million, respectively, as of January 1, 2022. The difference between the right-of-use assets and the lease liabilities was recorded to eliminate existing deferred rent balances and remaining balances of lease incentives recorded under Topic 840. The adoption of the new standard did not materially impact the Company's condensed consolidated statements of operations and had no impact on the Company's condensed consolidated statements of cash flows. See Note 18. Leases for further information.
Accounting Pronouncements Issued Not Yet Adopted
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Entities will be required to use a model that will result in the earlier recognition of allowances for losses for trade and other receivables, held-to-maturity debt securities, loans, and other instruments. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. ASU 2016-13, as subsequently amended for various technical issues, is effective for emerging growth companies following private company adoption dates for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”), subsequently clarified in January 2021 by ASU 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The main provisions of this update provide optional expedients and exceptions for contracts, hedging relationships, and other transactions that reference the London Inter-bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and, once adopted, may be applied prospectively to contract modifications and hedging relationships through December 31, 2022. We are currently evaluating the new guidance to determine the impact ASU 2020-04 and ASU 2021-01 will have on our consolidated financial statements.
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) (“ASU 2021-08”). The new guidance creates an exception to the general recognition and measurement principle for contract assets and contract liabilities from contracts with customers acquired in a business combination. Under this exception, an acquirer applies Topic 606 to recognize and measure contract assets and contract liabilities on the acquisition date. Topic 805 generally requires the acquirer in a business combination to recognize and measure the assets it acquires and liabilities it assumes at fair value on the acquisition date. This generally will result in companies recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date. This new guidance is effective for emerging growth companies following private business adoption dates, for the fiscal years beginning after December 15, 2023, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE FROM CONTRACTS WITH CUSTOMERS
3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
REVENUE FROM CONTRACTS WITH CUSTOMERS REVENUE FROM CONTRACTS WITH CUSTOMERS
We provide technology enabled solutions and advisory services to assist our clients with workflows across product developments, sales, member experience, clinical management, core operations and business intelligence and analytics. We generate our revenues through our two reporting segments: (i) Technology Enabled Solutions and (ii) Advisory Services.
Technology Enabled Solutions
We help health plans grow membership and revenue as well as operate more effectively and efficiently. We also assist our clients in managing the compliance and administrative requirements imposed under government sponsored health plans. Our technology solutions are primarily delivered through a web-based customizable application. This application is used to identify, track, and administer contractual services, or benefits provided under a client’s plan to its Medicare and Medicaid beneficiaries. We also provide analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. With our technology enabled solutions, we offer the following services:
Health Plan Management provides technology-enabled plan administration services for government-sponsored health plans. Our service encompasses eligibility and enrollment processing, member services, premium billing, payment processing, reconciliation and other related services. In addition, we provide technology enabled services to manage supplemental benefits provided to members through their Medicare Advantage plans. Our services include benefit design and administration, member eligibility and engagement, analytics and reporting.
Software Services provide additional services to our clients for ad hoc enhancements on their existing software solutions.
Data Analytics provide payment tools and data analytics to improve revenue accuracy and identify gaps in quality, clinical care and compliance. Increasingly we are combining these analytics capabilities with our Health Plan Management offerings.
Supplemental Benefit Services include product fulfillment, as well as catalog development and product distribution. Many of these services are provided through our technology enabled solutions.
Advisory Services
We provide Advisory Services that complement our technology enabled solutions, including sales and marketing strategies, provider network strategies, compliance, Star ratings, quality, clinical, pharmacy, analytics and risk adjustment.
Revenue Recognition
We recognize revenue under ASC Topic 606, Revenue from Contracts with Customers. We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for contracts that are within the scope of the standard, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Disaggregation of revenue
The following tables present disaggregated revenue by reporting segment:
(in thousands)For the Three Months Ended
March 31, 2022
Technology
Enabled
Solutions
Advisory
Services
Total
Supplemental Benefit Services$50,228 $— $50,228 
Health Plan Management25,862 — 25,862 
Consulting Services2,327 13,457 15,784 
Software Services2,191 85 2,276 
Data Analytics2,558 — 2,558 
Total$83,166 $13,542 $96,708 
(in thousands)For the Three Months Ended
March 31, 2021
Technology
Enabled
Solutions
Advisory
Services
Total
Supplemental Benefit Services$39,104 $— $39,104 
Health Plan Management23,942 — 23,942 
Consulting Services1,038 13,049 14,087 
Software Services2,730 — 2,730 
Data Analytics2,768 — 2,768 
Total$69,582 $13,049 $82,631 
The revenue recognition pattern, point in time or over time, is consistent within all revenue categories with the exception of Data Analytics which includes revenue recognized on both a point in time and over time basis. The amount of point in time revenue within Data Analytics was $0.6 million and $1.4 million during the three months ended March 31, 2022, and 2021, respectively.
Contract Balances
The timing of our revenue recognition, invoicing, and cash collections results in billed accounts receivable, unbilled receivables, and deferred revenue. Accounts receivable includes unbilled receivable balances of $17.4 million and $7.0 million as of March 31, 2022, and December 31, 2021, respectively.
Deferred revenue represents payments received from our customers in advance of recognition of revenue. Deferred revenue that will be recognized during the succeeding 12 months is recognized as current deferred revenue and the remaining portion is recognized as non-current deferred revenue within Other long-term liabilities. Revenue recognized during the three months ended March 31, 2022, and 2021 that was included in the deferred revenue balance at the beginning of the period was $4.4 million and $3.9 million, respectively.
Remaining Performance Obligations
Transaction price allocated to remaining performance obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes contract liabilities and non-cancelable amounts that will be invoiced and recognized as revenue in future periods.
The timing and amount of revenue recognition for our remaining performance obligations are influenced by several factors and therefore the amount of remaining obligations may not be a meaningful indicator of future results. Total RPO equaled $8.4 million as of March 31, 2022, of which we expect to recognize approximately $4.2 million over the next 12 months. The remaining $4.2 million is expected to be recognized in fiscal years 2023, 2024, 2025, 2026 and 2027 by $3.0 million, $1.1 million, $0.1 million, $7.5 thousand and $7.5 thousand, respectively.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
ACQUISITIONS
3 Months Ended
Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
ACQUISITIONS ACQUISITIONS
On January 9, 2022, Convey’s indirect wholly-owned subsidiary, D-M-S Holdings Parent, LLC (f/k/a Dragon Holdings Parent, LLC), a Delaware limited liability company (“Buyer”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Briggs Medical Service Company, a Delaware corporation (“Seller”), and D-M-S Holdings, Inc. d/b/a HealthSmart International, a Delaware corporation (“Target”), pursuant to which, on the terms and subject to the conditions set forth in the Purchase Agreement, Buyer agreed to acquire from Seller all of the issued and outstanding capital stock of Target (the acquisition of such capital stock, the “Acquisition”). Target provides a diverse portfolio of health, wellness and diagnostic products centered on home based care outcomes, and the Company intends to leverage the Target’s supply chain and logistics expertise to get high quality products to members faster and at a lower cost.
On February 1, 2022, Buyer completed its acquisition of all of the issued and outstanding capital stock of the Target. The Acquisition was consummated pursuant to the Purchase Agreement.
Pursuant to the terms set forth in the Purchase Agreement, at closing Buyer paid to Seller cash in an amount equal to $74.7 million, subject to certain adjustments for, among other things, Target’s cash, indebtedness and net working capital (the “Closing Purchase Price”). If the Target achieves certain amounts of net revenue in calendar year 2022, Buyer will pay to Seller cash up to an additional $15 million. A portion of the Closing Purchase Price was deposited into an escrow account held by an
escrow agent and will be released to Buyer or Seller, as applicable, following the final determination of any purchase price adjustment.
In connection with the Purchase Agreement, CHS obtained a first lien incremental term loan facility under CHS’s existing First Lien Credit Agreement in an aggregate principal amount of $78 million, for the purpose of financing the Acquisition and paying fees and expenses related thereto. See Note 9. Credit Facility for additional information related to the incremental term loan facility.
The Acquisition was accounted for using the acquisition method of accounting under which assets and liabilities of the Target were recorded at their respective fair values including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. A deferred tax liability has been recorded for the excess of financial statement basis over tax basis of the acquired assets and assumed liabilities with a corresponding increase to goodwill. The goodwill attributable to the Acquisition has been recorded as a non-current asset and is not amortized, but is subject to an annual review for impairment. Such goodwill, which is non-deductible for income tax purposes, is part of the Technology Enabled Solutions segment.
The Acquisition price was allocated to the tangible and identified intangible assets acquired and liabilities assumed as of the closing date. The fair values assigned to tangible and identifiable intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions. The estimated fair values of assets acquired and liabilities assumed are considered preliminary and are based on the most recent information available. The Company believes that the information provides a reasonable basis for assigning the fair values of assets acquired and liabilities assumed. Thus, the provisional measurements of fair value set forth below are subject to change. The Company expects to finalize the valuation as soon as practicable, but not later than one year from the acquisition date.
The following table summarizes the Acquisition date fair value of the allocation of the purchase consideration assigned to each major class of assets acquired and liabilities assumed as of February 1, 2022, the acquisition date:
Estimated Fair Value
(in thousands)
ASSETS ACQUIRED
Cash $112 
Accounts receivable 6,481 
Inventories22,879 
Prepaid expenses and other current assets 1,840 
Property and equipment1,269 
Operating lease right-of-use-assets4,908 
Total identifiable assets acquired 37,489 
Fair value of intangible assets
Trade names 8,600 
Customer relationships 25,500 
Total fair value of intangible assets acquired 34,100 
Total assets acquired $71,589 
LIABILITIES ASSUMED
Accounts payable $2,937 
Accrued expenses 3,895 
Operating lease liabilities, current portion1,003 
Deferred taxes10,222 
Operating lease liabilities, net of current portion3,905 
Total liabilities assumed 21,962 
Net identifiable assets49,627 
Goodwill27,352 
Total consideration$76,979 
Indications of fair value of the intangible assets acquired in connection with the Acquisition were determined using either the income, market or replacement cost methodologies. The intangible assets are being amortized over periods which reflect the pattern in which economic benefits of the assets are expected to be realized. The trade names and customer relationships are being amortized on a straight-line basis over an estimated useful life of twenty years and seventeen years, respectively. The goodwill recognized is primarily attributable to synergies of the business and the acquisition of workforce knowledgeable of product development and supply chain expertise in the healthcare industry.
The following table summarizes the purchase consideration transferred in connection with the Acquisition and consists of the following:
(in thousands)March 31, 2022
Initial purchase price$74,725 
Earn-out (contingent consideration)2,254 
Total consideration$76,979 
Included in the condensed consolidated statement of operations and comprehensive income (loss) for the three months ended March 31, 2022, are net sales of $7.2 million and net loss of $1.6 million, related to the Target’s operations since the acquisition date of February 1, 2022.
Unaudited Supplemental Pro Forma Information
The following table presents the unaudited pro forma combined results of operations of the Company and Target for the three months ended March 31, 2022 and 2021, as if the acquisition had occurred on January 1, 2021. The pro forma information presented is for informational purposes only and is not indicative of results of operations that would have been achieved had the Acquisition taken place at the beginning of the period.
For the Three Months Ended
March 31
(in thousands)20222021
Net revenue101,174 97,567 
Net income (loss)205 (299)
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS
3 Months Ended
Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
PREPAID EXPENSES AND OTHER CURRENT ASSETS PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid expenses and other current assets consist of the following:
(in thousands)March 31, 2022December 31, 2021
Prepaid expenses and other advances$5,896 $6,904 
Software licenses828 2,547 
Insurance527 1,271 
Inventory purchase advances1,390 23 
Cloud computing subscription & implementation costs822 4,841 
Other current assets1,346 983 
Total prepaid expenses and other current assets$10,809 $16,569 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY AND EQUIPMENT
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
Property and equipment consist of the following:
(in thousands)
Estimated Life
(in years)
March 31, 2022December 31, 2021
Office and computer equipment
3 – 7 years
$16,399 $14,442 
Leasehold improvements
Up to 10 years
10,542 10,503 
Furniture and fixtures
3 – 7 years
4,064 4,054 
Software
3 – 5 years
2,366 2,277 
33,371 31,276 
Less: accumulated depreciation(12,419)(10,876)
Property and equipment, net$20,952 $20,400 
Depreciation expense for the three months ended March 31, 2022, and 2021 totaled $1.5 million and $1.4 million, respectively.
We lease various equipment and software under finance leases. The depreciation expense associated with the assets under finance leases for the three months ended March 31, 2022, and 2021, totaled $89 thousand and $0.1 million, respectively. Assets held under finance leases are included in property and equipment as follows:
(in thousands)March 31, 2022December 31, 2021
Office and computer equipment$1,682 $1,682 
Less: accumulated depreciation(742)(656)
Total financing leases included in property and equipment$940 $1,026 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSETS AND GOODWILL
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS AND GOODWILL INTANGIBLE ASSETS AND GOODWILL
The activity for goodwill as of March 31, 2022 is as follows:
(in thousands)
Balance at December 31, 2021$455,206 
Measurement period adjustments — 
Acquisitions (see Note 4)27,352 
Impairment — 
Balance at March 31, 2022$482,558 
The carrying amount of goodwill by reporting unit as of March 31, 2022 is $88.9 million for Advanced Plan Administration (“APA”), $190.2 million for Supplemental Benefits Administration (“SBA”), $138.2 million for Value Based Payment Assurance (“VBPA”), $37.9 million for Advisory Services (“Advisory”) and $27.4 million for HealthSmart acquisition, respectively.
The goodwill allocated to the Technology Enabled Solutions and Advisory Services reportable segments is $444.7 million and $37.9 million, respectively as of March 31, 2022. Goodwill is assessed for impairment on an annual basis (on October 1 of each year) and on an interim basis when indicators of impairment exist.
As a result of the decline in our stock price since December 31, 2021, we performed an interim impairment test for goodwill for APA, SBA, VBPA and Advisory reporting units using the quantitative approach as of March 31, 2022. Since HealthSmart was recently acquired, no impairment test was performed on that reporting unit. Based on our evaluation performed, we determined the fair value of each of the reporting units exceeded its respective carrying amount, and therefore, we determined that goodwill was not impaired at any of our reporting units as of March 31, 2022. We define “headroom” as the percentage difference between the fair value of a reporting unit and its carrying value. For the interim impairment test, the headroom for the reporting units ranged between eight percent to sixty-five percent. Our SBA reporting unit and our VBPA reporting unit have headroom at the low-end of that range (8.4% for SBA and 12.5% for VBPA) and could experience
impairment in the future if we do not achieve our profitability projections, there is a change in key assumptions underlying the valuation or if we continue to experience a substantial decrease in our stock price.
Evaluation of goodwill for impairment requires judgment, including the identification of reporting units, assignment of assets, liabilities and goodwill to reporting units and determination of the fair value of each reporting unit. We estimate the fair value of our reporting units using a combination of an income approach, utilizing a discounted cash flow analysis, and a market approach, using market multiples. Under the income approach, we estimate projected future cash flows, the timing of such cash flows and long-term growth rates, and determine the appropriate discount rate that reflects the risk inherent in the projected future cash flows. The discount rate used is based on a market participant weighted-average cost of capital and may be adjusted for the relevant risk associated with business-specific characteristics and the uncertainty related to the reporting unit’s ability to execute on the projected future cash flows. Under the market approach, we estimate fair value based on market multiples of revenues and earnings derived from comparable publicly-traded companies with characteristics similar to the reporting unit. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions and other factors. The assumptions and estimates used in determining the fair values of the reporting units contain uncertainties, and any changes to these assumptions and estimates could have a negative impact and result in a future impairment.
The carrying value of identifiable intangible assets consisted of the following as of March 31, 2022:
(in thousands)
Gross
Carrying
Amount
Accumulated
Amortization
Net Carrying
Amount
Amortized intangible assets
Trade names$35,900 $(3,830)$32,070 
Customer relationships214,500 (44,636)169,864 
Technology47,800 (12,348)35,452 
Capitalized software development costs13,026 (2,419)10,607 
Total intangible assets$311,226 $(63,233)$247,993 
The carrying value of identifiable intangible assets consisted of the following as of December 31, 2021:
(in thousands)
Gross
Carrying
Amount
Accumulated
Amortization
Net Carrying
Amount
Amortized intangible assets
Trade names$27,300 $(3,395)$23,905 
Customer relationships189,000 (40,091)148,909 
Technology47,800 (11,153)36,647 
Capitalized software development costs12,454 (1,901)10,553 
Total intangible assets$276,554 $(56,540)$220,014 
Amortization expense for Trade names, Customer relationships and Technology for the three months ended March 31, 2022, and 2021, totaled $6.2 million and $5.9 million, respectively.
Amortization expense for Capitalized software development costs for the three months ended March 31, 2022, and 2021, totaled $0.5 million and $0.1 million, respectively.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
ACCRUED EXPENSES
3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES ACCRUED EXPENSES
Accrued expenses and other current liabilities consist of the following:
(in thousands)March 31, 2022December 31, 2021
Incentive bonus$257 $15,214 
Employee related7,784 11,154 
Sales and use tax6,365 6,865 
Rebates2,372 4,276 
Accrued interest83 637 
Accrued professional fees5,538 7,046 
Refundable deposits4,626 — 
Other3,013 3,366 
Total accrued expenses$30,038 $48,558 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
CREDIT FACILITY
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
CREDIT FACILITY CREDIT FACILITY
On September 4, 2019, we entered into the First Lien Credit Agreement (the “Credit Agreement”). The Credit Agreement provides for senior secured credit facilities consisting of (i) a $225.0 million closing date term loan (the “Term Facility”) and loans thereunder (the “Term Loans”) and (ii) a $40.0 million revolving credit facility (the “Revolving Facility”) (collectively, the “Credit Facility”). The Term Facility has a seven-year term which expires on September 4, 2026 and the Revolving Facility has a five-year term which expires on September 4, 2024. We paid debt issuance costs of approximately $6.1 million on the closing date of the Credit Facility, $5.2 million is being amortized over the life of the Term Facility (84 months) and $0.9 million is being amortized over the term of the Revolving Facility (60 months) on a straight-line method. The Revolving Facility includes a letter of credit sub-facility (subject to a sublimit not to exceed $10.0 million) and a swing line loan sub-facility (subject to a sublimit not to exceed $10.0 million).
On April 8, 2020, we amended the Credit Agreement to establish an incremental loan facility in an aggregate principal amount equal to $25.0 million for an incremental term loan request (the “2020 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $1.1 million on the closing date of the 2020 Incremental Term Loan.
On February 12, 2021, we amended the Credit Agreement to establish an incremental term loan in an aggregate principal amount equal to $78.0 million (the “2021 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $2.4 million on the closing date of the 2021 Incremental Term Loan.
On February 1, 2022, we further amended the Credit Agreement to establish an incremental term loan in an aggregate principal amount equal to $78.0 million (the “2022 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $2.6 million on the closing date of the 2022 Incremental Term Loan, which is being amortized over the life of the 2022 Incremental Term Loan. The proceeds of the term loans borrowed under the 2022 Incremental Term Loan were used to finance the HealthSmart acquisition (see Note 4) and pay fees and expenses related thereto. The 2022 Incremental Term Loan was accounted for as a debt modification.
The Credit Agreement includes an uncommitted incremental facility, which provides that we have the right at any time to request term loan increases, additional term loan facilities, revolving commitment increases and/or additional revolving credit facilities, in an aggregate principal amount, together with the aggregate principal amount of permitted incremental equivalent debt under the Credit Agreement, not to exceed (a) the sum of the greater of (i) $46.9 million and (ii) 100.0% of Consolidated EBITDA (as defined in the Credit Agreement) of CHS and its restricted subsidiaries for the most recently ended period of four consecutive fiscal quarters of CHS (calculated on a pro forma basis), plus (b) certain additional amounts, including an unlimited amount subject to pro forma compliance with a leverage ratio test.
Interest Rate and Fees
Borrowings under the Credit Agreement (other than borrowings of swing line loans) bear interest at a rate per annum equal to, at our election, either (i) the LIBOR for the relevant interest period (subject to a floor of 1.00% per annum) plus an applicable margin, as defined in the Credit Agreement, or (ii) a base rate plus an applicable margin, as defined in the Credit Agreement. We elected to use the LIBOR rate for the Term Loans and the Revolving Facility. The Credit Agreement provides for the replacement of LIBOR with a successor or alternative index rate in the event LIBOR is phased-out.
In addition to paying interest on the outstanding principal of the Credit Facility, we are required to pay a commitment fee in respect of any unused commitments under the Revolving Facility at a rate that is subject to adjustment based upon the First Lien Net Leverage Ratio, as defined in the Credit Agreement (maximum debt to Earnings Before Interest, Income Tax, Depreciation and Amortization (“EBITDA”), as defined in the Credit Agreement) at such time and ranges from 0.375% to 0.500% per annum. We are also required to pay customary letter of credit fees and certain other agency fees.
On July 12, 2021, CHS entered into Amendment No. 4 to the Credit Agreement (“Amendment No. 4”). Amendment No. 4 amends the Credit Agreement to provide for, among other things, (i) the reduction of the Applicable Rate (as defined in the Credit Agreement) for Eurodollar Rate Loans (as defined in the Credit Agreement) from 5.25% to 4.75% and, for Base Rate Loans (as defined in the Credit Agreement), from 4.25% to 3.75%, and (ii) the reduction of the floor for the Eurodollar Rate (as defined in the Credit Agreement) from 1.00% to 0.75% for the Closing Date Term Loans (as defined in the Credit Agreement). Amendment No. 4 was accounted for as a debt modification.
Covenants
The Credit Facility contains a financial covenant that requires us to maintain as of the last day of each period of four consecutive quarters of the Company, a First Lien Net Leverage Ratio not to exceed 7.4 to 1.0 if, as of the last day of any fiscal quarter of the Company, there are outstanding revolving loans and letters of credit (excluding (i) undrawn letters of credit in an aggregate face amount up to $10.0 million and (ii) letters of credit (whether drawn or undrawn) to the extent reimbursed, cash collateralized or backstopped on terms reasonably acceptable to the applicable issuing bank on or prior to the date that is three business days following the end of the applicable period of four consecutive fiscal quarters of CHS in an aggregate principal amount exceeding 35% of the aggregate principal amount of the Revolving Facility at such time. We were in compliance with our debt covenants at March 31, 2022.
Prepayments and Mandatory Prepayment
Under the terms of the Credit Agreement, we are permitted to voluntarily prepay outstanding loans or commitments in whole or part without premium or penalty other than certain exceptions described in the Credit Agreement; however, the Credit Agreement requires us to prepay outstanding term loans, subject to certain exceptions and limitations with (i) 50% of our annual excess cash flow, subject to certain step-downs based upon the First Lien Net Leverage Ratio; (ii) 100% of the net cash proceeds of certain asset sales or casualty events; and (iii) 100% of the net cash proceeds of certain incurrences or issuances of indebtedness. We were not required to prepay outstanding term loans based on our 2021 results.
Scheduled Repayments
In connection with the prepayment noted under the “Extinguishment of Debt” below, no additional scheduled installments of principal are required on the Term Facility.
We are required to make scheduled quarterly payments on the 2022 Incremental Term Loan. We are required to make quarterly payments commencing with the quarter ending June 30, 2022, in an amount equal to 0.25% of the aggregate principal amount of the 2022 Incremental Term Loan outstanding on February 1, 2022 with the balance due upon maturity date.
Guarantees and Collateral
All obligations under the Credit Agreement are unconditionally guaranteed by Parent and certain subsidiaries. All obligations under the Credit Agreement are secured, subject to permitted liens and other exceptions and limitations, by first priority security interests in substantially all the assets of the Company and each guarantor (including all the equity interests of CHS).
Extinguishment of Debt
On June 18, 2021, $131.5 million from the IPO proceeds (see Note 1) were used to repay the principal balance, accrued but unpaid interest, and prepayment premium under the Credit Agreement. The 2020 Incremental Term Loan and the 2021 Incremental Term Loan were repaid in full and the remainder of the proceeds were used to repay a portion of the Term Facility. The prepayment for the Term Facility was applied to the remaining scheduled installments of principal.
Other Information
As of March 31, 2022, and December 31, 2021, unamortized deferred financing costs for the Term Loans totaled $5.4 million and $3.0 million, respectively. Amortization of deferred financing costs for the three months ended March 31, 2022, and 2021, totaled $0.3 million and $0.9 million, respectively.
As of March 31, 2022, and December 31, 2021, unamortized deferred financing costs associated with the Revolving Facility totaled $0.5 million for each period, and were included in Other assets in the condensed consolidated balance sheets. Amortization of deferred financing costs was approximately $50 thousand for each of the three months ended March 31, 2022, and 2021.
Amortization of deferred financing costs is included within Interest expense in the condensed consolidated statement of operations and comprehensive income (loss).
For the three months ended March 31, 2022, and 2021, the average interest rate for the Term Facility was 5.5% and 6.3%, respectively. As of March 31, 2022, and December 31, 2021, the aggregate principal balance was $192.6 million for each period.
For the three months ended March 31, 2022, the average interest rate for the 2022 Incremental Term Loan was 5.5%. As of March 31, 2022, the aggregate principal balance was $78.0 million.
For the three months ended March 31, 2022, and 2021, the average interest rate for the Revolving Facility was 2.75% for each period. As of March 31, 2022, and December 31, 2021, the available balance was $39.4 million. On January 23, 2020, we established an irrevocable transferable letter of credit (“LOC”) in the favor of a lessor totaling $0.5 million. The LOC expired on January 31, 2021, however, per the terms of the agreement, the LOC automatically extends for a one year period upon the expiration date and each anniversary thereafter, unless at least 60 days prior to such expiration date or anniversary written notice is provided that we elect not to extend the LOC. The LOC was automatically extended for a one year period on January 31, 2022.
Debt consists of the following as of March 31, 2022, and December 31, 2021:
(in thousands)March 31, 2022December 31, 2021
Term loans$270,631 $192,631 
Less: deferred financing costs(5,368)(2,988)
Term loans, net of deferred financing costs265,263 189,643 
Less: current portion(780)— 
$264,483 $189,643 
Debt Maturities Schedule
The required principal payments for Term Loans for each of the five years and thereafter following the balance sheet date are as follows:
(in thousands)
For the nine months ending December 31, 2022$585 
2023780 
2024780 
2025780 
2026267,706 
Total $270,631 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
SHAREHOLDERS’ EQUITY
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
SHAREHOLDERS’ EQUITY SHAREHOLDERS’ EQUITY
As of March 31, 2022, we are authorized to issue 500,000,000 shares of common stock, par value $0.01 per share and 25,000,000 shares of preferred stock, par value $0.01 per share. See Note 1 for additional information related to the Stock Split and IPO.
In February 2021, our Board, through a unanimous written consent, adopted a written resolution declaring a special dividend of $1.18 per share of common stock totaling $74.5 million in cash (“Special Dividend”) ultimately to be distributed to the shareholders of Convey. Of the Special Dividend, $72.2 million was paid to existing shareholders and $2.3 million was paid to outstanding and vested stock option holders. The Special Dividend was paid out during the three months ended March 31, 2021.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED COMPENSATION
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
On September 4, 2019, our Board adopted the Cannes Holding Parent, Inc. 2019 Equity Incentive Plan (the “2019 Equity Plan”). The 2019 Equity Plan was terminated and replaced and superseded by the 2021 Plan (as defined below) on the effective date of the 2021 Plan and no further grant of awards under the 2019 Equity Plan have been made since such effective date. Outstanding awards granted under the 2019 Equity Plan remain in effect pursuant to their terms.
On June 4, 2021, in connection with the IPO, the Company adopted the Convey Holding Parent, Inc. 2021 Omnibus Incentive Compensation Plan (the “2021 Plan”). The 2021 Plan has a term of ten years.
In March 2021, pursuant to the 2019 Equity Plan, Convey issued option awards to acquire 69,300 shares of Convey’s common stock with an exercise price of $9.92 per share and a term of ten (10) years. The awards were comprised of time-vesting options which vest 25% on each anniversary date from the vesting commencement date.
In June 2021, in connection with the IPO and pursuant to the 2021 Plan, Convey issued option awards to acquire 497,321 shares of Convey’s common stock with an exercise price of $14.00 per share and a term of ten (10) years. In addition, Convey issued 198,929 restricted stock units (“RSUs”) with a grant date fair value of $13.00 per unit. The option awards and RSUs are time-vesting awards which vest 25% on the first anniversary of the commencement date, and the remainder will vest in 12 equal 3-month installments over the following three years.
In August 2021, pursuant to the 2021 Plan, Convey issued option awards to acquire 20,380 shares of Convey’s common stock with an exercise price of $9.20 per share and a term of five (5) years. In addition, Convey issued 8,152 RSUs with a grant date fair value of $9.20 per unit. The option awards and RSUs were fully vested as of the date of the grant.
In March 2022, pursuant to the 2021 Plan, the Company issued 2,500,459 RSUs and 1,243,220 performance restricted stock units (“PSUs”) with a grant date fair value of $6.70 per unit. The grants are time-vesting awards which vest 25% on the first anniversary of the commencement date, and the remainder will vest in 12 equal 3-month installments over the following three years. The PSUs have a performance condition that affects vesting and is subject to the Company meeting certain annual Adjusted Earnings Before Interest, Income Tax, Depreciation and Amortization (“Adjusted EBITDA”) target.
The following table summarizes the total share-based compensation expense included in the condensed consolidated statements of operations and comprehensive income (loss):
For the Three Months Ended
March 31,
(in thousands)20222021
Selling, general and administrative$1,264 $990 
Total stock-based compensation expense$1,264 $990 
Stock Option Modification
On February 15, 2021, our Board approved a stock option award modification (the “Modification”) whereby the exercise price of certain previously granted and still outstanding unvested stock option awards held by current employees and certain executives were reduced by $1.18 per award, which represented the cash payment made for the vested awards as part of the Special Dividend. No other terms of the repriced stock options were modified, and the modified stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the Modification, 3,653,837 unvested stock options outstanding with an original exercise price of $7.94 were modified.
There was no incremental stock-based compensation expense as there was no incremental fair value generated as a result of the Modification.
Stock Option Grants
Stock option activity and information about stock options outstanding are summarized in the following table:
Stock Option Awards
Weighted Average Exercise Price
Weighted Average Remaining Contractual Life (Years)
Outstanding at December 31, 20215,636,154 $7.68 8.29
Granted— — — 
Exercised— — — 
Forfeited— — — 
Outstanding at March 31, 20225,636,154 7.68 7.99
Vested or expect to vest as of March 31, 20225,636,154 7.68 7.99
Vested and Exercisable as of March 31, 20222,876,085 7.53 7.88
The stock options are equity-based awards and their aggregate intrinsic value outstanding and exercisable at March 31, 2022, is $0.
As of March 31, 2022, there was approximately $9.4 million total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted average period of 2.11 years.
We estimate the fair value of the time-vesting stock option awards on the date of grant using the Black-Scholes Merton model. The time-vesting options have a service condition. Option valuation models, including the Black-Scholes Merton model, require the input of certain assumptions that involve judgment. Changes in the input assumptions can materially affect the fair value estimates and, ultimately, how much we recognize as stock-based compensation expense.
Restricted Stock Units
Activity and information about non-vested RSUs outstanding are summarized in the following table:
Restricted Stock Units
Weighted Average Grant Date Fair Value (in thousands)
Outstanding at December 31, 2021154,286 $2,006 
Granted3,743,679 25,083 
Vested— — 
Forfeited— — 
Outstanding at March 31, 20223,897,965 $27,089 
One RSU gives the right to one share of the Company’s common stock. RSUs that vest based on service are measured based on the fair value of the underlying stock on the date of grant. Compensation with respect to RSU awards is expensed on a straight-line basis over the vesting period.
As of March 31, 2022, there was approximately $26.6 million total unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted average period of 3.88 years.
Long-Term Incentive Awards
In March 2020, Convey issued fifty-six (56) Long-Term Incentive (LTI) awards with a total grant-date fair value of $1.1 million to employees. These awards vest upon satisfaction of the performance condition as determined by our Board at its sole discretion, subject to the participants continued employment or service. The performance condition is satisfied by TPG meeting a certain multiple-of-money return, on a scale, prior to or upon (i) TPG in the aggregate beneficially owning less than 20% of the voting equity securities of the Company or (ii) the date on which a change in control occurs. The awards contain a market condition with an implicit performance condition. No awards have vested as of March 31, 2022, as such events did not occur during the three months ended March 31, 2022. No awards have been granted or cancelled during the three months ended March 31, 2022. The awards do not expire. On the date the performance condition is met, any unvested awards will be forfeited.
LTI Awards
Outstanding as of December 31, 202143
Forfeited(4)
Outstanding as of March 31, 202239
Settlement of the award can be made, as determined by our Board at its sole discretion, (i) in cash, (ii) common stock, or (iii) in other property acceptable to our Board. The LTIs are treated as liability-based awards under Accounting Standards Codification (“ASC”) Topic 718, Compensation — Stock Compensation, (“ASC 718”) and the Company shall recognize compensation expense for the LTIs upon the liquidity event occurring.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
EMPLOYEE SAVINGS PLAN
3 Months Ended
Mar. 31, 2022
Retirement Benefits [Abstract]  
EMPLOYEE SAVINGS PLAN EMPLOYEE SAVINGS PLANWe offer our employees a savings plan pursuant to Section 401(k) of the Internal Revenue Code (the “Code”), whereby employees may contribute a percentage of their compensation, not to exceed the maximum amount allowable under the Code. At the discretion of our Board, we may elect to make matching or other contributions into the savings plan. We made matching contributions of $0.9 million and $0.7 million for the three months ended March 31, 2022, and 2021, respectively, to our employee savings plan, which is included within Selling, general and administrative expenses, Cost of services and Cost of products in the condensed consolidated statement of operations and comprehensive income (loss).
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
TAXES
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
TAXES TAXESOur tax provision or benefit from income taxes for interim periods is determined using an estimate of our global annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment.
Our quarterly tax provision, and our quarterly estimate of our annual effective tax rate, is subject to change resulting from several factors, including variability in forecasting our pre-tax and taxable income and loss due to external changes in market conditions, changes in statutes, regulations and administrative practices, principles, and interpretations related to tax. Our effective tax rate can be more or less volatile based on the amount of pre-tax income or loss. For example, the impact of discrete items and non-deductible expenses on our effective tax rate is greater when our pre-tax income is lower.
Our income tax (expense) benefit for the three months ended March 31, 2022, and 2021, was $0.7 million and $1.0 million, respectively. For the three months ended March 31, 2022, our effective tax rate of 37.0%, before discrete items, was above the U.S. statutory rate of 21.0% primarily due to foreign taxes, state taxes and non-deductible compensation for covered employees. For the three months ended March 31, 2021, our effective tax rate of 22.5%, before discrete items, was slightly above the U.S. statutory rate of 21.0% primarily due to foreign taxes, state taxes, tax on Global Intangible Low-Taxed Income, disallowed wage expense and fringe benefits and certain other non-deductible items. We did not have any unrecognized tax benefits as a result of tax positions taken during a prior period or during the current period. No interest or penalties were recorded as a result of tax uncertainties.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
TRANSACTION RELATED COSTS
3 Months Ended
Mar. 31, 2022
Acquisition Related and Deferred Offering Costs [Abstract]  
TRANSACTION RELATED COSTS TRANSACTION RELATED COSTS
The following table represents the components of Transaction related costs as reported in the condensed consolidated statements of operations and comprehensive income (loss):
For the Three Months Ended
March 31,
(in thousands)20222021
Mergers and acquisitions related costs$640 $30 
Public company readiness costs— 1,056 
Total$640 $1,086 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Employment Agreements
We have employment agreements with various executives. The agreements have open-ended terms providing that employment shall continue until terminated by either party in accordance with the agreement. In addition to salary, bonuses, and benefits, the agreements also provide for termination benefits if the agreements are terminated by us for reasons other than cause or by the executives for good reason.
Inventory Purchases
As of March 31, 2022 and December 31, 2021, we have contractual commitments to purchase inventory from certain manufacturers totaling $3.1 million and $5.2 million, respectively.
Legal Proceedings
We are involved in various lawsuits, claims, inquiries, and other regulatory and compliance matters, most of which are routine to the nature of our business. When it is probable that a loss will be incurred and where a range of the loss can be reasonably estimated, the best estimate within the range is accrued. When the best estimate within the range cannot be determined, the low end of the range is accrued. The ultimate resolution of these claims could affect future results of operations should our exposure be materially different from our estimates or should liabilities be incurred that were not previously accrued. Potential insurance reimbursements are not offset against potential liabilities.
Because of the uncertainties associated with claims resolution and litigation, future losses to resolve these matters could be higher than the liabilities we have accrued; however, we are unable to reasonably estimate a range of potential losses. If new information were to become available that allowed us to reasonably estimate a range of potential losses in an amount higher or lower than what we have accrued, we would adjust our accrued liabilities accordingly. Based upon current information, we concluded that the impact of the resolution of these matters would not be, individually or in the aggregate, material to our financial position, results of operations or cash flows. Additional lawsuits, claims, inquiries, and other regulatory and compliance matters could arise in the future. The range of losses for resolving any future matters would be assessed as they arise.
Sales Tax Accrual
ASC Topic 450, Contingencies, (“ASC 450”) requires an estimated loss to be accrued by a charge to income if it is probable that a liability has been incurred at the date of the financial statements and the amount of the liability can be reasonably estimated. We recognized liabilities for contingencies related to state sales and use tax deemed probable and estimable totaling $6.4 million and $6.9 million at March 31, 2022, and December 31, 2021, respectively. These are included in accrued liabilities in our condensed consolidated balance sheets.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS
3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
TPG Management Service Agreement
On September 4, 2019, in connection with the Merger, we had entered into a management services agreement (“MSA”) with TPG. Under the MSA, TPG agreed to provide certain financial, strategic advisory services, and consulting services in exchange for (i) reimbursement of certain expenses incurred by TPG and (ii) an aggregate annual retainer fee of 1% based on our previous year’s consolidated EBITDA determined by our Board. Additional services may be provided in exchange for the fees structured within the MSA. During the three months ended March 31, 2022, and 2021, we paid management and consulting fees of $0 and $0.2 million, respectively. Also, during the three months ended March 31, 2022, and 2021, we paid TPG a fee of $1.0 million and $1.0 million for services provided in connection with establishing: (i) the 2022 Incremental Term Loan and (ii) the 2021 Incremental Term Loan, respectively.
In the event the MSA was terminated by an IPO or business combination and TPG continues to hold at least 10% of equity of the Company upon closing of such transaction, we were required to pay TPG the net present value of the remaining portion of management and consulting fees that would have been incurred until three years after the date of such termination, as well as certain other expenses of TPG. In connection with the IPO completed in June 2021, the MSA was terminated and we paid TPG a $2.3 million termination fee. The termination fee is included within Selling, general and administrative expenses in the condensed consolidated statement of operations and comprehensive income (loss). There were no amounts payable to TPG as of March 31, 2022, or December 31, 2021.
EIR Partners Consulting Agreement
We have a Consulting Agreement with EIR Partners, LLC (“EIR”), a former member of our Board, and a current shareholder. Under the terms of the Consulting Agreement, EIR provides consulting services for the purpose of analyzing and reviewing potential sellers in the marketplace for the benefit of the Company as agreed to from time-to-time. As compensation for service, the Company remits to EIR $10 thousand monthly, plus reasonable out-of-pocket expenses incurred in the performance of the duties under the Consulting Agreement. The Consulting Agreement may be terminated by either party upon providing 10 days advance written notice and unless terminated, automatically renews for additional terms of one year. For the three months ended March 31, 2022, and 2021, $20 thousand and $30 thousand were paid for services rendered, respectively. The Consulting Agreement is still active with the Company.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT INFORMATION
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
ASC 280 establishes the standards for reporting information about segments in financial statements. In applying the criteria set forth in ASC 280, we have determined that we have two reportable segments: Technology Enabled Solutions and Advisory Services. These reportable segments reflect the manner in which the Chief Operating Decision Maker (“CODM”) group assesses information for decision-making purposes. The CODM group consists of our Chief Executive Officer and Chief Financial Officer.
The key factors used to identify these reportable segments are the organization and alignment of our internal operations and the nature of our products and services. This reflects how the CODM group monitors performance, allocates resources, and makes strategic and operational decisions.
In addition to the reportable segments, we have the “Unallocated” classification which includes those profit and loss items not allocated to either reportable segment. Unallocated includes corporate costs, primarily relating to group wide functions, including but not limited to, finance, tax and legal.
We present reportable segment revenue and Segment Adjusted EBITDA. Segment Adjusted EBITDA is the financial measure by which management and the CODM group allocate resources and analyze the performance of the reportable segments.
Segment Adjusted EBITDA represents each segment’s earnings before interest, tax, depreciation and amortization and is further adjusted to exclude certain items of a significant or unusual nature, including but not limited to, COVID-19 cost impacts, sales and use tax, non-cash stock compensation expense, transaction related costs, acquisition bonus expense, inventory step-up and other costs. Other includes costs such as management and board of directors fees and fees associated with obtaining the incremental term loans.
We do not report assets by reportable segment, as this metric is not used by the CODM group to allocate resources to the segments.
Presented in the tables below is revenue and Segment Adjusted EBITDA by reportable segment:
For the Three Months Ended
March 31, 2022
(in thousands)
Technology Enabled
Solutions
Advisory
Services
Revenue$83,166 $13,542 
Segment Adjusted EBITDA$12,370 $5,323 
For the Three Months Ended
March 31, 2021
(in thousands)
Technology Enabled
Solutions
Advisory
Services
Revenue$69,582 $13,049 
Segment Adjusted EBITDA$16,307 $3,338 
The following table presents a reconciliation of Segment Adjusted EBITDA to the condensed consolidated U.S. GAAP net income (loss) from operations:
(in thousands)For the Three Months Ended
March 31,
20222021
Technology Enabled Solutions Segment Adjusted EBITDA$12,370 $16,307 
Advisory Services Segment Adjusted EBITDA5,323 3,338 
Total$17,693 $19,645 
Unallocated(1)
$(2,377)$(2,048)
Adjustments to reconcile to U.S. GAAP net income (loss)
Depreciation and amortization(8,252)(7,372)
Interest, net(3,719)(5,467)
Income tax provision676 1,007 
Cost of COVID-19(2)
(274)(1,185)
Sales and use tax— (1,498)
Non-cash stock compensation expense(1,264)(990)
Transaction related costs(640)(1,086)
Acquisition bonus expense(58)(192)
Inventory step-up(3)
(1,892)— 
Other(4)
(1,047)(1,748)
Net income (loss)$(1,154)$(934)
________________________
(1)Represents certain corporate costs associated with the executive compensation, legal, accounting, finance and other costs not specifically attributable to the segments.
(2)Expenses incurred due to the COVID-19 pandemic are primarily related to higher pricing from vendors due to supply chain disruptions and product shortages and higher employee costs due to hazard pay for our employees. While we had
previously expected that these costs would not be an adjustment in the calculation of Segment Adjusted EBITDA after 2021, the COVID-19 pandemic has not subsided and during 2022, to a lesser extent, we have continued to incur higher product costs due to higher pricing from vendors for certain items (e.g., masks and other similar high demand products). We now expect that these expenses will not be an adjustment in the calculation of Segment Adjusted EBITDA after 2022.
(3)Incremental cost of products associated with the step-up of inventory recognized in purchase accounting for the HealthSmart acquisition.
(4)These adjustments include individual adjustments related to management and board of directors fees and fees associated with obtaining the incremental term loans.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES
3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
LEASES LEASES
We lease office space, warehouse and distribution space, and equipment under non-cancelable operating and finance leases expiring at various dates through 2029.
We determine whether an arrangement is a lease at inception, based on the (1) conveyed rights to obtain substantially all economic benefits from using the asset and (2) the right to direct the uses to which the asset is put.
Our lease population does not include any residual value guarantees, and therefore none were considered in the calculation of the lease balances. We have leases with variable payments, most commonly in the form of common area maintenance charges which are based on actual costs incurred. These variable payments were excluded from the right-of-use asset and lease liability balances since they are not fixed or in-substance fixed payments. We have lease agreements with lease and non-lease components. We elected the practical expedient to account for lease and non-lease components as a single lease component.
For leases with terms greater than 12 months, right-of-use assets and lease liabilities are recognized at the implementation date of Topic 842 or lease commencement date based on the present value of the future lease payments over the lease term. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, we utilize our incremental borrowing rate. Our lease agreements generally do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at either the implementation date of Topic 842 or at lease commencement for leases entered into thereafter in determining the present value of future payments. Lease expense for net present value of payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less with purchase options or extension options that are not reasonably certain to be exercised are not recorded on the condensed consolidated financial statements.
The components of lease expense were as follows:
(in thousands)Three Months Ended March 31, 2022
Operating lease costs$1,246 
Variable lease costs760 
Short-term lease costs326 
Finance lease cost
Amortization of right-of-use assets89
Interest on lease liabilities6
Total lease expense$2,427 
The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:
(in thousands) Operating LeasesFinance Leases
For the nine months ending December 31, 2022$4,852 $397 
20236,469 368 
20245,694 139 
20254,150 89 
20262,316 — 
Thereafter 3,297 — 
Total $26,778 $993 
Less: amounts representing interest $(2,550)$(52)
Net present value of lease obligations $24,228 $941 
The following table presents the balances for operating and finance right-of-use assets and lease liabilities:
(in thousands) ClassificationMarch 31, 2022
Assets
Operating lease assetsRight-of-use assets$18,574 
Finance lease assetsProperty and equipment940 
Total lease assets$19,514 
Liabilities
Current liabilities
Operating lease liabilitiesOperating lease liabilities$5,605 
Finance lease liabilitiesFinance lease obligations501
Non-current liabilities
Operating lease liabilitiesOperating lease liabilities18,623 
Finance lease liabilitiesFinance lease obligations440 
Total lease liabilities$25,169 
The table below presents additional information related to our leases as of March 31, 2022:
(in thousands)
Three Months Ended March 31, 2022
Supplemental cash flow information and non-cash activity:
Cash paid for amounts related to lease liabilities:
Operating cash flows from finance leases (interest)$
Operating cash flows from operating leases$1,541 
Financing cash flows from finance leases (principal payments)$86 
Weighted Average Remaining Lease Term (in years):
Operating leases4.7
Finance leases2.3
Weighted Average Discount Rate:
Operating leases4.1 %
Finance leases3.9 %
LEASES LEASES
We lease office space, warehouse and distribution space, and equipment under non-cancelable operating and finance leases expiring at various dates through 2029.
We determine whether an arrangement is a lease at inception, based on the (1) conveyed rights to obtain substantially all economic benefits from using the asset and (2) the right to direct the uses to which the asset is put.
Our lease population does not include any residual value guarantees, and therefore none were considered in the calculation of the lease balances. We have leases with variable payments, most commonly in the form of common area maintenance charges which are based on actual costs incurred. These variable payments were excluded from the right-of-use asset and lease liability balances since they are not fixed or in-substance fixed payments. We have lease agreements with lease and non-lease components. We elected the practical expedient to account for lease and non-lease components as a single lease component.
For leases with terms greater than 12 months, right-of-use assets and lease liabilities are recognized at the implementation date of Topic 842 or lease commencement date based on the present value of the future lease payments over the lease term. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, we utilize our incremental borrowing rate. Our lease agreements generally do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at either the implementation date of Topic 842 or at lease commencement for leases entered into thereafter in determining the present value of future payments. Lease expense for net present value of payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less with purchase options or extension options that are not reasonably certain to be exercised are not recorded on the condensed consolidated financial statements.
The components of lease expense were as follows:
(in thousands)Three Months Ended March 31, 2022
Operating lease costs$1,246 
Variable lease costs760 
Short-term lease costs326 
Finance lease cost
Amortization of right-of-use assets89
Interest on lease liabilities6
Total lease expense$2,427 
The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:
(in thousands) Operating LeasesFinance Leases
For the nine months ending December 31, 2022$4,852 $397 
20236,469 368 
20245,694 139 
20254,150 89 
20262,316 — 
Thereafter 3,297 — 
Total $26,778 $993 
Less: amounts representing interest $(2,550)$(52)
Net present value of lease obligations $24,228 $941 
The following table presents the balances for operating and finance right-of-use assets and lease liabilities:
(in thousands) ClassificationMarch 31, 2022
Assets
Operating lease assetsRight-of-use assets$18,574 
Finance lease assetsProperty and equipment940 
Total lease assets$19,514 
Liabilities
Current liabilities
Operating lease liabilitiesOperating lease liabilities$5,605 
Finance lease liabilitiesFinance lease obligations501
Non-current liabilities
Operating lease liabilitiesOperating lease liabilities18,623 
Finance lease liabilitiesFinance lease obligations440 
Total lease liabilities$25,169 
The table below presents additional information related to our leases as of March 31, 2022:
(in thousands)
Three Months Ended March 31, 2022
Supplemental cash flow information and non-cash activity:
Cash paid for amounts related to lease liabilities:
Operating cash flows from finance leases (interest)$
Operating cash flows from operating leases$1,541 
Financing cash flows from finance leases (principal payments)$86 
Weighted Average Remaining Lease Term (in years):
Operating leases4.7
Finance leases2.3
Weighted Average Discount Rate:
Operating leases4.1 %
Finance leases3.9 %
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Consolidation
Basis of Presentation and Consolidation
The accompanying condensed consolidated financial statements are unaudited and include the accounts of Convey and our wholly-owned subsidiaries. They have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our condensed consolidated statements of operations and comprehensive income (loss), shareholders’ equity, and cash flows for the three months ended March 31, 2022, and 2021, and the condensed consolidated balance sheet as of March 31, 2022, reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results for the periods shown.
Consolidation Our condensed consolidated balance sheet as of December 31, 2021, has been derived from our audited consolidated financial statements as of that date. Our condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2021, which include a complete set of footnote disclosures, including our significant accounting policies, and are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 23, 2022 (“Form 10-K”). The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information currently available to us and based on various other assumptions that we conclude to be reasonable under the circumstances. While management concludes that such estimates are reasonable when considered in conjunction with our condensed consolidated balance sheets and statements of operations and comprehensive income (loss) taken as a whole, actual results could differ materially from those estimates.
Acquisitions
Acquisitions
We allocate the purchase consideration to the identifiable net assets acquired, including intangible assets and liabilities assumed, based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, is recorded as goodwill. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition
date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to the condensed consolidated statements of operations and comprehensive income (loss).
Determining the fair value of assets acquired and liabilities assumed requires significant judgment, including the selection of valuation methodologies which techniques include the royalty method, the multi-period excess earnings method, the cost approach, the market approach, and the probability weighted assessment method as considered necessary. Significant assumptions used in those methodologies include, but are not limited to, growth rates, discount rates, customer attrition rates, expected levels of revenues, earnings, cash flows and tax rates. The use of different valuation methodologies and assumptions is highly subjective and inherently uncertain and, as a result, actual results may differ materially from estimates.
Customer Concentrations
Customer Concentrations
Revenue and Accounts receivable from our major customers are as follows:
Revenues
For the Three Months Ended
March 31,
(in thousands, except percentages)
20222021
Customer A
$27,108 $19,626 
    % of total revenue
28.0 %23.8 %
Customer B
$16,712 $16,766 
    % of total revenue
17.3 %20.3 %
Accounts Receivable
(in thousands, except percentages)
March 31, 2022December 31, 2021
Customer A$8,119 $13,161 
    % of total accounts receivable11.2 %21.0 %
Customer B$11,688 $15,174 
    % of total accounts receivable16.1 %24.2 %
Our customer base is highly concentrated. Revenue may significantly decline if we were to lose one or more of our major customers. However, our risk is reduced due to our significant customers having multiple product delivery solutions under separate contracts.
Contingent Consideration
Contingent Consideration
We recognized an earn-out liability in connection with the November 2018 acquisition of HealthScape Advisors, LLC (“HealthScape Advisors”) and Pareto Intelligence LLC (“Pareto Intelligence”), which represented contingent consideration.
The initial fair value of the earn-out liability was determined by employing a Monte-Carlo simulation model. The underlying simulated variable was adjusted revenue discounted by the market price of risk embedded in the revenue metrics. The revenue volatility estimate was based on a study of historical asset volatility and implied volatility for a set of comparable public companies, adjusted by our operating leverage. The earn-out payments were calculated based on simulated revenue metrics and payment thresholds as set forth in the HealthScape Advisors and Pareto Intelligence purchase agreement. The calculated payments were further discounted back to present value using cost of debt reflecting our credit risk. The fair value of the earn-out liability at each reporting date subsequent to the acquisition was measured using a probability weighted approach. Any change in fair value was recognized in the condensed consolidated statements of operations and comprehensive income (loss).
On September 4, 2019, Cannes Parent, Inc. (“Cannes”), a direct subsidiary of Convey, entered into an agreement to acquire all of the outstanding stock of Convey Health Solutions, Inc. through the merger of Cannes Merger Sub, Inc. (“Merger Sub”) and Convey Health Parent, Inc. (“Parent”) (the “Merger”) with Parent surviving as a direct subsidiary of Cannes. The Merger principally occurred through an investment from TPG Cannes Aggregation, L.P., which is primarily funded by partners of TPG Partners VIII, L.P. and TPG Healthcare Partners, L.P. or any parallel fund or their alternative investment vehicles (collectively, “TPG”). In connection with the Merger, we recognized a holdback liability, which represented contingent consideration. The
initial fair value of the holdback liabilities and at each subsequent reporting date was measured using a probability weighted approach. Any change in fair value was recognized in the consolidated statements of operations and comprehensive income (loss).
In connection with the acquisition of HealthSmart in February 2022, we recognized an earn-out liability which represented contingent consideration. The initial fair value of the earn-out liability was determined by employing a Black-Scholes Merton model. The earn-out payments were calculated based on projected revenue metrics and payment thresholds as set forth in the HealthSmart purchase agreement. The calculated payments were further discounted back to present value using the cost of debt reflecting our credit risk.
Net Income (Loss) Per Common Share
Net Income (Loss) Per Common Share
Basic income (loss) per share is computed by dividing net income (loss) attributable to common shareholders (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted net income (loss) per common share attributable to common shareholders is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period adjusted for the dilutive effects of common stock equivalents. In periods when losses from operations are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which supersedes the previous guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for virtually all of their leases except those which meet the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or financing. Classification is based on criteria that are similar to those applied in previous lease accounting, but without explicit bright lines. The recognition of these lease assets and lease liabilities represents a change from previous U.S. GAAP requirements, which did not require lease assets and lease liabilities to be recognized for most leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee, have not significantly changed from previous U.S. GAAP requirements. The Company adopted the provisions of Topic 842 on January 1, 2022, using the modified retrospective approach. All comparative periods prior to January 1, 2022 are not adjusted and continue to be reported in accordance with Topic 840.
The Company elected to utilize the package of practical expedients permitted within the new standard, which among other things, allowed the Company not to reassess prior conclusions about lease identification, classification and initial direct costs of existing leases as of the date of adoption. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the Company’s condensed consolidated balance sheet which resulted in recognizing those lease payments in the condensed consolidated statements of operations on a straight-line basis over the lease term.
Adoption of the new standard resulted in the recording of right-of-use assets and corresponding lease liabilities of $14.7 million and $20.7 million, respectively, as of January 1, 2022. The difference between the right-of-use assets and the lease liabilities was recorded to eliminate existing deferred rent balances and remaining balances of lease incentives recorded under Topic 840. The adoption of the new standard did not materially impact the Company's condensed consolidated statements of operations and had no impact on the Company's condensed consolidated statements of cash flows. See Note 18. Leases for further information.
Accounting Pronouncements Issued Not Yet Adopted
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Entities will be required to use a model that will result in the earlier recognition of allowances for losses for trade and other receivables, held-to-maturity debt securities, loans, and other instruments. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. ASU 2016-13, as subsequently amended for various technical issues, is effective for emerging growth companies following private company adoption dates for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”), subsequently clarified in January 2021 by ASU 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The main provisions of this update provide optional expedients and exceptions for contracts, hedging relationships, and other transactions that reference the London Inter-bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and, once adopted, may be applied prospectively to contract modifications and hedging relationships through December 31, 2022. We are currently evaluating the new guidance to determine the impact ASU 2020-04 and ASU 2021-01 will have on our consolidated financial statements.
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) (“ASU 2021-08”). The new guidance creates an exception to the general recognition and measurement principle for contract assets and contract liabilities from contracts with customers acquired in a business combination. Under this exception, an acquirer applies Topic 606 to recognize and measure contract assets and contract liabilities on the acquisition date. Topic 805 generally requires the acquirer in a business combination to recognize and measure the assets it acquires and liabilities it assumes at fair value on the acquisition date. This generally will result in companies recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date. This new guidance is effective for emerging growth companies following private business adoption dates, for the fiscal years beginning after December 15, 2023, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
Revenue and Accounts receivable from our major customers are as follows:
Revenues
For the Three Months Ended
March 31,
(in thousands, except percentages)
20222021
Customer A
$27,108 $19,626 
    % of total revenue
28.0 %23.8 %
Customer B
$16,712 $16,766 
    % of total revenue
17.3 %20.3 %
Accounts Receivable
(in thousands, except percentages)
March 31, 2022December 31, 2021
Customer A$8,119 $13,161 
    % of total accounts receivable11.2 %21.0 %
Customer B$11,688 $15,174 
    % of total accounts receivable16.1 %24.2 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2022:
(in thousands)
Balance at December 31, 2021$— 
Fair value of contingent consideration in connection with the HealthSmart acquisition2,254 
Payments — 
Change in fair value— 
Balance at March 31, 2022$2,254 
The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2021:
(in thousands)
Balance at December 31, 2020$20,538 
Payments— 
Change in fair value— 
Balance at March 31, 2021$20,538 
Schedule of Earnings per Share, Basic and Diluted
For the Three Months Ended
March 31,
(in thousands, except per share data)20222021
Net income (loss) attributable to common shareholders
Net income (loss)$(1,154)$(934)
Net income (loss) attributable to common shareholders$(1,154)$(934)
Weighted-average common shares outstanding:
Basic and diluted73,194,171 61,321,424 
Net income (loss) per share:
Basic and diluted$(0.02)$(0.02)
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following tables present disaggregated revenue by reporting segment:
(in thousands)For the Three Months Ended
March 31, 2022
Technology
Enabled
Solutions
Advisory
Services
Total
Supplemental Benefit Services$50,228 $— $50,228 
Health Plan Management25,862 — 25,862 
Consulting Services2,327 13,457 15,784 
Software Services2,191 85 2,276 
Data Analytics2,558 — 2,558 
Total$83,166 $13,542 $96,708 
(in thousands)For the Three Months Ended
March 31, 2021
Technology
Enabled
Solutions
Advisory
Services
Total
Supplemental Benefit Services$39,104 $— $39,104 
Health Plan Management23,942 — 23,942 
Consulting Services1,038 13,049 14,087 
Software Services2,730 — 2,730 
Data Analytics2,768 — 2,768 
Total$69,582 $13,049 $82,631 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
ACQUISITIONS (Tables)
3 Months Ended
Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the Acquisition date fair value of the allocation of the purchase consideration assigned to each major class of assets acquired and liabilities assumed as of February 1, 2022, the acquisition date:
Estimated Fair Value
(in thousands)
ASSETS ACQUIRED
Cash $112 
Accounts receivable 6,481 
Inventories22,879 
Prepaid expenses and other current assets 1,840 
Property and equipment1,269 
Operating lease right-of-use-assets4,908 
Total identifiable assets acquired 37,489 
Fair value of intangible assets
Trade names 8,600 
Customer relationships 25,500 
Total fair value of intangible assets acquired 34,100 
Total assets acquired $71,589 
LIABILITIES ASSUMED
Accounts payable $2,937 
Accrued expenses 3,895 
Operating lease liabilities, current portion1,003 
Deferred taxes10,222 
Operating lease liabilities, net of current portion3,905 
Total liabilities assumed 21,962 
Net identifiable assets49,627 
Goodwill27,352 
Total consideration$76,979 
Schedule of Business Acquisitions, by Acquisition
The following table summarizes the purchase consideration transferred in connection with the Acquisition and consists of the following:
(in thousands)March 31, 2022
Initial purchase price$74,725 
Earn-out (contingent consideration)2,254 
Total consideration$76,979 
Business Acquisition, Pro Forma Information
The following table presents the unaudited pro forma combined results of operations of the Company and Target for the three months ended March 31, 2022 and 2021, as if the acquisition had occurred on January 1, 2021. The pro forma information presented is for informational purposes only and is not indicative of results of operations that would have been achieved had the Acquisition taken place at the beginning of the period.
For the Three Months Ended
March 31
(in thousands)20222021
Net revenue101,174 97,567 
Net income (loss)205 (299)
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
3 Months Ended
Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
(in thousands)March 31, 2022December 31, 2021
Prepaid expenses and other advances$5,896 $6,904 
Software licenses828 2,547 
Insurance527 1,271 
Inventory purchase advances1,390 23 
Cloud computing subscription & implementation costs822 4,841 
Other current assets1,346 983 
Total prepaid expenses and other current assets$10,809 $16,569 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY AND EQUIPMENT (Tables)
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment consist of the following:
(in thousands)
Estimated Life
(in years)
March 31, 2022December 31, 2021
Office and computer equipment
3 – 7 years
$16,399 $14,442 
Leasehold improvements
Up to 10 years
10,542 10,503 
Furniture and fixtures
3 – 7 years
4,064 4,054 
Software
3 – 5 years
2,366 2,277 
33,371 31,276 
Less: accumulated depreciation(12,419)(10,876)
Property and equipment, net$20,952 $20,400 
Schedule of Finance Leased Assets Assets held under finance leases are included in property and equipment as follows:
(in thousands)March 31, 2022December 31, 2021
Office and computer equipment$1,682 $1,682 
Less: accumulated depreciation(742)(656)
Total financing leases included in property and equipment$940 $1,026 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSETS AND GOODWILL (Tables)
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The activity for goodwill as of March 31, 2022 is as follows:
(in thousands)
Balance at December 31, 2021$455,206 
Measurement period adjustments — 
Acquisitions (see Note 4)27,352 
Impairment — 
Balance at March 31, 2022$482,558 
Schedule of Finite-Lived Intangible Assets
The carrying value of identifiable intangible assets consisted of the following as of March 31, 2022:
(in thousands)
Gross
Carrying
Amount
Accumulated
Amortization
Net Carrying
Amount
Amortized intangible assets
Trade names$35,900 $(3,830)$32,070 
Customer relationships214,500 (44,636)169,864 
Technology47,800 (12,348)35,452 
Capitalized software development costs13,026 (2,419)10,607 
Total intangible assets$311,226 $(63,233)$247,993 
The carrying value of identifiable intangible assets consisted of the following as of December 31, 2021:
(in thousands)
Gross
Carrying
Amount
Accumulated
Amortization
Net Carrying
Amount
Amortized intangible assets
Trade names$27,300 $(3,395)$23,905 
Customer relationships189,000 (40,091)148,909 
Technology47,800 (11,153)36,647 
Capitalized software development costs12,454 (1,901)10,553 
Total intangible assets$276,554 $(56,540)$220,014 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
ACCRUED EXPENSES (Tables)
3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accrued expenses and other current liabilities consist of the following:
(in thousands)March 31, 2022December 31, 2021
Incentive bonus$257 $15,214 
Employee related7,784 11,154 
Sales and use tax6,365 6,865 
Rebates2,372 4,276 
Accrued interest83 637 
Accrued professional fees5,538 7,046 
Refundable deposits4,626 — 
Other3,013 3,366 
Total accrued expenses$30,038 $48,558 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
CREDIT FACILITY (Tables)
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Line of Credit Facilities
Debt consists of the following as of March 31, 2022, and December 31, 2021:
(in thousands)March 31, 2022December 31, 2021
Term loans$270,631 $192,631 
Less: deferred financing costs(5,368)(2,988)
Term loans, net of deferred financing costs265,263 189,643 
Less: current portion(780)— 
$264,483 $189,643 
Contractual Obligation, Fiscal Year Maturity
The required principal payments for Term Loans for each of the five years and thereafter following the balance sheet date are as follows:
(in thousands)
For the nine months ending December 31, 2022$585 
2023780 
2024780 
2025780 
2026267,706 
Total $270,631 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Share-based Payment Arrangement, Expensed and Capitalized, Amount
The following table summarizes the total share-based compensation expense included in the condensed consolidated statements of operations and comprehensive income (loss):
For the Three Months Ended
March 31,
(in thousands)20222021
Selling, general and administrative$1,264 $990 
Total stock-based compensation expense$1,264 $990 
Share-based Payment Arrangement, Option, Activity
Stock option activity and information about stock options outstanding are summarized in the following table:
Stock Option Awards
Weighted Average Exercise Price
Weighted Average Remaining Contractual Life (Years)
Outstanding at December 31, 20215,636,154 $7.68 8.29
Granted— — — 
Exercised— — — 
Forfeited— — — 
Outstanding at March 31, 20225,636,154 7.68 7.99
Vested or expect to vest as of March 31, 20225,636,154 7.68 7.99
Vested and Exercisable as of March 31, 20222,876,085 7.53 7.88
Share-based Payment Arrangement, Restricted Stock Unit, Activity
Activity and information about non-vested RSUs outstanding are summarized in the following table:
Restricted Stock Units
Weighted Average Grant Date Fair Value (in thousands)
Outstanding at December 31, 2021154,286 $2,006 
Granted3,743,679 25,083 
Vested— — 
Forfeited— — 
Outstanding at March 31, 20223,897,965 $27,089 
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
LTI Awards
Outstanding as of December 31, 202143
Forfeited(4)
Outstanding as of March 31, 202239
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
TRANSACTION RELATED COSTS (Tables)
3 Months Ended
Mar. 31, 2022
Acquisition Related and Deferred Offering Costs [Abstract]  
Schedule of Acquisition Related and Deferred Offering Costs
The following table represents the components of Transaction related costs as reported in the condensed consolidated statements of operations and comprehensive income (loss):
For the Three Months Ended
March 31,
(in thousands)20222021
Mergers and acquisitions related costs$640 $30 
Public company readiness costs— 1,056 
Total$640 $1,086 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Presented in the tables below is revenue and Segment Adjusted EBITDA by reportable segment:
For the Three Months Ended
March 31, 2022
(in thousands)
Technology Enabled
Solutions
Advisory
Services
Revenue$83,166 $13,542 
Segment Adjusted EBITDA$12,370 $5,323 
For the Three Months Ended
March 31, 2021
(in thousands)
Technology Enabled
Solutions
Advisory
Services
Revenue$69,582 $13,049 
Segment Adjusted EBITDA$16,307 $3,338 
The following table presents a reconciliation of Segment Adjusted EBITDA to the condensed consolidated U.S. GAAP net income (loss) from operations:
(in thousands)For the Three Months Ended
March 31,
20222021
Technology Enabled Solutions Segment Adjusted EBITDA$12,370 $16,307 
Advisory Services Segment Adjusted EBITDA5,323 3,338 
Total$17,693 $19,645 
Unallocated(1)
$(2,377)$(2,048)
Adjustments to reconcile to U.S. GAAP net income (loss)
Depreciation and amortization(8,252)(7,372)
Interest, net(3,719)(5,467)
Income tax provision676 1,007 
Cost of COVID-19(2)
(274)(1,185)
Sales and use tax— (1,498)
Non-cash stock compensation expense(1,264)(990)
Transaction related costs(640)(1,086)
Acquisition bonus expense(58)(192)
Inventory step-up(3)
(1,892)— 
Other(4)
(1,047)(1,748)
Net income (loss)$(1,154)$(934)
________________________
(1)Represents certain corporate costs associated with the executive compensation, legal, accounting, finance and other costs not specifically attributable to the segments.
(2)Expenses incurred due to the COVID-19 pandemic are primarily related to higher pricing from vendors due to supply chain disruptions and product shortages and higher employee costs due to hazard pay for our employees. While we had
previously expected that these costs would not be an adjustment in the calculation of Segment Adjusted EBITDA after 2021, the COVID-19 pandemic has not subsided and during 2022, to a lesser extent, we have continued to incur higher product costs due to higher pricing from vendors for certain items (e.g., masks and other similar high demand products). We now expect that these expenses will not be an adjustment in the calculation of Segment Adjusted EBITDA after 2022.
(3)Incremental cost of products associated with the step-up of inventory recognized in purchase accounting for the HealthSmart acquisition.
(4)These adjustments include individual adjustments related to management and board of directors fees and fees associated with obtaining the incremental term loans.
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES (Tables)
3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
Lease, Cost
The components of lease expense were as follows:
(in thousands)Three Months Ended March 31, 2022
Operating lease costs$1,246 
Variable lease costs760 
Short-term lease costs326 
Finance lease cost
Amortization of right-of-use assets89
Interest on lease liabilities6
Total lease expense$2,427 
The table below presents additional information related to our leases as of March 31, 2022:
(in thousands)
Three Months Ended March 31, 2022
Supplemental cash flow information and non-cash activity:
Cash paid for amounts related to lease liabilities:
Operating cash flows from finance leases (interest)$
Operating cash flows from operating leases$1,541 
Financing cash flows from finance leases (principal payments)$86 
Weighted Average Remaining Lease Term (in years):
Operating leases4.7
Finance leases2.3
Weighted Average Discount Rate:
Operating leases4.1 %
Finance leases3.9 %
Lessee, Operating Lease, Liability, Maturity
The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:
(in thousands) Operating LeasesFinance Leases
For the nine months ending December 31, 2022$4,852 $397 
20236,469 368 
20245,694 139 
20254,150 89 
20262,316 — 
Thereafter 3,297 — 
Total $26,778 $993 
Less: amounts representing interest $(2,550)$(52)
Net present value of lease obligations $24,228 $941 
Finance Lease, Liability, Fiscal Year Maturity
The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:
(in thousands) Operating LeasesFinance Leases
For the nine months ending December 31, 2022$4,852 $397 
20236,469 368 
20245,694 139 
20254,150 89 
20262,316 — 
Thereafter 3,297 — 
Total $26,778 $993 
Less: amounts representing interest $(2,550)$(52)
Net present value of lease obligations $24,228 $941 
Assets And Liabilities, Lessee
The following table presents the balances for operating and finance right-of-use assets and lease liabilities:
(in thousands) ClassificationMarch 31, 2022
Assets
Operating lease assetsRight-of-use assets$18,574 
Finance lease assetsProperty and equipment940 
Total lease assets$19,514 
Liabilities
Current liabilities
Operating lease liabilitiesOperating lease liabilities$5,605 
Finance lease liabilitiesFinance lease obligations501
Non-current liabilities
Operating lease liabilitiesOperating lease liabilities18,623 
Finance lease liabilitiesFinance lease obligations440 
Total lease liabilities$25,169 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
BUSINESS AND BASIS OF PRESENTATION (Details)
$ / shares in Units, $ in Millions
Jun. 18, 2021
USD ($)
$ / shares
shares
Jun. 04, 2021
shares
Mar. 31, 2022
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
Class of Stock [Line Items]        
Common stock par value (in usd per share) | $ / shares     $ 0.01 $ 0.01
Stock split, conversion ratio   126    
Common stock shares authorized   1,000,000 500,000,000 500,000,000
Sale of stock, net proceeds | $ $ 131.5      
Preferred stock shares authorized     25,000,000 0
Preferred stock par value (in usd per share) | $ / shares     $ 0.01 $ 0.01
Voting Common Stock        
Class of Stock [Line Items]        
Common stock shares authorized   915,000    
Nonvoting Common Stock        
Class of Stock [Line Items]        
Common stock shares authorized   85,000    
IPO        
Class of Stock [Line Items]        
Sale of stock, number of shares issued in transaction 13,333,334      
Sale of stock, price per share (in usd per share) | $ / shares $ 14.00      
Sale of stock, consideration received on transaction | $ $ 146.1      
IPO - Company Shares        
Class of Stock [Line Items]        
Sale of stock, number of shares issued in transaction 11,666,667      
IPO - Shares From Existing Shareholders        
Class of Stock [Line Items]        
Sale of stock, number of shares issued in transaction 1,666,667      
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Concentration Risk [Line Items]      
Net revenues $ 96,708 $ 82,631  
Accounts receivable, net of allowance for doubtful accounts of $69 as of March 31, 2022, and December 31, 2021 72,707   $ 62,813
Revenue Benchmark | Customer Concentration Risk | Customer A      
Concentration Risk [Line Items]      
Net revenues $ 27,108 $ 19,626  
Concentration risk, percentage 28.00% 23.80%  
Revenue Benchmark | Customer Concentration Risk | Customer B      
Concentration Risk [Line Items]      
Net revenues $ 16,712 $ 16,766  
Concentration risk, percentage 17.30% 20.30%  
Accounts Receivable | Customer Concentration Risk | Customer A      
Concentration Risk [Line Items]      
Concentration risk, percentage 11.20%   21.00%
Accounts receivable, net of allowance for doubtful accounts of $69 as of March 31, 2022, and December 31, 2021 $ 8,119   $ 13,161
Accounts Receivable | Customer Concentration Risk | Customer B      
Concentration Risk [Line Items]      
Concentration risk, percentage 16.10%   24.20%
Accounts receivable, net of allowance for doubtful accounts of $69 as of March 31, 2022, and December 31, 2021 $ 11,688   $ 15,174
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earn-Out and Holdback Liabilities Reconciliation (Details) - Fair Value, Inputs, Level 3 - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance $ 0 $ 20,538
Ending balance 2,254 20,538
Earn-Out Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value of contingent consideration in connection with the HealthSmart acquisition 2,254  
Change in fair value of contingent consideration 0 0
Holdback Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value of contingent consideration in connection with the HealthSmart acquisition $ 0 $ 0
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss (income) Per Common Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Net income (loss) attributable to common shareholders    
Net income (loss) $ (1,154) $ (934)
Net income (loss) $ (1,154) $ (934)
Weighted-average common shares outstanding:    
Weighted-average common shares outstanding: basic 73,194,171 61,321,424
Weighted-average common shares outstanding: diluted 73,194,171 61,321,424
Income (loss) per common share – Basic and diluted    
Net income (loss) per common share - basic (in usd per share) $ (0.02) $ (0.02)
Net income (loss) per common share - diluted (in usd per share) $ (0.02) $ (0.02)
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Jan. 01, 2022
Dec. 31, 2021
Accounting Policies [Abstract]        
Antidilutive securities excluded from computation of earnings per share, amount 9,534,119,000 5,690,664,000    
Operating lease right-of-use assets $ 18,574   $ 14,700 $ 0
Net present value of lease obligations $ 24,228   $ 20,700  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)
3 Months Ended
Mar. 31, 2022
USD ($)
segment
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Disaggregation of Revenue [Line Items]      
Number of reportable segments | segment 2    
Net revenues $ 96,708,000 $ 82,631,000  
Unbilled receivables, current 17,400,000   $ 7,000,000
Contract with customer, liability, revenue recognized 4,400,000 3,900,000  
Revenue, remaining performance obligation, amount $ 8,400,000    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01      
Disaggregation of Revenue [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months    
Revenue, remaining performance obligation, amount $ 4,200,000    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01      
Disaggregation of Revenue [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year    
Revenue, remaining performance obligation, amount $ 3,000,000    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01      
Disaggregation of Revenue [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year    
Revenue, remaining performance obligation, amount $ 1,100,000    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01      
Disaggregation of Revenue [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year    
Revenue, remaining performance obligation, amount $ 100,000    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01      
Disaggregation of Revenue [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year    
Revenue, remaining performance obligation, amount $ 7,500    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01      
Disaggregation of Revenue [Line Items]      
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year    
Revenue, remaining performance obligation, amount $ 7,500    
Data Analytics      
Disaggregation of Revenue [Line Items]      
Net revenues 2,558,000 2,768,000  
Data Analytics | Transferred at Point in Time      
Disaggregation of Revenue [Line Items]      
Net revenues $ 600,000 $ 1,400,000  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Net revenues $ 96,708 $ 82,631
Supplemental Benefit Services    
Disaggregation of Revenue [Line Items]    
Net revenues 50,228 39,104
Health Plan Management    
Disaggregation of Revenue [Line Items]    
Net revenues 25,862 23,942
Consulting Services    
Disaggregation of Revenue [Line Items]    
Net revenues 15,784 14,087
Software Services    
Disaggregation of Revenue [Line Items]    
Net revenues 2,276 2,730
Data Analytics    
Disaggregation of Revenue [Line Items]    
Net revenues 2,558 2,768
Technology Enabled Solutions    
Disaggregation of Revenue [Line Items]    
Net revenues 83,166 69,582
Technology Enabled Solutions | Supplemental Benefit Services    
Disaggregation of Revenue [Line Items]    
Net revenues 50,228 39,104
Technology Enabled Solutions | Health Plan Management    
Disaggregation of Revenue [Line Items]    
Net revenues 25,862 23,942
Technology Enabled Solutions | Consulting Services    
Disaggregation of Revenue [Line Items]    
Net revenues 2,327 1,038
Technology Enabled Solutions | Software Services    
Disaggregation of Revenue [Line Items]    
Net revenues 2,191 2,730
Technology Enabled Solutions | Data Analytics    
Disaggregation of Revenue [Line Items]    
Net revenues 2,558 2,768
Advisory Services    
Disaggregation of Revenue [Line Items]    
Net revenues 13,542 13,049
Advisory Services | Supplemental Benefit Services    
Disaggregation of Revenue [Line Items]    
Net revenues 0 0
Advisory Services | Health Plan Management    
Disaggregation of Revenue [Line Items]    
Net revenues 0 0
Advisory Services | Consulting Services    
Disaggregation of Revenue [Line Items]    
Net revenues 13,457 13,049
Advisory Services | Software Services    
Disaggregation of Revenue [Line Items]    
Net revenues 85 0
Advisory Services | Data Analytics    
Disaggregation of Revenue [Line Items]    
Net revenues $ 0 $ 0
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.1
ACQUISITIONS - Narrative (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Feb. 01, 2022
Jan. 09, 2022
Business Acquisition [Line Items]        
Net revenue $ 101,174,000 $ 97,567,000    
Net loss $ (205,000) $ 299,000    
Trade names        
Business Acquisition [Line Items]        
Finite-lived intangible asset, useful life 20 years      
Customer relationships        
Business Acquisition [Line Items]        
Finite-lived intangible asset, useful life 17 years      
D-M-S Holdings, Inc.        
Business Acquisition [Line Items]        
Net revenue $ 7,200,000      
Net loss $ 1,600,000      
Purchase Agreement        
Business Acquisition [Line Items]        
Debt instrument, repurchase amount       $ 74,700,000
Purchase agreement, revenue threshold       $ 15,000,000
2022 Incremental Term Loans        
Business Acquisition [Line Items]        
Debt instrument, face amount     $ 78,000,000  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.1
ACQUISITIONS - Assets and Liabilities Acquired (Details) - USD ($)
$ in Thousands
3 Months Ended
Feb. 01, 2022
Mar. 31, 2022
Dec. 31, 2021
LIABILITIES ASSUMED      
Goodwill   $ 482,558 $ 455,206
D-M-S Holdings, Inc.      
ASSETS ACQUIRED      
Cash $ 112    
Accounts receivable 6,481    
Inventories 22,879    
Prepaid expenses and other current assets 1,840    
Property and equipment 1,269    
Operating lease right-of-use-assets 4,908    
Total identifiable assets acquired 37,489    
Total fair value of intangible assets acquired 34,100    
Total assets acquired 71,589    
LIABILITIES ASSUMED      
Accounts payable 2,937    
Accrued expenses 3,895    
Operating lease liabilities, current portion 1,003    
Deferred taxes 10,222    
Operating lease liabilities, net of current portion 3,905    
Total liabilities assumed 21,962    
Net identifiable assets 49,627    
Goodwill 27,352    
Total consideration 76,979 $ 76,979  
D-M-S Holdings, Inc. | Trade names      
ASSETS ACQUIRED      
Total fair value of intangible assets acquired 8,600    
D-M-S Holdings, Inc. | Customer relationships      
ASSETS ACQUIRED      
Total fair value of intangible assets acquired $ 25,500    
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.1
ACQUISITIONS - Purchase Consideration (Details) - D-M-S Holdings, Inc. - USD ($)
$ in Thousands
3 Months Ended
Feb. 01, 2022
Mar. 31, 2022
Business Acquisition [Line Items]    
Initial purchase price   $ 74,725
Earn-out (contingent consideration)   2,254
Total consideration $ 76,979 $ 76,979
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.1
ACQUISITIONS - Pro Forma Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Business Combination and Asset Acquisition [Abstract]    
Net revenue $ 101,174 $ 97,567
Net income (loss) $ 205 $ (299)
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid expenses and other advances $ 5,896 $ 6,904
Software licenses 828 2,547
Insurance 527 1,271
Inventory purchase advances 1,390 23
Cloud computing subscription & implementation costs 822 4,841
Other current assets 1,346 983
Total prepaid expenses and other current assets $ 10,809 $ 16,569
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 33,371 $ 31,276
Less: accumulated depreciation (12,419) (10,876)
Property and equipment, net 20,952 20,400
Office and computer equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 16,399 14,442
Office and computer equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Life (in years) 3 years  
Office and computer equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Life (in years) 7 years  
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 10,542 10,503
Leasehold improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Life (in years) 10 years  
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 4,064 4,054
Furniture and fixtures | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Life (in years) 3 years  
Furniture and fixtures | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Life (in years) 7 years  
Software    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 2,366 $ 2,277
Software | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Life (in years) 3 years  
Software | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Life (in years) 5 years  
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 1,550 $ 1,386
Capital lease, depreciation expense $ 89 $ 100
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY AND EQUIPMENT - Assets Held Under Capital Leases (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Less: accumulated depreciation $ (742) $ (656)
Total financing leases included in property and equipment 940 1,026
Office and computer equipment    
Property, Plant and Equipment [Line Items]    
Office and computer equipment $ 1,682 $ 1,682
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSETS AND GOODWILL - Goodwill Activity (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 455,206
Measurement period adjustments 0
Acquisitions 27,352
Impairment 0
Goodwill, ending balance $ 482,558
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 482,558   $ 455,206
Minimum      
Finite-Lived Intangible Assets [Line Items]      
Percentage of fair value in excess of carrying amount 8.00%    
Maximum      
Finite-Lived Intangible Assets [Line Items]      
Percentage of fair value in excess of carrying amount 65.00%    
Advanced Plan Administration      
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 88,900    
Supplemental Benefits Administration      
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 190,200    
Percentage of fair value in excess of carrying amount 8.40%    
Value Based Analytics      
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 138,200    
Percentage of fair value in excess of carrying amount 12.50%    
HealthSmart      
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 27,400    
Tradenames, Customer Relationships and Technology      
Finite-Lived Intangible Assets [Line Items]      
Amortization of intangible assets 6,200 $ 5,900  
Capitalized software development costs      
Finite-Lived Intangible Assets [Line Items]      
Amortization of intangible assets 500 $ 100  
Advisory Services      
Finite-Lived Intangible Assets [Line Items]      
Goodwill 37,900    
Technology Enabled Solutions      
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 444,700    
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSETS AND GOODWILL - Carrying Value of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 311,226 $ 276,554
Accumulated Amortization (63,233) (56,540)
Net Carrying Amount 247,993 220,014
Trade names    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 35,900 27,300
Accumulated Amortization (3,830) (3,395)
Net Carrying Amount 32,070 23,905
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 214,500 189,000
Accumulated Amortization (44,636) (40,091)
Net Carrying Amount 169,864 148,909
Technology    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 47,800 47,800
Accumulated Amortization (12,348) (11,153)
Net Carrying Amount 35,452 36,647
Capitalized software development costs    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 13,026 12,454
Accumulated Amortization (2,419) (1,901)
Net Carrying Amount $ 10,607 $ 10,553
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.1
ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Incentive bonus $ 257 $ 15,214
Employee related 7,784 11,154
Sales and use tax 6,365 6,865
Rebates 2,372 4,276
Accrued interest 83 637
Accrued professional fees 5,538 7,046
Refundable deposits 4,626 0
Other 3,013 3,366
Total accrued expenses $ 30,038 $ 48,558
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.1
CREDIT FACILITY - Narrative (Details)
3 Months Ended
Jun. 18, 2021
USD ($)
Sep. 04, 2019
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Feb. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Feb. 12, 2021
USD ($)
Apr. 08, 2020
USD ($)
Jan. 23, 2020
USD ($)
Line of Credit Facility [Line Items]                  
Payment of debt issuance cost   $ 6,100,000 $ 2,631,000 $ 2,133,000          
Amortization of debt issuance costs     309,000 328,000          
Consolidated EBITDA, maximum amount     $ 46,900,000            
Consolidated EBITDA, percentage     1.000            
Debt instrument, leverage ratio     7.4            
Annual excess cash flow, percentage     0.50            
Net cash proceeds of certain asset sales or casualty events, percentage     1            
Net cash proceeds of debt, percentage     1            
Long-term debt, gross     $ 270,631,000     $ 192,631,000      
Long-term debt, irrevocable letter of credit threshold                 $ 500,000
Long-term debt, irrevocable letter of credit, extension period     1 year            
IPO                  
Line of Credit Facility [Line Items]                  
Prepayment premium on early repayment of term loan $ 131,500,000                
Minimum                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     0.375%            
Maximum                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     0.50%            
London Interbank Offered Rate (LIBOR)                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     1.00%            
Revolving Credit Facility                  
Line of Credit Facility [Line Items]                  
Amortization of debt issuance costs     $ 50,000 $ 50,000          
Unamortized debt issuance expense     $ 500,000     500,000      
Long-term debt, weighted average interest rate, over time     2.75% 2.75%          
Long-term debt, gross     $ 39,400,000     39,400,000      
Undrawn Letter Of Credit                  
Line of Credit Facility [Line Items]                  
Debt instrument, face amount     $ 10,000,000            
Secured Debt                  
Line of Credit Facility [Line Items]                  
Amortization of debt issuance costs   $ 5,200,000              
Debt issuance costs, amortization period   84 months              
Long-term debt, weighted average interest rate, over time     5.50% 6.30%          
Long-term debt, gross     $ 192,600,000     192,600,000      
Line of Credit | Revolving Credit Facility                  
Line of Credit Facility [Line Items]                  
Line of credit facility, maximum borrowing capacity   $ 40,000,000              
Debt instrument, term   5 years              
Amortization of debt issuance costs   $ 900,000              
Debt issuance costs, amortization period   60 months              
Line of Credit | Bridge Loan                  
Line of Credit Facility [Line Items]                  
Line of credit facility, maximum borrowing capacity   $ 10,000,000              
2022 Incremental Term Loans                  
Line of Credit Facility [Line Items]                  
Long-term debt, gross     78,000,000            
Term Loans                  
Line of Credit Facility [Line Items]                  
Amortization of debt issuance costs     $ 300,000 $ 900,000          
Debt instrument, aggregate principal amount, payment, percentage     0.0025            
Unamortized debt issuance expense     $ 5,400,000     $ 3,000,000      
Term Loans | Secured Debt                  
Line of Credit Facility [Line Items]                  
Debt instrument, face amount   $ 225,000,000              
Debt instrument, term   7 years              
2020 Incremental Term Loan                  
Line of Credit Facility [Line Items]                  
Long-term debt, weighted average interest rate, over time     5.50%            
2020 Incremental Term Loan | Secured Debt                  
Line of Credit Facility [Line Items]                  
Debt instrument, face amount               $ 25,000,000  
Debt issuance costs, gross               $ 1,100,000  
2021 Incremental Term Loan | Secured Debt                  
Line of Credit Facility [Line Items]                  
Debt instrument, face amount             $ 78,000,000    
Debt issuance costs, gross             $ 2,400,000    
2022 Incremental Term Loans                  
Line of Credit Facility [Line Items]                  
Debt instrument, face amount         $ 78,000,000        
2022 Incremental Term Loans | Secured Debt                  
Line of Credit Facility [Line Items]                  
Debt issuance costs, gross         $ 2,600,000        
Credit Agreement | London Interbank Offered Rate (LIBOR) | Minimum                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     5.25%            
Credit Agreement | London Interbank Offered Rate (LIBOR) | Maximum                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     4.75%            
Credit Agreement | Base Rate | Minimum                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     4.25%            
Credit Agreement | Base Rate | Maximum                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     3.75%            
Credit Agreement | Eurodollar | Minimum                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     1.00%            
Credit Agreement | Eurodollar | Maximum                  
Line of Credit Facility [Line Items]                  
Debt instrument, basis spread on variable rate     0.75%            
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.1
CREDIT FACILITY - Schedule of Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
Long-term debt, gross $ 270,631 $ 192,631
Less: deferred financing costs (5,368) (2,988)
Term loans, net of deferred financing costs 265,263 189,643
Term loans, current portion (780) 0
Term loans, net of current portion $ 264,483 $ 189,643
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.1
CREDIT FACILITY - Debt Maturities Schedule (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Debt Instrument, Redemption [Line Items]    
Term loans, net of deferred financing costs $ 270,631 $ 192,631
Term Loans    
Debt Instrument, Redemption [Line Items]    
2022 585  
2023 780  
2024 780  
2025 780  
2026 267,706  
Term loans, net of deferred financing costs $ 270,631  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.1
SHAREHOLDERS’ EQUITY (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Feb. 28, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Jun. 04, 2021
Dividends Payable [Line Items]          
Common stock shares authorized   500,000,000   500,000,000 1,000,000
Common stock par value (in usd per share)   $ 0.01   $ 0.01  
Preferred stock shares authorized   25,000,000   0  
Preferred stock par value (in usd per share)   $ 0.01   $ 0.01  
Dividends payable, amount per share (in usd per share) $ 1.18        
Dividends payable, current $ 74,500        
Payments of dividends   $ 0 $ 74,500    
Dividends Paid, Existing Shareholders          
Dividends Payable [Line Items]          
Payments of dividends 2,300        
Dividends Paid, Outstanding and Vested Option Holders          
Dividends Payable [Line Items]          
Payments of dividends $ 72,200        
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED COMPENSATION - Narrative (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jun. 03, 2021
Mar. 31, 2022
USD ($)
$ / shares
shares
Aug. 31, 2021
$ / shares
shares
Jun. 30, 2021
$ / shares
shares
Mar. 31, 2021
$ / shares
shares
Mar. 31, 2020
award
Mar. 31, 2022
USD ($)
installment
segment
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
Feb. 15, 2021
$ / shares
shares
Sep. 30, 2020
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options outstanding, weighted average exercise price (in usd per share) | $ / shares   $ 7.68         $ 7.68 $ 7.68    
Granted (in shares)     8,152 198,929            
Number of installments | installment             12      
Installment period             3 months      
Options, nonvested, weighted average grant date fair value, reduction (in usd per share) | $ / shares                 $ 1.18  
Options nonvested, number of shares                 3,653,837  
Option, nonvested, weighted average exercise price (in usd per share) | $ / shares                 $ 7.94  
Options, outstanding, intrinsic value | $   $ 0         $ 0      
Options, exercisable, intrinsic value | $   0         $ 0 $ 0    
Number of awards | segment             1      
Number of long term incentive awards | award           56        
2021 Omnibus Incentive Compensation Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Share-based payment award expiration period 10 years                  
Share-based Payment Arrangement, Option                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Award vesting rights, percentage       25.00% 25.00%          
Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount | $   9,400         $ 9,400      
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition             2 years 1 month 9 days      
Share-based Payment Arrangement, Option | 2021 Omnibus Incentive Compensation Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Share-based payment award expiration period     5 years              
Share-based payment award, shares issued in period     20,380 497,321            
Options outstanding, weighted average exercise price (in usd per share) | $ / shares     $ 9.20 $ 14.00            
Share-based Payment Arrangement, Option | 2019 Equity Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Share-based payment award expiration period       10 years 10 years          
Share-based payment award, shares issued in period         69,300          
Options outstanding, weighted average exercise price (in usd per share) | $ / shares               $ 9.92    
Share-based Payment Arrangement, Option | 2021 Equity Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Options outstanding, weighted average exercise price (in usd per share) | $ / shares         $ 6.70          
Restricted Stock Units                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Award vesting rights, percentage       25.00%            
Granted (in shares)             3,743,679      
Outstanding at beginning of period (in shares) | $ / shares     $ 9.20 $ 13.00            
Award vesting period             3 years      
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition             3 years 10 months 17 days      
Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount | $   $ 26,600         $ 26,600      
Exercised (in shares)             0      
Restricted Stock Units | 2021 Equity Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Granted (in shares)   2,500,459                
Performance Shares                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Award vesting rights, percentage       25.00%            
Performance Shares | 2021 Equity Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Granted (in shares)   1,243,220                
LTI Awards                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Granted (in shares)             0      
Equity instruments other than options, aggregate intrinsic value, nonvested | $                   $ 1,100
Exercised (in shares)             0      
Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period             0      
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED COMPENSATION - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 1,264 $ 990
Selling, general and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 1,264 $ 990
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED COMPENSATION - Stock Option Activity (Details) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Stock Option Awards    
Beginning balance (in shares) 5,636,154  
Granted (in shares) 0  
Exercised (in shares) 0  
Forfeited (in shares) 0  
Ending balance (in shares) 5,636,154 5,636,154
Vested or expect to vest (in shares) 5,636,154  
Vested or expect to vest (in shares) 2,876,085  
Weighted Average Exercise Price    
Beginning balance (in usd per share) $ 7.68  
Granted (in usd per share) 0  
Exercised (in usd per share) 0  
Forfeited (in usd per share) 0  
Ending balance (in usd per share) 7.68 $ 7.68
Vested or expect to vest at end of period (in usd per share) 7.68  
Vested or expect to vest at end of period (in usd per share) $ 7.53  
Weighted Average Remaining Contractual Life (Years)    
Weighted Average Remaining Contractual Life (Years) 7 years 11 months 26 days 8 years 3 months 14 days
Weighted average remaining contractual life vested or expect to vest 7 years 11 months 26 days  
Weighted average remaining contractual life vested or expect to vest 7 years 10 months 17 days  
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Aug. 31, 2021
Jun. 30, 2021
Mar. 31, 2022
Restricted Stock Units      
Granted (in shares) 8,152 198,929  
Restricted Stock Units      
Restricted Stock Units      
Outstanding at beginning of period (in shares)     154,286
Granted (in shares)     3,743,679
Exercised (in shares)     0
Forfeited (in shares)     0
Outstanding at end of period (in shares)     3,897,965
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Outstanding at beginning of period (in usd per share)     $ 2,006
Granted (in usd per share)     25,083
Exercised (in usd per share)     0
Forfeited (in usd per share)     0
Outstanding at end of period (in usd per share)     $ 27,089
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED COMPENSATION - Long Term Incentive Activity (Details) - LTI Awards
3 Months Ended
Mar. 31, 2022
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Outstanding at beginning of period (in shares) 43
Forfeited (in shares) (4)
Outstanding at end of period (in shares) 39
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.1
EMPLOYEE SAVINGS PLAN (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Retirement Benefits [Abstract]    
Defined contribution plan, cost $ 0.9 $ 0.7
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.1
TAXES (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Tax Disclosure [Abstract]    
Income tax (expense) benefit $ 676 $ 1,007
Effective income tax rate reconciliation, percent 37.00% 22.50%
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.1
TRANSACTION RELATED COSTS (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Acquisition Related and Deferred Offering Costs [Abstract]    
Mergers and acquisitions related costs $ 640 $ 30
Public company readiness costs 0 1,056
Total $ 640 $ 1,086
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]    
Contractual obligation $ 3.1 $ 5.2
Loss contingency accrual $ 6.4 $ 6.9
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS (Details)
1 Months Ended 3 Months Ended
Jun. 30, 2021
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Related Party Transaction [Line Items]        
Related party, equity held, percent   0.10    
Related party, payment, term   3 years    
Affiliated Entity        
Related Party Transaction [Line Items]        
Annual retainer fee   0.01    
Affiliated Entity | TPG Management and Consulting Fees        
Related Party Transaction [Line Items]        
Related party transaction, amounts of transaction   $ 0 $ 200,000  
Affiliated Entity | TPG Management Service Agreement        
Related Party Transaction [Line Items]        
Related party transaction, amounts of transaction   1,000,000 1,000,000  
Loss on contract termination $ 2,300,000      
Due from related parties, current       $ 0
Affiliated Entity | EIR Partners Consulting Agreement        
Related Party Transaction [Line Items]        
Related party transaction, amounts of transaction   $ 20,000 $ 30,000  
Related party transaction, renewal term   1 year    
Affiliated Entity | EIR Partners Monthly Consulting Agreement        
Related Party Transaction [Line Items]        
Related party transaction, amounts of transaction   $ 10,000    
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT INFORMATION - Narrative (Details)
3 Months Ended
Mar. 31, 2022
segment
Segment Reporting [Abstract]  
Number of reportable segments 2
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Segment Reporting Information [Line Items]    
Net revenues $ 96,708 $ 82,631
Segment Adjusted EBITDA 17,693 19,645
Unallocated (2,377) (2,048)
Adjustments to reconcile to U.S. GAAP net income (loss)    
Depreciation and amortization (8,252) (7,372)
Interest expense (3,719) (5,467)
Income tax provision 676 1,007
Cost of COVID-19 (274) (1,185)
Sales and use tax 0 (1,498)
Non-cash stock compensation expense (1,264) (990)
Transaction related costs (640) (1,086)
Acquisition bonus expense (58) (192)
Inventory step-up (1,892) 0
Other (1,047) (1,748)
Net income (loss) (1,154) (934)
Technology Enabled Solutions    
Segment Reporting Information [Line Items]    
Net revenues 83,166 69,582
Segment Adjusted EBITDA 12,370 16,307
Advisory Services    
Segment Reporting Information [Line Items]    
Net revenues 13,542 13,049
Segment Adjusted EBITDA $ 5,323 $ 3,338
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES - Components of Lease Expense (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
Leases [Abstract]  
Operating lease costs $ 1,246
Variable lease costs 760
Short-term lease costs 326
Finance lease cost  
Amortization of right-of-use assets 89
Interest on lease liabilities 6
Total lease expense $ 2,427
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES - Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Jan. 01, 2022
Operating Leases    
For the nine months ending December 31, 2022 $ 4,852  
2023 6,469  
2024 5,694  
2025 4,150  
2026 2,316  
Thereafter 3,297  
Total 26,778  
Less: amounts representing interest (2,550)  
Net present value of lease obligations 24,228 $ 20,700
Finance Leases    
For the nine months ending December 31, 2022 397  
2023 368  
2024 139  
2025 89  
2026 0  
Thereafter 0  
Total 993  
Less: amounts representing interest (52)  
Net present value of lease obligations $ 941  
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES - Lease Balances (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Jan. 01, 2022
Dec. 31, 2021
ASSETS      
Operating lease right-of-use assets $ 18,574 $ 14,700 $ 0
Finance lease assets 940    
Total lease assets $ 19,514    
Finance lease, right-of-use asset, statement of financial position Property and equipment, net    
Current liabilities      
Operating lease liabilities, current portion $ 5,605   0
Finance lease liabilities 501   498
Non-current liabilities      
Operating lease liabilities, net of current portion 18,623   0
Finance leases obligations, net of current portion 440   $ 528
Total lease liabilities $ 25,169    
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES - Additional Lease Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash paid for amounts related to lease liabilities:    
Operating cash flows from finance leases (interest) $ 6  
Operating cash flows from operating leases 1,541  
Financing cash flows from finance leases (principal payments) $ 86 $ 31
Weighted Average Remaining Lease Term (in years):    
Operating leases 4 years 8 months 12 days  
Finance leases 2 years 3 months 18 days  
Weighted Average Discount Rate:    
Operating leases 4.10%  
Finance leases 3.90%  
XML 87 cnvy-20220331_htm.xml IDEA: XBRL DOCUMENT 0001787640 2022-01-01 2022-03-31 0001787640 2022-04-29 0001787640 2022-03-31 0001787640 2021-12-31 0001787640 us-gaap:ServiceMember 2022-01-01 2022-03-31 0001787640 us-gaap:ServiceMember 2021-01-01 2021-03-31 0001787640 us-gaap:ProductMember 2022-01-01 2022-03-31 0001787640 us-gaap:ProductMember 2021-01-01 2021-03-31 0001787640 2021-01-01 2021-03-31 0001787640 us-gaap:CommonStockMember 2021-12-31 0001787640 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001787640 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001787640 us-gaap:RetainedEarningsMember 2021-12-31 0001787640 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001787640 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001787640 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001787640 us-gaap:CommonStockMember 2022-03-31 0001787640 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001787640 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001787640 us-gaap:RetainedEarningsMember 2022-03-31 0001787640 us-gaap:CommonStockMember 2020-12-31 0001787640 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001787640 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001787640 us-gaap:RetainedEarningsMember 2020-12-31 0001787640 2020-12-31 0001787640 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001787640 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001787640 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001787640 us-gaap:CommonStockMember 2021-03-31 0001787640 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001787640 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001787640 us-gaap:RetainedEarningsMember 2021-03-31 0001787640 2021-03-31 0001787640 2021-06-04 2021-06-04 0001787640 2021-06-04 0001787640 cnvy:VotingCommonStockMember 2021-06-04 0001787640 us-gaap:NonvotingCommonStockMember 2021-06-04 0001787640 us-gaap:IPOMember 2021-06-18 2021-06-18 0001787640 us-gaap:IPOMember 2021-06-18 0001787640 cnvy:IPOCompanySharesMember 2021-06-18 2021-06-18 0001787640 cnvy:IPOSharesFromExistingShareholdersMember 2021-06-18 2021-06-18 0001787640 2021-06-18 0001787640 cnvy:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001787640 cnvy:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001787640 cnvy:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001787640 cnvy:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001787640 cnvy:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-03-31 0001787640 cnvy:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-12-31 0001787640 cnvy:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001787640 cnvy:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001787640 cnvy:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-03-31 0001787640 cnvy:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-12-31 0001787640 cnvy:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001787640 cnvy:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001787640 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001787640 us-gaap:FairValueInputsLevel3Member cnvy:EarnOutLiabilitiesMember 2022-01-01 2022-03-31 0001787640 us-gaap:FairValueInputsLevel3Member cnvy:HoldbackLiabilitiesMember 2022-01-01 2022-03-31 0001787640 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001787640 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001787640 us-gaap:FairValueInputsLevel3Member cnvy:HoldbackLiabilitiesMember 2021-01-01 2021-03-31 0001787640 us-gaap:FairValueInputsLevel3Member cnvy:EarnOutLiabilitiesMember 2021-01-01 2021-03-31 0001787640 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001787640 2022-01-01 0001787640 us-gaap:ProductMember cnvy:TechnologyEnabledSolutionsMember 2022-01-01 2022-03-31 0001787640 us-gaap:ProductMember cnvy:AdvisoryServicesMember 2022-01-01 2022-03-31 0001787640 us-gaap:HealthCareMember cnvy:TechnologyEnabledSolutionsMember 2022-01-01 2022-03-31 0001787640 us-gaap:HealthCareMember cnvy:AdvisoryServicesMember 2022-01-01 2022-03-31 0001787640 us-gaap:HealthCareMember 2022-01-01 2022-03-31 0001787640 cnvy:ConsultingMember cnvy:TechnologyEnabledSolutionsMember 2022-01-01 2022-03-31 0001787640 cnvy:ConsultingMember cnvy:AdvisoryServicesMember 2022-01-01 2022-03-31 0001787640 cnvy:ConsultingMember 2022-01-01 2022-03-31 0001787640 us-gaap:TechnologyServiceMember cnvy:TechnologyEnabledSolutionsMember 2022-01-01 2022-03-31 0001787640 us-gaap:TechnologyServiceMember cnvy:AdvisoryServicesMember 2022-01-01 2022-03-31 0001787640 us-gaap:TechnologyServiceMember 2022-01-01 2022-03-31 0001787640 cnvy:DataAnalyticsMember cnvy:TechnologyEnabledSolutionsMember 2022-01-01 2022-03-31 0001787640 cnvy:DataAnalyticsMember cnvy:AdvisoryServicesMember 2022-01-01 2022-03-31 0001787640 cnvy:DataAnalyticsMember 2022-01-01 2022-03-31 0001787640 cnvy:TechnologyEnabledSolutionsMember 2022-01-01 2022-03-31 0001787640 cnvy:AdvisoryServicesMember 2022-01-01 2022-03-31 0001787640 us-gaap:ProductMember cnvy:TechnologyEnabledSolutionsMember 2021-01-01 2021-03-31 0001787640 us-gaap:ProductMember cnvy:AdvisoryServicesMember 2021-01-01 2021-03-31 0001787640 us-gaap:HealthCareMember cnvy:TechnologyEnabledSolutionsMember 2021-01-01 2021-03-31 0001787640 us-gaap:HealthCareMember cnvy:AdvisoryServicesMember 2021-01-01 2021-03-31 0001787640 us-gaap:HealthCareMember 2021-01-01 2021-03-31 0001787640 cnvy:ConsultingMember cnvy:TechnologyEnabledSolutionsMember 2021-01-01 2021-03-31 0001787640 cnvy:ConsultingMember cnvy:AdvisoryServicesMember 2021-01-01 2021-03-31 0001787640 cnvy:ConsultingMember 2021-01-01 2021-03-31 0001787640 us-gaap:TechnologyServiceMember cnvy:TechnologyEnabledSolutionsMember 2021-01-01 2021-03-31 0001787640 us-gaap:TechnologyServiceMember cnvy:AdvisoryServicesMember 2021-01-01 2021-03-31 0001787640 us-gaap:TechnologyServiceMember 2021-01-01 2021-03-31 0001787640 cnvy:DataAnalyticsMember cnvy:TechnologyEnabledSolutionsMember 2021-01-01 2021-03-31 0001787640 cnvy:DataAnalyticsMember cnvy:AdvisoryServicesMember 2021-01-01 2021-03-31 0001787640 cnvy:DataAnalyticsMember 2021-01-01 2021-03-31 0001787640 cnvy:TechnologyEnabledSolutionsMember 2021-01-01 2021-03-31 0001787640 cnvy:AdvisoryServicesMember 2021-01-01 2021-03-31 0001787640 cnvy:DataAnalyticsMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-03-31 0001787640 cnvy:DataAnalyticsMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0001787640 2022-04-01 2022-03-31 0001787640 2023-01-01 2022-03-31 0001787640 2024-01-01 2022-03-31 0001787640 2025-01-01 2022-03-31 0001787640 2026-01-01 2022-03-31 0001787640 2027-01-01 2022-03-31 0001787640 cnvy:PurchaseAgreementMember 2022-01-09 0001787640 cnvy:A2022IncrementalTermLoansMember 2022-02-01 0001787640 cnvy:DMSHoldingsIncMember 2022-02-01 0001787640 cnvy:DMSHoldingsIncMember us-gaap:TradeNamesMember 2022-02-01 0001787640 cnvy:DMSHoldingsIncMember us-gaap:CustomerRelationshipsMember 2022-02-01 0001787640 cnvy:DMSHoldingsIncMember 2022-02-01 2022-02-01 0001787640 us-gaap:TradeNamesMember 2022-01-01 2022-03-31 0001787640 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0001787640 cnvy:DMSHoldingsIncMember 2022-01-01 2022-03-31 0001787640 cnvy:DMSHoldingsIncMember 2022-03-31 0001787640 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-03-31 0001787640 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-03-31 0001787640 us-gaap:MachineryAndEquipmentMember 2022-03-31 0001787640 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001787640 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-03-31 0001787640 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001787640 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001787640 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-03-31 0001787640 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-03-31 0001787640 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001787640 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001787640 srt:MinimumMember us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-03-31 0001787640 srt:MaximumMember us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-03-31 0001787640 us-gaap:SoftwareDevelopmentMember 2022-03-31 0001787640 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001787640 cnvy:AdvancedPlanAdministrationMember 2022-03-31 0001787640 cnvy:SupplementalBenefitsAdministrationMember 2022-03-31 0001787640 cnvy:ValueBasedAnalyticsMember 2022-03-31 0001787640 cnvy:AdvisoryServicesMember 2022-03-31 0001787640 cnvy:HealthSmartMember 2022-03-31 0001787640 cnvy:TechnologyEnabledSolutionsMember 2022-03-31 0001787640 srt:MinimumMember 2022-03-31 0001787640 srt:MaximumMember 2022-03-31 0001787640 us-gaap:TradeNamesMember 2022-03-31 0001787640 us-gaap:CustomerRelationshipsMember 2022-03-31 0001787640 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-03-31 0001787640 us-gaap:SoftwareDevelopmentMember 2022-03-31 0001787640 us-gaap:TradeNamesMember 2021-12-31 0001787640 us-gaap:CustomerRelationshipsMember 2021-12-31 0001787640 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0001787640 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001787640 cnvy:TradenamesCustomerRelationshipsAndTechnologyMember 2022-01-01 2022-03-31 0001787640 cnvy:TradenamesCustomerRelationshipsAndTechnologyMember 2021-01-01 2021-03-31 0001787640 us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-03-31 0001787640 us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-03-31 0001787640 cnvy:TermLoansMember us-gaap:SecuredDebtMember 2019-09-04 0001787640 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-09-04 0001787640 cnvy:TermLoansMember us-gaap:SecuredDebtMember 2019-09-04 2019-09-04 0001787640 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-09-04 2019-09-04 0001787640 2019-09-04 2019-09-04 0001787640 us-gaap:SecuredDebtMember 2019-09-04 2019-09-04 0001787640 us-gaap:BridgeLoanMember us-gaap:LineOfCreditMember 2019-09-04 0001787640 cnvy:A2020IncrementalTermLoanMember us-gaap:SecuredDebtMember 2020-04-08 0001787640 cnvy:A2021IncrementalTermLoanMember us-gaap:SecuredDebtMember 2021-02-12 0001787640 cnvy:A2022IncrementalTermLoansMember us-gaap:SecuredDebtMember 2022-02-01 0001787640 us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0001787640 srt:MinimumMember 2022-01-01 2022-03-31 0001787640 srt:MaximumMember 2022-01-01 2022-03-31 0001787640 srt:MinimumMember cnvy:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0001787640 srt:MaximumMember cnvy:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0001787640 srt:MinimumMember cnvy:CreditAgreementMember us-gaap:BaseRateMember 2022-01-01 2022-03-31 0001787640 srt:MaximumMember cnvy:CreditAgreementMember us-gaap:BaseRateMember 2022-01-01 2022-03-31 0001787640 srt:MinimumMember cnvy:CreditAgreementMember us-gaap:EurodollarMember 2022-01-01 2022-03-31 0001787640 srt:MaximumMember cnvy:CreditAgreementMember us-gaap:EurodollarMember 2022-01-01 2022-03-31 0001787640 cnvy:UndrawnLetterOfCreditMember 2022-03-31 0001787640 cnvy:TermLoansMember 2022-01-01 2022-03-31 0001787640 cnvy:TermLoansMember 2022-03-31 0001787640 cnvy:TermLoansMember 2021-12-31 0001787640 cnvy:TermLoansMember 2021-01-01 2021-03-31 0001787640 us-gaap:RevolvingCreditFacilityMember 2022-03-31 0001787640 us-gaap:RevolvingCreditFacilityMember 2021-12-31 0001787640 us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-03-31 0001787640 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-03-31 0001787640 us-gaap:SecuredDebtMember 2022-01-01 2022-03-31 0001787640 us-gaap:SecuredDebtMember 2021-01-01 2021-03-31 0001787640 us-gaap:SecuredDebtMember 2021-12-31 0001787640 us-gaap:SecuredDebtMember 2022-03-31 0001787640 cnvy:A2020IncrementalTermLoanMember 2022-01-01 2022-03-31 0001787640 cnvy:A2022IncrementalTermLoansMember 2022-03-31 0001787640 2020-01-23 0001787640 cnvy:TermLoansMember 2022-03-31 0001787640 2021-02-28 0001787640 cnvy:DividendsPaidOutstandingAndVestedOptionHoldersMember 2021-02-01 2021-02-28 0001787640 cnvy:DividendsPaidExistingShareholdersMember 2021-02-01 2021-02-28 0001787640 cnvy:A2021OmnibusIncentiveCompensationPlanMember 2021-06-03 2021-06-03 0001787640 us-gaap:EmployeeStockOptionMember cnvy:A2019EquityPlanMember 2021-03-01 2021-03-31 0001787640 us-gaap:EmployeeStockOptionMember cnvy:A2019EquityPlanMember 2021-12-31 0001787640 us-gaap:EmployeeStockOptionMember 2021-03-01 2021-03-31 0001787640 us-gaap:EmployeeStockOptionMember cnvy:A2021OmnibusIncentiveCompensationPlanMember 2021-06-01 2021-06-30 0001787640 us-gaap:EmployeeStockOptionMember cnvy:A2021OmnibusIncentiveCompensationPlanMember 2021-06-30 0001787640 us-gaap:EmployeeStockOptionMember cnvy:A2019EquityPlanMember 2021-06-01 2021-06-30 0001787640 2021-06-01 2021-06-30 0001787640 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0001787640 us-gaap:EmployeeStockOptionMember 2021-06-01 2021-06-30 0001787640 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001787640 us-gaap:EmployeeStockOptionMember cnvy:A2021OmnibusIncentiveCompensationPlanMember 2021-08-01 2021-08-31 0001787640 us-gaap:EmployeeStockOptionMember cnvy:A2021OmnibusIncentiveCompensationPlanMember 2021-08-31 0001787640 2021-08-01 2021-08-31 0001787640 us-gaap:RestrictedStockUnitsRSUMember 2021-08-31 0001787640 us-gaap:RestrictedStockUnitsRSUMember cnvy:A2021EquityPlanMember 2022-03-01 2022-03-31 0001787640 us-gaap:PerformanceSharesMember cnvy:A2021EquityPlanMember 2022-03-01 2022-03-31 0001787640 us-gaap:EmployeeStockOptionMember cnvy:A2021EquityPlanMember 2021-03-31 0001787640 us-gaap:PerformanceSharesMember 2021-06-01 2021-06-30 0001787640 us-gaap:RestrictedStockUnitsRSUMember 2021-06-01 2021-06-30 0001787640 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001787640 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001787640 2021-02-15 0001787640 2021-01-01 2021-12-31 0001787640 us-gaap:EmployeeStockOptionMember 2022-03-31 0001787640 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001787640 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001787640 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001787640 2020-03-01 2020-03-31 0001787640 cnvy:LongTermIncentiveAwardsMember 2020-09-30 0001787640 cnvy:LongTermIncentiveAwardsMember 2022-01-01 2022-03-31 0001787640 cnvy:LongTermIncentiveAwardsMember 2021-12-31 0001787640 cnvy:LongTermIncentiveAwardsMember 2022-03-31 0001787640 srt:AffiliatedEntityMember 2022-03-31 0001787640 cnvy:TPGManagementAndConsultingFeesMember srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001787640 cnvy:TPGManagementAndConsultingFeesMember srt:AffiliatedEntityMember 2021-01-01 2021-03-31 0001787640 cnvy:TPGTermLoanFeesMember srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001787640 cnvy:TPGTermLoanFeesMember srt:AffiliatedEntityMember 2021-01-01 2021-03-31 0001787640 cnvy:TPGTermLoanFeesMember srt:AffiliatedEntityMember 2021-06-01 2021-06-30 0001787640 cnvy:TPGTermLoanFeesMember srt:AffiliatedEntityMember 2021-12-31 0001787640 cnvy:EIRPartnersMonthlyConsultingAgreementMember srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001787640 cnvy:EIRPartnersConsultingAgreementMember srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001787640 cnvy:EIRPartnersConsultingAgreementMember srt:AffiliatedEntityMember 2021-01-01 2021-03-31 shares iso4217:USD iso4217:USD shares pure cnvy:segment cnvy:installment cnvy:award 0001787640 --12-31 2022 Q1 false P1Y P1Y P1Y P1Y P1Y P10Y P10Y http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet 10-Q true 2022-03-31 false 001-40506 Convey Health Solutions Holdings, Inc. DE 84-2099378 100 SE 3rd Avenue, 26th Floor Fort Lauderdale FL 33394 800 559-9358 Common Stock, $0.01 par value per share CNVY NYSE Yes Yes Non-accelerated Filer false true false false 73194171 20866000 38811000 69000 69000 72707000 62813000 36408000 14060000 10809000 16569000 140790000 132253000 20952000 20400000 247993000 220014000 482558000 455206000 18574000 0 5667000 2030000 916534000 829903000 11156000 13868000 30038000 48558000 5605000 0 501000 498000 9494000 7472000 780000 0 57574000 70396000 18623000 0 440000 528000 35094000 25992000 264483000 189643000 2475000 5595000 378689000 292154000 0.01 0.01 25000000 0 0 0 0 0 0 0 0 0 0 0 0 0.01 0.01 500000000 500000000 73194171 73194171 73194171 73194171 732000 732000 571516000 570252000 17000 31000 -34420000 -33266000 537845000 537749000 916534000 829903000 46480000 43527000 50228000 39104000 96708000 82631000 25477000 24021000 37236000 26527000 23214000 20099000 8252000 7372000 640000 1086000 94819000 79105000 1889000 3526000 3719000 5467000 -3719000 -5467000 -1830000 -1941000 -676000 -1007000 -1154000 -934000 -0.02 -0.02 -0.02 -0.02 -1154000 -934000 -14000 -7000 -1168000 -941000 73194171 732000 570252000 31000 -33266000 537749000 1264000 1264000 -14000 -14000 -1154000 -1154000 73194171 732000 571516000 17000 -34420000 537845000 61321424 613000 492747000 78000 -23288000 470150000 990000 990000 -7000 -7000 74500000 74500000 -934000 -934000 61321424000 613000 419237000 71000 24222000 395699000 -1154000 -934000 1550000 1386000 6702000 5986000 253000 0 0 342000 90000 399000 -10000 0 -1120000 -963000 309000 328000 1264000 990000 1246000 0 1892000 0 3414000 -4662000 1450000 3207000 -3903000 -843000 -26222000 -22100000 2022000 -358000 -1541000 0 -15660000 -12626000 74613000 0 1836000 3063000 1105000 1287000 -77554000 -4350000 78000000 78000000 2631000 2133000 0 821000 86000 31000 0 74500000 75283000 515000 -14000 -7000 -17945000 -16468000 38811000 49086000 20866000 32618000 20866000 28938000 0 3560000 0 120000 20866000 32618000 250000 216000 3986000 4961000 672000 471000 BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convey Health Solutions Holdings, Inc. (collectively with its subsidiaries, which includes our main operating subsidiary, Convey Health Solutions, Inc., “we”, “us”, “our”, “Convey” or the “Company”) provides technology enabled solutions to payors within the large and growing government sponsored health plan market. Our platform combines proprietary modular technology and end-to-end solutions to serve as an extension of our clients’ operations and core systems. Our clients are primarily Medicare Advantage, Medicare Part D and Employer Group Waiver Plans, as well as Pharmacy Benefit Managers. Convey is a United States (“U.S.”) based holding company incorporated in Delaware. Our principal executive offices are located in Fort Lauderdale, Florida.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, Convey’s indirect wholly-owned subsidiary, D-M-S Holdings Parent, LLC (f/k/a Dragon Holdings Parent, LLC), a Delaware limited liability company, acquired all of the issued and outstanding capital stock of D-M-S Holdings, Inc. d/b/a HealthSmart International, a Delaware corporation (“HealthSmart”). HealthSmart provides a diverse portfolio of health, wellness and diagnostic products centered on home based care outcomes. See Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Split</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO (as defined below), in June 2021, Convey’s Board of Directors (the “Board”) and stockholders approved a forward split of shares of Convey’s common stock, par value $0.01 per share, on a 126-for-1 basis (the “Stock Split”), which became effective as of June 4, 2021. Prior to the Stock Split, we were authorized to issue 1,000,000 shares of common stock of which (i) 915,000 shares were designated as voting common stock and (ii) 85,000 shares were designated as non-voting common stock. In connection with the Stock Split, the total number of authorized shares of common stock was proportionately increased and the par value of the common stock was not adjusted as a result of the Stock Split. In addition, all authorized shares of common stock were designated voting common stock. All references to common stock, options to purchase common stock, per share data and related information contained in our condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Stock Split.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial Public Offering</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, we closed our initial public offering (“IPO”) of our common stock through an underwritten sale of 13,333,334 shares of our common stock at a price of $14.00 per share. In the offering, we sold 11,666,667 shares and a selling stockholder sold 1,666,667 shares. The aggregate net proceeds to us from the offering after deducting underwriting discounts and commissions and other offering expenses payable by us, were approximately $146.1 million. We used approximately $131.5 million of the net proceeds from the IPO to repay outstanding indebtedness under our credit agreement. We did not receive any of the proceeds from the sale by the selling stockholder.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the closing of the IPO, on June 17, 2021, our Second Amended and Restated Certificate of Incorporation (the “Charter”) and our Second Amended and Restated Bylaws, became effective. The Charter, among other things, provides that our authorized capital stock consists of 500,000,000 shares of common stock, par value $0.01 per share and 25,000,000 shares of preferred stock, par value $0.01 per share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and include the accounts of Convey and our wholly-owned subsidiaries. They have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our condensed consolidated statements of operations and comprehensive income (loss), shareholders’ equity, and cash flows for the three months ended March 31, 2022, and 2021, and the condensed consolidated balance sheet as of March 31, 2022, reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results for the periods shown.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated balance sheet as of December 31, 2021, has been derived from our audited consolidated financial statements as of that date. Our condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2021, which include a complete set of footnote disclosures, including our significant accounting policies, and are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 23, 2022 (“Form 10-K”). The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter ended March 31, 2020, concerns related to the spread of novel coronavirus (“COVID-19”) began to create global business disruptions as well as disruptions in our operations. COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. Governments at the national, state and local level in the U.S., and globally, have implemented varying measures in an effort to contain the virus, including social distancing, travel restrictions, border closures, limitations on public gatherings of people, work from home and supply chain logistical changes. While some of these actions have eased, escalating transmission rates (including of the Delta and Omicron variants of COVID-19), uneven vaccination and vaccination booster rates and further governmental guidance and orders may result in having to reimplement certain of these measures or implementing new and additional ones. The spread of COVID-19 has also caused significant volatility in the U.S. and international markets and has had and continues to have widespread, rapidly evolving and unpredictable impacts on global society, economics, financial markets and business practices. The impact of COVID-19 on our business has resulted in elongated sales cycles, postponement of customer contract renewals, and slower implementation of software solutions for our clients, as well as a reduction in billable hours in one of our reportable segments, the Advisory Services segment. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic and the various responses to the COVID-19 pandemic continues to impact our business, operations or financial condition will depend on numerous evolving factors that we may not be able to accurately predict, including, but not limited to, the duration, severity and scope of the COVID-19 pandemic (including due to new variants, such as Delta and Omicron); actions by governmental entities, businesses and individuals that have been and continue to be taken in response to the pandemic; the effect on our clients and demand by clients, clients and our clients’ members for and ability to pay for our solutions and services; and disruptions or restrictions on our employees’ ability to work and travel. The impact of these factors and others on our suppliers and clients could persist for some time after governments ease their restrictions and after the overall number of COVID-19 cases in the United States decreases.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context with the unknown future impacts of COVID-19 using information that is reasonably available to us at this time. While our current assessment of our estimates did not have a material impact on our condensed consolidated financial statements as of and for the three months ended March 31, 2022, as additional information becomes available to us, our future assessment of our estimates, including our expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact our consolidated financial statements in future reporting periods.</span></div> 0.01 0.01 126 1000000 915000 85000 13333334 14.00 11666667 1666667 146100000 131500000 500000000 500000000 0.01 0.01 25000000 0.01 0.01 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and include the accounts of Convey and our wholly-owned subsidiaries. They have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our condensed consolidated statements of operations and comprehensive income (loss), shareholders’ equity, and cash flows for the three months ended March 31, 2022, and 2021, and the condensed consolidated balance sheet as of March 31, 2022, reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results for the periods shown.</span></div> Our condensed consolidated balance sheet as of December 31, 2021, has been derived from our audited consolidated financial statements as of that date. Our condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2021, which include a complete set of footnote disclosures, including our significant accounting policies, and are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 23, 2022 (“Form 10-K”). The results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. All significant intercompany balances and transactions have been eliminated in consolidation. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information currently available to us and based on various other assumptions that we conclude to be reasonable under the circumstances. While management concludes that such estimates are reasonable when considered in conjunction with our condensed consolidated balance sheets and statements of operations and comprehensive income (loss) taken as a whole, actual results could differ materially from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the purchase consideration to the identifiable net assets acquired, including intangible assets and liabilities assumed, based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, is recorded as goodwill. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to the condensed consolidated statements of operations and comprehensive income (loss). </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair value of assets acquired and liabilities assumed requires significant judgment, including the selection of valuation methodologies which techniques include the royalty method, the multi-period excess earnings method, the cost approach, the market approach, and the probability weighted assessment method as considered necessary. Significant assumptions used in those methodologies include, but are not limited to, growth rates, discount rates, customer attrition rates, expected levels of revenues, earnings, cash flows and tax rates. The use of different valuation methodologies and assumptions is highly subjective and inherently uncertain and, as a result, actual results may differ materially from estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Concentrations</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and Accounts receivable from our major customers are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">Revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">(in thousands, except percentages)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer A</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">27,108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">19,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total revenue</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">28.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">23.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer B</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16,766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total revenue</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">17.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">20.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">Accounts Receivable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">(in thousands, except percentages)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">8,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">13,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">11.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer B</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">11,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">15,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">24.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customer base is highly concentrated. Revenue may significantly decline if we were to lose one or more of our major customers. However, our risk is reduced due to our significant customers having multiple product delivery solutions under separate contracts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized an earn-out liability in connection with the November 2018 acquisition of HealthScape Advisors, LLC (“HealthScape Advisors”) and Pareto Intelligence LLC (“Pareto Intelligence”), which represented contingent consideration. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial fair value of the earn-out liability was determined by employing a Monte-Carlo simulation model. The underlying simulated variable was adjusted revenue discounted by the market price of risk embedded in the revenue metrics. The revenue volatility estimate was based on a study of historical asset volatility and implied volatility for a set of comparable public companies, adjusted by our operating leverage. The earn-out payments were calculated based on simulated revenue metrics and payment thresholds as set forth in the HealthScape Advisors and Pareto Intelligence purchase agreement. The calculated payments were further discounted back to present value using cost of debt reflecting our credit risk. The fair value of the earn-out liability at each reporting date subsequent to the acquisition was measured using a probability weighted approach. Any change in fair value was recognized in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2019, Cannes Parent, Inc. (“Cannes”), a direct subsidiary of Convey, entered into an agreement to acquire all of the outstanding stock of Convey Health Solutions, Inc. through the merger of Cannes Merger Sub, Inc. (“Merger Sub”) and Convey Health Parent, Inc. (“Parent”) (the “Merger”) with Parent surviving as a direct subsidiary of Cannes. The Merger principally occurred through an investment from TPG Cannes Aggregation, L.P., which is primarily funded by partners of TPG Partners VIII, L.P. and TPG Healthcare Partners, L.P. or any parallel fund or their alternative investment vehicles (collectively, “TPG”). In connection with the Merger, we recognized a holdback liability, which represented contingent consideration. The </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial fair value of the holdback liabilities and at each subsequent reporting date was measured using a probability weighted approach. Any change in fair value was recognized in the consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of HealthSmart in February 2022, we recognized an earn-out liability which represented contingent consideration. The initial fair value of the earn-out liability was determined by employing a Black-Scholes Merton model. The earn-out payments were calculated based on projected revenue metrics and payment thresholds as set forth in the HealthSmart purchase agreement. The calculated payments were further discounted back to present value using the cost of debt reflecting our credit risk.</span></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration in connection with the HealthSmart acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income (Loss) Per Common Share</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is computed by dividing net income (loss) attributable to common shareholders (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted net income (loss) per common share attributable to common shareholders is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period adjusted for the dilutive effects of common stock equivalents. In periods when losses from operations are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,194,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,321,424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, and 2021, 9,534,119 and 5,690,664 of potentially dilutive share-based awards outstanding, respectively, were excluded from the computation of diluted net income (loss) per share related to common shareholders as their effect was anti-dilutive. See Note 11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which supersedes the previous guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for virtually all of their leases except those which meet the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or financing. Classification is based on criteria that are similar to those applied in previous lease accounting, but without explicit bright lines. The recognition of these lease assets and lease liabilities represents a change from previous U.S. GAAP requirements, which did not require lease assets and lease liabilities to be recognized for most leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee, have not significantly changed from previous U.S. GAAP requirements. The Company adopted the provisions of Topic 842 on January 1, 2022, using the modified retrospective approach. All comparative periods prior to January 1, 2022 are not adjusted and continue to be reported in accordance with Topic 840.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to utilize the package of practical expedients permitted within the new standard, which among other things, allowed the Company not to reassess prior conclusions about lease identification, classification and initial direct costs of existing leases as of the date of adoption. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the Company’s condensed consolidated balance sheet which resulted in recognizing those lease payments in the condensed consolidated statements of operations on a straight-line basis over the lease term.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the new standard resulted in the recording of right-of-use assets and corresponding lease liabilities of $14.7 million and $20.7 million, respectively, as of January 1, 2022. The difference between the right-of-use assets and the lease liabilities was recorded to eliminate existing deferred rent balances and remaining balances of lease incentives recorded under Topic 840. The adoption of the new standard did not materially impact the Company's condensed consolidated statements of operations and had no impact on the Company's condensed consolidated statements of cash flows. See Note 18. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Issued Not Yet Adopted</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326) (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Entities will be required to use a model that will result in the earlier recognition of allowances for losses for trade and other receivables, held-to-maturity debt securities, loans, and other instruments. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. ASU 2016-13, as subsequently amended for various technical issues, is effective for emerging growth companies following private company adoption dates for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 848) (“ASU 2020-04”), subsequently clarified in January 2021 by ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 848) (“ASU 2021-01”). The main provisions of this update provide optional expedients and exceptions for contracts, hedging relationships, and other transactions that reference the London Inter-bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and, once adopted, may be applied prospectively to contract modifications and hedging relationships through December 31, 2022. We are currently evaluating the new guidance to determine the impact ASU 2020-04 and ASU 2021-01 will have on our consolidated financial statements. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 805) (“ASU 2021-08”). The new guidance creates an exception to the general recognition and measurement principle for contract assets and contract liabilities from contracts with customers acquired in a business combination. Under this exception, an acquirer applies Topic 606 to recognize and measure contract assets and contract liabilities on the acquisition date. Topic 805 generally requires the acquirer in a business combination to recognize and measure the assets it acquires and liabilities it assumes at fair value on the acquisition date. This generally will result in companies recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date. This new guidance is effective for emerging growth companies following private business adoption dates, for the fiscal years beginning after December 15, 2023, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information currently available to us and based on various other assumptions that we conclude to be reasonable under the circumstances. While management concludes that such estimates are reasonable when considered in conjunction with our condensed consolidated balance sheets and statements of operations and comprehensive income (loss) taken as a whole, actual results could differ materially from those estimates.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the purchase consideration to the identifiable net assets acquired, including intangible assets and liabilities assumed, based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, is recorded as goodwill. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to the condensed consolidated statements of operations and comprehensive income (loss). </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair value of assets acquired and liabilities assumed requires significant judgment, including the selection of valuation methodologies which techniques include the royalty method, the multi-period excess earnings method, the cost approach, the market approach, and the probability weighted assessment method as considered necessary. Significant assumptions used in those methodologies include, but are not limited to, growth rates, discount rates, customer attrition rates, expected levels of revenues, earnings, cash flows and tax rates. The use of different valuation methodologies and assumptions is highly subjective and inherently uncertain and, as a result, actual results may differ materially from estimates.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Concentrations</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and Accounts receivable from our major customers are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">Revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">(in thousands, except percentages)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer A</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">27,108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">19,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total revenue</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">28.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">23.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer B</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16,766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total revenue</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">17.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">20.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">Accounts Receivable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">(in thousands, except percentages)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">8,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">13,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">11.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer B</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">11,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">15,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">24.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customer base is highly concentrated. Revenue may significantly decline if we were to lose one or more of our major customers. However, our risk is reduced due to our significant customers having multiple product delivery solutions under separate contracts.</span></div> <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and Accounts receivable from our major customers are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">Revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">(in thousands, except percentages)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer A</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">27,108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">19,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total revenue</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">28.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">23.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer B</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16,766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total revenue</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">17.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">20.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">Accounts Receivable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:82%">(in thousands, except percentages)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:73%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">8,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">13,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">11.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Customer B</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">11,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">15,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">    % of total accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">24.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">%</span></td></tr></table></div> 27108000 19626000 0.280 0.238 16712000 16766000 0.173 0.203 8119000 13161000 0.112 0.210 11688000 15174000 0.161 0.242 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized an earn-out liability in connection with the November 2018 acquisition of HealthScape Advisors, LLC (“HealthScape Advisors”) and Pareto Intelligence LLC (“Pareto Intelligence”), which represented contingent consideration. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial fair value of the earn-out liability was determined by employing a Monte-Carlo simulation model. The underlying simulated variable was adjusted revenue discounted by the market price of risk embedded in the revenue metrics. The revenue volatility estimate was based on a study of historical asset volatility and implied volatility for a set of comparable public companies, adjusted by our operating leverage. The earn-out payments were calculated based on simulated revenue metrics and payment thresholds as set forth in the HealthScape Advisors and Pareto Intelligence purchase agreement. The calculated payments were further discounted back to present value using cost of debt reflecting our credit risk. The fair value of the earn-out liability at each reporting date subsequent to the acquisition was measured using a probability weighted approach. Any change in fair value was recognized in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2019, Cannes Parent, Inc. (“Cannes”), a direct subsidiary of Convey, entered into an agreement to acquire all of the outstanding stock of Convey Health Solutions, Inc. through the merger of Cannes Merger Sub, Inc. (“Merger Sub”) and Convey Health Parent, Inc. (“Parent”) (the “Merger”) with Parent surviving as a direct subsidiary of Cannes. The Merger principally occurred through an investment from TPG Cannes Aggregation, L.P., which is primarily funded by partners of TPG Partners VIII, L.P. and TPG Healthcare Partners, L.P. or any parallel fund or their alternative investment vehicles (collectively, “TPG”). In connection with the Merger, we recognized a holdback liability, which represented contingent consideration. The </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial fair value of the holdback liabilities and at each subsequent reporting date was measured using a probability weighted approach. Any change in fair value was recognized in the consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of HealthSmart in February 2022, we recognized an earn-out liability which represented contingent consideration. The initial fair value of the earn-out liability was determined by employing a Black-Scholes Merton model. The earn-out payments were calculated based on projected revenue metrics and payment thresholds as set forth in the HealthSmart purchase agreement. The calculated payments were further discounted back to present value using the cost of debt reflecting our credit risk.</span></div> <div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration in connection with the HealthSmart acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of our Level 3 earn-out and holdback liabilities for the three months ended March 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,538 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 -2254000 0 0 2254000 20538000 0 0 20538000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income (Loss) Per Common Share</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is computed by dividing net income (loss) attributable to common shareholders (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted net income (loss) per common share attributable to common shareholders is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period adjusted for the dilutive effects of common stock equivalents. In periods when losses from operations are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,194,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,321,424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -1154000 -934000 -1154000 -934000 73194171 73194171 61321424 61321424 -0.02 -0.02 -0.02 -0.02 9534119000 5690664000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which supersedes the previous guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for virtually all of their leases except those which meet the definition of a short-term lease. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or financing. Classification is based on criteria that are similar to those applied in previous lease accounting, but without explicit bright lines. The recognition of these lease assets and lease liabilities represents a change from previous U.S. GAAP requirements, which did not require lease assets and lease liabilities to be recognized for most leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee, have not significantly changed from previous U.S. GAAP requirements. The Company adopted the provisions of Topic 842 on January 1, 2022, using the modified retrospective approach. All comparative periods prior to January 1, 2022 are not adjusted and continue to be reported in accordance with Topic 840.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to utilize the package of practical expedients permitted within the new standard, which among other things, allowed the Company not to reassess prior conclusions about lease identification, classification and initial direct costs of existing leases as of the date of adoption. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the Company’s condensed consolidated balance sheet which resulted in recognizing those lease payments in the condensed consolidated statements of operations on a straight-line basis over the lease term.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of the new standard resulted in the recording of right-of-use assets and corresponding lease liabilities of $14.7 million and $20.7 million, respectively, as of January 1, 2022. The difference between the right-of-use assets and the lease liabilities was recorded to eliminate existing deferred rent balances and remaining balances of lease incentives recorded under Topic 840. The adoption of the new standard did not materially impact the Company's condensed consolidated statements of operations and had no impact on the Company's condensed consolidated statements of cash flows. See Note 18. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Issued Not Yet Adopted</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326) (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. Entities will be required to use a model that will result in the earlier recognition of allowances for losses for trade and other receivables, held-to-maturity debt securities, loans, and other instruments. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. ASU 2016-13, as subsequently amended for various technical issues, is effective for emerging growth companies following private company adoption dates for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 848) (“ASU 2020-04”), subsequently clarified in January 2021 by ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 848) (“ASU 2021-01”). The main provisions of this update provide optional expedients and exceptions for contracts, hedging relationships, and other transactions that reference the London Inter-bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and, once adopted, may be applied prospectively to contract modifications and hedging relationships through December 31, 2022. We are currently evaluating the new guidance to determine the impact ASU 2020-04 and ASU 2021-01 will have on our consolidated financial statements. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 805) (“ASU 2021-08”). The new guidance creates an exception to the general recognition and measurement principle for contract assets and contract liabilities from contracts with customers acquired in a business combination. Under this exception, an acquirer applies Topic 606 to recognize and measure contract assets and contract liabilities on the acquisition date. Topic 805 generally requires the acquirer in a business combination to recognize and measure the assets it acquires and liabilities it assumes at fair value on the acquisition date. This generally will result in companies recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date. This new guidance is effective for emerging growth companies following private business adoption dates, for the fiscal years beginning after December 15, 2023, with early adoption permitted. We are currently evaluating the new guidance to determine the impact it will have on our consolidated financial statements.</span></div> 14700000 20700000 REVENUE FROM CONTRACTS WITH CUSTOMERS<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide technology enabled solutions and advisory services to assist our clients with workflows across product developments, sales, member experience, clinical management, core operations and business intelligence and analytics. We generate our revenues through our two reporting segments: (i) Technology Enabled Solutions and (ii) Advisory Services.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Technology Enabled Solutions</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We help health plans grow membership and revenue as well as operate more effectively and efficiently. We also assist our clients in managing the compliance and administrative requirements imposed under government sponsored health plans. Our technology solutions are primarily delivered through a web-based customizable application. This application is used to identify, track, and administer contractual services, or benefits provided under a client’s plan to its Medicare and Medicaid beneficiaries. We also provide analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. With our technology enabled solutions, we offer the following services:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Health Plan Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides technology-enabled plan administration services for government-sponsored health plans. Our service encompasses eligibility and enrollment processing, member services, premium billing, payment processing, reconciliation and other related services. In addition, we provide technology enabled services to manage supplemental benefits provided to members through their Medicare Advantage plans. Our services include benefit design and administration, member eligibility and engagement, analytics and reporting.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Software Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provide additional services to our clients for ad hoc enhancements on their existing software solutions.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Data Analytics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provide payment tools and data analytics to improve revenue accuracy and identify gaps in quality, clinical care and compliance. Increasingly we are combining these analytics capabilities with our Health Plan Management offerings.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Supplemental Benefit Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include product fulfillment, as well as catalog development and product distribution. Many of these services are provided through our technology enabled solutions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Advisory Services</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide Advisory Services that complement our technology enabled solutions, including sales and marketing strategies, provider network strategies, compliance, Star ratings, quality, clinical, pharmacy, analytics and risk adjustment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue under ASC Topic 606, Revenue from Contracts with Customers. We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for contracts that are within the scope of the standard, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of revenue</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present disaggregated revenue by reporting segment:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31, 2022</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technology<br/>Enabled<br/>Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Advisory<br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental Benefit Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Plan Management</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,862 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,862 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Analytics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,166 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,708 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31, 2021</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Technology<br/>Enabled<br/>Solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Advisory<br/>Services</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental Benefit Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Plan Management</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Analytics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,582 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,049 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,631 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue recognition pattern, point in time or over time, is consistent within all revenue categories with the exception of Data Analytics which includes revenue recognized on both a point in time and over time basis. The amount of point in time revenue within Data Analytics was $0.6 million and $1.4 million during the three months ended March 31, 2022, and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of our revenue recognition, invoicing, and cash collections results in billed accounts receivable, unbilled receivables, and deferred revenue. Accounts receivable includes unbilled receivable balances of $17.4 million and $7.0 million as of March 31, 2022, and December 31, 2021, respectively.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents payments received from our customers in advance of recognition of revenue. Deferred revenue that will be recognized during the succeeding 12 months is recognized as current deferred revenue and the remaining portion is recognized as non-current deferred revenue within Other long-term liabilities. Revenue recognized during the three months ended March 31, 2022, and 2021 that was included in the deferred revenue balance at the beginning of the period was $4.4 million and $3.9 million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes contract liabilities and non-cancelable amounts that will be invoiced and recognized as revenue in future periods.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and amount of revenue recognition for our remaining performance obligations are influenced by several factors and therefore the amount of remaining obligations may not be a meaningful indicator of future results. Total RPO equaled $8.4 million as of March 31, 2022, of which we expect to recognize approximately $4.2 million over the next 12 months. The remaining $4.2 million is expected to be recognized in fiscal years 2023, 2024, 2025, 2026 and 2027 by $3.0 million, $1.1 million, $0.1 million, $7.5 thousand and $7.5 thousand, respectively.</span></div> 2 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present disaggregated revenue by reporting segment:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31, 2022</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technology<br/>Enabled<br/>Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Advisory<br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental Benefit Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Plan Management</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,862 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,862 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Analytics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,166 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,708 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31, 2021</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Technology<br/>Enabled<br/>Solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Advisory<br/>Services</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental Benefit Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Plan Management</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Analytics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,582 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,049 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,631 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 50228000 0 50228000 25862000 0 25862000 2327000 13457000 15784000 2191000 85000 2276000 2558000 0 2558000 83166000 13542000 96708000 39104000 0 39104000 23942000 0 23942000 1038000 13049000 14087000 2730000 0 2730000 2768000 0 2768000 69582000 13049000 82631000 600000 1400000 17400000 7000000 P12M 4400000 3900000 8400000 4200000 P12M 4200000 3000000 1100000 100000 7500 7500 ACQUISITIONS<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2022, Convey’s indirect wholly-owned subsidiary, D-M-S Holdings Parent, LLC (f/k/a Dragon Holdings Parent, LLC), a Delaware limited liability company (“Buyer”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Briggs Medical Service Company, a Delaware corporation (“Seller”), and D-M-S Holdings, Inc. d/b/a HealthSmart International, a Delaware corporation (“Target”), pursuant to which, on the terms and subject to the conditions set forth in the Purchase Agreement, Buyer agreed to acquire from Seller all of the issued and outstanding capital stock of Target (the acquisition of such capital stock, the “Acquisition”). Target provides a diverse portfolio of health, wellness and diagnostic products centered on home based care outcomes, and the Company intends to leverage the Target’s supply chain and logistics expertise to get high quality products to members faster and at a lower cost.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, Buyer completed its acquisition of all of the issued and outstanding capital stock of the Target. The Acquisition was consummated pursuant to the Purchase Agreement.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Purchase Agreement, at closing Buyer paid to Seller cash in an amount equal to $74.7 million, subject to certain adjustments for, among other things, Target’s cash, indebtedness and net working capital (the “Closing Purchase Price”). If the Target achieves certain amounts of net revenue in calendar year 2022, Buyer will pay to Seller cash up to an additional $15 million. A portion of the Closing Purchase Price was deposited into an escrow account held by an </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">escrow agent and will be released to Buyer or Seller, as applicable, following the final determination of any purchase price adjustment.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Purchase Agreement, CHS obtained a first lien incremental term loan facility under CHS’s existing First Lien Credit Agreement in an aggregate principal amount of $78 million, for the purpose of financing the Acquisition and paying fees and expenses related thereto. See Note 9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information related to the incremental term loan facility.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Acquisition was accounted for using the acquisition method of accounting under which assets and liabilities of the Target were recorded at their respective fair values including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets. A deferred tax liability has been recorded for the excess of financial statement basis over tax basis of the acquired assets and assumed liabilities with a corresponding increase to goodwill. The goodwill attributable to the Acquisition has been recorded as a non-current asset and is not amortized, but is subject to an annual review for impairment. Such goodwill, which is non-deductible for income tax purposes, is part of the Technology Enabled Solutions segment.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Acquisition price was allocated to the tangible and identified intangible assets acquired and liabilities assumed as of the closing date. The fair values assigned to tangible and identifiable intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions. The estimated fair values of assets acquired and liabilities assumed are considered preliminary and are based on the most recent information available. The Company believes that the information provides a reasonable basis for assigning the fair values of assets acquired and liabilities assumed. Thus, the provisional measurements of fair value set forth below are subject to change. The Company expects to finalize the valuation as soon as practicable, but not later than one year from the acquisition date.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Acquisition date fair value of the allocation of the purchase consideration assigned to each major class of assets acquired and liabilities assumed as of February 1, 2022, the acquisition date:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS ACQUIRED</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,489 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of intangible assets </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of intangible assets acquired </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,100 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES ASSUMED</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,905 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,962 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,979 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indications of fair value of the intangible assets acquired in connection with the Acquisition were determined using either the income, market or replacement cost methodologies. The intangible assets are being amortized over periods which reflect the pattern in which economic benefits of the assets are expected to be realized. The trade names and customer relationships are being amortized on a straight-line basis over an estimated useful life of twenty years and seventeen years, respectively. The goodwill recognized is primarily attributable to synergies of the business and the acquisition of workforce knowledgeable of product development and supply chain expertise in the healthcare industry.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase consideration transferred in connection with the Acquisition and consists of the following:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial purchase price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earn-out (contingent consideration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,979 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the condensed consolidated statement of operations and comprehensive income (loss) for the three months ended March 31, 2022, are net sales of $7.2 million and net loss of $1.6 million, related to the Target’s operations since the acquisition date of February 1, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Supplemental Pro Forma Information </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined results of operations of the Company and Target for the three months ended March 31, 2022 and 2021, as if the acquisition had occurred on January 1, 2021. The pro forma information presented is for informational purposes only and is not indicative of results of operations that would have been achieved had the Acquisition taken place at the beginning of the period.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 74700000 15000000 78000000 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Acquisition date fair value of the allocation of the purchase consideration assigned to each major class of assets acquired and liabilities assumed as of February 1, 2022, the acquisition date:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS ACQUIRED</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,489 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of intangible assets </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of intangible assets acquired </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,100 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES ASSUMED</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,905 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,962 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,979 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 112000 6481000 22879000 1840000 1269000 4908000 37489000 8600000 25500000 34100000 71589000 2937000 3895000 1003000 10222000 3905000 21962000 49627000 27352000 76979000 P20Y P17Y <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase consideration transferred in connection with the Acquisition and consists of the following:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial purchase price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earn-out (contingent consideration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,979 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 74725000 2254000 76979000 7200000 -1600000 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined results of operations of the Company and Target for the three months ended March 31, 2022 and 2021, as if the acquisition had occurred on January 1, 2021. The pro forma information presented is for informational purposes only and is not indicative of results of operations that would have been achieved had the Acquisition taken place at the beginning of the period.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 101174000 97567000 205000 -299000 PREPAID EXPENSES AND OTHER CURRENT ASSETS<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other advances</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory purchase advances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cloud computing subscription &amp; implementation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other advances</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory purchase advances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cloud computing subscription &amp; implementation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5896000 6904000 828000 2547000 527000 1271000 1390000 23000 822000 4841000 1346000 983000 10809000 16569000 PROPERTY AND EQUIPMENT<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Estimated Life<br/>(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 – 7 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 10 years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,542 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,503 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 – 7 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 – 5 years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,419)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,876)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,952 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March 31, 2022, and 2021 totaled $1.5 million and $1.4 million, respectively.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease various equipment and software under finance leases. The depreciation expense associated with the assets under finance leases for the three months ended March 31, 2022, and 2021, totaled $89 thousand and $0.1 million, respectively. Assets held under finance leases are included in property and equipment as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(742)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing leases included in property and equipment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Estimated Life<br/>(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 – 7 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 10 years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,542 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,503 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 – 7 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 – 5 years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,419)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,876)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,952 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P3Y P7Y 16399000 14442000 P10Y 10542000 10503000 P3Y P7Y 4064000 4054000 P3Y P5Y 2366000 2277000 33371000 31276000 12419000 10876000 20952000 20400000 1500000 1400000 89000 100000 Assets held under finance leases are included in property and equipment as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(742)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing leases included in property and equipment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1682000 1682000 742000 656000 940000 1026000 INTANGIBLE ASSETS AND GOODWILL<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity for goodwill as of March 31, 2022 is as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,206 </span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions (see Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,558 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of goodwill by reporting unit as of March 31, 2022 is $88.9 million for Advanced Plan Administration (“APA”), $190.2 million for Supplemental Benefits Administration (“SBA”), $138.2 million for Value Based Payment Assurance (“VBPA”), $37.9 million for Advisory Services (“Advisory”) and $27.4 million for HealthSmart acquisition, respectively.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill allocated to the Technology Enabled Solutions and Advisory Services reportable segments is $444.7 million and $37.9 million, respectively as of March 31, 2022. Goodwill is assessed for impairment on an annual basis (on October 1 of each year) and on an interim basis when indicators of impairment exist.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the decline in our stock price since December 31, 2021, we performed an interim impairment test for goodwill for APA, SBA, VBPA and Advisory reporting units using the quantitative approach as of March 31, 2022. Since HealthSmart was recently acquired, no impairment test was performed on that reporting unit. Based on our evaluation performed, we determined the fair value of each of the reporting units exceeded its respective carrying amount, and therefore, we determined that goodwill was not impaired at any of our reporting units as of March 31, 2022. We define “headroom” as the percentage difference between the fair value of a reporting unit and its carrying value. For the interim impairment test, the headroom for the reporting units ranged between eight percent to sixty-five percent. Our SBA reporting unit and our VBPA reporting unit have headroom at the low-end of that range (8.4% for SBA and 12.5% for VBPA) and could experience </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment in the future if we do not achieve our profitability projections, there is a change in key assumptions underlying the valuation or if we continue to experience a substantial decrease in our stock price.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluation of goodwill for impairment requires judgment, including the identification of reporting units, assignment of assets, liabilities and goodwill to reporting units and determination of the fair value of each reporting unit. We estimate the fair value of our reporting units using a combination of an income approach, utilizing a discounted cash flow analysis, and a market approach, using market multiples. Under the income approach, we estimate projected future cash flows, the timing of such cash flows and long-term growth rates, and determine the appropriate discount rate that reflects the risk inherent in the projected future cash flows. The discount rate used is based on a market participant weighted-average cost of capital and may be adjusted for the relevant risk associated with business-specific characteristics and the uncertainty related to the reporting unit’s ability to execute on the projected future cash flows. Under the market approach, we estimate fair value based on market multiples of revenues and earnings derived from comparable publicly-traded companies with characteristics similar to the reporting unit. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions and other factors. The assumptions and estimates used in determining the fair values of the reporting units contain uncertainties, and any changes to these assumptions and estimates could have a negative impact and result in a future impairment.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of identifiable intangible assets consisted of the following as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Gross<br/>Carrying<br/>Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Accumulated<br/>Amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Net Carrying<br/>Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,830)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,070 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,348)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,452 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,226 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,233)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,993 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of identifiable intangible assets consisted of the following as of December 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Gross<br/>Carrying<br/>Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Accumulated<br/>Amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Net Carrying<br/>Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,300 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,395)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,905 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,554 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,540)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,014 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for Trade names, Customer relationships and Technology for the three months ended March 31, 2022, and 2021, totaled $6.2 million and $5.9 million, respectively.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for Capitalized software development costs for the three months ended March 31, 2022, and 2021, totaled $0.5 million and $0.1 million, respectively.</span></div> <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity for goodwill as of March 31, 2022 is as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,206 </span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions (see Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,558 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 455206000 0 27352000 0 482558000 88900000 190200000 138200000 37900000 27400000 444700000 37900000 0.08 0.65 0.084 0.125 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of identifiable intangible assets consisted of the following as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Gross<br/>Carrying<br/>Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Accumulated<br/>Amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Net Carrying<br/>Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,830)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,070 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,348)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,452 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,226 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,233)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,993 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of identifiable intangible assets consisted of the following as of December 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Gross<br/>Carrying<br/>Amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Accumulated<br/>Amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Net Carrying<br/>Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,300 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,395)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,905 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,800 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,554 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,540)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,014 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 35900000 3830000 32070000 214500000 44636000 169864000 47800000 12348000 35452000 13026000 2419000 10607000 311226000 63233000 247993000 27300000 3395000 23905000 189000000 40091000 148909000 47800000 11153000 36647000 12454000 1901000 10553000 276554000 56540000 220014000 6200000 5900000 500000 100000 ACCRUED EXPENSES<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive bonus</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and use tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,865 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refundable deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,038 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive bonus</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and use tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,865 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refundable deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,038 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 257000 15214000 7784000 11154000 6365000 6865000 2372000 4276000 83000 637000 5538000 7046000 4626000 0 3013000 3366000 30038000 48558000 CREDIT FACILITY<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2019, we entered into the First Lien Credit Agreement (the “Credit Agreement”). The Credit Agreement provides for senior secured credit facilities consisting of (i) a $225.0 million closing date term loan (the “Term Facility”) and loans thereunder (the “Term Loans”) and (ii) a $40.0 million revolving credit facility (the “Revolving Facility”) (collectively, the “Credit Facility”). The Term Facility has a seven-year term which expires on September 4, 2026 and the Revolving Facility has a five-year term which expires on September 4, 2024. We paid debt issuance costs of approximately $6.1 million on the closing date of the Credit Facility, $5.2 million is being amortized over the life of the Term Facility (84 months) and $0.9 million is being amortized over the term of the Revolving Facility (60 months) on a straight-line method. The Revolving Facility includes a letter of credit sub-facility (subject to a sublimit not to exceed $10.0 million) and a swing line loan sub-facility (subject to a sublimit not to exceed $10.0 million).</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2020, we amended the Credit Agreement to establish an incremental loan facility in an aggregate principal amount equal to $25.0 million for an incremental term loan request (the “2020 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $1.1 million on the closing date of the 2020 Incremental Term Loan.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we amended the Credit Agreement to establish an incremental term loan in an aggregate principal amount equal to $78.0 million (the “2021 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $2.4 million on the closing date of the 2021 Incremental Term Loan.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, we further amended the Credit Agreement to establish an incremental term loan in an aggregate principal amount equal to $78.0 million (the “2022 Incremental Term Loan”) bearing interest at the Eurodollar Rate (as defined in the Credit Agreement) expiring September 4, 2026. We capitalized debt issuance costs of approximately $2.6 million on the closing date of the 2022 Incremental Term Loan, which is being amortized over the life of the 2022 Incremental Term Loan. The proceeds of the term loans borrowed under the 2022 Incremental Term Loan were used to finance the HealthSmart acquisition (see Note 4) and pay fees and expenses related thereto. The 2022 Incremental Term Loan was accounted for as a debt modification.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes an uncommitted incremental facility, which provides that we have the right at any time to request term loan increases, additional term loan facilities, revolving commitment increases and/or additional revolving credit facilities, in an aggregate principal amount, together with the aggregate principal amount of permitted incremental equivalent debt under the Credit Agreement, not to exceed (a) the sum of the greater of (i) $46.9 million and (ii) 100.0% of Consolidated EBITDA (as defined in the Credit Agreement) of CHS and its restricted subsidiaries for the most recently ended period of four consecutive fiscal quarters of CHS (calculated on a pro forma basis), plus (b) certain additional amounts, including an unlimited amount subject to pro forma compliance with a leverage ratio test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate and Fees</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement (other than borrowings of swing line loans) bear interest at a rate per annum equal to, at our election, either (i) the LIBOR for the relevant interest period (subject to a floor of 1.00% per annum) plus an applicable margin, as defined in the Credit Agreement, or (ii) a base rate plus an applicable margin, as defined in the Credit Agreement. We elected to use the LIBOR rate for the Term Loans and the Revolving Facility. The Credit Agreement provides for the replacement of LIBOR with a successor or alternative index rate in the event LIBOR is phased-out.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to paying interest on the outstanding principal of the Credit Facility, we are required to pay a commitment fee in respect of any unused commitments under the Revolving Facility at a rate that is subject to adjustment based upon the First Lien Net Leverage Ratio, as defined in the Credit Agreement (maximum debt to Earnings Before Interest, Income Tax, Depreciation and Amortization (“EBITDA”), as defined in the Credit Agreement) at such time and ranges from 0.375% to 0.500% per annum. We are also required to pay customary letter of credit fees and certain other agency fees.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, CHS entered into Amendment No. 4 to the Credit Agreement (“Amendment No. 4”). Amendment No. 4 amends the Credit Agreement to provide for, among other things, (i) the reduction of the Applicable Rate (as defined in the Credit Agreement) for Eurodollar Rate Loans (as defined in the Credit Agreement) from 5.25% to 4.75% and, for Base Rate Loans (as defined in the Credit Agreement), from 4.25% to 3.75%, and (ii) the reduction of the floor for the Eurodollar Rate (as defined in the Credit Agreement) from 1.00% to 0.75% for the Closing Date Term Loans (as defined in the Credit Agreement). Amendment No. 4 was accounted for as a debt modification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenants</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility contains a financial covenant that requires us to maintain as of the last day of each period of four consecutive quarters of the Company, a First Lien Net Leverage Ratio not to exceed 7.4 to 1.0 if, as of the last day of any fiscal quarter of the Company, there are outstanding revolving loans and letters of credit (excluding (i) undrawn letters of credit in an aggregate face amount up to $10.0 million and (ii) letters of credit (whether drawn or undrawn) to the extent reimbursed, cash collateralized or backstopped on terms reasonably acceptable to the applicable issuing bank on or prior to the date that is three business days following the end of the applicable period of four consecutive fiscal quarters of CHS in an aggregate principal amount exceeding 35% of the aggregate principal amount of the Revolving Facility at such time. We were in compliance with our debt covenants at March 31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepayments and Mandatory Prepayment</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Credit Agreement, we are permitted to voluntarily prepay outstanding loans or commitments in whole or part without premium or penalty other than certain exceptions described in the Credit Agreement; however, the Credit Agreement requires us to prepay outstanding term loans, subject to certain exceptions and limitations with (i) 50% of our annual excess cash flow, subject to certain step-downs based upon the First Lien Net Leverage Ratio; (ii) 100% of the net cash proceeds of certain asset sales or casualty events; and (iii) 100% of the net cash proceeds of certain incurrences or issuances of indebtedness. We were not required to prepay outstanding term loans based on our 2021 results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scheduled Repayments</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the prepayment noted under the “Extinguishment of Debt” below, no additional scheduled installments of principal are required on the Term Facility.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to make scheduled quarterly payments on the 2022 Incremental Term Loan. We are required to make quarterly payments commencing with the quarter ending June 30, 2022, in an amount equal to 0.25% of the aggregate principal amount of the 2022 Incremental Term Loan outstanding on February 1, 2022 with the balance due upon maturity date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees and Collateral</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All obligations under the Credit Agreement are unconditionally guaranteed by Parent and certain subsidiaries. All obligations under the Credit Agreement are secured, subject to permitted liens and other exceptions and limitations, by first priority security interests in substantially all the assets of the Company and each guarantor (including all the equity interests of CHS).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Extinguishment of Debt</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, $131.5 million from the IPO proceeds (see Note 1) were used to repay the principal balance, accrued but unpaid interest, and prepayment premium under the Credit Agreement. The 2020 Incremental Term Loan and the 2021 Incremental Term Loan were repaid in full and the remainder of the proceeds were used to repay a portion of the Term Facility. The prepayment for the Term Facility was applied to the remaining scheduled installments of principal.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Information</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, and December 31, 2021, unamortized deferred financing costs for the Term Loans totaled $5.4 million and $3.0 million, respectively. Amortization of deferred financing costs for the three months ended March 31, 2022, and 2021, totaled $0.3 million and $0.9 million, respectively.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, and December 31, 2021, unamortized deferred financing costs associated with the Revolving Facility totaled $0.5 million for each period, and were included in Other assets in the condensed consolidated balance sheets. Amortization of deferred financing costs was approximately $50 thousand for each of the three months ended March 31, 2022, and 2021.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of deferred financing costs is included within Interest expense in the condensed consolidated statement of operations and comprehensive income (loss).</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, and 2021, the average interest rate for the Term Facility was 5.5% and 6.3%, respectively. As of March 31, 2022, and December 31, 2021, the aggregate principal balance was $192.6 million for each period.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, the average interest rate for the 2022 Incremental Term Loan was 5.5%. As of March 31, 2022, the aggregate principal balance was $78.0 million.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, and 2021, the average interest rate for the Revolving Facility was 2.75% for each period. As of March 31, 2022, and December 31, 2021, the available balance was $39.4 million. On January 23, 2020, we established an irrevocable transferable letter of credit (“LOC”) in the favor of a lessor totaling $0.5 million. The LOC expired on January 31, 2021, however, per the terms of the agreement, the LOC automatically extends for a one year period upon the expiration date and each anniversary thereafter, unless at least 60 days prior to such expiration date or anniversary written notice is provided that we elect not to extend the LOC. The LOC was automatically extended for a one year period on January 31, 2022.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following as of March 31, 2022, and December 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,368)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans, net of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,643 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,643 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Maturities Schedule</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required principal payments for Term Loans for each of the five years and thereafter following the balance sheet date are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the nine months ending December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 225000000 40000000 P7Y P5Y 6100000 5200000 P84M 900000 P60M 10000000 10000000 25000000 1100000 78000000 2400000 78000000 2600000 46900000 1.000 0.0100 0.00375 0.00500 0.0525 0.0475 0.0425 0.0375 0.0100 0.0075 7.4 10000000 0.50 1 1 0.0025 131500000 5400000 3000000 300000 900000 500000 500000 50000 50000 0.055 0.063 192600000 192600000 0.055 78000000 0.0275 0.0275 39400000 39400000 500000 P1Y P1Y <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following as of March 31, 2022, and December 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,368)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans, net of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,643 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,643 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 270631000 192631000 5368000 2988000 265263000 189643000 780000 0 264483000 189643000 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required principal payments for Term Loans for each of the five years and thereafter following the balance sheet date are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the nine months ending December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 585000 780000 780000 780000 267706000 270631000 SHAREHOLDERS’ EQUITY<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we are authorized to issue 500,000,000 shares of common stock, par value $0.01 per share and 25,000,000 shares of preferred stock, par value $0.01 per share. See Note 1 for additional information related to the Stock Split and IPO.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board, through a unanimous written consent, adopted a written resolution declaring a special dividend of $1.18 per share of common stock totaling $74.5 million in cash (“Special Dividend”) ultimately to be distributed to the shareholders of Convey. Of the Special Dividend, $72.2 million was paid to existing shareholders and $2.3 million was paid to outstanding and vested stock option holders. The Special Dividend was paid out during the three months ended March 31, 2021.</span></div> 500000000 0.01 25000000 0.01 1.18 74500000 72200000 2300000 SHARE-BASED COMPENSATION<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2019, our Board adopted the Cannes Holding Parent, Inc. 2019 Equity Incentive Plan (the “2019 Equity Plan”). The 2019 Equity Plan was terminated and replaced and superseded by the 2021 Plan (as defined below) on the effective date of the 2021 Plan and no further grant of awards under the 2019 Equity Plan have been made since such effective date. Outstanding awards granted under the 2019 Equity Plan remain in effect pursuant to their terms.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, in connection with the IPO, the Company adopted the Convey Holding Parent, Inc. 2021 Omnibus Incentive Compensation Plan (the “2021 Plan”). The 2021 Plan has a term of ten years.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, pursuant to the 2019 Equity Plan, Convey issued option awards to acquire 69,300 shares of Convey’s common stock with an exercise price of $9.92 per share and a term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMxOGUwOGQ4OWU5YTQ0NjU4YzQxMzY2YjgxZGVlZGJjL3NlYzozMThlMDhkODllOWE0NDY1OGM0MTM2NmI4MWRlZWRiY182MS9mcmFnOjNiNzY4MzYzMmYxNDQxMjJhMWNjZTIwNjI2MDhhZDYyL3RleHRyZWdpb246M2I3NjgzNjMyZjE0NDEyMmExY2NlMjA2MjYwOGFkNjJfMjM0Mg_8901a8c8-280e-4afa-9ab4-1f594f97aa92">ten</span> (10) years. The awards were comprised of time-vesting options which vest 25% on each anniversary date from the vesting commencement date.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, in connection with the IPO and pursuant to the 2021 Plan, Convey issued option awards to acquire 497,321 shares of Convey’s common stock with an exercise price of $14.00 per share and a term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMxOGUwOGQ4OWU5YTQ0NjU4YzQxMzY2YjgxZGVlZGJjL3NlYzozMThlMDhkODllOWE0NDY1OGM0MTM2NmI4MWRlZWRiY182MS9mcmFnOjNiNzY4MzYzMmYxNDQxMjJhMWNjZTIwNjI2MDhhZDYyL3RleHRyZWdpb246M2I3NjgzNjMyZjE0NDEyMmExY2NlMjA2MjYwOGFkNjJfMjY4MQ_4d8ef7ae-b3bd-4c40-89f4-1356ea89c6ae">ten</span> (10) years. In addition, Convey issued 198,929 restricted stock units (“RSUs”) with a grant date fair value of $13.00 per unit. The option awards and RSUs are time-vesting awards which vest 25% on the first anniversary of the commencement date, and the remainder will vest in 12 equal 3-month installments over the following three years.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, pursuant to the 2021 Plan, Convey issued option awards to acquire 20,380 shares of Convey’s common stock with an exercise price of $9.20 per share and a term of five (5) years. In addition, Convey issued 8,152 RSUs with a grant date fair value of $9.20 per unit. The option awards and RSUs were fully vested as of the date of the grant.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, pursuant to the 2021 Plan, the Company issued 2,500,459 RSUs and 1,243,220 performance restricted stock units (“PSUs”) with a grant date fair value of $6.70 per unit. The grants are time-vesting awards which vest 25% on the first anniversary of the commencement date, and the remainder will vest in 12 equal 3-month installments over the following three years. The PSUs have a performance condition that affects vesting and is subject to the Company meeting certain annual Adjusted Earnings Before Interest, Income Tax, Depreciation and Amortization (“Adjusted EBITDA”) target.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total share-based compensation expense included in the condensed consolidated statements of operations and comprehensive income (loss):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Modification</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2021, our Board approved a stock option award modification (the “Modification”) whereby the exercise price of certain previously granted and still outstanding unvested stock option awards held by current employees and certain executives were reduced by $1.18 per award, which represented the cash payment made for the vested awards as part of the Special Dividend. No other terms of the repriced stock options were modified, and the modified stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the Modification, 3,653,837 unvested stock options outstanding with an original exercise price of $7.94 were modified.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no incremental stock-based compensation expense as there was no incremental fair value generated as a result of the Modification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Grants</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity and information about stock options outstanding are summarized in the following table:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Option Awards</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,636,154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,636,154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expect to vest as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,636,154 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.53 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.88</span></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock options are equity-based awards and their aggregate intrinsic value outstanding and exercisable at March 31, 2022, is $0.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, there was approximately $9.4 million total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted average period of 2.11 years.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the time-vesting stock option awards on the date of grant using the Black-Scholes Merton model. The time-vesting options have a service condition. Option valuation models, including the Black-Scholes Merton model, require the input of certain assumptions that involve judgment. Changes in the input assumptions can materially affect the fair value estimates and, ultimately, how much we recognize as stock-based compensation expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity and information about non-vested RSUs outstanding are summarized in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,286 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897,965 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,089 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One RSU gives the right to one share of the Company’s common stock. RSUs that vest based on service are measured based on the fair value of the underlying stock on the date of grant. Compensation with respect to RSU awards is expensed on a straight-line basis over the vesting period.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, there was approximately $26.6 million total unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted average period of 3.88 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Incentive Awards</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Convey issued fifty-six (56) Long-Term Incentive (LTI) awards with a total grant-date fair value of $1.1 million to employees. These awards vest upon satisfaction of the performance condition as determined by our Board at its sole discretion, subject to the participants continued employment or service. The performance condition is satisfied by TPG meeting a certain multiple-of-money return, on a scale, prior to or upon (i) TPG in the aggregate beneficially owning less than 20% of the voting equity securities of the Company or (ii) the date on which a change in control occurs. The awards contain a market condition with an implicit performance condition. No awards have vested as of March 31, 2022, as such events did not occur during the three months ended March 31, 2022. No awards have been granted or cancelled during the three months ended March 31, 2022. The awards do not expire. On the date the performance condition is met, any unvested awards will be forfeited.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LTI Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of the award can be made, as determined by our Board at its sole discretion, (i) in cash, (ii) common stock, or (iii) in other property acceptable to our Board. The LTIs are treated as liability-based awards under Accounting Standards Codification (“ASC”) Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation — Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 718”) and the Company shall recognize compensation expense for the LTIs upon the liquidity event occurring.</span></div> P10Y 69300 9.92 P10Y 0.25 497321 14.00 P10Y 198929 13.00 0.25 P3Y 20380 9.20 P5Y 8152 9.20 2500459 1243220 6.70 6.70 0.25 0.25 12 P3M <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total share-based compensation expense included in the condensed consolidated statements of operations and comprehensive income (loss):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1264000 990000 1264000 990000 1.18 3653837 7.94 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity and information about stock options outstanding are summarized in the following table:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Option Awards</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,636,154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,636,154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expect to vest as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,636,154 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Exercisable as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.53 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.88</span></td></tr></table></div> 5636154 7.68 P8Y3M14D 0 0 0 0 0 0 5636154 7.68 P7Y11M26D 5636154 7.68 P7Y11M26D 2876085 7.53 P7Y10M17D 0 0 0 9400000 P2Y1M9D <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity and information about non-vested RSUs outstanding are summarized in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,286 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897,965 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,089 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 154286 2006000 3743679 25083000 0 0 0 0 3897965 27089000 1 26600000 P3Y10M17D 56 1100000 0 0 0 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LTI Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr></table> 43 4 39 EMPLOYEE SAVINGS PLANWe offer our employees a savings plan pursuant to Section 401(k) of the Internal Revenue Code (the “Code”), whereby employees may contribute a percentage of their compensation, not to exceed the maximum amount allowable under the Code. At the discretion of our Board, we may elect to make matching or other contributions into the savings plan. We made matching contributions of $0.9 million and $0.7 million for the three months ended March 31, 2022, and 2021, respectively, to our employee savings plan, which is included within Selling, general and administrative expenses, Cost of services and Cost of products in the condensed consolidated statement of operations and comprehensive income (loss). 900000 700000 TAXESOur tax provision or benefit from income taxes for interim periods is determined using an estimate of our global annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment.<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly tax provision, and our quarterly estimate of our annual effective tax rate, is subject to change resulting from several factors, including variability in forecasting our pre-tax and taxable income and loss due to external changes in market conditions, changes in statutes, regulations and administrative practices, principles, and interpretations related to tax. Our effective tax rate can be more or less volatile based on the amount of pre-tax income or loss. For example, the impact of discrete items and non-deductible expenses on our effective tax rate is greater when our pre-tax income is lower.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax (expense) benefit for the three months ended March 31, 2022, and 2021, was $0.7 million and $1.0 million, respectively. For the three months ended March 31, 2022, our effective tax rate of 37.0%, before discrete items, was above the U.S. statutory rate of 21.0% primarily due to foreign taxes, state taxes and non-deductible compensation for covered employees. For the three months ended March 31, 2021, our effective tax rate of 22.5%, before discrete items, was slightly above the U.S. statutory rate of 21.0% primarily due to foreign taxes, state taxes, tax on Global Intangible Low-Taxed Income, disallowed wage expense and fringe benefits and certain other non-deductible items. We did not have any unrecognized tax benefits as a result of tax positions taken during a prior period or during the current period. No interest or penalties were recorded as a result of tax uncertainties.</span></div> -700000 -1000000 0.370 0.225 TRANSACTION RELATED COSTS<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the components of Transaction related costs as reported in the condensed consolidated statements of operations and comprehensive income (loss):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company readiness costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt double #000000;border-top:0.25pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the components of Transaction related costs as reported in the condensed consolidated statements of operations and comprehensive income (loss):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company readiness costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt double #000000;border-top:0.25pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 640000 30000 0 1056000 640000 1086000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employment agreements with various executives. The agreements have open-ended terms providing that employment shall continue until terminated by either party in accordance with the agreement. In addition to salary, bonuses, and benefits, the agreements also provide for termination benefits if the agreements are terminated by us for reasons other than cause or by the executives for good reason.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory Purchases</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, we have contractual commitments to purchase inventory from certain manufacturers totaling $3.1 million and $5.2 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, inquiries, and other regulatory and compliance matters, most of which are routine to the nature of our business. When it is probable that a loss will be incurred and where a range of the loss can be reasonably estimated, the best estimate within the range is accrued. When the best estimate within the range cannot be determined, the low end of the range is accrued. The ultimate resolution of these claims could affect future results of operations should our exposure be materially different from our estimates or should liabilities be incurred that were not previously accrued. Potential insurance reimbursements are not offset against potential liabilities.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the uncertainties associated with claims resolution and litigation, future losses to resolve these matters could be higher than the liabilities we have accrued; however, we are unable to reasonably estimate a range of potential losses. If new information were to become available that allowed us to reasonably estimate a range of potential losses in an amount higher or lower than what we have accrued, we would adjust our accrued liabilities accordingly. Based upon current information, we concluded that the impact of the resolution of these matters would not be, individually or in the aggregate, material to our financial position, results of operations or cash flows. Additional lawsuits, claims, inquiries, and other regulatory and compliance matters could arise in the future. The range of losses for resolving any future matters would be assessed as they arise.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Tax Accrual</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 450”) requires an estimated loss to be accrued by a charge to income if it is probable that a liability has been incurred at the date of the financial statements and the amount of the liability can be reasonably estimated. We recognized liabilities for contingencies related to state sales and use tax deemed probable and estimable totaling $6.4 million and $6.9 million at March 31, 2022, and December 31, 2021, respectively. These are included in accrued liabilities in our condensed consolidated balance sheets.</span></div> 3100000 5200000 6400000 6900000 RELATED PARTY TRANSACTIONS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TPG Management Service Agreement</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2019, in connection with the Merger, we had entered into a management services agreement (“MSA”) with TPG. Under the MSA, TPG agreed to provide certain financial, strategic advisory services, and consulting services in exchange for (i) reimbursement of certain expenses incurred by TPG and (ii) an aggregate annual retainer fee of 1% based on our previous year’s consolidated EBITDA determined by our Board. Additional services may be provided in exchange for the fees structured within the MSA. During the three months ended March 31, 2022, and 2021, we paid management and consulting fees of $0 and $0.2 million, respectively. Also, during the three months ended March 31, 2022, and 2021, we paid TPG a fee of $1.0 million and $1.0 million for services provided in connection with establishing: (i) the 2022 Incremental Term Loan and (ii) the 2021 Incremental Term Loan, respectively.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the MSA was terminated by an IPO or business combination and TPG continues to hold at least 10% of equity of the Company upon closing of such transaction, we were required to pay TPG the net present value of the remaining portion of management and consulting fees that would have been incurred until three years after the date of such termination, as well as certain other expenses of TPG. In connection with the IPO completed in June 2021, the MSA was terminated and we paid TPG a $2.3 million termination fee. The termination fee is included within Selling, general and administrative expenses in the condensed consolidated statement of operations and comprehensive income (loss). There were no amounts payable to TPG as of March 31, 2022, or December 31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EIR Partners Consulting Agreement</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Consulting Agreement with EIR Partners, LLC (“EIR”), a former member of our Board, and a current shareholder. Under the terms of the Consulting Agreement, EIR provides consulting services for the purpose of analyzing and reviewing potential sellers in the marketplace for the benefit of the Company as agreed to from time-to-time. As compensation for service, the Company remits to EIR $10 thousand monthly, plus reasonable out-of-pocket expenses incurred in the performance of the duties under the Consulting Agreement. The Consulting Agreement may be terminated by either party upon providing 10 days advance written notice and unless terminated, automatically renews for additional terms of one year. For the three months ended March 31, 2022, and 2021, $20 thousand and $30 thousand were paid for services rendered, respectively. The Consulting Agreement is still active with the Company.</span></div> 0.01 0 200000 1000000 1000000 0.10 P3Y -2300000 0 10000 P1Y 20000 30000 SEGMENT INFORMATION<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 280 establishes the standards for reporting information about segments in financial statements. In applying the criteria set forth in ASC 280, we have determined that we have two reportable segments: Technology Enabled Solutions and Advisory Services. These reportable segments reflect the manner in which the Chief Operating Decision Maker (“CODM”) group assesses information for decision-making purposes. The CODM group consists of our Chief Executive Officer and Chief Financial Officer.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key factors used to identify these reportable segments are the organization and alignment of our internal operations and the nature of our products and services. This reflects how the CODM group monitors performance, allocates resources, and makes strategic and operational decisions.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the reportable segments, we have the “Unallocated” classification which includes those profit and loss items not allocated to either reportable segment. Unallocated includes corporate costs, primarily relating to group wide functions, including but not limited to, finance, tax and legal.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present reportable segment revenue and Segment Adjusted EBITDA. Segment Adjusted EBITDA is the financial measure by which management and the CODM group allocate resources and analyze the performance of the reportable segments.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment Adjusted EBITDA represents each segment’s earnings before interest, tax, depreciation and amortization and is further adjusted to exclude certain items of a significant or unusual nature, including but not limited to, COVID-19 cost impacts, sales and use tax, non-cash stock compensation expense, transaction related costs, acquisition bonus expense, inventory step-up and other costs. Other includes costs such as management and board of directors fees and fees associated with obtaining the incremental term loans.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not report assets by reportable segment, as this metric is not used by the CODM group to allocate resources to the segments.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the tables below is revenue and Segment Adjusted EBITDA by reportable segment:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Technology Enabled<br/>Solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Advisory<br/>Services</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,370 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,323 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Technology Enabled<br/>Solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Advisory<br/>Services</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,582 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,307 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,338 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of Segment Adjusted EBITDA to the condensed consolidated U.S. GAAP net income (loss) from operations:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology Enabled Solutions Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advisory Services Segment Adjusted EBITDA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile to U.S. GAAP net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and use tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition bonus expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory step-up</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________________</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents certain corporate costs associated with the executive compensation, legal, accounting, finance and other costs not specifically attributable to the segments.</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Expenses incurred due to the COVID-19 pandemic are primarily related to higher pricing from vendors due to supply chain disruptions and product shortages and higher employee costs due to hazard pay for our employees. While we had </span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previously expected that these costs would not be an adjustment in the calculation of Segment Adjusted EBITDA after 2021, the COVID-19 pandemic has not subsided and during 2022, to a lesser extent, we have continued to incur higher product costs due to higher pricing from vendors for certain items (e.g., masks and other similar high demand products). We now expect that these expenses will not be an adjustment in the calculation of Segment Adjusted EBITDA after 2022.</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Incremental cost of products associated with the step-up of inventory recognized in purchase accounting for the HealthSmart acquisition.</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">These adjustments include individual adjustments related to management and board of directors fees and fees associated with obtaining the incremental term loans.</span></div> 2 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the tables below is revenue and Segment Adjusted EBITDA by reportable segment:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Technology Enabled<br/>Solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Advisory<br/>Services</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,370 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,323 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Technology Enabled<br/>Solutions</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">Advisory<br/>Services</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,582 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,307 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,338 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of Segment Adjusted EBITDA to the condensed consolidated U.S. GAAP net income (loss) from operations:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology Enabled Solutions Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advisory Services Segment Adjusted EBITDA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile to U.S. GAAP net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and use tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition bonus expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory step-up</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________________</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents certain corporate costs associated with the executive compensation, legal, accounting, finance and other costs not specifically attributable to the segments.</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Expenses incurred due to the COVID-19 pandemic are primarily related to higher pricing from vendors due to supply chain disruptions and product shortages and higher employee costs due to hazard pay for our employees. While we had </span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previously expected that these costs would not be an adjustment in the calculation of Segment Adjusted EBITDA after 2021, the COVID-19 pandemic has not subsided and during 2022, to a lesser extent, we have continued to incur higher product costs due to higher pricing from vendors for certain items (e.g., masks and other similar high demand products). We now expect that these expenses will not be an adjustment in the calculation of Segment Adjusted EBITDA after 2022.</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Incremental cost of products associated with the step-up of inventory recognized in purchase accounting for the HealthSmart acquisition.</span></div><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">These adjustments include individual adjustments related to management and board of directors fees and fees associated with obtaining the incremental term loans.</span></div> 83166000 13542000 12370000 5323000 69582000 13049000 16307000 3338000 12370000 16307000 5323000 3338000 17693000 19645000 2377000 2048000 8252000 7372000 3719000 5467000 -676000 -1007000 274000 1185000 0 1498000 1264000 990000 640000 1086000 58000 192000 1892000 0 1047000 1748000 -1154000 -934000 LEASES<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space, warehouse and distribution space, and equipment under non-cancelable operating and finance leases expiring at various dates through 2029. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is a lease at inception, based on the (1) conveyed rights to obtain substantially all economic benefits from using the asset and (2) the right to direct the uses to which the asset is put.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lease population does not include any residual value guarantees, and therefore none were considered in the calculation of the lease balances. We have leases with variable payments, most commonly in the form of common area maintenance charges which are based on actual costs incurred. These variable payments were excluded from the right-of-use asset and lease liability balances since they are not fixed or in-substance fixed payments. We have lease agreements with lease and non-lease components. We elected the practical expedient to account for lease and non-lease components as a single lease component.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases with terms greater than 12 months, right-of-use assets and lease liabilities are recognized at the implementation date of Topic 842 or lease commencement date based on the present value of the future lease payments over the lease term. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, we utilize our incremental borrowing rate. Our lease agreements generally do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at either the implementation date of Topic 842 or at lease commencement for leases entered into thereafter in determining the present value of future payments. Lease expense for net present value of payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less with purchase options or extension options that are not reasonably certain to be exercised are not recorded on the condensed consolidated financial statements.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the nine months ending December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net present value of lease obligations </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balances for operating and finance right-of-use assets and lease liabilities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMxOGUwOGQ4OWU5YTQ0NjU4YzQxMzY2YjgxZGVlZGJjL3NlYzozMThlMDhkODllOWE0NDY1OGM0MTM2NmI4MWRlZWRiY181MjkvZnJhZzowZDVmNjU3MWZjNGQ0MTI3YmVjYmZkN2Q1YzA5MGM1NS90YWJsZTozNTg2ZTljNTY5Njg0Y2NiODE0ZWEwZjA3YjNhOTUyOC90YWJsZXJhbmdlOjM1ODZlOWM1Njk2ODRjY2I4MTRlYTBmMDdiM2E5NTI4XzMtMS0xLTEtNjAxNzU_630984f1-e820-4d50-a87c-65d652611560">Property and equipment</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,169 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents additional information related to our leases as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information and non-cash activity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts related to lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases (interest)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases (principal payments)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> LEASES<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space, warehouse and distribution space, and equipment under non-cancelable operating and finance leases expiring at various dates through 2029. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is a lease at inception, based on the (1) conveyed rights to obtain substantially all economic benefits from using the asset and (2) the right to direct the uses to which the asset is put.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lease population does not include any residual value guarantees, and therefore none were considered in the calculation of the lease balances. We have leases with variable payments, most commonly in the form of common area maintenance charges which are based on actual costs incurred. These variable payments were excluded from the right-of-use asset and lease liability balances since they are not fixed or in-substance fixed payments. We have lease agreements with lease and non-lease components. We elected the practical expedient to account for lease and non-lease components as a single lease component.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases with terms greater than 12 months, right-of-use assets and lease liabilities are recognized at the implementation date of Topic 842 or lease commencement date based on the present value of the future lease payments over the lease term. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, we utilize our incremental borrowing rate. Our lease agreements generally do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at either the implementation date of Topic 842 or at lease commencement for leases entered into thereafter in determining the present value of future payments. Lease expense for net present value of payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less with purchase options or extension options that are not reasonably certain to be exercised are not recorded on the condensed consolidated financial statements.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the nine months ending December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net present value of lease obligations </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balances for operating and finance right-of-use assets and lease liabilities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMxOGUwOGQ4OWU5YTQ0NjU4YzQxMzY2YjgxZGVlZGJjL3NlYzozMThlMDhkODllOWE0NDY1OGM0MTM2NmI4MWRlZWRiY181MjkvZnJhZzowZDVmNjU3MWZjNGQ0MTI3YmVjYmZkN2Q1YzA5MGM1NS90YWJsZTozNTg2ZTljNTY5Njg0Y2NiODE0ZWEwZjA3YjNhOTUyOC90YWJsZXJhbmdlOjM1ODZlOWM1Njk2ODRjY2I4MTRlYTBmMDdiM2E5NTI4XzMtMS0xLTEtNjAxNzU_630984f1-e820-4d50-a87c-65d652611560">Property and equipment</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,169 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents additional information related to our leases as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information and non-cash activity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts related to lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases (interest)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases (principal payments)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents additional information related to our leases as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information and non-cash activity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts related to lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases (interest)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases (principal payments)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 1246000 760000 326000 89000 6000 2427000 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the nine months ending December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net present value of lease obligations </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our scheduled future minimum lease payments under operating and finance leases, recorded on the condensed consolidated balance sheet as of March 31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the nine months ending December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #FFFFFF;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net present value of lease obligations </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#CCEEFF;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4852000 397000 6469000 368000 5694000 139000 4150000 89000 2316000 0 3297000 0 26778000 993000 2550000 52000 24228000 941000 <div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balances for operating and finance right-of-use assets and lease liabilities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMxOGUwOGQ4OWU5YTQ0NjU4YzQxMzY2YjgxZGVlZGJjL3NlYzozMThlMDhkODllOWE0NDY1OGM0MTM2NmI4MWRlZWRiY181MjkvZnJhZzowZDVmNjU3MWZjNGQ0MTI3YmVjYmZkN2Q1YzA5MGM1NS90YWJsZTozNTg2ZTljNTY5Njg0Y2NiODE0ZWEwZjA3YjNhOTUyOC90YWJsZXJhbmdlOjM1ODZlOWM1Njk2ODRjY2I4MTRlYTBmMDdiM2E5NTI4XzMtMS0xLTEtNjAxNzU_630984f1-e820-4d50-a87c-65d652611560">Property and equipment</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,169 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 18574000 940000 19514000 5605000 501000 18623000 440000 25169000 6000 1541000 86000 P4Y8M12D P2Y3M18D 0.041 0.039 Excludes amortization of intangible assets and depreciation, which are separately stated below. EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 89 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 230 376 1 true 74 0 false 7 false false R1.htm 0001001 - Document - Cover Sheet http://www.conveyhealthsolutions.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Sheet http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY Sheet http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101101 - Disclosure - BUSINESS AND BASIS OF PRESENTATION Sheet http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATION BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 2110103 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS Sheet http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS REVENUE FROM CONTRACTS WITH CUSTOMERS Notes 9 false false R10.htm 2114104 - Disclosure - ACQUISITIONS Sheet http://www.conveyhealthsolutions.com/role/ACQUISITIONS ACQUISITIONS Notes 10 false false R11.htm 2120105 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS Sheet http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS PREPAID EXPENSES AND OTHER CURRENT ASSETS Notes 11 false false R12.htm 2123106 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 12 false false R13.htm 2128107 - Disclosure - INTANGIBLE ASSETS AND GOODWILL Sheet http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILL INTANGIBLE ASSETS AND GOODWILL Notes 13 false false R14.htm 2133108 - Disclosure - ACCRUED EXPENSES Sheet http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSES ACCRUED EXPENSES Notes 14 false false R15.htm 2136109 - Disclosure - CREDIT FACILITY Sheet http://www.conveyhealthsolutions.com/role/CREDITFACILITY CREDIT FACILITY Notes 15 false false R16.htm 2141110 - Disclosure - SHAREHOLDERS??? EQUITY Sheet http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITY SHAREHOLDERS??? EQUITY Notes 16 false false R17.htm 2143111 - Disclosure - SHARE-BASED COMPENSATION Sheet http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATION SHARE-BASED COMPENSATION Notes 17 false false R18.htm 2150112 - Disclosure - EMPLOYEE SAVINGS PLAN Sheet http://www.conveyhealthsolutions.com/role/EMPLOYEESAVINGSPLAN EMPLOYEE SAVINGS PLAN Notes 18 false false R19.htm 2152113 - Disclosure - TAXES Sheet http://www.conveyhealthsolutions.com/role/TAXES TAXES Notes 19 false false R20.htm 2154114 - Disclosure - TRANSACTION RELATED COSTS Sheet http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTS TRANSACTION RELATED COSTS Notes 20 false false R21.htm 2157115 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.conveyhealthsolutions.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 21 false false R22.htm 2159116 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 22 false false R23.htm 2161117 - Disclosure - SEGMENT INFORMATION Sheet http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 23 false false R24.htm 2165118 - Disclosure - LEASES Sheet http://www.conveyhealthsolutions.com/role/LEASES LEASES Notes 24 false false R25.htm 2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 26 false false R27.htm 2311302 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables) Sheet http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables) Tables http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS 27 false false R28.htm 2315303 - Disclosure - ACQUISITIONS (Tables) Sheet http://www.conveyhealthsolutions.com/role/ACQUISITIONSTables ACQUISITIONS (Tables) Tables http://www.conveyhealthsolutions.com/role/ACQUISITIONS 28 false false R29.htm 2321304 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Sheet http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Tables http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS 29 false false R30.htm 2324305 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENT 30 false false R31.htm 2329306 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables) Sheet http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLTables INTANGIBLE ASSETS AND GOODWILL (Tables) Tables http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILL 31 false false R32.htm 2334307 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESTables ACCRUED EXPENSES (Tables) Tables http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSES 32 false false R33.htm 2337308 - Disclosure - CREDIT FACILITY (Tables) Sheet http://www.conveyhealthsolutions.com/role/CREDITFACILITYTables CREDIT FACILITY (Tables) Tables http://www.conveyhealthsolutions.com/role/CREDITFACILITY 33 false false R34.htm 2344309 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONTables SHARE-BASED COMPENSATION (Tables) Tables http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATION 34 false false R35.htm 2355310 - Disclosure - TRANSACTION RELATED COSTS (Tables) Sheet http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSTables TRANSACTION RELATED COSTS (Tables) Tables http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTS 35 false false R36.htm 2362311 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATION 36 false false R37.htm 2366312 - Disclosure - LEASES (Tables) Sheet http://www.conveyhealthsolutions.com/role/LEASESTables LEASES (Tables) Tables http://www.conveyhealthsolutions.com/role/LEASES 37 false false R38.htm 2402401 - Disclosure - BUSINESS AND BASIS OF PRESENTATION (Details) Sheet http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails BUSINESS AND BASIS OF PRESENTATION (Details) Details http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATION 38 false false R39.htm 2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration (Details) Sheet http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration (Details) Details 39 false false R40.htm 2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earn-Out and Holdback Liabilities Reconciliation (Details) Sheet http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earn-Out and Holdback Liabilities Reconciliation (Details) Details 40 false false R41.htm 2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss (income) Per Common Share (Details) Sheet http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss (income) Per Common Share (Details) Details 41 false false R42.htm 2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details 42 false false R43.htm 2412406 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Sheet http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) Details 43 false false R44.htm 2413407 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of revenue (Details) Sheet http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of revenue (Details) Details 44 false false R45.htm 2416408 - Disclosure - ACQUISITIONS - Narrative (Details) Sheet http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails ACQUISITIONS - Narrative (Details) Details 45 false false R46.htm 2417409 - Disclosure - ACQUISITIONS - Assets and Liabilities Acquired (Details) Sheet http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails ACQUISITIONS - Assets and Liabilities Acquired (Details) Details 46 false false R47.htm 2418410 - Disclosure - ACQUISITIONS - Purchase Consideration (Details) Sheet http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails ACQUISITIONS - Purchase Consideration (Details) Details 47 false false R48.htm 2419411 - Disclosure - ACQUISITIONS - Pro Forma Information (Details) Sheet http://www.conveyhealthsolutions.com/role/ACQUISITIONSProFormaInformationDetails ACQUISITIONS - Pro Forma Information (Details) Details 48 false false R49.htm 2422412 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Sheet http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Details http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables 49 false false R50.htm 2425413 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) Sheet http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails PROPERTY AND EQUIPMENT - Property and Equipment (Details) Details 50 false false R51.htm 2426414 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details) Sheet http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTNarrativeDetails PROPERTY AND EQUIPMENT - Narrative (Details) Details 51 false false R52.htm 2427415 - Disclosure - PROPERTY AND EQUIPMENT - Assets Held Under Capital Leases (Details) Sheet http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails PROPERTY AND EQUIPMENT - Assets Held Under Capital Leases (Details) Details 52 false false R53.htm 2430416 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Goodwill Activity (Details) Sheet http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLGoodwillActivityDetails INTANGIBLE ASSETS AND GOODWILL - Goodwill Activity (Details) Details 53 false false R54.htm 2431417 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) Sheet http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) Details 54 false false R55.htm 2432418 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Carrying Value of Intangible Assets (Details) Sheet http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails INTANGIBLE ASSETS AND GOODWILL - Carrying Value of Intangible Assets (Details) Details 55 false false R56.htm 2435419 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails ACCRUED EXPENSES (Details) Details http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESTables 56 false false R57.htm 2438420 - Disclosure - CREDIT FACILITY - Narrative (Details) Sheet http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails CREDIT FACILITY - Narrative (Details) Details 57 false false R58.htm 2439421 - Disclosure - CREDIT FACILITY - Schedule of Debt (Details) Sheet http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails CREDIT FACILITY - Schedule of Debt (Details) Details 58 false false R59.htm 2440422 - Disclosure - CREDIT FACILITY - Debt Maturities Schedule (Details) Sheet http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails CREDIT FACILITY - Debt Maturities Schedule (Details) Details 59 false false R60.htm 2442423 - Disclosure - SHAREHOLDERS??? EQUITY (Details) Sheet http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails SHAREHOLDERS??? EQUITY (Details) Details http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITY 60 false false R61.htm 2445424 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details) Sheet http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails SHARE-BASED COMPENSATION - Narrative (Details) Details 61 false false R62.htm 2446425 - Disclosure - SHARE-BASED COMPENSATION - Stock-based Compensation Expense (Details) Sheet http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockbasedCompensationExpenseDetails SHARE-BASED COMPENSATION - Stock-based Compensation Expense (Details) Details 62 false false R63.htm 2447426 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details) Sheet http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails SHARE-BASED COMPENSATION - Stock Option Activity (Details) Details 63 false false R64.htm 2448427 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) Sheet http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) Details 64 false false R65.htm 2449428 - Disclosure - SHARE-BASED COMPENSATION - Long Term Incentive Activity (Details) Sheet http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails SHARE-BASED COMPENSATION - Long Term Incentive Activity (Details) Details 65 false false R66.htm 2451429 - Disclosure - EMPLOYEE SAVINGS PLAN (Details) Sheet http://www.conveyhealthsolutions.com/role/EMPLOYEESAVINGSPLANDetails EMPLOYEE SAVINGS PLAN (Details) Details http://www.conveyhealthsolutions.com/role/EMPLOYEESAVINGSPLAN 66 false false R67.htm 2453430 - Disclosure - TAXES (Details) Sheet http://www.conveyhealthsolutions.com/role/TAXESDetails TAXES (Details) Details http://www.conveyhealthsolutions.com/role/TAXES 67 false false R68.htm 2456431 - Disclosure - TRANSACTION RELATED COSTS (Details) Sheet http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSDetails TRANSACTION RELATED COSTS (Details) Details http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSTables 68 false false R69.htm 2458432 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.conveyhealthsolutions.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.conveyhealthsolutions.com/role/COMMITMENTSANDCONTINGENCIES 69 false false R70.htm 2460433 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONS 70 false false R71.htm 2463434 - Disclosure - SEGMENT INFORMATION - Narrative (Details) Sheet http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONNarrativeDetails SEGMENT INFORMATION - Narrative (Details) Details 71 false false R72.htm 2464435 - Disclosure - SEGMENT INFORMATION (Details) Sheet http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails SEGMENT INFORMATION (Details) Details http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONTables 72 false false R73.htm 2467436 - Disclosure - LEASES - Components of Lease Expense (Details) Sheet http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails LEASES - Components of Lease Expense (Details) Details 73 false false R74.htm 2468437 - Disclosure - LEASES - Future Minimum Lease Payments (Details) Sheet http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails LEASES - Future Minimum Lease Payments (Details) Details 74 false false R75.htm 2469438 - Disclosure - LEASES - Lease Balances (Details) Sheet http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails LEASES - Lease Balances (Details) Details 75 false false R76.htm 2470439 - Disclosure - LEASES - Additional Lease Information (Details) Sheet http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails LEASES - Additional Lease Information (Details) Details 76 false false All Reports Book All Reports cnvy-20220331.htm cnvy-20220331.xsd cnvy-20220331_cal.xml cnvy-20220331_def.xml cnvy-20220331_lab.xml cnvy-20220331_pre.xml q12022exhibit311.htm q12022exhibit312.htm q12022exhibit321.htm q12022exhibit322.htm http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 94 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cnvy-20220331.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 230, "dts": { "calculationLink": { "local": [ "cnvy-20220331_cal.xml" ] }, "definitionLink": { "local": [ "cnvy-20220331_def.xml" ] }, "inline": { "local": [ "cnvy-20220331.htm" ] }, "labelLink": { "local": [ "cnvy-20220331_lab.xml" ] }, "presentationLink": { "local": [ "cnvy-20220331_pre.xml" ] }, "schema": { "local": [ "cnvy-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 587, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 8, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 13 }, "keyCustom": 52, "keyStandard": 324, "memberCustom": 34, "memberStandard": 37, "nsprefix": "cnvy", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.conveyhealthsolutions.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114104 - Disclosure - ACQUISITIONS", "role": "http://www.conveyhealthsolutions.com/role/ACQUISITIONS", "shortName": "ACQUISITIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120105 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS", "role": "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123106 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128107 - Disclosure - INTANGIBLE ASSETS AND GOODWILL", "role": "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILL", "shortName": "INTANGIBLE ASSETS AND GOODWILL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133108 - Disclosure - ACCRUED EXPENSES", "role": "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSES", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136109 - Disclosure - CREDIT FACILITY", "role": "http://www.conveyhealthsolutions.com/role/CREDITFACILITY", "shortName": "CREDIT FACILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141110 - Disclosure - SHAREHOLDERS\u2019 EQUITY", "role": "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITY", "shortName": "SHAREHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143111 - Disclosure - SHARE-BASED COMPENSATION", "role": "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATION", "shortName": "SHARE-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150112 - Disclosure - EMPLOYEE SAVINGS PLAN", "role": "http://www.conveyhealthsolutions.com/role/EMPLOYEESAVINGSPLAN", "shortName": "EMPLOYEE SAVINGS PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152113 - Disclosure - TAXES", "role": "http://www.conveyhealthsolutions.com/role/TAXES", "shortName": "TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "cnvy:AcquisitionRelatedAndDeferredOfferingCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2154114 - Disclosure - TRANSACTION RELATED COSTS", "role": "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTS", "shortName": "TRANSACTION RELATED COSTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "cnvy:AcquisitionRelatedAndDeferredOfferingCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157115 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.conveyhealthsolutions.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159116 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161117 - Disclosure - SEGMENT INFORMATION", "role": "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATION", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2165118 - Disclosure - LEASES", "role": "http://www.conveyhealthsolutions.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)", "role": "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - ACQUISITIONS (Tables)", "role": "http://www.conveyhealthsolutions.com/role/ACQUISITIONSTables", "shortName": "ACQUISITIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "role": "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329306 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)", "role": "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLTables", "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334307 - Disclosure - ACCRUED EXPENSES (Tables)", "role": "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337308 - Disclosure - CREDIT FACILITY (Tables)", "role": "http://www.conveyhealthsolutions.com/role/CREDITFACILITYTables", "shortName": "CREDIT FACILITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344309 - Disclosure - SHARE-BASED COMPENSATION (Tables)", "role": "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONTables", "shortName": "SHARE-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "cnvy:ScheduleOfAcquisitionRelatedAndDeferredOfferingCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2355310 - Disclosure - TRANSACTION RELATED COSTS (Tables)", "role": "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSTables", "shortName": "TRANSACTION RELATED COSTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "cnvy:ScheduleOfAcquisitionRelatedAndDeferredOfferingCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2362311 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2366312 - Disclosure - LEASES (Tables)", "role": "http://www.conveyhealthsolutions.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - BUSINESS AND BASIS OF PRESENTATION (Details)", "role": "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails", "shortName": "BUSINESS AND BASIS OF PRESENTATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i5ed00015e53744f4b41cef69e8584f38_D20210604-20210604", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration (Details)", "role": "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i940b4bff8fe445f4a0246940b7b824be_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)", "role": "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i1a611845d16b47b79bc1a07f016aaeb4_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earn-Out and Holdback Liabilities Reconciliation (Details)", "role": "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earn-Out and Holdback Liabilities Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i1a611845d16b47b79bc1a07f016aaeb4_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss (income) Per Common Share (Details)", "role": "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss (income) Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "role": "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "role": "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnbilledReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of revenue (Details)", "role": "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "if66b3743a3084ff990fca7ac426aa871_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - ACQUISITIONS - Narrative (Details)", "role": "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "shortName": "ACQUISITIONS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id9e4194e25c1474fac5ecb16e15b4489_D20220101-20220331", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - ACQUISITIONS - Assets and Liabilities Acquired (Details)", "role": "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "shortName": "ACQUISITIONS - Assets and Liabilities Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "ia28917970dbb43f395c0f4d53073d98a_I20220201", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i709fa1914643441189c407b9f6927453_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - ACQUISITIONS - Purchase Consideration (Details)", "role": "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails", "shortName": "ACQUISITIONS - Purchase Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i709fa1914643441189c407b9f6927453_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419411 - Disclosure - ACQUISITIONS - Pro Forma Information (Details)", "role": "http://www.conveyhealthsolutions.com/role/ACQUISITIONSProFormaInformationDetails", "shortName": "ACQUISITIONS - Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "role": "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i39972af05252413d91ca5528f5b69f0e_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY", "role": "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i39972af05252413d91ca5528f5b69f0e_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "role": "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)", "role": "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTNarrativeDetails", "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "cnvy:CapitalLeaseIncomeStatementDepreciationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - PROPERTY AND EQUIPMENT - Assets Held Under Capital Leases (Details)", "role": "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails", "shortName": "PROPERTY AND EQUIPMENT - Assets Held Under Capital Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "ic6282e13a31441708183dc18f1fb32ef_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430416 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Goodwill Activity (Details)", "role": "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLGoodwillActivityDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Goodwill Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)", "role": "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i5d01a6a0f2514016bf7b4bc9a45be0a6_I20220331", "decimals": "2", "lang": "en-US", "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432418 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Carrying Value of Intangible Assets (Details)", "role": "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Carrying Value of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435419 - Disclosure - ACCRUED EXPENSES (Details)", "role": "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails", "shortName": "ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i09ad00adc0144f489609f42e9e75c6b8_D20190904-20190904", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438420 - Disclosure - CREDIT FACILITY - Narrative (Details)", "role": "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails", "shortName": "CREDIT FACILITY - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i09ad00adc0144f489609f42e9e75c6b8_D20190904-20190904", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - CREDIT FACILITY - Schedule of Debt (Details)", "role": "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails", "shortName": "CREDIT FACILITY - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440422 - Disclosure - CREDIT FACILITY - Debt Maturities Schedule (Details)", "role": "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails", "shortName": "CREDIT FACILITY - Debt Maturities Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i3e60c0203bb648a69412b5dbfe6fd633_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherAmortizationOfDeferredCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details)", "role": "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails", "shortName": "SHAREHOLDERS\u2019 EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i813ee818103c44b3a6e05e97898900a7_I20210228", "decimals": "2", "lang": "en-US", "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445424 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)", "role": "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "INF", "lang": "en-US", "name": "cnvy:ShareBasedPaymentArrangementNumberOfInstallments", "reportCount": 1, "unique": true, "unitRef": "installment", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446425 - Disclosure - SHARE-BASED COMPENSATION - Stock-based Compensation Expense (Details)", "role": "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockbasedCompensationExpenseDetails", "shortName": "SHARE-BASED COMPENSATION - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "ic6282e13a31441708183dc18f1fb32ef_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447426 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details)", "role": "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails", "shortName": "SHARE-BASED COMPENSATION - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i8bc49b0fffcd4595afec3f3e965e3d6d_D20210801-20210831", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448427 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)", "role": "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "shortName": "SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "iaf326d569e01468497aa5fcf099f986e_I20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i9ced216fc57b4496bdb4a4c6dda88c34_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449428 - Disclosure - SHARE-BASED COMPENSATION - Long Term Incentive Activity (Details)", "role": "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails", "shortName": "SHARE-BASED COMPENSATION - Long Term Incentive Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i9ced216fc57b4496bdb4a4c6dda88c34_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451429 - Disclosure - EMPLOYEE SAVINGS PLAN (Details)", "role": "http://www.conveyhealthsolutions.com/role/EMPLOYEESAVINGSPLANDetails", "shortName": "EMPLOYEE SAVINGS PLAN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453430 - Disclosure - TAXES (Details)", "role": "http://www.conveyhealthsolutions.com/role/TAXESDetails", "shortName": "TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cnvy:ScheduleOfAcquisitionRelatedAndDeferredOfferingCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456431 - Disclosure - TRANSACTION RELATED COSTS (Details)", "role": "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSDetails", "shortName": "TRANSACTION RELATED COSTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cnvy:ScheduleOfAcquisitionRelatedAndDeferredOfferingCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458432 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.conveyhealthsolutions.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - BUSINESS AND BASIS OF PRESENTATION", "role": "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATION", "shortName": "BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "cnvy:RelatedPartyTransactionEquityHeldPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460433 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "cnvy:RelatedPartyTransactionEquityHeldPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463434 - Disclosure - SEGMENT INFORMATION - Narrative (Details)", "role": "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONNarrativeDetails", "shortName": "SEGMENT INFORMATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464435 - Disclosure - SEGMENT INFORMATION (Details)", "role": "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails", "shortName": "SEGMENT INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "cnvy:SegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467436 - Disclosure - LEASES - Components of Lease Expense (Details)", "role": "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails", "shortName": "LEASES - Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468437 - Disclosure - LEASES - Future Minimum Lease Payments (Details)", "role": "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails", "shortName": "LEASES - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cnvy:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469438 - Disclosure - LEASES - Lease Balances (Details)", "role": "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails", "shortName": "LEASES - Lease Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cnvy:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "id519a16136c243fa8987fe260b8e68d5_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470439 - Disclosure - LEASES - Additional Lease Information (Details)", "role": "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails", "shortName": "LEASES - Additional Lease Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110103 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS", "role": "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS", "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cnvy-20220331.htm", "contextRef": "i2c560c5aefd04377bb07dff174ac4c62_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 74, "tag": { "cnvy_A2019EquityPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Equity Plan", "label": "2019 Equity Plan [Member]", "terseLabel": "2019 Equity Plan" } } }, "localname": "A2019EquityPlanMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_A2020IncrementalTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Incremental Term Loan", "label": "2020 Incremental Term Loan [Member]", "terseLabel": "2020 Incremental Term Loan" } } }, "localname": "A2020IncrementalTermLoanMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_A2021EquityPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Equity Plan", "label": "2021 Equity Plan [Member]", "terseLabel": "2021 Equity Plan" } } }, "localname": "A2021EquityPlanMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_A2021IncrementalTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Incremental Term Loan", "label": "2021 Incremental Term Loan [Member]", "terseLabel": "2021 Incremental Term Loan" } } }, "localname": "A2021IncrementalTermLoanMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_A2021OmnibusIncentiveCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Omnibus Incentive Compensation Plan", "label": "2021 Omnibus Incentive Compensation Plan [Member]", "terseLabel": "2021 Omnibus Incentive Compensation Plan" } } }, "localname": "A2021OmnibusIncentiveCompensationPlanMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_A2022IncrementalTermLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Incremental Term Loans", "label": "2022 Incremental Term Loans [Member]", "terseLabel": "2022 Incremental Term Loans" } } }, "localname": "A2022IncrementalTermLoansMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_AcquisitionRelatedAndDeferredOfferingCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Related and Deferred Offering Costs", "label": "Acquisition Related and Deferred Offering Costs [Abstract]" } } }, "localname": "AcquisitionRelatedAndDeferredOfferingCostsAbstract", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "xbrltype": "stringItemType" }, "cnvy_AcquisitionRelatedAndDeferredOfferingCostsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Related and Deferred Offering Costs", "label": "Acquisition Related and Deferred Offering Costs [Text Block]", "terseLabel": "TRANSACTION RELATED COSTS" } } }, "localname": "AcquisitionRelatedAndDeferredOfferingCostsTextBlock", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTS" ], "xbrltype": "textBlockItemType" }, "cnvy_AdvancedPlanAdministrationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Plan\u00a0Administration", "label": "Advanced Plan\u00a0Administration [Member]", "terseLabel": "Advanced Plan\u00a0Administration" } } }, "localname": "AdvancedPlanAdministrationMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_AdvisoryServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advisory Services", "label": "Advisory Services [Member]", "terseLabel": "Advisory Services" } } }, "localname": "AdvisoryServicesMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "cnvy_AnnualExcessCashFlowPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual Excess Cash Flow, Percentage", "label": "Annual Excess Cash Flow, Percentage", "terseLabel": "Annual excess cash flow, percentage" } } }, "localname": "AnnualExcessCashFlowPercentage", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "pureItemType" }, "cnvy_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Assets And Liabilities, Lessee" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "cnvy_BusinessCombinationAcquisitionRelatedAndDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 }, "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Acquisition Related and Deferred Offering Costs", "label": "Business Combination, Acquisition Related and Deferred Offering Costs", "negatedTerseLabel": "Transaction related costs", "terseLabel": "Transaction related costs", "totalLabel": "Total" } } }, "localname": "BusinessCombinationAcquisitionRelatedAndDeferredOfferingCosts", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails", "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_BusinessCombinationAcquisitionRelatedCostsBonusExpense": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Acquisition Related Costs, Bonus Expense", "label": "Business Combination, Acquisition Related Costs, Bonus Expense", "negatedLabel": "Acquisition bonus expense" } } }, "localname": "BusinessCombinationAcquisitionRelatedCostsBonusExpense", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liability, Current", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liability, Current", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityNonCurrent": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liability, Non-Current", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liability, Non-Current", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityNonCurrent", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Right-Of-Use Asset", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Right-Of-Use Asset", "terseLabel": "Operating lease right-of-use-assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_CapitalLeaseIncomeStatementDepreciationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capital Lease, Income Statement, Depreciation Expense", "label": "Capital Lease, Income Statement, Depreciation Expense", "terseLabel": "Capital lease, depreciation expense" } } }, "localname": "CapitalLeaseIncomeStatementDepreciationExpense", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts related to lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "cnvy_CloudComputingSubscriptionAndImplementationCosts": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cloud Computing Subscription And Implementation Costs", "label": "Cloud Computing Subscription And Implementation Costs", "terseLabel": "Cloud computing subscription & implementation costs" } } }, "localname": "CloudComputingSubscriptionAndImplementationCosts", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_ConsolidatedEBITDAThresholdMaximumAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consolidated EBITDA, Threshold Maximum Amount", "label": "Consolidated EBITDA, Threshold Maximum Amount", "terseLabel": "Consolidated EBITDA, maximum amount" } } }, "localname": "ConsolidatedEBITDAThresholdMaximumAmount", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_ConsolidatedEBITDAThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated EBITDA, Threshold Percentage", "label": "Consolidated EBITDA, Threshold Percentage", "terseLabel": "Consolidated EBITDA, percentage" } } }, "localname": "ConsolidatedEBITDAThresholdPercentage", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "pureItemType" }, "cnvy_ConsultingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting", "label": "Consulting [Member]", "terseLabel": "Consulting Services" } } }, "localname": "ConsultingMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails" ], "xbrltype": "domainItemType" }, "cnvy_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A", "label": "Customer A [Member]", "terseLabel": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "cnvy_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B", "label": "Customer B [Member]", "terseLabel": "Customer B" } } }, "localname": "CustomerBMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "cnvy_DMSHoldingsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "D-M-S Holdings, Inc.", "label": "D-M-S Holdings, Inc. [Member]", "terseLabel": "D-M-S Holdings, Inc." } } }, "localname": "DMSHoldingsIncMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails" ], "xbrltype": "domainItemType" }, "cnvy_DataAnalyticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Data Analytics", "label": "Data Analytics [Member]", "terseLabel": "Data Analytics" } } }, "localname": "DataAnalyticsMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_DebtInstrumentAggregatePrincipalAmountPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Aggregate Principal Amount, Payment, Percentage", "label": "Debt Instrument, Aggregate Principal Amount, Payment, Percentage", "terseLabel": "Debt instrument, aggregate principal amount, payment, percentage" } } }, "localname": "DebtInstrumentAggregatePrincipalAmountPaymentPercentage", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "pureItemType" }, "cnvy_DebtInstrumentLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Leverage Ratio", "label": "Debt Instrument, Leverage Ratio", "terseLabel": "Debt instrument, leverage ratio" } } }, "localname": "DebtInstrumentLeverageRatio", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "pureItemType" }, "cnvy_DebtIssuanceCostsAmortizationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Issuance Costs, Amortization Period", "label": "Debt Issuance Costs, Amortization Period", "terseLabel": "Debt issuance costs, amortization period" } } }, "localname": "DebtIssuanceCostsAmortizationPeriod", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "durationItemType" }, "cnvy_DividendsPaidExistingShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends Paid, Existing Shareholders", "label": "Dividends Paid, Existing Shareholders [Member]", "terseLabel": "Dividends Paid, Existing Shareholders" } } }, "localname": "DividendsPaidExistingShareholdersMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "cnvy_DividendsPaidOutstandingAndVestedOptionHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends Paid, Outstanding and Vested Option Holders", "label": "Dividends Paid, Outstanding and Vested Option Holders [Member]", "terseLabel": "Dividends Paid, Outstanding and Vested Option Holders" } } }, "localname": "DividendsPaidOutstandingAndVestedOptionHoldersMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "cnvy_EIRPartnersConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EIR Partners Consulting Agreement", "label": "EIR Partners Consulting Agreement [Member]", "terseLabel": "EIR Partners Consulting Agreement" } } }, "localname": "EIRPartnersConsultingAgreementMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "cnvy_EIRPartnersMonthlyConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EIR Partners Monthly Consulting Agreement", "label": "EIR Partners Monthly Consulting Agreement [Member]", "terseLabel": "EIR Partners Monthly Consulting Agreement" } } }, "localname": "EIRPartnersMonthlyConsultingAgreementMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "cnvy_EarnOutLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earn-Out Liabilities", "label": "Earn-Out Liabilities [Member]", "terseLabel": "Earn-Out Liabilities" } } }, "localname": "EarnOutLiabilitiesMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "domainItemType" }, "cnvy_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Payments", "negatedTerseLabel": "Fair value of contingent consideration in connection with the HealthSmart acquisition" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease Cost", "label": "Finance Lease Cost", "totalLabel": "Total lease expense" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_FinanceLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, to be Paid, after Year Four", "label": "Finance Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_HealthSmartMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HealthSmart", "label": "HealthSmart [Member]", "terseLabel": "HealthSmart" } } }, "localname": "HealthSmartMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_HoldbackLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holdback Liabilities", "label": "Holdback Liabilities [Member]", "terseLabel": "Holdback Liabilities" } } }, "localname": "HoldbackLiabilitiesMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "domainItemType" }, "cnvy_IPOCompanySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO - Company Shares", "label": "IPO - Company Shares [Member]", "terseLabel": "IPO - Company Shares" } } }, "localname": "IPOCompanySharesMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "cnvy_IPOSharesFromExistingShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO - Shares From Existing Shareholders", "label": "IPO - Shares From Existing Shareholders [Member]", "terseLabel": "IPO - Shares From Existing Shareholders" } } }, "localname": "IPOSharesFromExistingShareholdersMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "cnvy_InventoryStepUp": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory Step-Up", "label": "Inventory Step-Up", "negatedTerseLabel": "Inventory step-up", "terseLabel": "Inventory step-up" } } }, "localname": "InventoryStepUp", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability", "label": "Lease Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_LeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease, Right-of-Use Asset", "label": "Lease, Right-of-Use Asset", "totalLabel": "Total lease assets" } } }, "localname": "LeaseRightOfUseAsset", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_LeasesWeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases, Weighted Average Discount Rate", "label": "Leases, Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted Average Discount Rate:" } } }, "localname": "LeasesWeightedAverageDiscountRateAbstract", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "cnvy_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_LongTermDebtIrrevocableLetterOfCreditExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Irrevocable Letter Of Credit, Extension Period", "label": "Long-term Debt, Irrevocable Letter Of Credit, Extension Period", "terseLabel": "Long-term debt, irrevocable letter of credit, extension period" } } }, "localname": "LongTermDebtIrrevocableLetterOfCreditExtensionPeriod", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "durationItemType" }, "cnvy_LongTermDebtIrrevocableLetterOfCreditThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Irrevocable Letter Of Credit Threshold", "label": "Long-term Debt, Irrevocable Letter Of Credit Threshold", "terseLabel": "Long-term debt, irrevocable letter of credit threshold" } } }, "localname": "LongTermDebtIrrevocableLetterOfCreditThreshold", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_LongTermIncentiveAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Incentive Awards", "label": "Long Term Incentive Awards [Member]", "terseLabel": "LTI Awards" } } }, "localname": "LongTermIncentiveAwardsMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_NetCashProceedsOfCertainAssetSalesOrCasualtyEventsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Cash Proceeds Of Certain Asset Sales Or Casualty Events, Percentage", "label": "Net Cash Proceeds Of Certain Asset Sales Or Casualty Events, Percentage", "terseLabel": "Net cash proceeds of certain asset sales or casualty events, percentage" } } }, "localname": "NetCashProceedsOfCertainAssetSalesOrCasualtyEventsPercentage", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "pureItemType" }, "cnvy_NetCashProceedsOfDebtPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Cash Proceeds Of Debt, Percentage", "label": "Net Cash Proceeds Of Debt, Percentage", "terseLabel": "Net cash proceeds of debt, percentage" } } }, "localname": "NetCashProceedsOfDebtPercentage", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "pureItemType" }, "cnvy_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-Cash Lease Expense", "label": "Non-Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "cnvy_NumberOfAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Awards", "label": "Number Of Awards", "terseLabel": "Number of awards" } } }, "localname": "NumberOfAwards", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "cnvy_NumberOfLongTermIncentiveAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Long Term Incentive Awards", "label": "Number Of Long Term Incentive Awards", "terseLabel": "Number of long term incentive awards" } } }, "localname": "NumberOfLongTermIncentiveAwards", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "cnvy_OtherExpensesCARESAct": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Expenses, CARES Act", "label": "Other Expenses, CARES Act", "negatedTerseLabel": "Cost of COVID-19" } } }, "localname": "OtherExpensesCARESAct", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_PublicCompanyReadinessCosts": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSDetails": { "order": 1.0, "parentTag": "cnvy_BusinessCombinationAcquisitionRelatedAndDeferredOfferingCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Public Company Readiness Costs", "label": "Public Company Readiness Costs", "terseLabel": "Public company readiness costs" } } }, "localname": "PublicCompanyReadinessCosts", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Agreement", "label": "Purchase Agreement [Member]", "terseLabel": "Purchase Agreement" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_PurchaseAgreementRevenueThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase Agreement, Revenue Threshold", "label": "Purchase Agreement, Revenue Threshold", "terseLabel": "Purchase agreement, revenue threshold" } } }, "localname": "PurchaseAgreementRevenueThreshold", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_RelatedPartyTransactionAnnualRetainerFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Annual Retainer Fee", "label": "Related Party Transaction, Annual Retainer Fee", "terseLabel": "Annual retainer fee" } } }, "localname": "RelatedPartyTransactionAnnualRetainerFee", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "pureItemType" }, "cnvy_RelatedPartyTransactionEquityHeldPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Equity Held, Percent", "label": "Related Party Transaction, Equity Held, Percent", "terseLabel": "Related party, equity held, percent" } } }, "localname": "RelatedPartyTransactionEquityHeldPercent", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "pureItemType" }, "cnvy_RelatedPartyTransactionPaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Payment, Term", "label": "Related Party Transaction, Payment, Term", "terseLabel": "Related party, payment, term" } } }, "localname": "RelatedPartyTransactionPaymentTerm", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "durationItemType" }, "cnvy_RelatedPartyTransactionRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Renewal Term", "label": "Related Party Transaction, Renewal Term", "terseLabel": "Related party transaction, renewal term" } } }, "localname": "RelatedPartyTransactionRenewalTerm", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "durationItemType" }, "cnvy_SaleOfStockNetProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Net Proceeds", "label": "Sale Of Stock, Net Proceeds", "terseLabel": "Sale of stock, net proceeds" } } }, "localname": "SaleOfStockNetProceeds", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_ScheduleOfAcquisitionRelatedAndDeferredOfferingCostsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Acquisition Related and Deferred Offering Costs", "label": "Schedule Of Acquisition Related and Deferred Offering Costs [Table Text Block]", "terseLabel": "Schedule of Acquisition Related and Deferred Offering Costs" } } }, "localname": "ScheduleOfAcquisitionRelatedAndDeferredOfferingCostsTableTextBlock", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSTables" ], "xbrltype": "textBlockItemType" }, "cnvy_ScheduleOfFinanceLeasedAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Finance Leased Assets", "label": "Schedule of Finance Leased Assets [Table Text Block]", "terseLabel": "Schedule of Finance Leased Assets" } } }, "localname": "ScheduleOfFinanceLeasedAssetsTableTextBlock", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "cnvy_SegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Segment Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization", "label": "Segment Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization", "terseLabel": "Segment Adjusted EBITDA" } } }, "localname": "SegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_SegmentAdjustedEarningsBeforeInterestUnallocated": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Segment Adjusted Earnings Before Interest, Unallocated", "label": "Segment Adjusted Earnings Before Interest, Unallocated", "negatedTerseLabel": "Unallocated" } } }, "localname": "SegmentAdjustedEarningsBeforeInterestUnallocated", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period", "terseLabel": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cnvy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValueAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value, Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value, Amount", "negatedTerseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValueAmount", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Amount", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAmount", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Amount", "periodEndLabel": "Outstanding at end of period (in usd per share)", "periodStartLabel": "Outstanding at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueAmount", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value, Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value, Amount", "negatedTerseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_ShareBasedCompensationArrangementByShareBasedPaymentAwardInstallmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Installment Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Installment Period", "terseLabel": "Installment period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInstallmentPeriod", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "cnvy_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueReduction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value, Reduction", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value, Reduction", "terseLabel": "Options, nonvested, weighted average grant date fair value, reduction (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueReduction", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "perShareItemType" }, "cnvy_ShareBasedPaymentArrangementNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Number Of Installments", "label": "Share-Based Payment Arrangement, Number Of Installments", "terseLabel": "Number of installments" } } }, "localname": "ShareBasedPaymentArrangementNumberOfInstallments", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "cnvy_SoftwareLicensesCurrent": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Software Licenses, Current", "label": "Software Licenses, Current", "terseLabel": "Software licenses" } } }, "localname": "SoftwareLicensesCurrent", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "cnvy_SupplementalBenefitsAdministrationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Benefits Administration", "label": "Supplemental Benefits Administration [Member]", "terseLabel": "Supplemental Benefits Administration" } } }, "localname": "SupplementalBenefitsAdministrationMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_TPGManagementAndConsultingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TPG Management and Consulting Fees", "label": "TPG Management and Consulting Fees [Member]", "terseLabel": "TPG Management and Consulting Fees" } } }, "localname": "TPGManagementAndConsultingFeesMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "cnvy_TPGTermLoanFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TPG Term Loan Fees", "label": "TPG Term Loan Fees [Member]", "terseLabel": "TPG Management Service Agreement" } } }, "localname": "TPGTermLoanFeesMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "cnvy_TechnologyEnabledSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology Enabled Solutions", "label": "Technology Enabled Solutions [Member]", "terseLabel": "Technology Enabled Solutions" } } }, "localname": "TechnologyEnabledSolutionsMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "cnvy_TermLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loans", "label": "Term Loans [Member]", "terseLabel": "Term Loans" } } }, "localname": "TermLoansMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_TradenamesCustomerRelationshipsAndTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tradenames, Customer Relationships and Technology", "label": "Tradenames, Customer Relationships and Technology [Member]", "terseLabel": "Tradenames, Customer Relationships and Technology" } } }, "localname": "TradenamesCustomerRelationshipsAndTechnologyMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_UndrawnLetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undrawn Letter Of Credit", "label": "Undrawn Letter Of Credit [Member]", "terseLabel": "Undrawn Letter Of Credit" } } }, "localname": "UndrawnLetterOfCreditMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_ValueBasedAnalyticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value Based Analytics", "label": "Value Based Analytics [Member]", "terseLabel": "Value Based Analytics" } } }, "localname": "ValueBasedAnalyticsMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "cnvy_VotingCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting Common Stock", "label": "Voting Common Stock [Member]", "terseLabel": "Voting Common Stock" } } }, "localname": "VotingCommonStockMember", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "cnvy_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Lease Term", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted Average Remaining Lease Term (in years):" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.conveyhealthsolutions.com/20220331", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.conveyhealthsolutions.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r357", "r499", "r500", "r502", "r583", "r596" ], "lang": { "en-us": { "role": { "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity.", "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Contractual Obligation, Fiscal Year Maturity" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYTables" ], "xbrltype": "textBlockItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r195", "r334", "r341", "r567" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r261", "r297", "r368", "r370", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r565", "r568", "r584", "r585" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r261", "r297", "r368", "r370", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r565", "r568", "r584", "r585" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r195", "r334", "r341", "r567" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r192", "r334", "r339", "r519", "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r192", "r334", "r339", "r519", "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r261", "r297", "r347", "r368", "r370", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r565", "r568", "r584", "r585" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r261", "r297", "r347", "r368", "r370", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r565", "r568", "r584", "r585" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r43", "r507" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r29", "r197", "r198" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $69 as of March\u00a031, 2022, and December\u00a031, 2021" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r14", "r15", "r48" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Incentive bonus" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r14", "r15", "r48" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r229" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r60", "r61", "r62", "r554", "r573", "r574" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r59", "r62", "r68", "r69", "r70", "r118", "r119", "r120", "r450", "r569", "r570", "r598" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r30" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r118", "r119", "r120", "r398", "r399", "r400", "r454" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r372", "r374", "r403", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdvancesOnInventoryPurchases": { "auth_ref": [ "r56" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.", "label": "Advances on Inventory Purchases", "terseLabel": "Inventory purchase advances" } } }, "localname": "AdvancesOnInventoryPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r374", "r395", "r402" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r36", "r199", "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r80", "r98", "r281", "r475" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r98", "r218", "r224" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r112", "r174", "r181", "r188", "r201", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r446", "r451", "r465", "r505", "r507", "r536", "r552" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r12", "r57", "r112", "r201", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r446", "r451", "r465", "r505", "r507" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r375", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BridgeLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.", "label": "Bridge Loan [Member]", "terseLabel": "Bridge Loan" } } }, "localname": "BridgeLoanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r367", "r369" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r367", "r369", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business Acquisition, Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r425", "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "negatedLabel": "Net loss", "terseLabel": "Net income (loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r425", "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Net revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r424" ], "calculation": { "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSDetails": { "order": 2.0, "parentTag": "cnvy_BusinessCombinationAcquisitionRelatedAndDeferredOfferingCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Mergers and acquisitions related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/TRANSACTIONRELATEDCOSTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r436", "r437", "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r435", "r438", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Earn-out (contingent consideration)" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "ACQUISITIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 1.0, "parentTag": "cnvy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total identifiable assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "ASSETS ACQUIRED" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred taxes" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 2.0, "parentTag": "cnvy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Total fair value of intangible assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "LIABILITIES ASSUMED" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net identifiable assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r102", "r103", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capitalized software and property and equipment, net included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareImpairments1": { "auth_ref": [ "r586", "r587" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss from capitalized computer software costs.", "label": "Capitalized Computer Software, Impairments", "terseLabel": "Write off capitalized software costs" } } }, "localname": "CapitalizedComputerSoftwareImpairments1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r39", "r100" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r100", "r105" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, cash equivalents and restricted cash as of the end of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r466" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r39" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r109", "r112", "r133", "r134", "r135", "r137", "r139", "r145", "r146", "r147", "r201", "r245", "r250", "r251", "r252", "r256", "r257", "r295", "r296", "r300", "r304", "r465", "r593" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r52", "r240", "r540", "r558" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 15)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r237", "r238", "r239", "r241", "r578" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r242", "r579" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Contingent Consideration" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r118", "r119", "r454" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r27", "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r27", "r507" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "#REF!" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r66", "r67", "r77", "r543", "r560" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r155", "r156", "r195", "r462", "r463", "r577" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r155", "r156", "r195", "r462", "r463", "r575", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r155", "r156", "r195", "r462", "r463", "r575", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r150", "r550" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Customer Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r155", "r156", "r195", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r153", "r155", "r156", "r157", "r462", "r464", "r577" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r155", "r156", "r195", "r462", "r463", "r577" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r107", "r448" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r321", "r322", "r335" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current portion" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with customer, liability, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r338" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Refundable deposits" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Contractual obligation" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "auth_ref": [ "r74", "r75" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Cost of services and products, excluding depreciation, depletion, and amortization" } } }, "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r154", "r195" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Rebates" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r108", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r275", "r282", "r283", "r284", "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "CREDIT FACILITY" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r23", "r24", "r111", "r116", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r287", "r288", "r289", "r290", "r476", "r537", "r538", "r551" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r24", "r285", "r538", "r551" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross", "totalLabel": "Term loans, net of deferred financing costs" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r258", "r287", "r288", "r474", "r476", "r477" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r50", "r111", "r116", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r287", "r288", "r289", "r290", "r476" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument, Redemption [Line Items]", "terseLabel": "Debt Instrument, Redemption [Line Items]" } } }, "localname": "DebtInstrumentRedemptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.", "label": "Debt Instrument Redemption [Table]", "terseLabel": "Debt Instrument Redemption [Table]" } } }, "localname": "DebtInstrumentRedemptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Debt instrument, repurchase amount" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r478" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "negatedTerseLabel": "Less: deferred financing costs" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs, gross" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r406", "r407" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred taxes, net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r99" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan, cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/EMPLOYEESAVINGSPLANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r98", "r227" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r98", "r227" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r98", "r169" ], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "negatedTerseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r334", "r339", "r340", "r341", "r342", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r375", "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r318", "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Dividend" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]", "terseLabel": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]", "terseLabel": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Dividends payable, amount per share (in usd per share)" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r15", "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable, current" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Dividends Payable [Line Items]", "terseLabel": "Dividends Payable [Line Items]" } } }, "localname": "DividendsPayableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableTable": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.", "label": "Dividends Payable [Table]", "terseLabel": "Dividends Payable [Table]" } } }, "localname": "DividendsPayableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r7", "r18", "r28", "r115", "r248", "r250", "r251", "r255", "r256", "r257", "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Due from related parties, current" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r78", "r123", "r124", "r125", "r126", "r127", "r131", "r133", "r137", "r138", "r139", "r142", "r143", "r455", "r456", "r544", "r561" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per common share - basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Income (loss) per common share\u2009\u2013\u2009Basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r78", "r123", "r124", "r125", "r126", "r127", "r133", "r137", "r138", "r139", "r142", "r143", "r455", "r456", "r544", "r561" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per common share - diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r466" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate reconciliation, percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/TAXESDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r68", "r69", "r70", "r118", "r119", "r120", "r122", "r128", "r130", "r144", "r202", "r311", "r318", "r398", "r399", "r400", "r413", "r414", "r454", "r467", "r468", "r469", "r470", "r471", "r472", "r569", "r570", "r571", "r598" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExciseAndSalesTaxes": { "auth_ref": [ "r72" ], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of excise and sales taxes included in sales and revenues, which are then deducted as a cost of sales. Includes excise taxes, which are applied to specific types of transactions or items (such as gasoline or alcohol); and sales, use and value added taxes, which are applied to a broad class of revenue-producing transactions involving a wide range of goods and services.", "label": "Excise and Sales Taxes", "negatedTerseLabel": "Sales and use tax" } } }, "localname": "ExciseAndSalesTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r273", "r287", "r288", "r348", "r350", "r351", "r352", "r353", "r354", "r355", "r363", "r457", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r273", "r287", "r288", "r348", "r350", "r351", "r352", "r353", "r354", "r355", "r363", "r457", "r510" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r458", "r461" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r458", "r461" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Change in fair value of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r273", "r287", "r288", "r348", "r350", "r351", "r352", "r353", "r354", "r355", "r363", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarnOutandHoldbackLiabilitiesReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r482", "r486", "r495" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails": { "order": 2.0, "parentTag": "cnvy_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r484", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases (interest)" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r480", "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Net present value of lease obligations" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r480" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails": { "order": 2.0, "parentTag": "cnvy_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Finance Lease, Liability, Fiscal Year Maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r480" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails": { "order": 3.0, "parentTag": "cnvy_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance leases obligations, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "For the nine months ending December 31, 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amounts representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r483", "r490" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payment on finance leases", "terseLabel": "Financing cash flows from finance leases (principal payments)" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r479" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails": { "order": 1.0, "parentTag": "cnvy_LeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r482", "r486", "r495" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails": { "order": 1.0, "parentTag": "cnvy_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, right-of-use asset, statement of financial position" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r492", "r495" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r491", "r495" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r223" ], "calculation": { "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r219", "r220", "r223", "r225", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r223", "r521" ], "calculation": { "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r219", "r222" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r223", "r520" ], "calculation": { "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnContractTermination": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.", "label": "Gain (Loss) on Contract Termination", "negatedTerseLabel": "Loss on contract termination" } } }, "localname": "GainLossOnContractTermination", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r98" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "(Gain) loss from disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r208", "r210", "r507", "r535" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLGoodwillActivityDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLGoodwillActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS AND GOODWILL" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILL" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r98", "r209", "r212", "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLGoodwillActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r213", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Measurement period adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLGoodwillActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLGoodwillActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HealthCareMember": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Service provided for prevention, maintenance, diagnosis or treatment of physical and mental health.", "label": "Health Care [Member]", "terseLabel": "Health Plan\u00a0Management" } } }, "localname": "HealthCareMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r81", "r99", "r123", "r124", "r125", "r126", "r136", "r139", "r443" ], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r73", "r174", "r180", "r184", "r187", "r190", "r534", "r541", "r547", "r562" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Adjustments to reconcile to U.S. GAAP net income (loss)" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r231", "r234" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r113", "r410", "r411", "r412", "r415", "r417", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/TAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r114", "r129", "r130", "r172", "r408", "r416", "r418", "r563" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax provision", "negatedTerseLabel": "Income tax (expense) benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails", "http://www.conveyhealthsolutions.com/role/TAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r95", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r97" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and other accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r97" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r97", "r518" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r97" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r97", "r490" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r97" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r217", "r221" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r71", "r168", "r473", "r475", "r546" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r545" ], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r92", "r94", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r15", "r16", "r48" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r55", "r507" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r205" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Provision for inventory reserve" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "For the nine months ending December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r494" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amounts representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47", "r112", "r182", "r201", "r245", "r246", "r247", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r447", "r451", "r452", "r465", "r505", "r506" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r112", "r201", "r465", "r507", "r539", "r556" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49", "r112", "r201", "r245", "r246", "r247", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r447", "r451", "r452", "r465", "r505", "r506", "r507" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r45", "r111" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r24", "r272", "r286", "r287", "r288", "r538", "r553" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Term loans, net of deferred financing costs" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedTerseLabel": "Term loans, current portion", "terseLabel": "Term loans, current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r116", "r243", "r277" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r116", "r243", "r277" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r116", "r243", "r277" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r116", "r243", "r277" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r116" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Term loans, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.", "label": "Long-term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Long-term debt, weighted average interest rate, over time" } } }, "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r50", "r244" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYDebtMaturitiesScheduleDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Office and computer equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r96", "r99" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r63", "r65", "r70", "r76", "r99", "r112", "r121", "r123", "r124", "r125", "r126", "r129", "r130", "r136", "r174", "r180", "r184", "r187", "r190", "r201", "r245", "r246", "r247", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r456", "r465", "r542", "r559" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss)", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Net income (loss) attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvotingCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors.", "label": "Nonvoting Common Stock [Member]", "terseLabel": "Nonvoting Common Stock" } } }, "localname": "NonvotingCommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r174", "r180", "r184", "r187", "r190" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r487", "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r480" ], "calculation": { "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Net present value of lease obligations" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESFutureMinimumLeasePaymentsDetails", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r480" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails": { "order": 4.0, "parentTag": "cnvy_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r480" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails": { "order": 1.0, "parentTag": "cnvy_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r485", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r479" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails": { "order": 2.0, "parentTag": "cnvy_LeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/LEASESLeaseBalancesDetails", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r492", "r495" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r491", "r495" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESAdditionalLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r453" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14", "r15", "r16", "r48" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAmortizationOfDeferredCharges": { "auth_ref": [ "r82", "r98" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of other deferred costs recognized in the income statement.", "label": "Amortization of Other Deferred Charges", "terseLabel": "Amortization expense" } } }, "localname": "OtherAmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r56", "r507" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": { "order": 6.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r444", "r445", "r449" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r82" ], "calculation": { "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "negatedTerseLabel": "Other" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Employee-related Liabilities, Current", "terseLabel": "Employee related" } } }, "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financial activities:" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r8", "r11", "r207" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other advances" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "terseLabel": "Prepayment premium on early repayment of term loan" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r90" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of debt issuance cost", "terseLabel": "Payment of debt issuance cost" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r88" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Dividend", "terseLabel": "Payments of dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r85", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Initial purchase price" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r85" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisition, net of cash received" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r86" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment, net" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopSoftware": { "auth_ref": [ "r86" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Develop Software", "negatedTerseLabel": "Capitalized software development costs" } } }, "localname": "PaymentsToDevelopSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r347", "r349", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "EMPLOYEE SAVINGS PLAN" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/EMPLOYEESAVINGSPLAN" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r375", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r26", "r295" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r26", "r295" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r26", "r507" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value; 25,000,000 shares authorized and no shares issued or outstanding as of March\u00a031, 2022 and no shares authorized, issued or outstanding as of December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r37", "r38" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r9", "r11", "r206", "r207" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r87" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Products", "verboseLabel": "Supplemental Benefit Services" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r229", "r482", "r486" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r58", "r230", "r486" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "totalLabel": "Total financing leases included in property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r19", "r228", "r479" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "terseLabel": "Office and computer equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r230" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r233", "r580", "r581", "r582" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r228" ], "calculation": { "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r230", "r507", "r548", "r557" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r228" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Life (in\u00a0years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r79", "r204" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debt" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r357", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r499", "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related party transaction, amounts of transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r357", "r499", "r500", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r357", "r499", "r502", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r497", "r498", "r500", "r503", "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r89" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Principal payment on term loan" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "terseLabel": "Percentage of fair value in excess of carrying amount" } } }, "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r4", "r17", "r105" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r13", "r21", "r105", "r576" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "verboseLabel": "Restricted cash, non-current" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r31", "r318", "r401", "r507", "r555", "r572", "r574" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r118", "r119", "r120", "r122", "r128", "r130", "r202", "r398", "r399", "r400", "r413", "r414", "r454", "r569", "r571" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r165", "r166", "r179", "r185", "r186", "r192", "r193", "r195", "r333", "r334", "r519" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails", "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r323", "r324", "r325", "r326", "r327", "r328", "r331", "r332", "r337", "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE FROM CONTRACTS WITH CUSTOMERS" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r329" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, remaining performance obligation, amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Net revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock, consideration received on transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, number of shares issued in transaction" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r15", "r43" ], "calculation": { "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales and Excise Tax Payable, Current", "terseLabel": "Sales and use tax" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r155", "r195" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACCRUEDEXPENSESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSPurchaseConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r374", "r394", "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r219", "r222", "r520" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r219", "r222" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r214", "r216" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "terseLabel": "Schedule of Line of Credit Facilities" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r41", "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTAssetsHeldUnderCapitalLeasesDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r174", "r177", "r183", "r214" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r174", "r177", "r183", "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r375", "r397" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Restricted Stock Unit, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r379", "r388", "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r53", "r109", "r145", "r146", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r304", "r309", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r153", "r155", "r156", "r157", "r462", "r464" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk, by Risk Factor" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r161", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r190", "r195", "r235", "r236", "r564" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r161", "r163", "r164", "r174", "r178", "r184", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Services" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r97" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "negatedLabel": "Non-cash stock compensation expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Exercised (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Life (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested or expect to vest at end of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options, outstanding, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r381", "r397" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Option Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in usd per share)", "periodStartLabel": "Beginning balance (in usd per share)", "terseLabel": "Options outstanding, weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested or expect to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested or expect to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested or expect to vest at end of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Share-based payment award, shares issued in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r373", "r378" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONLongTermIncentiveActivityDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "terseLabel": "Equity instruments other than options, aggregate intrinsic value, nonvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Share-based payment award expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options, exercisable, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Options nonvested, number of shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "terseLabel": "Option, nonvested, weighted average exercise price (in usd per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life vested or expect to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life vested or expect to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r488", "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease costs" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r106", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Software", "verboseLabel": "Capitalized software development costs" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/PROPERTYANDEQUIPMENTPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r161", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r190", "r195", "r214", "r232", "r235", "r236", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails", "http://www.conveyhealthsolutions.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r25", "r26", "r27", "r109", "r112", "r133", "r134", "r135", "r137", "r139", "r145", "r146", "r147", "r201", "r245", "r250", "r251", "r252", "r256", "r257", "r295", "r296", "r300", "r304", "r311", "r465", "r593" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r54", "r68", "r69", "r70", "r118", "r119", "r120", "r122", "r128", "r130", "r144", "r202", "r311", "r318", "r398", "r399", "r400", "r413", "r414", "r454", "r467", "r468", "r469", "r470", "r471", "r472", "r569", "r570", "r571", "r598" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r118", "r119", "r120", "r144", "r519" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r26", "r27", "r311", "r318", "r383" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r27", "r33", "r34", "r112", "r200", "r201", "r465", "r507" ], "calculation": { "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r110", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r318", "r320" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SHAREHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock split, conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/BUSINESSANDBASISOFPRESENTATIONDetails", "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TechnologyServiceMember": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Technology assistance, including but not limited to, training, installation, engineering, and software design.", "label": "Technology Service [Member]", "terseLabel": "Software Services" } } }, "localname": "TechnologyServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSDisaggregationofrevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r334", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]", "terseLabel": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r334", "r344" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/ACQUISITIONSAssetsandLiabilitiesAcquiredDetails", "http://www.conveyhealthsolutions.com/role/ACQUISITIONSNarrativeDetails", "http://www.conveyhealthsolutions.com/role/INTANGIBLEASSETSANDGOODWILLCarryingValueofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]", "terseLabel": "Transferred at Point in Time" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized debt issuance expense" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnbilledReceivablesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.", "label": "Unbilled Receivables, Current", "terseLabel": "Unbilled receivables, current" } } }, "localname": "UnbilledReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r148", "r149", "r151", "r152", "r158", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r489", "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/LEASESComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/CREDITFACILITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r132", "r139" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding: diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r131", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding: basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted-average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.conveyhealthsolutions.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossincomePerCommonShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r405": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r421": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r496": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r504": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756" }, "r588": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r589": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r590": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r591": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r592": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r593": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r594": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r595": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r596": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r597": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 95 0001628280-22-013673-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-013673-xbrl.zip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Ά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

5?,WII^(K3Q<0B3)@G^TA'; M++.4A)>RS^HU)^]DNM$8,P,G AN/J758)"R5+S)8-:R91?--UP2RX/6#X,)X MC/=8TQV_+)IJ--_1]D#K!,'Y+L >5T,_ADD#9ZT(Q+4B#2N%&2XK-Y5ZV-YI MN:G[4EY)WTD/X*Y2TH^ME'2+[K\;5"()(9&RAQO5'_>JHDG7U(CYXIHO]TB[ MNF,S9$GQ[(R/_>UW-.:RC'E.#,5F07A/SA9>$0M&>DX+79:Y6C4^KM%A+M," MGH!HQIRI)44 _CZ&CY/*"FB&&2AUK+F.3\[J$WY.H6XT1E (\%O7ZE>7#@"2 M?]K'6^>@&YBD^,(S)]/!PK6')MG^$\AA9]!W5E4])'*4RFAE&,W"DOE MQG%^"[5[TDWW[0' 2C][&?"&!L;!GV$Y'4;)_[G-DN!D8H7E?N971YX^QM'J M3L%2^-@16-K-?M6:\/%H.;>ZGY5NDB"I7.:NC-+.E\BDE-S M@6>-25LN'66M+$Y!%XT5>ISJI<%OTR>8$)%BZ7&:M,_ZS?6MC\7]3C-K*^0T M/%"3Q&2>5+5X#2-@H9-!6PK'+<+2UO7EP3; \'^\_\_.$\)T]AQV()Q6;L-, M_"?39'$@\<1J-)YD_YFF](I%.REK*)WV\/1<& W&LVL[C8$[/DN0 F0X&'X( M?:PA,QR8#]5H.B^XU&[5O.A2.((%XS4B>!@8_J@_!'K*;%,)#0%@-&WN%"U4 M?5K\=7,_:&Y ;F6S$SE/E397#.OZQ9 M/EB^L^I<8TSY3SE+LQ(Z"2 3(V#EIW[6#[@3K7L!#.<:ENIYH$6>6*0Z;9H? MXZTKL.GP-$Z#J3L@HU]C@ DPB$[IOE6Z&)5&3)N["(SC8<)IV)Y)W7*CAQR) M<\#N-,!=37VTNK]P-L?65(BH]4D,VELU1P;1()4PPHA)&)YAX:KSX>A]+;Q2 M<9Y4;P3[-U]D[AAGUA\>5>-4_SBKW1AP(F^. 1QA>J M?EWH+4%)Z_T8U76[%D1 C79/0K^Y1+8/!PH$AQM8F=:KU-#![[UL.H"CP$^= MJP9S%\?BO^UP.$:RK]^5'"#348+#>44V6-/1M*I]3,E9-4HE5A!GF]MXL &P MH+0 3%B;G6T&3),.;K;^V1$CUK=?2[8_\'627O/2/<-!F_D[9[,9E:-F8?IC MH V34BH7H?K#$+O&P<\-K[QQ-161$HN3D=UCME5 M:18]V*NSRL/)!WC/A[;ARW1PAOEW+M6XQJ49K.H$.]SP'U)I0&<-)H -X=R M .=*QN)$9CAPEASZKMV$>LRE31C6,#![ M=0'TDM=$)_.#BJ'4\&/7'NPO61 M\L_@T,]@>UN_B9N.)T"F20>:X%MA%#@0V-^:=\?]X7E8.+ &*.*\_\F\I!X* MU872>4N%Z_#Z9DK'1GL&B*_J]]-V@8(VJD%M$-I[1J.DFZ2/Q^'HM!X+SW+; M?ZC&P]%%]BJ,/J2J<\WG\Y)8&R*$\%237I+J#B:DJ[7$I+*UASQ#[M8[A]P^ MG*:3QE*)-95>_L@2(;<$M$ QO44?)&I$,XI$!;MJ%&28H0]8U1\);H J"[Y^ M1O[1U.69DO9U'A(PH,X&2E@Z/G@U(,YT5&<[-VRR@. S=-)>J(M#3<9UD?M MI_7<0,@ DHVJIK?.V,&L6S1<7_0"8OII>CV"2XN1,-84MABH<0U'?W\XPV>0 MDDL B"@U22IVNW4-7*(R^J'RH$TW&S!7 !>1!&-L@OXUA3=JPMSSMAUSL!IAQO6 M>MC4JYMK'L/1DEAMYQCJTI5A]MJ%UR39V2C*()97T:P6#"T1S:Y?S(9.#]X/A M^:"USF:"=>%LIN,Z*WX>R$D3J1 AS7B()6D!-SZ8JM_"T;118^$K2#"MJI:X M!QN6H'F=-J45D(G$9UO1)M77NX?[ 0> BVEH^O:7]VL?1QU_NF7P9GQ%M4-, M(\>BD:LKKY/ M-&"WI!LT1G@- [V&O]NM[5\TRF$JL8D^@+DL^_SN5C/RJ96*Y#.I'0R7!(36 M T WK& O[WD%>W[G%>Q?S97PE300$)WWQ0N[][CQPI[N\L.37;I_\.ST\*^] MT_V#%WSWT^O\\*_7]/!T1^R>[.1O/[F+MY_>GZ]Z8=]^.CS=_?0BWWUS^!YF ME,/[/NT=]-\?'KP\?7OB+G9/^B=[G_Y]LG_P9WV#Z,4[H)6.JU_;5Z]W=[9=O ML1C]JYV_]G:>[3S>WCO(MA\_WG^]=["S]U?V?/_OG<<[3U]]07WZST]F>?*Y M+DN:4QV\-S(6I3+:%J;PW-"R]+Z\\TC ZW'8CT];//OUJ([MOGA'@Q'2BH)$ MKB.1IBB)@K\)AHVD==X(6FQBXA&<+4J3V>ENCNK%\L;RJ[-X9NK1;=2%6E%" M48]2->E*\PR51@%#!PU6A3]M+,M3,#U6U+F3J3]:3,RHK8[:H8YR$OV'I[-T M)=05&C.C+=V=#*(1.IFFS9#M5>G>4I&CA9!&LU04#*V:M3YH,A'&5T\7/0YU M?6RLE@T&P'"47&]+Q91J1>XRU0\-J/;I5N>MU0^8SO2T+>?4F+/H^ZWSMX9- M#*G6*4-S]S(ES%0C-SU-#LBYYV]A_]LQFE&3!;JPN-'2L.?'8;"8]W)-P.JS M\;G&G/O"M*/&7DV>&TQ/"UBB?3)-23MUQ*56TWR%5^47M;7F3NEP\1 _DWQS MQ]FIC=G^.+6,J)=?1X=_/<'07&A^_VD?@\GG[RSL&,V%(S(R2:2RBEBEW@N) MTAKSP'BI]49M8\TKT2W:X8V[J<+I@J:>\&80YCC<-&!8-/ZJ <#:487?O!RM M:]3$AV:HVO*\KY/TTA63F=7HF]O3=3[L;,MKOU#XB('>]N/YTS/;\?)UH>OF MBB>6UGJ5$*O0^K[HU4X#S!ZMZPT>#8<>_9];V4+ L(EA)&"OS,]G=98?HZ5I\ QO MP%?5A',:P#SSV!\/1V[BSM@RK_K/-(6ZYI>61L,+TY]<-(_4H=E3,/\J4I-! MJ[2!PC-(B3.+7W1#T&Y2P2OCCIMG4[;#PB]G!:%'0]L&#NMM3-0ZBU'4XR+] M7G8M9"M[M9@?N6#*IPR1%+P;IAR4Q94W"ZV#T&VZX6(@&EL4@L4]JH,B;>&X M]M^SU DSF8QJ1FH^F24@IH2H1-FMJZ0WVZK>XL6=M WF8SU K0Y/:S]7;6#C M%EQU@"D\LK!D4$6/80/[B3U/VKX5*6!]'!K'R'30YN? ![W%^MIK=CYJJE=8 M^=?9]\MZYYTG?J/D:TK>5>/WCU-!+/SI%S?Q][??!6^H-F5!%!>>2$<=T3$8 MXJPK"A&Y+MU:E]M-,-D?M^RW=/KC[WGO^94[#AXO.N['I4GL1R2]/R_P[V803_L(_C_<4-[!E;9),6UICAF8Q+L M,VS.QN&/]H>'(*C.^N;BCVJ0YIP>>MB,U=CO:/1_P(IVSO0;VR%M:OWQW)S= MHK5).QG!']^^N?EX*WWTKXE?_ZSD6ZHLKOR8;K$K/[MN6,:V"J:_:-CK/Q-* MWLED^8TG!*>'5/#_/1 /VN^UYP@(%N['-_^5Z&!TU2-GF(\R./J#9BR1Z]KH M^L$*\3;D"%_/DDV0(=<^;,?A9Q]QI$5#OA_B.N4.S[ZSQTE]QB NQ1P>5B32 MYIQ-DO@W/IAZHU>/IC[?[[W]BL/V/VO2J0Y2.M5NG4[U%-.I_MN._O5H=L]C M=CP_^&!N2.RS';W.RWB'V_I;;4Q-802?3!TL*H%. 20 @H<\O]DK._ EWC-TYU_T 3K;&O3\:@1KH2;.1SH40XQ?+L^^MUFJV M:%=M7\[(GUOLS6B49K?:C!^P#_^U2J+?:.&+"Q[AZ^[-BF]3C%Y2*VV,*@8I M\R@-!<,0?UE:Q:4-EQK/"U7IQ:HIW2A+S\!D>MS<1'I338Y;8GSZL?%K;C<9 MZP?FX\WJ2(K-M+B/WYY^[.^?/JO>'FS+_8.G']^^V3O9.WC!#D_^7>T=/#O9 M/=CK[[YY?;'WY)_^6_Y:M,_ NZ:'_'7Q]LV_CW>?'.6[!\^.W_)=!M\[W3W= M8;MO=C_N\M)DLH2503)>:ZUH@*0O.PQJJXH=7\W_(,?W8:/KI.FG\/K58G<05\' M?95U5+@HHS81.[?DQGE.)3,L!%U263:]6QKH8QWTW7?H^[0"?0!M6K-"$9I' M2D"L4:*Q8UJ9NQ ]"['4V.1#]XI+FHQO"/1MG&Z]42KT__._%-/ZX:7_^=\I MII[:ZC8QP<_8R_S2/;A4B&P(IM:7++^M1KF&JFLQP>D_Q:@/P:M/L!%/Z_ M;^#%^*QWYQ?A[Z]4FSK^ODO^7E6!1"&$8E83:Z(@4GM&0"G*B8H\MW!B%$Q! MX&^Q=4O;[R?D[XW3I'XR+^6?7^:E_,D-\I_/[/:\I,)*EA?4RX(Z0W.K (CR MW!0LL-AY'#=*YKQ:]S@Z4Q1<45+*P(AD*A!CG2-6!^4%5WG KF>LZ)6,?R.S M>U/\BAU8W8=UW0*L0'^RAFH?O/02.Z4711D*)B)3WI=Y['R$&P96:PIR+*0Q MA24B2DNDTY88*36AV(D9I))EQM=@57PK'V'G">P\@;^$I^ K-;W.4W!W0%BM M:6W4E\9B1:/"%CF1WFBBJ' D%X4641>L=!@L*;?$+^\IZ#R!WT0YZOC[+OE[ M5=$QD097%I2P$IARNUB6:=Y>V_U,GH2_U^>@2^&^U=VU7 MH';[EK/YOVO\Z7XDR'?YH5U^:&O>%$Q*5DK/N _2*:Z"I[K,J2P<58RYRQNI MK[M\6RDU%U)[8?*X+FWY"_AV3Y[RMV]VQ?Z;W?.]3^_9;IK;4S!C^B>')W^^ MWS_888=O8$YO7K-5DV?WX/ 8QH,QMP4V6]][ N\[>/]Q_\W>Z>Y?8-:TD([0HC"I5+$(0#QZI'F-Z4],_N\SW M#MENCVS.16\"4YH+*RF+UEBKJ8C,66J+@B5D8XQWR'9/D&W5F<-=D1?11< S M7A));4ZL493D*C)?NNB*R!\\8J+'"G;_H>TNXD3W-T1DU@N,7&FT_"*.Y&A# MX4I5*.&8+$JJ9.#!:.>8,%%ZUP6*?ACVK%\H--H[*CDC!8TYD87,B9%!DT*Z MG ?+3>0!L(=MW3*YYR=T)'>!HH:_2^YHKDSPRLI(A5%:T3PJ'F@,7(B50-&J MXM'Q]UWR]ZIN88TL14$IL7E.B71<$16=))'FN;(A]WDP#QYQ]DM="?EE7&%_ M?E7.W\]G%OY\QI\)D6DA)1-YE(%IL )+#N:$+21\XG3GUKI/ 'W9G3TIH7Z5A4=-L5[U8'1?5C7;7SLN:8%TXP' MX223N5:YMU0)L"1\$67L/%'W#(S6\J=Y#J?'-:&B"* MVI(HY33AN97E\E-;P86&)F[&4<%O96W]?>Q0 MLM .![X'3(D#8V^_\U#WT9L,LSZV@,'^?,-1=CH^ MESX= >/6S0']U&%'VVD:##]:[,$SK^Y_;#Y@ Y[4)N>LGUK;P),3F%2_@E$O MLM0OK^Y.D]K(CNMNP*E'4KK:^6/[I3X>GIY6=2>G[8&O&Y =A0$V&>L946I(F%"<"*E=T1;B]="46@4EFNSUMI=4XQ0E@Q;F$G+HJ*R M9/A7;H7)RW(CF[$,9WV='R]VY]RUMA?71=.3>1 6 M6C)CF?F]X8>4$UL+%^ PM=1B#:#F?X+I3XY?X=%FV_Y#-1Z.QKWL[[\?9[]A MMS].'U[VC?01>_A[ZC+RW(P"8,\.,'P?Y$[ 9L^+ USR>?M\VZAT%,Y&88P9 MQ7ZQ&_=23]6;-5>[1^>&_;(JT.VP6?IZ&]A+#O'=-V:P@0WC3G2NTLT]>;+\ HV%"\;N.-_;12/[S4 ML:V64FW[L/IU"\W0S@#$TUR3I$$B\KYM6A9FCY^&"7ROZ0W6_O+#$*>65M3V MXDHOGW7CQ;:?4W^!HR\T2T_-YA8?3MW!8 ,J7,7\UQ'$(HP WTVMVT]13.'Z MSJ:VGP0/_&:0FNC.5@M+0\G8-/*#[<$6:"/0>)L>O^U1G)F+NNM?$LXP*==L MXFSJ\WU=V8(TV^9YV"*@YN-AWV.+O#15F#2P9+-[EW'4E9PT:S!LCD8A-26L M)[TPN^5IQ^DH]8Y?/%KCWJ-ZT#!90XC8@?RH[H>'+=V"G;1='?'WJ:-[ZEB6 M2*!^Z8W(&#L[FIJI8=4X5FH:N="6L>F^N A%2"!-0T??S,Q&Y :XT1Y MV*IQ9^"V9L!=?S;':@,T-<*FGWB4E:_,Z*+I@OLA7/2R="$D;3><+ZQO1K!X MWDT/26P*WI(.4 VV TV-(0$%@$1G@S4LDKUJE=)F9L!8P^G1<=/^=;"QW 85@@R K;(Z* 2&@(F#D9H%D ,\%AGK?__F=G9Z<>(6T1 M?E;OC\/V8.W7FF\@$ _28##GT$_C9W6#&V!%>"J,!JEQ]^+4/P286!_F_!M> MWJP;0?:!>IIMA3>V>[H%9W&I5E/O5^I8OJ@898BX">IF6'0[_0+/HNM=?HO> MY6QEM[K>Y3]B+EWO\JYW^:RG^&=[D:_:_=*7GH:\#,I*3H/Q-"\D5UHRZ7(: M'ESQGL_Z"ZZ_U?\CX.IJ6VQ-<,PZ&#>J[(+NNJ+5?A^]]=?35J\0_9=[+V ) M$]RM9\&.IJA@H1=Q33^XU'%R6_W@&QKT?_:!Y,@K!]17:Z^397/^%F8I4-9) MW=S[Z\W2M)EW;77..K'?P/+\L6V\G\%!_X,S_WN.#;L-P^\/7@;4TV'6?YIQ M-7X]& ).C%)>PL[@; JSP. /)6F^DN[J,_?:=CR"(=!9)&"8Y(3RVA!RCQG M(*"DUN4M^BVOX-)ZADU,_WOX/;U]=>_D1-^U2VHT_ #X4?>Q7Z2$-LCS-W!K M/Q-S5D=VO50:Q:9QZ"0U#CT=IL:A(=ESJ6A$[>%M*T?\C-V;5;$%"L;=-$2^ MV;!W5'SENY;*J"VJI<(KOW]I-L9WNDAP-QOU>1T\[=2?IF_0#0N:X/4%1NXJ MH_<[K7X-U-+J[SBK]X>N[1:9OU986=I26\<,+2-EA3'!RIMF]LYT MB4:!0/T)*R:OZ0WC9<5AO*QFM)K(11IK.24X5A^#)Y_":/B39 /[][L'[_.] M-R\N#@_^.=D[>%GM/7E6'3[I'^\?O#S!8H-O^8[8A_>MYO+L\1L\,G M_^[OO=EE>W_MT-TW_WX/\\WW_MIENV_V3D!5@??_$W?7<_5RJ;W2>23*1=!9 M@G)$B1A)R&W.F/9:QCPEKG+&'_[0=. 9&WT9*C>*TOU$Y2BF, >LI/D-VEQ@ M5A+\U"*B&WRX^&(XO (-GS<&Z:]P1^([H>)Z'2*C)#6:><(8V&\RZ)(HGG/B M=:F9#@;D(+;@[?'\JZ](7(Y+WP<3[[6F>CD_M^2??1&.W51%W6@<*SWWED;K MM.4R%+G61E)5R#)8(Z,H;]RNY_O!5Z?/?1ERK=?Z '5..!H* DI=221WGFCO M M%EK@REP5(9.WWNQ_#PXTNB(9TZ=H?JV+>Q2Z] LK],-?A[.![O#+ !4/ [ M@Z=F-("O==CV+;#MDFOT-BAOCMF7 M>A"O+^]\PZIUC;M=P);[X12=]ZERW3 M:>FY--_(.O^&G/=5TN/FG42Z6C+:3TC*F]%^'BGU+_@K'VG^R!KO7VX]ZG9^_?GKQ@ MJ?[#FQUV> #OXV_/0:?#D^V/[X]/:S>GAPNQHQA?-B=\W>NM#Z%BYEWDN.CE MEX@@4VZ5UT+G&G2[@FMKJ"VHTM24N7">WAC&NM#+)F+;0NBEQ3:5Y\(8IXF5 MHB12*H,EYDLB.&A^JG!E*&075O[AUOA2Z.7FF=O-HKO0R]UNS4\C'V!''9M1Z*H +E0!Y+LO MWGF?"Y'+"(I)#D:7X0Q^D@6A''[+@BU"4)M8U6\O3+!(3[K:CJKN[QF00(;U M(0&:$RELV%5W1&JW?%L?>Z!G8UP+5O#!:_W3IHX9K*9*%9,&8;+RC)E,1I6= MUA&ZR1 ?PRU)PV"0$.O[I I& V1),QF.?F^+OLV+%-1UT;*Z%'%386TVRGBI M9E,;8X2Y5D-?#PU[.3RM!FGPK>Q)U4_S7I\KKF]QY!M-_N9;\37+\M-1>T.] M6=FLCER[8H_KPA(+H(P'5Y=B: =,A:S"?Z856-+H4TI5C.J!QMGY<1A@Q=JOEX7*[Y; ?#*'0<_[8?]N"H*$D-M#WQ#?JGDS:\L&/:W MWU$92F3=)";<>$+?/,KS R)'G^T0H&^2:U%7>+I/V1;/&BESD')W=NO8N_/? M=O2O1S-/Q@WR,+[+_F]: DL/960 NV>N9'DS,3?):[FQ376_*>RR[.,O6NV5 MK/[)RU,8Z^/AZ8MS&.-B]Z_7 M%ZMA@L,W;R_@L_-=_D]U^.2?_MY?;_.W;W8N]OY"HQSF\&0;C/&=\\.#?U]V M"SE7!;?.*L)\(8ED2A-M=21%<,*S7#@+AO@CUF.7W-#X*O[_4D?_%P+MC;O= M=E"UX5 E',E41:= MZ0PE55EA3,$%E\>"1%O<:BS9.2[U_$]Z4;WXC8[:6+_J>"YAO M8M5^O9WX,TKDVRW^YY'5=V=6 +'.Q75G07PKF7W)'>\0K2Y W\+K191('0IB MF!*DM"H/HBAR5\:OMR!NQ2%W;5M\QB_685R'<=_#'EG!N [&;@-C:Z9'T"!S MN">48=Z\*SFQ-@;"-3.*EZSTS'ZMZ?$#0>PGT)TW,.'_S6K&U)5Y4G]\4?AG M.?$6"6HUZ_:K8C>?\:%]_RG^!%1\G05XWP- =68H%GGQ=2I;=S&O%O(U/W]; MXX:NBOL63+9K+-E+R9?[,:48CO?G4)).Z68F#^UTA<_K"NM!$RMS5<8R$*:E M(I)S34Q>4F)E:(']-1C)5M3,>_1/"%T:Q\\*A@/<%93_)U9\2]EQ0_@0FW@8Z(]=C=+-G\JSP/]\6]T/D0?AH? MP@V]IUWMBU^R[/BUD9?VPN6W-:WYE0&8U8N>C$#^_TO/0X>>=XN>J M+Z&0EG%M)':4BT1B!6A5ECD100=F'#.AO,[W= _(H-.GO@DA.,H\I5R1:+$* M.)P]T874)/D@CQ/9A4;:VQ5UB\-#6P>EI7,?/UQ3^L^98N M_*W7^MH^!1DX^:DO''QQ[:_=@^U\_^#UQ]T#A^H,W7WQCGII9"D%*?+2$:EI M3A2-ECAJ&95Y<":(!X]T+Q>RQYA>4T<2V?S8\&E',-^+8-C>BW=2::MRZ@@5 M&"45.1),R4A>BH(Y'7-JY8-'>:_0M%<4Z_%1+%9X-IP 0E:FW[^8ETY,M$*L M&6-YQG,S\DOIN;T,".DL./QJ_Z*7G8=1:$L;^KIT(B*>FY\TOLA?6V^R+O4T M"GV#W[FBQJ09-W41Z]*.V3G\8KD>8O8JA&P/EI0QMK4<[;TC\$\CWKQ :B)S M\F?:662%,!BG';KC65X[ITNJ2+KZ/K>I[9X%(=L\*+%JX-EP7.$7_DC'!ML_ M+Q:(63\+3S4&#YT_8BR8-T /5SZR5G#J!\EOQE=V9^'OXU$[FS-S!/PR"N8] M,1$F^X?IGYN+\8-_+6LHH)XT@Q<8FEQ=^Y4KC/'.5ECK20"NP_K:_A]@M881 M?@OF9.[-7#)0GT!@_:]*,!6H\DH';:0L.O>E0\>I:*BB#E8 MEJ!N_60>W:KP\''_OR=.]5T^?X$^O]O_>>;)] M /]XMK.WO?=X9_OO[-4!_&+WZ=[!*^QD0=G#WYIR#,'_?N6J[\LR?YL.S-17 MD[6YUG^O8%$M\K7TI:]9-1Y/E[=G_MCK,P^:ZNRY[5>O9X_AJPD%*_[O8+"6^&\'PS/ ("7Y M[Z K'U?N.!M/0><%%3",ZU+FH_"A&D['V=&T\JDI#A8S[^/CF9F]?7U ^OM6 M!F]NWPCJ\W^F%=ZEZX?Q..#@P]2L^F@ NXB-JW&SR# 2K#!NX"MUDVK3O*KM M47V17O^A&DVFR2R OU"8UJIWOYY#4Z5U#B:$! QI_736QDZ11H; (R*2:*V[&PZ O4PC)MC@Y. R4\,'#-.T<-LTX\D&8VL$X+!D-4 M-MYDKFX5EZROV91>;[W:RO[:WG[>DD9BZY8*?076V'#2?G:35]8;/:.INNK^ MZ7 \:4YB;4$]((M9DYS:L=5,>F88PLZ %13J5SHS/LYB?WB.-?>K<6IE@$MJ M:=1>I!^1O'O9L0%;%5> (;1TE@G7ZJWP-]J+>L)HB9D!#-T@8LV4PP_5.%7_ MATG.>!@)Y-]FD$!FYJ^;CMNN!$"A-04"Z8Z&K96,]#(:&G<,_ K,A):Q&263 M:=9]X S^DPAL9?!$?[C&6:.#M$V-@C<[D+HU =(C$N"H1A&DO=G,Z=:&P?GB MP80^;&3M& !#OX]PEL[(N/=XDQC]&,FIX0 DD)Y\E=@"-O>TFN"#N!6ISC1L M)DQOW !YRPKF=(@(D1 #OW@$3 *P-SQOB*&=!QY$ E7DDG%[:MCDJ>[3 %1K MD=MK8JUP"V<8TYL!5(,Y>) )*&'2'@C236"D<=VQ(GRLQI,%A#/C!AJR)'<0 M5Y%689AE"CXU'GM$+,!0=I9TT7H+\;4P__X0SVSIJ>KUES9%<,/Y,=:7,6VG7@YL*G(Y,$'I(6HCM@_/!#J-WQ]7MP MK9O&%MO-N;='L4C.2YL[:9!XE%J/P+?7Q7^#N<,1.O2&=8^2=="'1__K%C4^ M?/ E%\%2)I7,E==>Y$YKY\%<8[GAJ_'U^/ MPS;._&8^XN+7,[P6.TU),,($-2:6.05B5))(X2@Q.O>$25JP(IC2,_W@$9-; MY16W98"$^RU:_7@RF#7-ZPC@)JW&]EZ\X]2RG)>*H#D.!%!&HG*7DZ \Y<8: M$6+ $OJ?(X!5KW\MD5:TE5H8@0H4PR@@\MLP.0^A :,K\&>.QXNH@\[]&KYJ MN1_Z56I>%>:R$0R- -"%L ?V0R-LZC%!O0/+ ;\T^S7,MA'+ S2 81D++TB> MQ@5=*:W#7 >UK?8,-(C& AI*%0A%-UD4D/_OE:+Q2MF%LS\V.'8[WG#P)4/. M->G%J(C:RNY70*2Q:7]D_ -MF#@=)>6O&M2P@HK5QGEVKG3D9#NU*P-H('L+ MFECC^=DPS6<'+*\IJ'(+OAUT$K1NFM81PD3OGM'XW 6U,P"M=)K.A#P&Y*HF MV=^IX]R/I/_6H21X\?NB1ZO=SM:SM;6XQXV573NP$*BJ4?+B)!?-W"T09TM? M5#C#"/TZC;U5S?=D*WL*Y%O#/TB=VK1-QGIM^J'<:-Z0?#/I2[7.VVJ\P8SZ M%8RZXE1)QEPM!Y)OK6GSAR;WJ#:9?#,=>#!4J8^!#0@@ N8R7(#( ML9-L/,MLZ,%(L/.]A>>7EH..+O/!5'TPRJ3[V-0I ^8+.2:A6;TP:V MV-Q;9E;7!PZ-C8>ZU=$Q@PL=J,WCC%#6[?]7[#]NX%PVHL& -L>*XQ@ :9Q- MZVA1^@2$38TMRZY*A+0ZJ)*>C+5;<8*F6))#/H%HG6D#7SBNSI:D#GQQ,#8- MX"?9.)IM)?+?WV R -SL(& 2:P;OL_UDH_EZH]N5_;WSY_[+620+A=>@E8KM M:*/:!#N;.60M&GSCUB/M9RULT>.T_-0H'6>]53.DA!U;H.>TI(7]36;@7*), MSU*L9CQ-C\)W>P"B+K2.^QZ;O#Z='Q7%Z(F:G[303"M6N_O:3(-D]4[+O)$#>V3GB^0EC ?JC[!E9_8M@' M'>-@F5MT32#1W NPHOEE8*66P6J)/!WHGI/D.YFC4!WN!%8-@S R_265&DEU M(;*'*AS0XED_+"'7LI>Y^=VBDR>%Z&8X5VM@;CJ>#$]3OJ=K='\,:V6VW6XW MW^ZM['5RW"24G4V\5T= TL.C!@O&C7.GH,5*6'R^DIO/NW')I'?4&8U)5]W* M9@?0[AK PBPL/WMDE.R$*]9T]?32\_7,0(]L1FI"M0N3J]+\ITA8( OFOT3/7V6'S$YEV1#IS7K,+YH6G[4LQ.98%FMW;+I4 MX,548'%U*C!.-T4:/IN?*LH'7?YPES_Y=.BL>2B:WLCC.47X8/ M 0ZP[[IWL_?6:OX4Y[,$_)>XI%E6!O*148! T%D4[G1-DH2%[:W!II)17TP2S)RF]C ME#DZ9:5GA8U.2YN7VD:FM'5W-9'[Y])^G>Z^?9L]>[N\BYQV\W'Y\ M\"I[LW/P/]GCUZ\.]G>?OGRU+G$72?C2Y/?/SV-YWE2KH+C)&7=<,J^5\;EF M@D?A ?6XN#+G^AY9B6_FOI/D8 MRICT.G1^C"IT:V!*5U4[P&&-(,/K+$>'FNI*2'>F4Z+/N@^X&1H/!OPQ_8M) MY<9)$:RU<$SQFJ+7)7'QW N!O[SZAF:!DTQSW^(_NM^KU.U3B8,\?3ACE> M+3'';U7[U>V635XU;'+3(,,/@8#KM,SK%KUAWC#@_^/0/X._3!_0Z:P/8R6# MM8$>=$DVZ2T)&#!(=PYHDI)QSFK<.$7PF=F^:'&B9SG&RE7)N*S-S?[X4E $ M:S\!66MYHI4,MOP,JCR8(!4F5B:[>C&1&LW0X7B627.$F9:#Y!K"S$*@M."7 MEK65[<-[%]!\ <5'"/> /Z,*+R6'/KPK18 ;$#2P9MO<3JZ=1=6GI+$G3X\S M;59L-5[\#;H$IN/:9=TDYE[TT&_NWO>6%A?F_BN\<]"*D1ZZPRV@E-\-W=X&$.HWH+ZW]4OAD*[/%1BKVVA]+*N9E4J'-6ZZU+ MHX U;Y(KVYQ-ILVH33KRD3E+9SBJQN\S/W0I#-TD'_\'%E--+A9$%H[6:_PV M[3'#1% N#I?/9DW2XJ5OS =NLFGG+I1VM_ZX*>(^GMSM21'^J0;JAYO$!,I"6FQ"*+ MB(+7_5N=#3UM#S]/XVR!97;Z@'6\KV\$5^N8F MS/GU6NR"NEHKDWA-[*R?#M'T+X$>_&(M%F;06-_1F@$."'D##\-0Z_N%0)%* M-K0C ]+B/9HUH*\O\=2:[]JV'LV4WCE@U0*J45-NG+O0 <$W X)7PS@YQ_-O M=;O[@ $S1EB0J4C"B^H'5.E#>%E+=6Y7K<@E>*UIX*:VC\1\ MIHM"^,]&5-X+8&WE=^NSBM-^K&HMI[=H&8+]8T#56/1I-1=Q&U\7"OK*3FN[ M:1:QX(ZZSDS86)_"FG=D\QP)+2"N+:5.#TO0U<#+9XV] MFM*2W$5/:)V48$;O0RV+44T,1U6M0*>WCK#,%SI7ESZSE/)UF\ZAKGJ#2"M':$;+]ZO$\ MT::7M6M->3YM(*H1>&TLJG9^K ]X?AR:+(;FB]G0XK6!<>V>&?;K:]_#TPJ] M.D=#3 ?+AISF&$S:')/9CF1> MZW%XJ'B.I-DDW^'FZ0( W$"Z:#,>VA$9 M=U>5C$E "RD:[7(6LZ>6LCOG9286+JF/W? LS'+TY[?5 M4\$ =+*O^%UB*MLW"6>+[N"9*M,L-[WOM_'OS9WOV<8^7/ ++SW3O"OY_X86 MC#^S=*.@'3(]WPZPG)RRD)>*/CT7\+L?FJ_B[06'/LM+O]FFG]UX$LG!W8Y] M!3W]AA8&[,#"26,!OG%,F4I7O&OS,.9)-39'1Z-P-*NRT>S"6H#Q#F/0RY/ M>%&:0LJN^*4#T.?OA PTCZ&$O7.>R*@,T<$$HK41/FKOO FK@5PX62]*SPJO MO'2"&E:66L0<_I53R\4-2VG=(SERL 1A*9(X;LO#H%;:4D^8!SSLQ7H$[*:^ M9EAE>L<\%2W5VX?5]L'4"W^T/SQL:U%7@S3G]-##9JPF?PV-AI5R^VE3ZX_G MF5E;M,[.:LJ#-V]N/MY*'ZTT#Z@_R_567O(K/Z9;[,K/KAN6L:V"Z2\:]OK/ MA)+=9/G-#JRI%[^21\GKAD4KU=%'P_/ZYWEKZ'O1:E/=J-/F;_5EO"D,X<=K MW3)FZV3Y3197IYG=I^6UM=T/L+9[MCM,U7*>XBW)_[:C?SVJ[\"U]T665G\Y M"0AZ&0DLH]7GNX/<[SV;1^O3'C41^_3S>M3^F@9@G]V-FW10_3FVM+7PZTU< M=5AT>W@CLAR":GT9BWYM(]I[W0ON1K[-6S8W^J6;Y&UV&[Q;5'=BRE F?7#. M2RE+J@TO/(IC(8= -X. %<;149:<"T*0QQUDLC"":(Y.1:6CEYX+DQ=E+F-."U$6AKM.#]PP M&&0K,*A\7D:J00_D'O1 .$1BN.5$Y[YD2G(=I-XH/? S=OTFF>\+Z6+U3J]G M?:\!_^5^Y$O1>*.!27M*I="E%+:PNF. M^X((SR,8J)$3I;&CN^-4\5Z*^]K@>GN=*W/^E5_&>[,A2T% MMY8'*1F7-H"ZH$)I@I8T=Z8SG#:',5<-)Z.%-))*4GI%B72B)-BGE CC%&!Q MT,::+S2<.LZ\<\Z,16%%*8415,D8M:;1F=(XR0MC5,DZN;EA[+FFT NC=1XM M,=YX(K4(1 D;"1,.!6HLI#<_3F[^"E$W8 ,LK98:RGTN6LMOM_2?#X\DJ'F" M*YX'5DCEF0UY7@00)%YXK?SGRE=T>'2O\&CO\9H>+YDUU#%0$HPHB$1GJRI" M3B*-448I6)%;P*.>X%^5([/F_Y/,A8E%SYJ'/XT0K+K6!21P<< M[Z*B'9]O&)^OQ5,DTZ55AL0<'8DQ6**YT23J(H^<%B*F1E2B)_..T7]B1JY<81$7F.F2.1V, %R6,I MK.$LEFC_L[Q7*GF/&/TGB@M<6?_AE_5J@-S)P;[%ZHY*@MV@!&=!166D+3A3 M731@LT#GU9H5 11AJ(F4Q%!&@A4\B1+2$F^YH*6BK*0E6A%,L\[E>,^8T\O@ MRX(R2:V47C!M*8B(DG)O-5XX_#[,V?'?;?AO5;MW2A1*44-R)Q1H]U02ZW-& M- U!1^&"<_3!(Y5WS'?/F,]*45CKJ(Q<2>ZY$<;!<9D@O?$A_T[,UTG&;\:9 MJ^IXX%R4P@22V^B(!(%(5!"!F++4S#M1:L]1,O*RZ-S]=\&,EQ?)ZAP#:Y[^ MD$?GG'4:;Y24W)0?ZM,@D[!^ ]Y/-" ?MJXPS8WQ)DDP[*,^&4#C27.?T!&09= M[L^7LOBJ&5#D/@^">2*\LT0:5Q!=\)Q0401E/6@@(O_6ER8Z)K^'3,Y+EDMI M62$*+WFNE+/0>/TR1&%+'XV0Q$LIB.16$14+0^#7-D8N M0+4&O4N)'BMNZ>7Y%HST?5RW'?9UV'=9=,GQ0@GME;%!5O1\[[+MOV+=JA8O2.RF-(;(P@4BO/%%*6:(,YX4IE;OP@G5-9F?L=BE?;J_IN_V@RO& M_&P)^*["^<85#=^HR785SKL*YU=5.&<_I,+YM01Q1:>6_'M(T,]N,!.W+8=> MBYS[6-![PT_A^@KJ]W?;[Q]@='74NSKJ7?W,FWOH2A%5#)1Z54:P%#DZJP/C M43,5=10Z>>A8ZZ%CG8?NRSQT)SOG>P='^>ZGI^>[;W;RPY.7Q[LG._G;DQ<2 M_GPZ/#D\WOWK!86Y?USUT.V>;+/])^]AKML?WY[T3_?^>GJQ>]*O]IX&3%_+PR;/+ZJCGW#/A8TFT+3B10L)/9<'PBIH//"]4@?4SA>XQ^JUN MPW95A#L4O >KODU- ,]SES/JE!&2AZ"4H=I%&DTN!'7R^Z/@SY82_/T <#4\ MJT6018GI@3F6 XQ>$6ORG#@MHXG,R*A\5T>]0\!?&P&=%;EGWOJE%QRJ4.G!VX8#*Y&:J6R3ME2$BN9(Y*7!LL5.\)RRJUE47N9;Y0>N)&I MU%T=]5M7:@Y&!( =$T,NE7>VD*7RI;/!%!I#F1TP;1(PK:<.EUX46K&"4*LM MD;D5 %$A$$6Q=H,J7>!@H'+1T[=-G^NJ-]Q]8C^82%J6H?11R0(4!2<9S3&_ M*S=5T?]WG)F MK@T'.:E=Z:4WRDKEI&.1J5(H5]I.;FX8>ZXJ])J5QD7JB3%>$TGS2$S!(XEY MKDLX4E%7,_A!%9NNY&I>X8_>=E]!"T<$9J#G^DHMYB/3]I0FFP@P\O.D;?,$9?N]LEE0Z1 M4Y*76+A1Q$"T-HP$3!5R8&;DU./5GQY5]ZEAPD\4%^CJJ*]I%TXR&9C1*B\E M4UQ'882*W"MK(I-Y!SH;!3KK==1U[A@&?$BA8DZD4H;HTN4$I KUQI92%!@- MZ)6"=B['>\:AJM$%I&CK4UF>-@!0"O2N?*+ABP.7RYJO6'J+QE)25< M2 I\"6=H2TN!YJ0IP:075LLN&'!?.=-SY7+#*2AQ6EH&,M-H4<0\4NZ-IK03 MFQO&GJNZ.K?>B=PI8EV(8)DK+&W, BF8,D$ZFNL@?YC8_!5B 5V1]9LA$2"+ M++7-M3(6%'AOE,;*@&4TA9*&=7F&FX5$Z_=-!%6QH,:04N6 1)%18CW>-^&6 M^IB7AC.5D*CHP@ _,9][XZ,O-%AR(DCE@BI4*0I/"P&_DCQVML#FL/BJ+6 U M+XM@0+M(?10HPS9+A2>YTDQ'4Y;2%EV1]5^ R?$&C5&QX+H,8&EZ2V3!#5+H].S.321@->MG9L!I,,JS2"J_-AJ-L"+N2_M'+JC%R\K@:8_WM[!QX M#+YG^OW9B,Y,PM%P5,%\\=-4"C5\=.$LO6,8L^6P8W9^7+EC>!DR*#RS,K%/ MP6?P&!S#<696)F8&?CZSS!J8U%:&BS.GPRE\#]ZU_$ [=C/KU8F8P? M_-E_"W/;/3CZM'NZ=[+WUVO^%N:P!W.$]]'#T\,*YBK>?NK'W4^['_=>O"NY M!!D3.,$P#NA?6A%C+9BB,G"MF L4;^G3K?7N7AEP71^/'TGL-C01N2]Y;HS( M'9>E!PVP9#HOC'"Y+$O_V72RCB;ND"8N,.G$

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�7O2NFY0.>1];3J.I6 MI]^96M1=52]_I0AU[HWI1:\4,U&'6-5N4'TYMU7*- -QCYV2:-*7FD]3]:IH MO"?=%/"+;D%.+S??%T\UR5WF[NKPU(J4$$$9##2>)5/B5NK_JVTT,-+.J EB MQ_04C+61P ^J]AN=->*!!J*7?2.%C8)#V]/F)>[K(^F"2E85&1D(M'1% MPTKJ#U*9EDC2JH_Q=47Q\YL#E,WQ^E(U_H"[7JMGW*G+QR_;W]=O^_MN MP%K:_KYM?]_:K_PR_,2?P$HNC6/^#:?R%=-&*M=VH#0<7ZN:&3 1N1 MI(V9^:?':WEF/?BOD @3J%=?HT\_66.$_6IX%5]CC_X^D .APJJ7;[K._*L; M-?Y,EZ&%/9J^)WZFG*YUIS]-[D M#2^*:_CP'SZ8RM9OMCK N>?T/IR&PC-Y&* MN//:WUT>B_W@?KV/Y21M#_]'#M_MGIT&(G#M1'@LE*'+7"\)682ST1T[<&,; MQQS&#A[^\D"UV>%/UO?V7A>IF>_F>TP6I?+T:4M411B73-M,]51?TQ,KY@,R MY\J^E)-'[:'H;WJNB/_DN2(Z0>T]!H ;#S875M5<,I#O_*^L-D>7VK.Z[KUGOW3_G M)^<7W[Z>[UW1(#O[P#DZ_GQ# ^E@[;VS4]L2%O?CF$61Y3 WL4,<0B>92&(3 M\#((.53!2IFB:^W_MX?&(TVBD^ MK(/B=QZ^%6C^^/T[D#\CKN;;&Y_4(+Q9!LB6@?LCG XGC2DIHM"TXK0J874 M,U*S8F=9%ZHICHY^ RZC]K.)GG:% >UJ:V8S JN]J=%Q]]->#8KIQK"KN\;G M>JPK?-_!S]1/"2M6^1E5Y+P&L=@5&+L(GX$0XLEE5J+#K7IV1[O>1M74DWI1 M&8[6UD-14AK.KD>SS_G?$0=73ZP',1O[CK[6RO]8C6?!*22P M]861RH[2^CWIY M;Z7#C/DB:7+_ 7/?Z> M0Y C'EK2\1S8=U (D<>CV(I=U[12;J?"-.\]!'D=L9-I6QZEC<\V!I#_=!31 M; -_3,,S3#N-$^%SYG#;9FXJ) O](&"FZWK2%";Z''=>+QP\Q0/_9D M&IF.ZUB2NQY@@R0*+-]U'9'<>[SQO0Y\&\RS9Z8&ZVCO-$T#TXVE9*!E+,"7 M@ZM5.I]Z"],P]B+/#_U MTL!-0\%#,^168LHH FGO6T\K<%KZ^R[]V6#?>)X4CBUB!BH7_B>6"8LM^#,$ MD6&FH1L'0MYAE,^]A9-I^[;D9IQ:9N):7$0 MP27W NM./0_M76RG@_],L\GUO^4@>2\+C*W^NK83<"AR9213',@:,2$"'T2V9[,H"$(F M/8\[CAE9(L#I:RN&9:$&E[2?5>1)=[31J42#G&9WPW?E5/2-R>P45)Z2FG9# MT37E+>#*-*=\2DG)=S@=P;A$#_TLSV@(9B_>%T<@Z'2C[Y@V*J>/\FPH6VH^ MV*8J69YR$,@:6GS/J;(&Q=FP;E^LS%4149SNJ$.IAJ=24' M _SO_/BHV2#75/FY#E<[UE!$4I*8U.,X_IJ.I(:\:V0K9?C.H>'[(!TKE)&T M;2\6;NHF0H8BD5*8EB.#$)2KK9&.7R$=WS'O.,;R';P]!LN.1E5=P?%LJUJ0 MLYI6/]STKDY-%X@T-%-F2PN C?1-+/\4S VMR W $K,ECF+;=;X#;)HE;""X M5$+APH>82E!'P+2?Z!.0, B[CG$F1S09>L70Y88C]$XC8^XW,8:66FB9?@]J M3M,PLDTA;2?U7"]V>)+$II5:D2T=T[63U4'>AJZOB'=_*M\6^; A:3-9OE') MK-]MCOCKD>W)S='>:2(=^*$7L#3A'G,C@.*A)3B+TM3U "N&@-5W7H_R%;XC M90:AQJX2JDF2K:O(ZR",7!WGW;Z"F8/#CP82V BS=]_,H,:V1I.JJ5 $ XN#Z1J5@8]'N92:O%(BL M$N]+$*)XHEH^JEGWXP$7,S=]-<9\ >WRLA'RHJ*3"9P/'#/#_^X:>^7R4%>] MUL[YEF>'CAOXH8@=VX^=.!'WGECPZ/Z/ MYVX[\\S^#Z][=8J]%GB0F P LA;,PT9QW+3,#1!$ 9N(/UPI:55SR52'M?! M=<<8#Z;E+*\/2'PZ87G*QKD JET1]=14#0J=#@LS8#05)U/*FIG6'+B*Z104 M62D?='SKEDX 9 W.&@M8IM( ";\N,?BK^@,4V00X$8M$,#)/B86C 3H=9C<& M"3*=Y%B4(JAV!,2(O%+!MUJ W&;1!4EH^6EJ)UCG">9NE(9QZKB6<#R+ M^X'_0(ON(ZZ(#UJ+;B'WY<--]^S422TW,D7(TB!(F!MX0/DRCIGO"\MT+=NR M[63G=3Y2]MRB.?? >>ZS ,2]8ET/(8]6G#XE#=T<>D?[GV]Z^V=N[V;/[>V= M^E[(/<^#(W 3F[FNY"SDCL/\,''"-(G2.! XJVN-T57+U/O&&K#KMP^ZUO+ M9A%.&H823B=TX?]2[L3>O0=DM,3QN,3AH6T3Q6GDV((Y'$UR7PK&>1*#PC5Y M$+M!&H3\EE$8-7&004NNFKFH0X$BIT"5M)2ENEI+9IC?@;7>G*Z=.9 T]GO$ M1-30V_1$U.#)$U$_R3/<]H\T)Q=.8N,24-W>IRJ7>\_\.OSL D:\[AY_<$!9 M7G????"^[G\=?#T>#'OP7^ 9Z^3\SZ5<[NX^ME \^]8]/_S6VQ?7O?W#JZ_[ M@XO>\!]X_HD)_P6>^2?K8@.,FRYU0$]26\38FLR3,7:;E8Q[B<625 :^)X*$ MQ^Y2I[(XE%$@'-.+4S?U[5C&CI .'(IC!6$4+2:@?CIXAP5OQF'O[=''[AZF MGCZD/]EWGSJ_RM@&F\>3H1][G@N_"T7JB01^QN/4Y(F[#5.BL6K+#LU9X%*J MT=#PYR@!&[HJ)]94/5>-SF.P 4!"G:G2H&:V9:-D2'7=&H\'UU4JAP#DC=76 M!G8J@-N!7(+?UJ50L)Q9TZ1&XMND67Z^5GOJY3Q9J*_B]QY%%(]2Q?!H$6D) M4"[C<-":-0[7"M/\U83!^<'-J6FZ@6T#?HHBX3(WP@(/UW999)JAD\@(N Z8 M>7*UPO]7U-M<$]PKXUB*_@@8Y>S:.""C-#$^Z98 RG^\5R7ZZOSKLJKJ6'$[ M^"P=8#<0Y8L981YN-M+]5TAO]C.9&D?*0PVDO _D42+M=?D%7%NYI]X<[7?K MK&5LLSJNZNS+.>Y!ODKT+=B07Y!O2+F/=.L\O).^ _JBT'57FGUW=N:%?5WVY8T@#MP(:\-['N6%R56_9&[*\.%9>FU[OBPZB2I MXUX?^^B=\5%V,TL?H +G.M8PQ0,&\8(V_$+@8;G!SKC(DZG0%9!E@YRRFG)* M[/ZA2&5V5('UI:.;"7Z\0'/4YU&U78EF+.RH4989T+7NBT),JH-4J,#0!PLG MAJY3:O^"M;.@=(8E]02I;X YHB2(C M]]! B0:XK3K]*^H5.1VIHJ2.O@M>$H/JQ+4,LF&F5M+1ZA-=M/R;6C=VRMJV MD_XBZSR*Y4U%1[C$;I[X>EIC@IC&SC%UMOONNB_0IIFO3!Y*KAHR76L:6,C+ M6&#&ZCAG7*?$ KGJY3I_Y0HZ;7NDW-8C)6A[I&S 6MH>*6V/E-JV_:ZMNF#; M"L^S L\,I"4#-Q0A3SPPAAWAB=2U HP:;;XB6J=%0)XK_50:DH/.T$*]+L"2 MO,!T/VR1 :I *I (!C+IY0Y ,/@YMIRK4>40C>,&S 0UE4X+@A6\>C8BC6\$ M(>J\+P5(,%1,"5($9Q":%F#-3DLL"%00]'NPX-8[HCP:00H.&,N1XN:BX8PS@X]XD&6PV 6A*K,3OU#\6^O[E\41G:5*G MN$82-3H0 'R[I8N^U,.9V?SGM?[RE_:J7IT*T%I1 MR ,6B]1B;A Z+/03R>PHL0.+)R+@WJ),-P,S\7ABIUA1CQ4KGIV:D9/&H>W* MR'07O:J;SR#OE1R?91L01Z#@QD:Q9)E_U]I8S4VO[B@JX,7U[RK83D-R8 ,& M?%S*5]4__JAFR60C>@WZT1_Z7AKKHX&P,".']EE]/8.^NZ:"OWKPI7ZR_GJ7 MOEJ8^*.^"^S=,/#7?FWN6FN_N^VVEK7K6]&#;GO[=T[H/LEB[3LO:'LF$JT? M@OK=21W55[& >9E_$]<_.LUY688 M55K&VH'Q/_D0GG4\W]WV]3<2I2H87?Y^AXV[\URP.[_UFB"R^3-,S>]NDN6@ M]JV3XFMG]FV$9+GCD,N/ M"HT]<"SA+SW[])>9;FH%OF',/]W[V%^\.G-V?P[,&@=_[AV^)8TZ_O#KS>C;!/;CY;O?.NVWOWM=\] M/[LZ^?(// ?O]<&$][5[^V_3;K8\?=H+0F[[G$GN8NE:G+#0$6"YNB%.P(E# MSTQW7H=.Q_(?>:[I9HR8_L'YT*T4_!6D8")L/W2B).2Q=&W+Y\*)I+""&2<'%XLS-^ NBT-3,FY%5NK8L6G'6)GC=#QW M7>>D;9""6X>SMPE.KW%HKJ&+EZ,E7J;(?S3@2^5BFC8JTCC0([MB)FLT7,HZ'*5L1LI(A9!)EN8O$TL063 M#HY1L!TTM7WL$B---PW\, Z\G==>Q['7]8GYZ1)F0P'CORA>VT:#VVCP5I!K M&PV^+1ILM='@%Q -=C8G%OF+1H,WZ 3::' ;#6[C("_/8L7^C-*3?I@&D1N( M(+(=TQ-V[/N)C)W ?D#GDS8.LFRBGF.^\9Z-W4RZ^SC)[V-VM)]D7\^3K'GSA'[_ZZ.#GN#19-U.[YGQ?=_1/S:/_L"B?Y]=X=NCW[KV$/GM&[^0O, M6N&>@ GU'W6\<)OC M(&TTN)6"#Y>"D>.GB>G8-HA#UXIYR.TX$K9TN>5&EBE;*;AE4G#141<[L1_X MW&%V:/K,=;!/8Q!'3(2V2+W0M:)84C38=)='GFZ/%-PZG+U-<+J-!K\DD?]H MP+<-U6R@!EB.!@=V(DR3!\Q/(LE<.&H6F3QE5N)+SS(3$48^: "_XYC!IL1J MVFCP5HN81T.5K8C92!&S"#)E&L2.SP5+0NQ>ZTB+A3*T62"DPV/;3\T$<)'3 M<9QP4R3,A@+&.T:#-Z5*&CNII?E@D-/\ 16@KCM@< .8,1^);* [6N3IVDII MW1U@S2"7S[N?=HUW>WOO:936W+ 6-:-@UF.MK:YNX^G;Q/"3NFN59BQ;(9Z% MVQ3YE?JWO5D6Y*.&>E]X@L#/R@U8("C=(?L1([J;=P1W+,1_OB#X1F[9TV>K M;' F[!DL.%FXZUMB._GEFOC/6V\IRT%>:8\[9.;'N96'\/?7[I.=_^#U1WV MP"I_._BZW[5.AA^5 M@FQ4^*<-@K="L8V(M$)QM5!2[ \%2)=>.1:3],OS_9M]/AE ML_TB'+-3$Y"VY[' ,6WFPH$",'-]YEF1(_Q4"NG$#XH>/P/;OP#,M'$*6=A''/F+FO/4]A*+C\< $Q)U:GNFFD1F"T2T=F?B)Y0MI MA2W@WFZAN BX4VZF:1B:++1Q6&Z0F(Q'@,/1:Z5LS\"*14&MB^';LHK$QWV4>^0<+J!4#RS6R' M17=\E4W@:>).R0G(U#2(%4NOJCHMB7_<4FQUEQ3[^WJB-O@>+X!:MSB!9O^V M8=B_6-+,LY@L54N?YD' OP>R]=<]I?)?T<_?L[CG"<$"*0,P5T*/Q7$(9.VD ML<.%3'D:[KP..[:WW,AL@Y1_FQ*S ="^9>IG8NI%1!\%J2MLRV8\D#%SDS % MIG8!UIM.'-C"B9-4[+P..DZPT4S] C#2%B>\5&9X!['Z@S#1BI=_@>+ST3%1 MM?&'9!X=?!MCUXJ>G+0B\[%$YM%R,D<4R+L*0):GT@LCW M'0_K-IQ.8"VW,KR[R+Q%'#Q3LD;+R$^'@UI&_@F,O(A]'%PS'_IH7GGW(DTVS2RLC[R,CE\#077)K"QY-)9>JCN/A.06ETR& M(@*6QB"NZ7-F^:Y,PRB*4@>3T3OFCY>=MWZ?)X_DKDNNM+R%_IPL>K9TRS=Y M.<&VFV^._CG<9V@6;UW.I;TFY[(UBI\H2?%HTL%I''E)[+LVT6B[PH9K9G.MP.;3_"VG8[<#?9 MX&T]5QO@N;J-25OP]H@ #[?J%\_.A@:!T?MZQZ/U9=@#Q26DYJ>X)Q\O7(!+@T$ 'CP@FQ M*V%@I];.ZRA:[IF_08SZ @#/%GMZC@OXL98(%/&BH7;EI/S%/#[/%\CZQS]S4CUG(T0V42NX[OK2="-".[_Z("&T=/QO,S(\;\/I!9F[M MFD?D] 6P9/I)[,>!9)[K.SJMR>&<\40FP@LM&X 4I36%R[F*&\3K+P N;;%_ MJ,',1IR/IF7K%=I$N$3B]$\\'YU\T$K/>TG/#TLXB=LRC6.P+8.8>\QU>.!%5%;'+WCD^ON M_LFIC#T_E:'/'#N)F2O$/P976-[NYJ;6/:W/< MRKQM3NW#^?:ZXMLS]^CXPZGOR2CQXI19KLFQ:T;".(]C)N+$,J5KQI;O;T]. M[0O ;D]40/I\V(VJBK80K[EMC>A/SR D6D%/TMXHT6ZDH[$LX-1&9RU^>PK\ M5M=6."+B?FPSP&F"N=+U6.0D*3,%Z&K'\@27#L7;W(WNGM0ZC3? :=QR\W.A MNCK^8WJIGUHFX[8GF>M9 8MY:C,_3<(X"J7%/1>Y.?BAR0ZM\_B%)!L&JZLK MOC>IX7LOK>?SJ9=XY2^QO(]VV1#]_ M0[/1%'90*Z)\U.9Q/:(F.EO"E4[@N+;K)RRV9<+<-.4L3CV;2IK=B\G]A<3']UI A2X;'$M\ <3UR? M<9.;S.->D$91X/D>B,W(>9%"^QNXWL?KKF M_^8=DPV7[Y 79]F(3BN$)\RW$ P76PCB)S]?D-&;-:8>__S'S^^+O^NXN \? M<7A-2=/K!- LST9 '<4X!Y$F59&5P<<8R#,^Z!A<". Y]'ATC#0;\9&0U*DG1]^(ONTH!\8:@^1-D5$&UP:?3(HL MGA*]X?0\?$ZI)F>6NR_@\.V-._RJZQD:O%,L]3"2:;WU5:-+ Q:;R&$F#%Y( M8UR IBQ@>74E'ES>A^? N<)W IYAI* ?C4LY2O*BK.Y83L=C^)'H(X6!L"FF M8]*91!;C(D^F LBAGP,)GNFV3OJNY->RHD9]OSZ_X07\DE^C(6/DT]F% MY:[QI8\3&*\D7)88"P$-I3EZTR'LHU!_"Z7,B8;GB$OOH(LQD^6 RE663/I5 MR+CQ*ZU4S-E/> PJ9#I9_Y.& A$2YR@\$Y':X<)N-?ZW7\QB;&>2Q87D%XRG ML-A7?'#%K\N=?\US)K"EOKD/"G;IW=>^89H^'1_01@/>RQ5F>P7(0!8J]O4_ M?&/68O0+1+/_E3E6*,TP"2,9<=?UO5"XEN/[<6@E4B:Q. UV7A^3P,36M B$ M1U@6RU_?55[^?,);]3P?[^*]/1W\?[N\=PQ]O M#WM[O3>'>W\;GX[A@^Y![_@3QN=-ZX_?-!:7R>]KWWI37O.WZ8A/DVRRM%;U MOPNR2%D1PO.LP#,#:I2CV M[-2,G#0.;5=&IKMS+SWZ3 ()T,EEED]+T!U8Q21(X_3Y!%546>F$JWPZ2 A0 MQ(@S#%[/Y 7-1LH,$(:8#M3F *?H@=Q&-9';./CS\'A_SR!I9J!AV%FC _M< M(Y=I7&8)_!(U53+%^DC\G=U!Y<0!!Y4EZJYOR) =I8D(+&E*Q:M(ZZ>[7:,(2\OR@;:*C,X%JX>!);NL*%PR]]!54IX MGRN]N>#XB,\"RJ@UX)XG56,5Z7 MU:G&.,#Z; 1+2?!XQ],"(!M0PPS1$^7AS_\M^6#2_P1'-H&OZ\J8EW"X[L8= M[C'Q)&\,&P?Q,9@F$OX+6YPE4SCUYM<-> X+ L!&/(G,'^>(G.'0DPP.>T+" M1&K,K?ZQ0"MYC%(&CQZ//6N0&3#TT!CD\*Z[RRA['E6OQMFDJ+X+-_YBR+1PCUS/L?_T:5(M\J:_IO"4Q9'L/]_QSDXN)Y_8U6 M]_SB\NOHK_[7F_SJZ_X_0[BWT_WR];SW[@-C9'ZR3FSVO M^ZYK]3Y%YM?_[9MB^,^(?XFF1^=_7O2^G-B]8_'MZ[!K?MV'M9TGV=PK M^1S_.>_N7UR=W'RV_O>F>WUT?&9U;SYXW?V#Z^[YP:EO26[1") X\IC+8YN% M;NBRP(\L'GJ.[:;NSDP![V'DR^=V+$7"I9TDKA.;4>#0WB>F*4SA)CN&+ 4? M(WXLIK+."W[:$ZZ31=HS7CQC'G(>2DLPSE.+N:FP&'=3DSF1[5BF-%/?#Q;/ MV'7LV#0]'\XV<.%\N 4(V@N2V+)$Y*7>XAG_?;#WZ>#32C?!W-]-:;<2?G^? MN.87Z@5FG(8NMWT@&$#XD>V'(N5 O5X(W&H6-#7T,RIH *T#Y [08FDF ,F,N9 LWDA^SFV R=4 MGI7*H8A;I:_ SR5 E3%I0S*X =IB/TT0J@-E2%?\IQ2B]E[2XZB30D98'V#R M)2_0,C$2T)0EJ,8BGP+"!N:.=HU[F=\;L9^)1&4.WQA7?4F& V+]HN C#1VR MDNP: H.4(B/'RN>+V<. )Y0M\)OU.]+;I;R&SR@64B($41""K*8)!VI4#E^P M*P!MCG(TK&(U-:M45@[67BNX 6!$*MSRF_T[?4)WQ9LJ_$*?3?%PX*.K?B;Z MC=_!HL?3R9TAZ88(X2\#K:>'BR\!>>#EJNA0+X*^PW_$@]/>8#)/Z2K$0R8#4;$"Q$ M^B>.&?-KPIQ@>Z+9(?+A,!_!^>K;8Z()WE=]CEYD#I T0U\5L188& 7Z?-79 MH9.YIB@N)E-MS<0#WR ;9 MY+I^6["8<5GPRVM:#>XYU=X88/@ L6@BADO4I]7C%W;)X&>%E'IAN%_ZTU%" M$D?]A=$3.)GJUW)0>3C0TXZQ33@;LL23#'D0?0O*$",K[/8[PJL"QR(C#:HE MU5]N&T>\K=Y6[R7*JM* #>;H4YCT8466#>0WFO2!#)*!-'<1[&PH" C_,Q"*K0M8UZ[Y&F)9 "24BZ;DX:ZMB:YD[-6^ET M,BVJ$ZEI-[^418/U\ 6)T%&-J1.GD-RT5#;=3%P3!R\M8^G)"X_+2FW,J9G- MZN;XWIG(:L<._::#;PLZ8:2<0YD20K#S"4:!JG4@(Y*?"]3M /:2(C)-4S'. MBR*_0JF.C]HU9C*NP2=GH 0*T@U)3H^A<;0HZU8^<+9@6OX(^1->#=C[DF># M*HXXU3HEIR>";5L LQV.R@G)7CAF6H\Y6_ )Y1\ZKBI%)?67N; M4-BJF"+4!4XW2!J7"DSKJ)D3%&&" M6Y&02L04#W)Y*,2'JP4I/Y&KPL]/;0;"%F ! 05V6ONOLO\.3Z4/AHOE@L&7 MNF#CFU'$0@\,_4!XTG2$M%*^9.X$GNGXJ2DBATLW#9,(#L+R; Y_)Q;GP9*- MO_&Z\+@_I^5KV5YQ-J$@CA&"P2"_*E_=4=7#VZC4BSJ*33E0\%8#/B[EJ^H? M?U2I0MF(UD8_^D/?2X>^5]08TN:IKV>1X%U318-U;8%^LOYZE[Y:2.A2WX76 MKN/Y:[\V=ZVUW]UV6\O?=5WWKK=]G.*)AY:\/BKEA7A%KH9ZEVKGTF%9Y9 MT9W[>R_\:Z9QW^_E-SM1^UF+J.?MKOW! M[AX?.+V;0_/K\.WYT7$7OC_P>OO_]$^&AU[O^.WPY%K_YG__ZL?#9'!T_AFP MU>>;K_LGW[K'PNF>?QR>?.EZW9N/_9/C"[/WY6UV)JFJ6.)P&2>&W!LMNFPF+L6[&\0.'84N=*A8DO;76Y5?,\&&O=BD:=/RO[9 MC@Y/_J7QKM\CSM@G0DPFS:OL;LJP55_<05X=+XLI.4P[G8S/7MU+F)M)A MW+0L)AVP!7T,O<7^SNO 7YZAL W=?GX%C/D)D\.9RCCY0:&TO9TMGG?0'1S M,>Q_*Y4>)I6Z2U*)FR"57#]F7A@DS+7=D(5![#*>N*Z7RCAT(V?GM6,_%H3: M**FT9=TK-EHXOFVF*9!DO(.WXN%M']MA&_6PC2$(Q>RF#IZO"#T^Z"2^KZ!; MY=143LV\R(^XIJ/TM@//#.4JK"8\CS5HK<0XI4 MI[%A@SVV1'*()F?MR'KG>U2JE MS5)I.LQU[(3%OF.QV/,LDWLI]ST0O7;'M9?;W/Y0K&;#V^MLAX/B6=K]W+59 M1ML^8ZY]1M2VS]B M;3M,]KV&75]W$/KZNY0)_?SRT'_KJI5NGPR+>"_;8[P M7(YP]S1PK=0)PX#%L/$,#B\$K.-C2W_A>;8IXM0.?W)=;Q/LM@=X^P%^.'52 M:2>!'S)/!!%S86=99 J+^:[GV['G"\NUMC-I6Z57QW*07QGE=(A]U&[@"5AU M4HJ^3*8#+#]091M8V3&<#A?+=E3%ZFTEJIV[UCGHC[$LLB*-$.!O1LZX>-GCUN[OA,\Z+:W?^>$WI,LUEW_=?.V]TM@ M5[X@L&?KMV3(WPQ8U\*.8Q!+:TKE&@3_]O$_QI/ M)YX5<[-W^^W#3W?\ZZ)[O>2=X\!HMNXMK< U3\X1_M[+K[?U_WN56_X^;J[/SCO?7G;7Z@+N.F> MBU/+"SP>2,D\T[69"Q"-\=#"O%O7BUP7S.C0WGGM=D)O>23N]M0%W'OB6BL# M6QGXZ#)PI6/A.[*O%6_W$V_UY.!#>)^]4ROT/"^P(M 7B>;.Z^=Z)$#:4\DW!Z:7=58E;D;>+.%O:7_>R&8%YC0:8N>-@+([4]E M#YY\?"4'EU+5:+YL0DP#N6<&0O7MC@6?X8[ MK_V.ZR^G>FY:Q=3#\]Q;)O\92&4E<[?\>S_^7< IGA/%,C9#YF*#'%=XB%-X MRD(N1)2*F-O.KO 4ACR?$NDL@ MQ!/>6E2]/48M;_]L M$%+S=,NV]V/;!>QA)V$2Q)YD283IQM+GC%O<8VZ8PM&%7BS]=.>UY?RPY?"( M3-MZ0KZ#/;S6$[)1V .[U;7HX_'$V(SP?/ M8N#P)P/$VG[9Y,H\HI#XOH8O$C&+. MW8 E(#YS)=^Q-PD]5@81\#/EF^GP,MI$LJ=UUAS9]E_;!!' M/V:#G>U#'L>SF2JM?^.I9!1U?+@5?1SG?\KW/$OV\"1:_/'X\NID.4\W"7A@ M!V :N5',7,>4+'*$S=(@"-TDC=>.&^O!!]WX.D6?CR< MG1?@A^LGPH]\SA(+MM1UN&)<-#MU?>L>GYU:KAV+B-O,]). N:8P5H&]\]KV.X#2MJ+"H"V?:D7>IHJ\[_G,6FEV7VEVW9!F-Q>G06@ZPDPE M ^DEF9MZV/(U\5DQO63G=10Y6R'*?FU/&>*#5P8?XBAJ' RLYP9C M X!ZB/1]#8C&>2VVB'S)8ON>;[_9$6T+7!]/ MU)_-NQ-OQ&GL"4M&5L12P4,&AVNQR$M3@+"Q<"3.V$I\#&=Z*Y*EED;)/A+G M/+.3L95^K?3[:;!UO=1K!=O]!-O,L7K3VQ>G=NS[D1US$&R^Q\ \#Q@/(INE M:1 ED6=RQX]W7J]H9K)I4JVMKKN-D7MR8FA(:USRP90Z JOFBWD,RZ/&L.7= M$>Z\F[H=K_!$6[/9VN$9E,,:4-R"W\?3$1=+7EN9^ F/5!>8","O%[-(6)@ M%$=QZH<.3SP OV['MG_8:_N(W//4^%@O]=[XN)6=K>S<&']P*QSO*QP7G,"A M"&Q7IIR97,;,C87/>.P!1\X0J7Y]].TGJ>T')I^ M6>Z-DK]G8P25ZZQM.C_7=!ZLO-"5EA5ZS+-\(%+;2EEH\IC%V._-38+$\KSM M;#J?YH-!?H5N>M6>71LY)77SU3W@2T2':[K*KQAH2]\O#:CX8P/Z^W6*?QY(UO:#A]=[,P!. MSE)8#2K:7[@;/ V\6-VX?!N(^?MCD]20\KO.(7_ ,3_TTE]A/NML[(+2ED\Z M#W[CWO[C,G)XC%>_;VK82W8'K'K%UJR_U25*5'F4?BXE2<5?PC%ZTSL^L[\> M@XU^?.+USL],,)2RH_T#\^N7@ZNOYWO.R7FO?W3\^?KHS:+MW[6.]K_"^N!^ MYQ?VT?['\Q,;UG;\<7!R_.>PNY]D7?O ZQT?NG-=*/>[%L[RBCC0K&UC&8(7 M@.V?^"Q,8\%<-PI\$&RUDWC:GAOV(>-["=Y][ M*-Q$L.P;ZV<)V.NO6AZ_E<>[<\&/WLWG4]\QH]!-+29#VV1NXIF,AX%@OI?X MGNU;%G7$?U^@>V%R3;X#^9]I-L8LVYK@?ISNVA*_G^D>7]*BK:*\'Q/5BO($ MGGEPZGBI\&T[83[G%JC'F+,HDBGCCB?,*+:B,$K12;Y)G<9>E@6WVG)6!7B/ M;;W=P69N*V3:"IEG[]C0FDM/J04^+&D!'\P@UY4QB\(4C*0XLECL!)*!J>3Z MB1L&023!7(HZGO58YM)/*9FI5E&1LZ>B0(\,]+;H'G=(]7S!SM+5JK81I-Y4 M'?O#]_@5' MOID6!6;2#'SS/#6/9I^1+!;JB#3_8Q6C&CQ[P1LNH9]F"-K31 MAC8>(]M;B^ 6K#\>6!=SL0UXGU,WJ>BU6&\E]STD]]F\ MY#X_.75"V^6!*5D0Y81RQ6/ ((U:12#PAS30$R6TN9Z3?)T'L10#>7CYB MXI$,NE_(0-\.]?C8ULP6*L@GWH(V*/U,%A#(+=$:08^M2@] C58)()^O>_M[ MWJGG!E&2ABESJ>\LM\ *2LR8F8%I\32V?,/;1YCFR-D1N?3_[: O":7>,>K<-'9YH:UK%L92^]&LUP/E)&N1B M/G'IYNS4LD/'DM)GL87#9"(>L%"*F/DACP,A3&&&V/W1ZUC^8TW=W/ V#_ G MDG0VFA+25&05>*;CIZ:('"[=-$PBEPO+LSG\G5B 3F1B3W,BGA5)F<'&)_=6H^E8=?U6"^Q*["(36;N2N M__K!A?G>;NC?[;9/5,M,1_3LU?D5Q3SI0E;K-&.>6E]*53R-H3:Z<%V_- Y MY"3&PPOEM\R#L'I'/DW'XX'$DB40;X*7?2-%X=<4=%C8-,)P"7Z+JNT28,>K M'_$P?%^)_93DPD7%LU&H\@WN]IC#QF +FUE[^EKIW-*G9L.R &_=>,?:7:&F M-B1V4C-$::1%/JQ[!VEE_ULU(.#N+7';!+?MMN >U+KLKC[ 0TU.>E3+T>BE M->L;7X !]ZUGO^T?[9^YW?T]LSO\Y^+D"ZSC^*_AUWWYVYHIY<8S@S<6I MB-S4 B.%!=)WF9M*DT5!$C+?A ]]/S1#S]EYO4D3R1\S8N_8)&0W6;ZL%[KY M?"A[R4OXP_'FC=N+>WO96EG[@)AZ-1#K5_"@_2S!^V%)\%HRY8DE8N8E5L!< M8;LLCE/)3"N*A1^Y01B!X+4ZWH_W2=V\,/JV(5\%1NZ"?,=%!A>.P6@<:S9J M,7"+@1\! [^O"&LFGEL)? \)_'E9 L>!E#R,61J9"7-#Z3+N62F3TK.2,/22 MF'L[K\,MPKZ5ZQL6*V\/]:ZZQ36IP4^5$KVQ*FYE2_K[1.9O,RHJFM8D75,T M?8GT;,V9&]BC[54R+9# 6_5V!_5V,:?>CHXO3OW4<[EKFRRU0@<;,$K&H\1G MD6.YD2M#^#;8>>WN!LL3"WY"K&>C)<%<^NA3)R\MG>=NXB!%AMN'#;< MUU- C8]\(ELD^'.1X"]6U36:#F-9/$KNIGLON%@1.=+X>UF(9A$ LUO5%4]L=Q!6^((%S.AV\FP-_MDT:ZMWZ-_<;G$RXX52C-,0B!# M[F*AGG!!O/AQ:"52)K$XC:R=ZD?]VCX;@ZA@<2'Y!>,IO.$K/KCBU^7.O^83 M[+,1:^[ZXH:MW98T?;)M45P PC$OB$1> ??( J^"-?&-68O1+U#B_]?WSR?8 M>4W#-['\X0TJBQ&V%.>O5YW]ZN('R_X)M1]+UB:1Z.%$#@U[U^CR$5 4AAW_ MSW^%MA7\49+=.2W+*A%Z;\0'UV5&51XZ6LX'^,*J1H2N^2C+Z6!"EVBTGX]* MXX[U'S^Q'(;N^"J;@(P0=^#CDWQJE/U\.D@,X+B$YFS.AG FLWV"]\:*F+3> M'C&W/<5L>_+9]F0CO.Q\.E( Y"J;]!?N4DX # Q52'C MYH^:B>S92 RFF/,O!Z6\@NND0?46<)H?IKP ^3&XAL,;Y\7$@,O?P@\-RV0? MC-^0&FSSC_H3^MOZX_=Z(=4W_V]WZX_Y>-VQXKORBOP!T>75AI8+AR] GW/8 M62P:>+>W][YQ'$/ >E,@@%W<,8,#.BQ%D8T;M %$(+)!IDX,;H:[6]^H^GGU M0#C+Z@1+2833@7](0Y]7K_K=C%.[^@[Z!%6MUTLX--B"&<$B^( 3**N- !ZX MXD7"!GE^@:NM*/*($M8L MCM8PDAGQ-+SA)"\0)QHIH-(2J*+ T1730DWZA?NETPF/MXU#D?E M!*15!Q=W33>,.=(-4A>(EZH'&-!!)M.R8\AO8Z D+92(Y.$1P['ZNY!GL%)< M) D_]3@M[N)I"<=2PBVJ90RXOD4Y 2DGS[)Y&:6NJF4C\,2GJ>@;Z\\*CN.Z MXKD.2FZRLA7H';@)8/AN36*ZV!&SJ2Y"Y]G<:^=F ?AV,YR6;GIG9YZ3@GP-$XZADW M848O69Z42"M&F0\E)K_A+:]!X0F.):ZPHUEZ?=O1Q%)P' =)5*;9S[C*BP0D M$YXJKWEQ]GJ=2@CI;X@&+Y<^EN4$+.CER]6K+7Z*)2FC9/%3H)S%C\:%3++E MWP,UG*^XK=JVI8MSQ'E #(M?@!"^6/SL*ALL77>%<&+Q0['J0X4\ZD^U>27G M/I##\6#%1B&151_-*$,=#I&$+(8D/TI@I0$O4,T@?7Y7-)73&/<*!>/%*+]2 M*FPZ4O\NLO*BU)]HC:BH%@33-3[MJI\!82!/QUAS?)UK?L0W*?+!KO$%*7%* M2I2GL'!)C 8<.:(ER0T$.E5I7 -'#W5L%V)(3MK(>P# M>)@Q[FE"\ZPO2=6L^P$\ YE-C$Q=-LX! J()J!4,_$P+&8"+ [W)0^ JO1YZ+#&[?K"FP>H5Y^@/UZ#( MKT%S8)P.8"%J@V\YB%II\F$.WY *#OS%LPK>F]=;X6/*R0)02MA.CS>ETA##O#WC=LQ'-DQ]-B/NQ5+FR M)FG!?U^>P$22B*F-,'WM]9U"%]=$2?P] MP"#*/NNS_P 7XJ8.)1'>L/:*K*/>BHK4#TJUP 8BPR6!%-*RI[%E]?V4'A;] M$9A09XHJ0 =+N)72HXW"9R[^,\W*;$;-I,XK@25IS^I;S6/NYFD"]XY*Y=Z& MIX"$*%1I ^S5@*-M(_(2^4#)#K*%I[15HL]'9_CW,!MEP^G0N$**&?!*N0!B MS#&* 9P[H: &9;3JXU6W5FRBSQ$EDH()6EJJ]A]\H)>.A'*F5)PAKL5 (_C% MTQP9:#OGPTP8"> /8"/2Q9I;Q.)NO F*<:SE;K0R6D>-7;X[^.=QG5F3 M 202;K>6T30HYT+(\40ABY3$(8K_<4+GM5KX_:&5.-CY6M:!=BP2>&116R@5 MX2(IY",E=>=: M6"[B #S-%3*MLJ&*=7++.),CHMLY4B$I MLWUDBW)G^D>.VT.9L.N*;#A5?" MTX/MIYOP\7@ B\+]4=S2^*&VD^%_.<)R%0]!.QMVA4\X"/+LDHMK347D6H"S MJOYE8 Q ]!7O8_U(HM2Q%G!-$9!D93$=U\(#MZ+I(VS(H/(:D!X8!E/M9IJ# M10TBHGMKX2U'*)@NY^]).G P(,0$"DF0DX#$#TCPCD'(A]X^+T!7-Q>(H$[1 M0:%2X$'2%H\QI&/@"!)"^6SR>/D:([-6W3"B=XU#3/ M&-]"*$2(8HA>@LR$YM1C_*/( "T!"5%$;\5C%(J>W\/*@P%[561$4[".K 0R MH1LJ D#6P;>^RF";+K.\H@LZMU4K4EZIA06I VJ(&+7")H)"MUX,(DOY<&8> M9N",K,(*((E*9=6H'9G]HO(GX1VS).,%/4-[#C+X364T 37P"ZVH-%%52*"R M_$A]-&R9@ES2F583UINO[]5>:_3:5')E(;[ M6YU$P]&W;.X (:'IT'"QU?ZS!4.]B5*4;_L]$+!QV#$H9F7M&3L? 2!5-M5. M=:QU0**6 %5D!/52.3-?/QV\V37>(5'HA2]X*ZYG41^R\08(XP =3^6"_L;? MKC?!=HTN2#<\_T[#JD8.X"";BNL96KQ4>U?P<9: YJC5C1Q=9D4^PKLIDD:D MH<#A.L-V%S;ICL8IW:A#/F5T^5VIJ]1/.@:ARF$,S%49:_IFG8;YO6 %SPS?U7Z7.2<#/6R]':QMKB&_(,\X MV!! TC.:U9LP1P&+/O!.TTQ#^[(*QX%YEJP*S,RB$I5/(Q<"M<,H67Q5Q1S+ M;TN7)D F8%K/O7O358R:'[!&5CWZ=FJ<\RPU=HB8M').2D.[9)O>P\I)V/B1 M=D,H( M4([7&U=+PL;Z*>!!KJ?TNN$POMVONZAC5,"AK",G: (TY?[!-W16X)$5$A>N MT#R8HP1+B+8GH!UA3QKC% @L3.%/ 2^A/!O?T;1XVI( UX*G!4%+XYT["YJT M:>VL0,EW3)5S=S8VT^KH$NU9>;5Y%L!WDV+>D$_R&@$EQRQQ\HXTW"@8>R3/ M+O&-<@VA_V;F4=#&LE#6'[+:$!,HI'&&P)B@+2O'Z&5&NE2W5FD$38?,"M=. ME:#4W:LSD^AGQ%)].1C/W:SVKFMW;3\;:S\.A0M4C =C&&6-TX=YT; ?-22# MOP%]D5>>'D0N"0""TW+.\\?R B^2RO8>R8+8B5\CAE:.D.DZ,^KRS.10=T1F88$YAZ@JDB5WEQ08&_7>.HZ3"MHA;-C0'FE,G< M5NO4B+E8(:T&G;.=RC^.$0E\12$;KO(.+FU$:YC[,%_(IZC-!^7-R,YD%7JE M7"MX"UCZWY+2XLD?,BT6]X:>/T&$G)7H_Y_E<%PI#[M44F@Z4JZ(IE,9L^'0 M8&DF[BWL*2VYN4VSY:M-;;A;8$]@QQ >+ZYQE !/,SEJNH0+J#1R'@K MXV**^E3W2NX@E+N4UW6J+ *' NV@JWX.ZI[E5VB5UAXQV-!]UF6?C'_G@X2< M$.]Y04SQ]]]OC-_2?UW\BQO[0.9 B:LN^1VVUM@'LX9\GQ7*J1K@5C$CC+X) MK=D;( +DPE23?CZ=D*-9M;D:(^Q3[BJ\=GZ%'; 3Q:Z1_"N&I?V;".K3D/PO MRFNF3G9N7< M8PV5:['<^&4EGW?G;D=I=)A(R<'Z)3N7 KII/LAR7)6BY0Z) M91(6)#O2Y$#!%3X(7F08CF9U(L25:8&%G@WA//R>V-&DG;( MR-G+QK)$CF-BP,NR(9B 3&+@W32CF0 8_*/\LX6HP9RRJD2=]LJ&FHI*[4A08JHK+.?5/[ @IC6CIO/NY^V M33Y^RD9UG 0M#,+VM>T$1#S1TD2A5@1!:@]I_:G"EMG4>LS4@\PBE5)41 M3T^I-:]^ !ZQPM5HTV;(;@*?)!,\6 -#I)3;JCT6^U(H *NG'UB$XBOOQ)SU MWPSYS))PKVM+ E]U=:X4:2!\H$JP.\\I7CN/-!O9/8@6 +S'Y%O)1VAIJ+RV M2?6;*K=B=6;!0IRA>IF[OD>,@G-$VJ:1UU4'U?>TU.[@A9CG16D@>5/RZ7#] M8L88_0(DHL8=Z"T!)7+.*99?94U5F<**0;-*8 Q!RNIB%IWM7L7TE&A6/AZ2 MX.3M4$G18BY19MMXLBG'*'.H>7):CE+H%C/"+O,!:331!\*0HS.E9I2]I%!% M+?*:TO*N(WFJ.E:&1>RO'']AE]@S;A/!2;\NS/WY'IWYO;'<76J5!S M.)XWCP2R(1T[-F2J:.Y#GV4H4Q >5D59K-8#E0'HSLU\E E?^A3I/M K/ MHQ@AJ:!Q;#(M:K!5O2P?C3#L)4<%:)GA+%\7U#BH+Z0Z0E< !+]1@$>55*=52X1),22OANC+5_0"TW8R>7'34SF0L MOA?(OD&6:D,7Q?0E'TPE4Z9'(;-A/ 7\3\L;YF ?- 3=7N6&+9??JI%VB(\G M^(DY;LH' (@QU(<[495L=:4+#ZP[T ]ZQS$HDY '8E,I<03!)V#3:T@>")! M\*;VBR@T](;LTW*>]_%T:Y7WJ;*=*N/Y3?=3[=3\J(B%7.P;("S>K-!!L%RE MGQ3Z*1HKKL( P,K]Z2@!6*;(,4](L2DP Y* VITJ_)6-^EF<352"YCI?DBYQ M&,],R-IET#0+YOVK,UN"2B?S.0.D=F5K+ZDLJZC*BC=NOF++24_*2?(;G?6_ MX5HJ52;_HTQFK-0E)+D!K-%=E+$&<3X1TS&??(W MS?)[-1; .('*16^&1&;IP92NHK0M9J97&AB^')#)WEAV?:9]=:;%\IGJ]VC3 M/^KT#[M-_]B M?SD](]-L4S_/>^P;!@ZV+P C-0;!3U12*C$C;%$R02?-V-? M@^R"_(6S@!46QY%W [WTE;Z=6;0D?R@@!?@>S85BOM"]X;K)YX-RZT/0C6#6 MDBG1F8OY5878*JUM#HA0#!BQ];;Y&+[,Y:%.KK 0Y$QA2^-XMF4'E(D#R+0^ MNPJ:'A_,H&FSXDV';;C!U.[N56'<)212,Q M66H^T[=.8= NMN^YN&NMCHCVUD.:V\N)Y,.RX=2=3V90=2H4!>*5^;L*#9,) M S)M;"0Y:OMFB&-6O;,0/UISV+O&6Y4]CNY#\E4.I'8BXS[,K;P98565.G,/ MKOL34.W57*N'1BJ'*/(2684LY&8FA/;=+GHLMY";R<7+*RC5K*;3O66F1:$L M%A7I)V^$.E5]ZK,)N,W1<[G.I)E.<-VZJ/=>JEXT2SDP+U512 MC@->S2CYF7[0*![3W K7:4\&)HI,QTC0=1"A&9L8439#W5PDGWG;:R>-*KB8 M-4VA#2$1D2 ;-E^ZV@Z,\NI8.OFGJ\83R:Q(@2Z\ _/5X<.Y!>"*8@D@>]4) ME7 <9>WEK]:D<]K/J$"![.*L5&EZ]38LE@BI-'_=>2"69]J?3Y$3$%]T$UWX MIT"XO@WL!E80%JK25AD%NW=JV_6T^71KLU/7]#)#U@?-_)X2%HTC3*;']]\R M=CX:&7]-02!;H8I-D8@4 ZJ_4L5?ZC557J8JC,;7K)3EX?NC6D]6T2:P$O.1 MSO6HX]HC14Y7139!^P]]O-2;R.DX#OY_URB!V66Y\B[8. -CK*KV]?\#8]TT MR85#OZ$R W+=Z-6IC*Q\D!B6U?%]'_Y_4-U>U7950:5&_93^P<+U.IOA[ Q[ M$DT0;DX4L$.ODLI+UH42S<>3)02:BLK?4095KU[U^E)CIJNXD\JF:Y9/UON, M&FB$&'+,K[EFN"FEG*%'#TOXOI'P #:';?%W+>47&&)AK,[UI<+*Q4MQ*IZA MKZJCG.$L?><+)K:HW&FLR%5E2W5FP_)JB:ZT4%IQR'?2MALE M9^HZ\?>Z3GS+!$R]_BN.'B5 :Y0R9IP-\IC&&JJWJL[L2UX %VKC[Z@XXZ.J M\!O^7Y<7HJ\(W%*Q='/7>%=#6ZYP/: MM'5PB@ 4-EK0&5U8?HIU?BC6OJC$KUE+#%421\^C/< V#<"E$MM!ZV)@54NM M*C!5R?UOLS?5++DO!Q-.2SB"8P7@@QN8<9V045'#[UC^1IV&+KD0E8F#OVK^ M'>ZRAWC9%4&;*-GAR[K MK8Y8%[G19562@K*XZG8S^:A2#N682CH:;T<(C%HW4JEA,A=5GW6*P)5]'E%Z MY:=)_8I9,^>QSED@WR4B33Z7WZ0RM74;DD2JI73JJLXZ>+#<^$(56Q)M:59$ M4I78OT(WN)!SG9Z:"ZEAYY@:5XOM\TD@LF[T%J -),BLMD69[O5QEI1UUI ^ M2O+LJT N?:[L8( H@]D5J@0WUF6CI($OL:TBF3S-Q LR6I")&9\P8F$RF:AY M%8(GU'Y4/5O5TE NE+Z?3E)!WB3:Q"+X!L)7 %LJ0J&.%'C_1I4OG+M"[+JG M'I8JD4"AA!OL0HEU!_5>U$EVV)LRH02LE)IVC*Z7'DGJ&^\%U^L />X+"4UT MN5<-.V9KA%U7,7IMRLQQ(3:>RPOTM $A#[/I$$&1;FE3?X/!S3(#S#B0>*BP M1V<%.B64!Z>VS1J0B2KY0%F"OZS73]Z=45G73R%LNXH+FBWBM9 M-_7!:*QJZ4?=+7(V-MC\1,%F## #R[\'&(B[3HKA']5!I@Y P_>?0,B.*>D!:7\#HL[-__TB M&[G_*KXJ=5,OU?PA%]1_5_-ZG:ZI>PZA&_5W?32VF<"Z6(S98RRZ*;;8!VH,]+F89T46>M=Q]I M(2%(6U94F\JJVF*Q/A>+<='YWDA!JQ$E6#P3Y1]5Q6MW.5W 3/RZ>:3U[E'# MU$0E>*?308I5&[.J0]RL-J7FJ:3<)T1C[SD8%N\U;'NO8=N_^0U@2/QSPX3: M<8TG&U#RBI!?ELS#K2Q5D><41YP6&353:;917,W$)+"&&&"C'%YMR"["VK[: M'_R3?E ]';T))"GJAG@5K[79*W7VBM-FKVS 6GYV]LJ2='XF\EMICZD\NQ'F MD@R,4O1E,ATH39DN-4NZTNS.T=/$R!J+\Y$JO*;,% I<*UB!MR%$DQ<>WZ M(A^N"@15]V[,"ZF>OJ;7:!VU/)X?+20'*6F;RFCK4/$62<@ M-6_5F;.09B$2U4Z/.+E2,DW7<9TAGMU!4+0T_%0T_!33@U6.86UCQK[ MCE;MGSDZ9JIO1#4#HXZ/E%)[NZZ:'?TXXO;S:3DAF:C]F8(/A.ZZCD_; MHPO@5@=_'A[O[^D,(95QM7JA&.W%!ZC&/KJMQ2R*9G<49!]@BGFAV^$V>F'H M^+!N-8B=8+5KMG)[S;GMZN\:GFC=RWQN2D!&A4$/<4$2E!KE5W/#2310J@Z. MFJD\QJ;:V\8/Q]3LMVHETVAKO)HVJA;AF%H!I%KKWO(6CQ/N;:,A]FR.7B,. MGJ\>)SJ7;*"&YV#>P C[TN#CZS2#N1[*\34JKZZ*6LG74Q2KCC/DZR;^F@V]ZSYC/5FPX\_="^LQE2' M8KYKOUYCK3:KQS8>0VD%.EOA4@Z4 I]U_=;-S34-U7*ET?1?-6DJ&Y6_53=K MH&$<&:8J@:BP!T&P$@AGC0PQBM=4YEAC];0A:54Z634_F8V$FN4_5--K*(%L M+GLGD3H>1;).35V:'7JC?:&6MA2-GY;3.H:R$"2IGUD5,L)_88>D,A(I5WQW M86+\/5N86J:SN3U,;P$&6R;=OU!$L*RZ+LXEG%!'=D2@0H#]-2OAQS??-?Z= M7\FJR0XVK;_#S-\Z2J8LN-4SFO5R5 <[3@]3/9"7ZY#DMTJ$SH. .HV)?EP/ MD\.D@;(9T2-Y1Z5.Y!6F].%Z3(^:\X6E#_4RFY,9Z!DJ(4C/],)_D=Q3M]1E M6,T1#W>X+2,C6=+A:W& MF!@-M\!=J.I+5LQA7MDN20F\V\ZR*C?[_]O[UN:VC2SMOX+*9K;D+8@F>*>U MFRI%MF>TF\1>RS-YWT]3( &*B$& P44RY]?ON70W&B!(D=2% (743"()M^X^ M]].GSX-[I3&I15'3XX*WD,]RZ<<;76P-(H%@UM!CT6BH(XE<'9B%+AF11%%G M_A5%X$K5$I2^"X- T ,N-A+PGCC0-1**[?*8COQ2@QY! M/XW::XJN&(8&0B'<.8XEE,LN?7[R7J@*#CTW*A23SPM=(YJ/_[8&,IY]FU;# MH<::9 HU-89^((Z>2B%CBPF]LX"97BJ\4LF68*Y^I%22LA)FB=BG,/Y:QJ?\'_2*+_7'#"U)HBPR9(I8LJW#5'H2QS-G M?!3G&[:P/D"6U6)))>V8X- P@@,_DB# M:=9J=6_GX@O6EJ/ER5!2J5TB_'>[OJ<"2 :9SZH MS#>F:-8IQP>*/KPGE0]^.7 ][L@0!G2H\!5R!D:?)3E"U&\%1H1E\P+"-\+0 M-N3SE-2QP%T?&@=!H4&?X!Q[?EW*%KNH2W=1093P%PM,S[-YR): #$4>H-V4 MJIX]/PF@@4Z?J9D L;"R!>VZ->#4CJSRX\],[.]2&1EG8N_]C<28!GTY];)# M:O8"P1K%P43Q$)]5Y:&L):9C^9,\P)8;4#ZP1OR[? ==#)TY3P2.-5FVS'$K M2YAFR2JTF.*DETE:E3HO\*'JW!$2,0E31T)4>RU2,VL]W;D623V5U?+"I);G MZ5+;%N 3&\+Y%,H_%ADOF8'5\@5<+APXLFZ83E FJD7#1'8!Y=/I6?$D]6SP MPWWZ3%:$A8MU7]))$(8GPZF44*(RT:P:Z1B8BKXU;OC7(ONU-EW )@\4X:WY M)]B@F?8?].Z@/AZAQ41G5H%@2P"5?W'OPN)XV;?! C1&VQ;C96.^X!INCAFF M&'8G]Y@NWS3:,FONB63[QAE*?H,5!IN.3>$0Z1%B-+7(ZWB;-^;6BU!E9WX^5VRSKP6G<\/NC) M;8.UK-:X5ZO!#G9]+9XO!&[[KQ^Z/\C[)'. J7.K<>=;XJYHTR.BGN==9_G= ML*1@,,MBB4^1C9F#GUJOC![:CR'_^XRR6&$*KW#B-TK2-R^'G%L;9[9]Y;8L M \O.9A?"E:-R@B7UY?0< S7114&U&?3?=HD9S!4 MC]?=N^=1>0_[VZ3S?BNZSSOHN(V+MY6:]9EE6OW>&O,\K73ML08-]S;G8K+AW7>O+] M($-9F/W&"*JSWPJ6*I?JR5G7'%KC0M7G0]*VA5^>RQZ\;B+US=Y@6#4BG8#B M*W@9-5-\F[<9GR-@V$G$2A:T)B)V-A@.]O8W*N01GSIY++/='E:(0">@_;98 MB$ZG;DF3][O45#3^X=[K.C([_4[57(^&2'DB#M:>XE6G;.IKINQH/*H/96NG4JLWX-.[\XG\_IVMFE:% ME^\>U"]V5AH?HV21!+O8E.59&A@-L%O2@X,I.;2!.N.\VRHI*\0#OWP2X,QZ M4ZB?;]SA7:G?&?:JY@PW)"I87M,:]:M&I!/0[8^,6.J@VW][^-A)#=5]YS'J M_G7GABVS,]A7X3<)_!FX8 U5>K?QX ]E M@T%O7VW1>/ O;G7;HT'5B'0"*OT5>/"7FPY^-R[PH05B!R:Q&__WQ=3E>-\- MVL;_K?Z 3^_.A@1'O[.) J^+[5]J&/WUFNCO\-!BM+>U;.*_%R82]6/O7%2- M3">@SI\I CR>.J=67354X?UF3^81V:'>OB>6FICTQ8G4MRI'I!-0X(_TQY^7 M%8R@E3[.!&196O\T3_4RY-Q751W^Q:!^XG M/,7R'#E8:(2C$8ZMPC$:[)OBKZQP5-3"OZ76GS\]8U?62X14W<0)G9UZL?YS MPS_UQ\+5"IY?_O/Y=1FTNM1!5@#-ZKVS[P@=0P+0$8J$'7USJ9TUPG#X/OY7 M0ODQ^ 6BSJR,Z9S;$RO$.T:G%5C*#$-H^WL#D&J]N]\99]Z;K=";XD6;1R3! M/.,YMEB^55"$ H@.<23BN;=<,L0+=?$^\[*/2K ^(P<&NHQ@H.F"4 'Q=7/[ M7]@760<)S,!Q\[BWWO0;W2?>Y/F^6M8_4SNR$0X/FQ&'28BB3J.!X:A54I#N M:K!W;S),:QXECN'Z*R'^A4'@^K1"B-:.V$.W'JK*;'@2=9"6=2X!*S(\[7PK MZS/XVA\9F')N5=0D,Y+*:0@D8DE^FS&W!?!%0*_!PPT22U% /?$?)4"J CE$ M+$%NZHW]OC74)X$/%;ES^ R"X^1ZSF&3;X6IJX;X67"=1-*U)Z$ +M;X5D#!HD).OG.0T@L5L;P/'A@MX3QP& @)\ *O\\X MONL.C,[%CX7_ M+5,4.>=\X2XF E4U\M#C-O$M :&$9SH3P59!SV6:R<=,0=AF)+1E8D!AW*N%D]>U:B0&UP% M.76CJMK71?LL@X,HK\V.(6&\5R8B548&SX3%%7*6"\;.]I:23U5"6CR?VW28VO"%\%:77PZ8\>W>A&:*B-F"?6.X,0*7P6&5 M73I,,7,8@5E^@X,H>E&L]$2*>R/_RL%)JY6$L9@,)AZ1S98W;(C[3"%[)DU0 MI?T=S[X-P+/RIEDP"G1T=.K !\!)\W&# Q/ZIRQS2E=64>9VAF_,>?+]7H4B M'-KH&%Q4)EBR"@Z$4F8B":RT$>J@@E+)W($,YIV,*4H18RQ>8:B\/'L4PAIY=VJNU!PN@H-EVA8RYY"O9J&KN2Y3W=#S<(J-D MI(1O!R=#CHM^A 6<4ZR&^C(@&-MPEMSCBT"Z*$TMKSHZ'+%8N;T061M&W9-1 M_V'[8&QXI26?@'.61H3HJ\BN(U#+VY(P](7.!\N6>8TF;UQX"W0)L\##G@*# MV%-FYUM[25[?G\ .E#E63BL*B:D"9^!/& ?SX!T.53#%P_R(4B:X+9W$T\BC M+73D)C"5Q*UZ@R[H!T]DC(J'AANUN1J-D(P0'V07($]K0(X.#/6JA\H96%\%LR/17; MX/IZ:%CNL5+&5'4EIO)Y+XR9/64C*[*!: ?A-IB1(P'046U,\8_X4KUV(HM8 M8#U'/4H50T43?"+HDQH M4Q*.30)P+[!M0G90Y%-%<5&$X)D0I827&(JYM1?,*8<8\MB#-1 G;SUW^W%\N+2U'Y=<1]GQ]^4KF5 MK*) R^>1_T<)/?(Q9VDPE0P!+J.'3ABF_,3<]22F[][:OJGM39O@%>%;,!,8 MN>B'T1_G*3RE2OU,% %D?*X$I3O6F"Y,-.DN;"EME6I=U))Y2(DE<.WNY,,B MVX.7 UA=J2G"V8P$!F1=4B[+6&8B2U(H8R,9FDFQU1X%!S#,GD>-)=PN/M]HP-A14"L%E!_:92NG'+!P6&Q47!.VYMB";9;U<.^"? M(QM8&^Q<*KU_S8=>5VGY^%&K'[4=4FZQ=#$4R7.SE^%-]C>PLC,,C:D^LE"W M*3U_K33RA)7/5IR>*B@5S(MJ0Y25;NQ4 ]/(A EXDF*/)&,<'ZNDYYB-%-$I MY?Q-TCPI5DEJ3\W2*/"0'WFOV?N./XOM&\E_FW",<#13>TGDX,J:!-6=?P[" MG']:_:)GA04S3],X"10-[<=I&\F4;4>[* MH^5%>*7*19TL*"D%?7S9WNY5>_L7[;V^NJY!4]=5@;&\9%U7M7)DY*D*0-$S MD2=[4SWEOE6(\I,0&NP-[G/J2A-"70X #MN;JE3UWSJ*6; !*C6U2G MM8Z??BF,R- +!3QY#?,.>-B"O!_\ ;VW.XCU]JGC:-CGZ=A'"'65^$)[54$J'L% G^(*_%NNV -S5[G( +[K MN!-@Z#A.;>5DK9>OPB?QOI:Q-H5\C*]+ 27&,,=!:-,T/;NLJF+'XE*K4]WB MTHJ6DSY8$ OV+&Q\"##?^:L=3>?,O%W+%&<9D0)N%OA_>D]20)Q:[G$ 2/!YE=-0R/?*H"18SADY,=>%3%(YU;X!G]M-_ M3J*W/Y5<%!^5H0ZO-+KSH0R2^+"ZWZ%*A(P1?ZPU:G<%HX^5VR]IX;=MK+:LUL,8'O7;[M>ZH MUPRV5H/M='=][=/TVWJP6=MX[=:2OC<<\+],EY?13BVX/@KEM$EY&Z"W=^C+ M=:K+^.AQG?!>&.[CS;3/"^HSP&9O7A4L6I M="1M=]*&O]+(2 \G<@^R^7DX<:_<:TOQB5P#7K'.AT-U1Z,0?,[/4/1*AM MB/121#H.@1HGN9:N0;%-X@&N07WSV]VAV>GN*R[-+L1+NP:# ^J2&BJ]M&O0 M-H?M<4.E:E.IMV]1:;.C=^+EX@\VPGS,CE\-):33-3O6OI4)38SSTE1JF^WQ MOM:FH=)+^]>F9?4;(E6;2$>BT$F[!'6N[MVI/>TK<9='9J??:6*::A-I:':' M#9$J3J31WL<9&Q*]M"-P'"$Z:4>@SKF!!_M_OQ('>;!WTJR)85Y\7[H]:O:E M*TZDLUYOL-:6JR%/= ?&P:3;>C/#IWM$D@RMY9T." MH]_YJJHABF"1KZP(XJQK#JUQLWU;70+US=Y@_T"F(=#+Y8:&O0/[!39$>CDU MUVEBRF8'7M^!IQ!3&'W3"-RDV8$_T"XY7XM":!._.:'(DZ/#H\L+]D-71< M$U!O/'#:/K E94/8*A/VK-O=P\T\59+6DW!-CJ0IEZGPG0T)CG[G:\@4(EJC MIV<+#XRN>1+ONJ 7G3"=^"Y;M$=8^\HMU8]'69IJ&Y@SR[3ZO:,PS9$3-HU< M-'*Q12[&W48J&JEHI"(O%9W.P5MM=9:*$T_N=X[3 +]V ?7;Q :^_4F@)FDP M3PL[NO4"9N+.0FLY#0WVV%QMAT9''PI0KE7;_!KI.HP6 7#6,H9 M[#*!D10U+W#*?9V%D)',7 M_A^YKK@$WYS'A@M3_:AE? MX;T_=EMM0WX, LC(M6/7\&+#B>"NP)BLC!^MUK@PUB2)O$E*8F DH3%-8Q!E M-S(6[F+B1O'<6QH3>H]\(/MYN=?3[ M_? >QNO8B0V7;7\%FBG&D221C=^OG91\%HAN-942-?R5 M$L7'R'F6U;(R5LI)RE!CLJ*0X/CLZ9^I%WO$HO"JO[FVG\QO@"2)F%EK;.AS M4B+B>T @YF3WNQ>3L/ ?#3#)]\D<7Y=)WQ8&%LO>ZP-=EB&/Y1V)"\SBXMYS MDKFPD?I3PFMK9X_8$_#1TF3S(YK]G[IXC.Y(K-4=%E .M7_/(SF:I7WKGD^ MR-_.[1D,]IWMW]NK^(>W>>$!R=$7L#CWC3.KG,4FN^%R*A5L;II90OLS4W9P'0DP]T'CK99FZK?G[ M>3^IO\5/$A-BT '#CN,088E@N#F:RV129*+>@VN1PB@IW)A.PS00O>K@ MHTD8K8! [O(\7=(BY%_3T1PZ)]4%C;E;AB_]#7>!?A<"A,[7DJ2,1B]N0U$$ M88:Q0>2!X0Y$&5Y0QS!#(4?^54..O"Q'CJR''.V A2GL17=-M-H:W[RH:'4W M1B"69L(.B4!RHJ!>*_C\^JNIB99I_.T+/23:58<01S/?FUK8SH$V5HI.48B! M7F!1,%#/C(TQ"8.TAL*PAIEV68:95@\QV(K_Q@(P:G7S_#_44C OROYM3>V# M1G6VCET4*9.A$AK/DWHY< M^"J,+N1;B>OKQ\ ZUL\7D3&[RF']U(-Y-V(6&:![7.2709YSK1=4W-NRELG& M@>>YM=P7@M'$P3:/(15^? MYJ*^^Z"!J#)_;PB]J8N#/$0IPN\W%9Y&.7NK)E0?"DVHZB&=Q1Y:(E+1@@.2 MR?X+QBDYF;3R81(!06?1:%"Y1(M#93UW7B"TTT$VGA: ?#UQZCS"E)*WXA-"#JQX_2$SGG M+1/;EO$QC9#SP0JZIABX)XG L0HN\"0$'9(?)"[AYK&0,K7].#1L8P9:*XSJ MIQ)NW%NRV-M*NB_X0T@P>)"6/#GOD M$-.0U;C,8N,;9&4[H!K:4%+P"ZT!3..9 MA[=U,"WC=Y=7/KD/R\CRSOCJ3N+#:\-XXVZSG'PK> M;CC!1<4UVFBA=@O!*L7!KO%;"$)N#5M5UK6:M32/J6YYC82O!6*";#)%)K># M%7(&*D3VD#S@"_#4$N*1VO$%^JA2<2_ 44V9UW%G*+SS'%8WE*T05L*17N1T M[KDSS2" IPOR#-*\L+^!;&+]'@@NI2_B*3BX["-DRREVBTH7$5UGT#2@*E,? M!7L>ICY\V*64-HQ*1)4JM8*Z"P>)^@P4 &C!=!(G7I("PP,_F>I-;#?+W96_ M7EY^;JH9LFJ&45/-4(&QO&0U ZLAX59*!J9J:5@&WU[&[COYPX6L6840%B=# M#UV(=PFN1TH72G%IGGPY8X)6FQE!')P37Q:76W2I4"#,UWK]UF#4W7BYW;(. MO-8=]0YZ.MX[=:28P1LC5ZFN'Y4 M4)IK*1;2&!]%\NXK)N^,7SEO]R'+VQE=2SF1KW!YKN9V<)L'$MB1IXYZ7&JW MR9V1,QFF\ H'PDF(B-UE0ME&\$B1%N"8K)]-?IP<[7QTJ-I\@4GL72",G@1E MYV26S&IX:9=#BPTC;5VOO^RCCA_?$*C2!UZ+!TB>HQG12:")-2-\\1$^)?;4 ML.)RN&W?Z"#AW.W(_T$G]!>>X_ANQ4[H[W>@_JA3&'5-:["]9>1AAZS5K%ZR M.<0K:/)0HV8-@['9'W5J#T'5,%V=F,[J M,=IYU$T_!C]X8?[5?:\.,I$NE1<]:V1WFFUF49WU]K6A3]-NMJ'2/E1J]\8-E:I-I=ZXVY"HXB0Z"H%J MZ!9L\8>L;L7] @(Z?<9$TG.@&55N$0_M#EGO_H_C@3EL'XAJ78M&CPT+GSH+ MCSKFH'O*0&0-"Y\Z"UL]LSW<%XZH3BQ\XMDWZT#:O3XWNX8P>1O.IE6HJJ+8 M@;N")0'-$)_V'4WYQ+.73S3[D_7PG3IF=WB,KHG=;0'.Q=@_>$RU/Q M]$4C'*]:.,;FH+>O?]0(1R,:]41.@ M9O_;T31X"&<>/+4+HBOC*0OPI=KULU4I\!R%K36T:P9GZ;;:CZ;P[@1N:[@3 M.*P,?#'#OT(,7HE-36UIO: ,5)&(5&5,A+WZJ->,Q[9JEDVMXID/.ZU>&1\. M6MUGUC0Y'!(=_#G/B"^' FK*=Q^.!$H3EB/<#PXQOR8Y]'=&00IX'8@64L5N M0$$Q2R %%7,468$+=%@V9&[QE"V1TIG(&=$?)+?G M_--R!OA-J%V)I\!T]Q#:Q[VS/)_FBKN7TL:O(A8\;E[<@XR@#+>.2AE4JW/<( M;./ TPB-$GDD01L'R5*NX3*R#MA&3'4*M##;&O;FKY M=Y>(:QOST'?8]A$^!>@W.U'8*S&#(8"N\L!V C^ 15J;)+&C.JG%"+\48/X M@>> A\ S0*2@*]!Y0 >8L[_B1;4GH!B!PQ!*&='(/&2;P"'#3:@P."X(*DR( M+L"VXMI+G6B$$PC22:?&3$!\0V)_%^R5#4*@PA!.H0]D<-%==I.(7 <.H)[B0]CP\411$)"S/S782.)0P@6'K#ZNC^ M/X'1H9E":4[$6@@%"G?3)_!/]P@,!*^/,FQE7?AA=1(UO%E*S"/MF\#S0EA: M 7"GO4'W#DR^-48MOG8C?AR_@W-"FSOQ HX.4*^ZX8PF,K4#1B-"2"5C%:9J M\')L,B1AN#&X##:F;$(&@:?9<1CP$VA+^.,)&G-=$J5E]G.^><%6*R(U6$<* MZVC<8!U58"POCW5T#&;37%_&($R%C$IW0&@WQF&S)1)NSNDEY+04#:X&H*9A M=Z)[ZX$KZ\6ZJRI]&5C[(%QX4S-[V-0\0T;3'=-0M]GPTU)[44 BFBWBW(:<"\%DYW1M.53A6PAQ2BI8=_39]^..>@,*L:^3W1HJM+\IBR4,%#POSLW?@J; MU'2[V&N*%1?0X=#L]U^\H4+#<*^6X7IFM__BQ?.OIHVB4OMZ."+2HT&SUHP M4EJ_<5!)-1](Z+>&JOJ&R@&!51 K0UBH+$*,[^LE5,% M KON[TL7X1P=NG?=08%!SH_((?_^;Z-.9Z!\GI2\=PU<;A14/!9Z+@99"=&P.%(X\[ M@RA-7>^.S-W]W,W[1%1$$WE8GTVE-!>HEAH*/1.%?J$S=9G+&0::AR#]A_AA M*NU6JE:EN.5:;3B<3MQ2MHGRB+AE.-2\PIP+U=MTG&!7V_P^C+F_&00PA$!2F!)[QXSG+ST9U$*9:Q4A"*9[;IR^[62%,>(9RY MXCR+QA]4]C(TU\!'0)84U_52H+[\*%PLO67")?*W$KZS< MF6NIK@ =DM;?)DU )GJ/E"4P?U.D[1[;2ZPSJ=4*C5<8IFL,U@ M\51-_RE/U>QQNF)S[]%A/4]B?!8=ER#R<3%F^4S^QS['+RI1LG3\LTD''3:I M'C_LC'OPX'2?:\VV,M5+>JV[+>@OW"T(OFMM].0K,M25:T<%UZR*#% ]H;'. MN\;_A\7;J=*Q63>U;KWS?@W6K68*Y]CB$R1LQVRWAU4D[&LXGOU1% .P,_D\KWII2/3").J/!PV)JDTBK&NV.A<-F1HR5:J[P;9ZG&==Z5]R MY65ZX=:SU/X/L([_P6&5%'NA=WS>;974MB#J&5<0G5EO=M_<><[(IH82UQFV MS4'7JGT#@Q,G4W]TQ!/_#8EVRP1T>^V&2!4GTF!H#MO[NNL-F6KA!SYUDY,3 MSYY]+CE-T.30]E[&@3FV]M7[36#9$*DA4N6B_X9,#9D:,M4UEW:,1::B\DU' M((\(5B".A'6!=$Z8X@$SVEAN>L$_=FFJ+?/==M]L]PX,;Y]B?2K>QK21CM$8FU:[UPA'(QR-<)3LDEIFM_VXRNQ&.AKI.%'I>'0- M]%%DH[R1_4LOX0A7\)\;_CFHH:A5[-IUS(:B6FW.RW\^ORZ#5K>'ZW!-CICYE]5C/W9S_#W8S7*3^+?5PFZSHVS_< /M#G'@+6)&Z\0_VT'.\>)K&L>P@:0>V MOXH]:HF'6D'TO.1TKY-UF@0V2_V$;^/CS=3]+C:P0-$QTB5B%7!W0C)@Q"_9 MR^($_B!X[G[N3>?,HA/7#9"%N0.HZ$H=.<2N]UXR-_YZ>?E9]B_$N^B[ZV/- M7@\#_3/U8+1&2NW[%O8WU_@C=6[%QUU).NXU:,=QNECR9)*Y#>+!S?F1S>&# M8833X+:#-'=NSF_JG?E-;.\9+EPSWX23%XU['^*:^V&@*F'V/QS?7KWN.:^ MY]Y1M]()3M*.PX":L[%IH!:(7C1-%]CY<8J#N>2F+\[T5+(W)NA"P*@*&!Q;A8P@.C=4&^R0;;V(K"K&X:Z " MK$&REJ":#B0 %*$ZV"O:>[Z-9!=>*Q3^6;:X][-3A+8Q; M>9>W6-I>A-\&!RU.T*;#6Q:H<;(6I0INOFY0)Y>(5\(Z0W9L==PIWB>)"#IL M^@T;TZ)S@E@1ZY0CKT9;ET"M8G'Q/F9_C7/W[^?,F,ZX#> MP6;ZK-J1MFG@)6@KI*S^F=I ](3*\@U["3K(!AILZ:U[0P/7FS1CAV@$50@2 M5(93,D?@GH%(%\=,O:35Y,* =71^<"WC9UN 9 6O;/]E*V@>I)=/Q>=?/+D MJ/\M?,C >UD7X"0$$8IS=[]CMVH4+;*>4N4:4_ 45]3\FLP?FS=24?!5=_V; M,'*U_C@Q]$-YPDBX1+BC-(GB$$K9'6T@^Z92,Z&BBL)P(96"'4M7&!<;E!8( M-ICOB(SAQ$WNT;M87PR[\'V:& Y#S9AN;:&2R0EN@7RFTIXX**6(BI,C=]M1 MXR$1D6-&U3#HR]]:QB=8' L@'BNA$C%ZZ1'Z4&8;/K GKNW T<)CFR%([! M.!NU>G^A<>(W\*56I]7GO^"KW]#?0.WYCNY6:-.6S973!'P9PYL1$X1$:FSK MC&X%CA.D9@8R1.[,"G_[PR7,JEC:.(^PC,BNX3N_N:N93O*QU>4\,C(T[& M>1#ZDGQ5@5LQ(D2$)GI=N;]+3*)& .N_)LUP76H&]9T-.JFHZW[/G-V21\IT M!ZMN&\M[)]KWR%*@6ZZ4N&FD"4SA7WP[N@"HUA! C?IW@\BH8$C$!N""1=\P M9,[>0!\3?X:P./' >0"']N_*F5K[Z+TV(R$)&!FQ!*E/LV086!T_*B<*=TM+F7]?HQ4C3M-8;[A#JN4\<0:&^D\H7&X M6KTB@[&@WKF@\ 34@QT%,$Y,WB#FEL,N/D-I4"RW3"?@E?JK\R2R'0()A$L! MX5?@5B>#)2AL$*STLXRA]\R#8I')2S@C<6_8N47%/$RV[0@D095R56F\0!#($@4(/ MUF(#^EUSD .5@VQP!TX.=^#(2>0O%/KE\@=1&(2H10[><^@\*\K55I&[<5WC MMQ"4?$=H(&#$S_]-P5E Q]_X M0JH8K8),]/PO.0*+D&['L-?> !&VJPH85W<;XL/"Q6'<&G]E-^^*C/?*N(%5 M3.NVY_ YC6+,J4C?XK\__7R#&64TI(8K9RH?+B"<)R\B3/O M#2=VT#T2/G!L+[)]-LHU8 :5O(][+R8G&WPLA?P5!N?ETT&O*\1/;/H&N FY M#X'C?H=NE7J+&8MV5.43JH(]D7J>K9!EI#YEAM$$+Y' M,242]YY2G[XWPTS,%M'4,@HF1%T)Y7Y\"!\XCC+I]XFK#5! ?R$[,B]2@(H6 M!%& $\RDV0+0/#^A&TX:L*7;HM M'[F%%^"V)X9@Q("7_W*L=\7B/9K)NG7K-,"U&BXC0[21U(M9YQ._J#-YE!&NIC; M +7Z:_8;"CR7>&C9&G@9+)9FXD0HF=\4E^&=X7">5.S)ZJCSVDC!/?=8VF"E;^AE/""PLUL@"^]#-7"QG")K9EFMSE\XS3]H67\AW4D'^N(GV!7V2&JJ)+30%+IC;(C$-]_S8:;?&"A?7<4FP.:V%1LB3*S%Q M;:HY4/1%&07)_B/$-%OPC3D],]:T)2D?ICPN2JHN@)3KP7M"@>W,TD\YV8BK M!N!'S+FFG'1"7P,5 JL0RGCA>R@+AR)&^4J^B+!B2_ MI9HYH(^98(5T#I82+%0IEYF%7FI'3B^EO)I[[LSXH(*63X3K'#&:-EW+_$!Q MS92U*")'PS(!#Z./*]^K!6-3?5F7:EDW%']\E57KHO;CX1>96EF(7M.+$;PQC84+I,N/5*0QLHDK']IQ<N7-<,[YKS M EF5Y\S#]'F$,0:8>VV>ND@]EK%!W/9(;'K MF@WGYL.5VC^-B +X'IP.>+/O'V8*D25FML5PD+P6804V/?2H=9RLL&+XL:L) MKE>Z2'E7F8MI%HLT0#O+G]0E,C.87#,C\=FSU '/3_X]7\LO)="'##>W/7V8J:XB13TB=1 M8IJ5*F=UXU*O!JN-AD)45V-H,P=1N7=]/],=I*JI% $5X=0.Y$X$L)N_TNOE M<;\_HJ,*E,G \C?A_7K@V%-J!Q8Z%E4M:J2!BUJ64R&TA8",D&0U6\@5DJ6% M,XUU,N<3,*PS656,(CWWEOAE"(EB#\>S8;I-^4!6/M#97#[0% (TA0#/'7)\ MQOVW,(U!\M\KQ^-7:1A^5X:A9FKX@ MO WO>>$1M3LZBXE/8<$9E092-:1PQR9V['$Z=YFQ0LZ7W_]P"Z4+96&OK/Y7 M"9^G<#O>[7SV*G<2N3NHT EM"LT&%U4YI6WU$.R!=H7EF5WV0(2WX''I(>[# M*H]-DLD-[KPHY!)MC"\HU,$9/!RC@ M\.I[-WN=-B<7_45T#&%X>, ,:YFXC,7-3K#BH0>YHIJW9MR("N9-5,C-0?E\ M6 NH%PU+'N12TI>>H XR'96)ELXGHYG<;B&/E/1*I%+7\0:?1G3\+?Y M@%%QTNNT MG)DZ#B!J6G8\'KZ?>+TC80*.NHWLA2QAUT*Y$NE;2SB!%S /@#*W*_4B4DQV M8JN=>#YT3C*GQ@RK(@K,,E'1SD5I2HHS>'Q\.M.\)IU1P__::3(/LV2>MQ ' M7O'W3%S\U44FKVF,"8\I!JIEDWQ8M?!&-](JLPZX11)YTT2\G7-;=Y[OPJ** M;\$GLA70IV_*Q9/'77#YT/AH(Y%EDJ!DP0D,7'^_= ;'IWCJ!.Q-55SKKW2R M 'A!=Y45R^K'!LJ=6R$=Y8T8YN$]J,C(%&=S=5_\?N["2V^9M)0(87/,=292 M/JB:2DEU*2>87%S&9Z)+MPFNOT*4N'1IJ3-F.R/_'O-H:1(N*'V:,2(S%OL: M>E',QC4( TK?4ODP'FF+!%/95/ZF_"98YUP219,W9CC\L&[0UR;#>NJ<]1FU M?L#GLAQZ_(9?PLN9T2_OU:B*%5^6]I#(^WX9(;7M_B#?:D+SH_:.4/3"3DWC MS6ES13]I'.=91V;0%>]0N4_B)5CH5A*,G(R,E@5:3%_1V80.M,D:>#)0G;8U MYAWR=J==[L-F55/:635U%$QKEB$.@'&';GG*"SX(CE2D]C'R_34$I8#!(G1, MY68.JP-@JHCBWYDA3C_E"QGE<# U&:NSX6N1M7#E$ON[D7%[$I*#L4V\A'\@G5+A@%*4LD%\'E:T\IV[ M90T.E\Q=M]E+Y*4R:; O+I>F(!]]F,UXIRW$\),T>OT38K]+@X+^;4RU.R++ M=(EUS^BI++PD<=6AYI]#.W*X# $$%,\UBB*P.S>_,V'SR4!VX/@D34\A!N(]'ITSOC0^H@L""@'7ZXL9 4XBR/P.'D-]V)NL7OGR690O">S&- MW\/HFV.O3'&Z'^NL()J^M:\@# ,I;DF7[;!M(9+]\WKW3 M64/X/0G_6>WDWX:4S8Q$$,OI)EAISP'W#8T:.D=DWJ?L]WTEF$ M 9W*VEC.I_L$KO#<%/]'W*RI>!_Y)/DZI76=RTLH=>YM)*4DIB.O4D+8N2\; MA @FUMPK])\YKO&F,K;]?8[57'HG1&ZR*%XE6[-%H>AFM'MY#G<^S/(26OY@ M:J=QUFJBQ",3.YIEOIJ^QZ@\.\Q.))Y?OMP8IE-OS5DJ<@C2;^!03?J6^;JE MO+%$,YCUY%#LX/.)F]P>#J\P30ZXLRDXR0I.NDW!207&\J(%)^UJ!]]7V>F_ M:ZG81,6[\0D56U;=^$4JMOKGZ#Z1MZW.FZ=+AQKS@%)5.2,NZGUFEV4CLS_7#3Z(41W:P+32NW:/,->N=*R-;K6VN*E=EHT6&3&\_3)8*+1V: MJ4AK<;PR?.\;&K D7'_ W&^,C9'+C%SO29HR]49-4Z83-XV%O/0+<>V&6LS+ M+U^-Z^OS3U__]N&+OWIMX,/[_6MBA_>LUK&+^XM:#$ZU.9B M?%RWS/I'ZLJ!1X\PXL/_BH2=3>?:2+7+%O@^S769S15SUU0@8?LR8,3.5>E4 M;=_(# WO-&F8!^OOXBPA=\T$(Y(&2VQV,$WX: !M'HO=+,J"VN( AFCF $^H M\6+-POK[B^WZ[_M^MQ;*HSN\$RH/;N=FD^\K(?-X M+[KZJC@XQY5XYLRWO86^P^/)AB2)AB*P1\LVWDW-VC5G+:#K=F#H"QV"\T5& MBW;HTH3!.]8ED&0M3VA8/ &MHR0OHWV*.1?*\XC:=EQ?SF*Y2>++DC':+X>5 MPIU!S@LO]&-,O$]3UNGT<,/4J[IANFQ1!P_C(T^U9ESUE:*>#-"F#+Q#[/Y0 MI9(@: Z70S\#\!E1!*Y-0ZR-F5L;<_,I@1F\!#Y9;,W/ANXM%)C>VZ+'\ =0QV&3M*+B&^"&(APH&KXN>E4874TV$/D5_<,; M>^8F*[WOV^NBTZ#B=.JW#,Z97F>U[*=!H5>;INL_29IN,'ZV-)V\#V8X/8=5 MPU+6=]R*9,O^R=%S>+GANM_GWL1++HX^P&=/[)51Z:)"&FS0,CXP,>IF6@AN M0PQ=^.K@T"U[JAWT)/;!CL:M(:#X4ZO M)5!OL1BPWD@W'?F^@!N^,]3\;CO:SV/%1@])MM7%IFW,M_\YB=[^]%N*H6U! M2XF5V[(H;5R2'W:ZM63]>/(O TS_X)*04(@EX1#_/27]ECEO[>D9!KCB2!MK M[:H;Y>T#%$9YGB3+^-W;M_?W]RT89^LVO'M[&4WGV"[HK>O^RV,U[+:8+O'G4[;:G?[X[?)HM/IMWLCQ_JG^QWTO-6:)\" H/"L$MO] MW%)Q&),\EQ&U.MB4!'OU44[UM[!E]#%U^Y%JY7_QW,"XXL[4E[>1*[JQPB5%XCTB#YF]Z)8;B%A M^A&F=P:?%Q_@?G:1*\$PX:JT^,@A-$=T$$;G_V,*#P/NWS OXV_<\5Y,D+R+ MP@(99Q^QIA)7&ECUO-?NMP=OWK1*N% HHD(4UF6WXJDX]-!;&RU9)2WYIX6L M)4;5M82&ZUHMZS\JI>)>6+N1T;_"@>@XGI]5F\CUSH4Z! ^U0V5?@7JB]LYL M@4H#&D;\';NC9G]7S2[YUUWZI%XB2 _H%/W# LW#Z+8[FU$\^ !36]M\:'1& MHS,.UQD=I3,ZC<[8HC/6.YHV.J/1&:]29W2DG]$!/Z-1&@<[&M;(^'OKIG75 M4E)L=?OM!T5]W!XTHMZ(^LN(>D>)>J<1]WU,P(TQZ*C_9^PL M1XTQ;.YJ_!X;^-+N]KDX,8JW+15"K;B-^OP23)P3()W'$@;GR=\H# M8UCI1UR8V.)L*9[;<9P\YMXU5=+QC1*VP#CS9 \?N"O;Y;?>E(3.;ZD([RDK MSR_QE-.FA>_LM/#_W/#/QGK$?&^O8N'F,?N>_0?O=ZS_^R/56&"A!I*SCC/; M/#55ERJGM[F2=/?Y_40E?L>OWB^M0*P32 I^@[&2#(2=;\]UJC;O_)J_.[[5:WVWGRUW9: MH]YN-?_[O+4W;/5'@Z<\2O 4^R>#ISB@IX# M$SO&N!!^N>_VB'+K,*=?[168!J[&?L:I':.+;UH5Q-??<64E1&9Y\D; HKX(61].Q9UMJ^]XTODWC S<^<.,#5WA. MC0]<4\*A#PPO#)/Y"KPN#VM!O\6ULO6GY +7FQ)U6N]2#WBMUEILMMF+Y87F ME_W#0S2WR(VIH_&K(%$5'.,UZFQTC'?=:]^X+U.5+=#*['8.-^]VOIV$S@K^ M,T\6_D__!U!+ P04 " #NBJI4CZ?0YXX4 J[P $0 &-N=GDM,C R M,C S,S$N>'-D[5UM<^(XMOX^OT*76W5KMNK2P>"\WDEO.<1)7$6 Q:1[^M.4 ML 7XCI$9RT["_OJ59#N\V)9?@(YW3=74- 'I.=)YCHZ.CF3YM[^_+VSPBEQB M.?BV(7UI-0#"AF-:>';;>!D_-*\:?__ZRR^__5>S^?O=J ?N'<-?(.R!KHN@ MATSP9GES\-U$Y$\P=9T%^.ZX?UJOL-G\RBMUG>7*M69S#[1;[?;NK^X-O$)7 M$,I7S0ZZNFS*EQ=7S>OIU;0Y-4WCG/XH=>#5_\YNY-9UY^JRTVZBE@F;7US*\YJ#OY(88<[2 @'8,DYMW][RYNSL[>WMRUOG MB^/.SMJMEG3V^W-/YT4;85G;PG]NE7Z?N'94OG/&?IY @J+B!GY=;14W'/R* M5G,$;6].'-OWJ$X)_79QQOK>ZG2DJ"H#M@2B+$P\B(T/4:;G-KW5$I'D.O3G M,_8SD]-JMJ1FFTJ"GN=:$]]##XZ[N$=3Z-O>;-TM6GM *O,.Q6F?(]@C[J[G&^/).S,99_A;XI#F#<%FB%9LU@Y:$WQ1O MS8:!2M?7UV?OS.*2VY%H-;Q\DWUL2NUB8M/,+[]L^E(-JQ'6[$V1/7V M;$/BD$JSB*R:_&^2LQD1*H^3\WT#58ZIFP"7NNW ML]VR.R@^0>8 ?^6?=\T\K!P6$53_I! M'_2T>V6LWM\I/:7?5?4G51WKY92?#2M@1N+,M"D=.M4KBJB),,$F* A100![ MHFY#QT/HTN[-D6?1!A^)QVT98E*9$@D Y^9?)/IK)!F/ZD4"T->O?J2%?_\:*-?QS',!+DB,U ;K7.RYC! MIJ#_^>^KMG3Y?R 0>*)]34=7T9\>>H/O1W(#:W@QR>>MUD49DAD^X )J1.K= MBZ[U59UYUCM%UZB:J8/3J4JXURM%9 :D@+RVU)*D(%"VB&$[Q'<1_2,"Y"Z8 M0S*Z-D%/A(6*N$<>M&QR!-XB9!%]MJU!M=+N#E_Y8ZS\.J9/J:FHY5YH36CP2.Q)?&&U1&0+S*7$-#=;8( (_ M$;FC[:%C6X:%R@W-@B)$Q+9;I\)]P!BQ;/QA;R/"V=QI9*G0Q0/?@]A\Q:<6+;%$N C1 W"H'_\),LIT1BQ/5W*/*U6 MWIY8BYJT28"V"42- ANM MO-.EE:*KE]Y/4<0BQ,C0(-F7M8+!RLSZ&+CF]9 M.82++>E*YOFX\I9$6P!8$\"O02/^!H;<3;%V -Z0D^VDTP==YLE??X:E[(H2 MV\6US!-T>]A%)*^6](_4;VK_17T8#9Z[@_YXI'3'^G=M_-1]T<>#9W54;CF9 MC2I<24HM*3YMA)B @8(/5,!@P0?NB;FUCO=86^3%%BXK)*D3#R9SL5C'%46F MR@_B@HM+$7I?B2T9RE%\ A"'5[(47TMM M5J^IVO<(F!)@Q+'1>2<>X6Z"U#$$VNS_0:(=(:#8L5W(K2LA/W6?RS:5H1"" M/ *QN9&74XR_?,M%YJ'XRR-#3.FEW+K.H#00PG.-FRG&2$[MB1[ZKC&'!'4I M39:)]M_0R TNIO:*SF@9U$;H8 O^Q*CKL$?MES\KF A7%F MNR7%<[,A+(AP^1D?C@Q":!!@GSC<4O4>P6D!>&'0VI8Z\75#;C[K&-'FT?P^ M[K8(OM#GMEE>9P]J:^EXV5'_\0^J%':P>\A.!95.TJR71$X]76)I=*6U9&?P]W.+Q62(7>.Y M+,52-2E\\L"4B^%KR ]!)P<9:N@@:9UB9XD;0=YDB=D MFR^8+J6[<&EYT.XANKXFAV8VCRPQV9>RE-5]C@8W'_7>KU2/(OPQ)'/E13?<%JC1?$H(S4"/-'$M+!'()2- M*HZ'KCOQ8%5,61WC(H&6'QW'?+-L6S'H)&1YJWT\; DQ0N?::NIT MI*1=;8[PD>6K+P%[G?](0A+&11TZ=\::NBONB/U7AL_*%VM5_J"EFT(L;>ZD.('-@( $"'45OM[^*I$(+&KNNS$ MYXT=)NKHJ;8U>9"8/0-2[+FNY';L&,PN376/R[<5S"ZY-GV;QL/W:++7GD,> M7#%[UW([=NPESEZ$S,)HAGTB,5G9)1^7R(=\(O(H1#(U/$//=_FQRTA!AQN5 M8GPAJ7)+;L<.2,1)Y42N1:Q)KB.Y![K4K]B=?6U)EJ3X:=#3?7R)A.SU.'5V_$Z(5'KJ.W+N%'ZUX3-;<9:_6R\%2CR".E+\!"X':G(DL E5>UKV MN<-)!"AYAZ+?-!B+WA._6!N_NJ^:$O6N.XY!K^] MW^PZBR7"A+=2?6F^1)_,P0L1S+<-#)M?4\0C/$"0F_4INQ_9W M!*2O987\GXB/\=%S\&R,W(7&[Q:DL^'QJ,\4)2;_6F[',N8"\IDTP,2!#WGU MYE]]'O8&/U155[YI_4=]V%/*+7^2<(1KG_.6%'\2)D(!(0Q@./5F8Y\1)X 3 MCJIS26['%CV)W-1RS(R5WTN>(@EJBL=%6XH_!L'KU4W#^UC^%H#8UMGYD$1] MU].V1PJ=+;L\*%-[[%T\LGF-"RQ_M3%_Z1!_FQF_ MP5;MEW[7APA/[ (OI?B#5!MHX0O/-O!.+#$M[+6!G0TK'E]7^;RWBK)9C M+/0R0V4T_K'A??IP")AY=UU+\29K(^W&L3;]8IZ&5IL_]KL448PH'U45+ M[B3<3YU&52U'E*X^,@>C]1\&H^<]MJ_C,,)1="%)\4>50A"P@5)K)O;9L4X# M$X;E%^PV\!RLU#$@CVOT,)O4V;!B']>1._$-Z@3*:K\W'5/T86G+QY8L=^([ MRTD#K(8,L8=VJ@FY:H(U-#L%S\%K?;8E4,R#[U$] M/5/8A;_@2AG"%;M&:J]'P_-BB^F\DCNQ\/J#S@ 8H :\R38IH<,+PS[$ 77>?% M%C)XV9([L?,,'PRNP4,R:W35]6]G[^0&+I<6[3+[)O@;8R=H._^*?H-LQ*]7 M9&P;^'7UQPC11B)S"%UO-78A)M!@Y=E%C-Z*W>DV1"X[7]4 <$(\E_YZVYA" MFZ &P'"!;AOY ;!EVRS6O&UXKD_KOT]MST+SY[18H+"25NSU1BR@F^&T2>%?Z YI87B&:%S3L]:"[RJ$L]DRA MAFF/??:]$KXR"0UITPUK"6UEX?C8"V?DT#SA#*6JJ33>YUJ\TFZU6QHV7/X] MM-EIR9X#L=C^LVI58330-DK7@8<9VCDZE%2X"OW@AD6(S\8$'U/4DES/^B<7 M.^1-$1ME5MTC&6!4*4<74Z:'<+ PXRHZLVQ5_?P.1N]O5S*FE=UB5;"_% V/ M$$9OP<@O2LY6U<\GYYOC\>F*OSJ;/2,@)BFU>!7(4C#VH:V^&VS"AF3^8#MO M.2:OK&J?.T=%LPL1$Q,K5@5"H@<>N">FX=&K8[ F]9#G(7X4ZP\9P8?D,3 M5]75NS8UWM=+%_0*9@R5_\R:>;3/<=W#6=/B36U%5X]*A MC093OISK(V_H.@9"9KJ_32M>U>[E6CB,Y]0A,O^WW_IC Z:JZN">_F[WSA'% M=2$.8J6[U;I(.!DJ-&@T68(7VG:8PA4MU0XIXO,7<-O)[1YZI0-]AD:L>LZ$ M^$Z= I9Q^'P"';(LR1$-VP&_AC)'EB2SWN>F24J;7)#W7G-%!MX,YQ,%E M*:3/=FV)A\SOR)K-V79/0.8CA?;NH8<^XL]@E^/PH^((3:RJ<]I\%9>>! M=(^V/WBSWM)%AK5Y0U*JJHO"5#72[_LL9!M,N1FDS\B[Q8XT%"WLH1ER<[1[ MQPY'B(6%46S$)E$E[$A:^%H X$B=93?GX%DNDPU2QCT:2"*4U;&TTI_=B^A6 MV<%T<[ED!H$O/P [1N_>G4V#OG0'5P3CB*L0+Y*2B[QIR.(&7F M(O[3B,:1V$?9:Y4<-2L; 7#TCX9GF&ARX2J0IT(7#WPO=\(FO7P5>L.2YXYM MF6Q'6[W3QO?*ARD]PW=VBCW#R6:#L^[[3/73>58[A6<'\F-K7%,BC/U2$^VE<( M9.=_V7@:42ZS8M(" )\=IOZ$C&T%DL:5SQC'DD%=Y'IT)N%=9OEA,G!I 1_: MWDI]92F+,AFF0J"?FW[2,&N0XZYT#RU?EJE]C)6K:N:!IYC"_ CI*B-55XST M,9%2NJJ=4\Q7BS 2D/MJ&5F165KI*L1EVG# IC"(@^D^>^K*9,F#S M;:[MW*!@5=YG_[[-0BT7XU-63.S1UJ%/!'J(4>"\8VK9CL+@X/=HK M#%15E<2O0.8I2['99E2J@O7F?R@D*Q@K@_3945F4?TXA*C-OG5KOTQ/9JC9B M![@Q MS%G[YD?X%,?\HX]_R,VR=3B/]4L^87,A*Y3 M%_#K+_\"4$L#!!0 ( .Z*JE1QS50Z_BD ,*R 0 5 8VYV>2TR,#(R M,#,S,5]C86PN>&UL[7U9;7=B7CNZ>D&6Y6A$NRR/)4S-/ M#"P)F],RZ2$IESV__B9(227)6B@1H(X\-\)A:Z'/22 _Y(9<_OJO7S^=O/B" ML_EX.OG;3_S/[*<7.$G3/)Y\^-M/[X]?@_OI7__^IS_]]?\ _,?+PS<+%[LSC L,+_X?;SX^.*WC/-_OBBSZ:<7OTUG_QQ_"0!_7_ZGW>GG;[/Q MAX^+%X()"+*U!R3II^R65P__?#7Q3STEDI %D. MH!@O$'11@#Z7$)WU*OCE0T_&DW_^I?X5PQQ?T.(F\^6W?_OIXV+Q^2\___S[ M[[__^6N?YM[[GY>_O?CH?'S3!^FQ M_.?_^/7-4?J(GP*,)_-%F*3Z@OGX+_/E#]],4U@L]_Q>NE[<^HGZ'9Q_#.J/ M@ N0_,]?Y_FGO__IQ8O5=LRF)WB(Y47]]_WA_I57INGD"W[[B.%D\7$^/3FM M-,WIIY]^KI_^>??@[:N]MT=[K^B+HX,W^Z]VCO=>O=QYL_-V=^_H'WM[QT>T MJ.5+%M\^X]]^FH\_?3[!\Y]]G&'YVT]I\N4;5.XSN2+M7]9XZL]_D)_"23H] M6>[6&_K^[-F5O)XKP:\+G&1<[>,Y*2?3=.5#)Y6+T]GY_SP)$4^6/QV=SN%# M")]'._,Y+N8C8YUROGBP3 E02EF(0@6(5B3FG4#G\]5=JRN;T]*6'"]A'I=L M/WLLL5_PG_%D,3__2=U@#HR?>JP?K[!,_ST\_?5H^$\8+_'3^_ZNE,OO9M//.%M\ M>W<2)HN=2=[[[]/QYRKLW^)B))W6QDMBBV %E#M@0#P?##1C0#-([$](3#&R07X[#N MWT%Y/U\)GY%7'J7S$=!H\LJ")CG#G0+#5;%*,ZE"Z8."N\A:!PWF&:&A&0N: MH>+-.,3QR7@QQCE9*4>+:?KGQ^D);>R\6BR+;R.K%/U.)_5(XB15@NBL)6F* ^%U6D6G8D%3CS>3 M"672RG5!PAU$#"]BQ;#;Q(\MVJJ"8I;2#YX%*45C+9 MQR2^3P(^K3_4%1<;LJ$9'*X&=LCY4K&$"-QQ1ZZ9YA"9"6"CD"'X3$3T,9GN MB)T]0AB&^<>ZIU_"R?+<+7;#;/:-SMV_AY-3'!7BCBNH0#I.CHKUM,\,,Y3@ M23Z7Q%T.?>3AG70-25D^'A7?R;]VO&B'^92FIT3,(28DPN()OL7%^6)=T@F+ M,!"D(V.XT/'VC@ZEEI""%>>%%=+VB2E?IF)("K$=YQ^]SPUO$_!S&.>]KY]Q M0M[J)%\*:YRO4&HN9"D%+$%+EIS MI4=,8>0=YL12!I,X22;N$+SG9/NA%5:BCB)A%UC2-U;1BU]Y99&_HHON]I&9(I]%C.WQ$B>,R.-T/R*RQ(K\_[DS3]A,?A MZR7"JC0F!\;E+ (0;1)4P 1>D&'2*,EX4%U@< ]A0S*!6F&B)2_:B;KI MY,,QSCZ]PKBX%. /+";E#+&-<015EQAM5I"4):3&9$3J%#2]D9XAV47-1,3F M.]_V8NTR'/^@QS'DM@)2.%Y 14MBBY$+QU4HT@>OT?1)L+F=IB%90ZW0T(@# MG2[;S@G[=HDL=#EJ$\D4RZ5F2WH),15%["17/FJG58Q;N'"[@;0A7<$VPT=3 M?C2#R>OQI&:3WDY4"XAE4\I:\/6-!:-I-\NH3+WVDQSV$#>E>MA5$ M6O*BARNU>Z'AN$O!(U@F%-1;$7#1&B YQEV0G.G8W:-J%'L^CVF]"]]J0.M\ MA<9Y';,,P'2-9J6HR9)S"FSUB44P@OF^4<6K] S4P7H,'FX+*F[ @):!YMDI MYAM6J)6(GL4,/"RO_DH&S[D#4VP6489H;9_0TJTD#=2_:@2)!FQH>%<_6F1&DU6.?PHT;B!FH#]8" M%)MN?6\?[$*<:2>-8Q$RF85D*Q8R$[.N60DB">^X(N*VZ8 ] !E/X'VU0$9# MAO3UP,XI8HI9)W.&PKBN&9D9:*T,G!%696>0Z-V>^_4 @#R![]4"(,V8T3,! M+(8@%>DNX,(&4)DG<)4BE+HX3>ZGSWUR1=NGP+Z;G<74EX]>)9D(H4W2M#(F M$RT/E8; (K&32_*ID]!)&9+GM2$2;KB\W6CKFR;#3B>7J##>%V^) M/UQ;3E0P7XO3/,B2ZH*Y,Z7/G=9U2H;D9#7F_D:;WL[CSGER*S$7,!PM(X1"E+IDVQ]/VU#\M@:HZI]_NO*4/_?KN<.\?]!_V_WUO_RU] MN_?FX*A=/Y0'OW@[+5,VVX]&757^D$&O")6F50ZQ84[+FI364M/G9['85:O/TL@'3F7"GD>#HH6Y& G8\ E94 R MSVF_A$FQC^%_*TE#\O^&@M/K(KH-/]L'7?_8KY%GR7M!*],I6U"12_ Y(:W1 MVRA8+\?\L?SX2S-LDLJGI+0C*<49?I0S,%K+U;$(3>UU[;DK[D"3[9BC[/K2S M5;ZVBW3C4H#\@A/:C9-*4OXTGHSGB[HW7RZ4BL$2O'(6$C>2:/,10DHD#%"R M*(OE(O3!W'KT#4F\M\55!_XT+)/X ]77P:R-TH;7&)73BMS/S&G-D@,FAU%% M)M#U:2]T!U%#"AVV14DK3FP,C>H9CUZ>SL<3G,]WIY\B62Q+HM)_GX[GR^CF M(2X#"43F>6G'0:%_:2NJ#)V/$*U*LGA 5 R41P_>> N"2[)LM50Z7]/UW[OC MFY,QI-A@&ZQLF37-I,SMGHZ**IAL&8F D@C9+$!PFHQ=%[,SLKA2^C0I6--S M?4Q49&7'GZ]0LQ2R#0:2$9Y\.3+G8_:A=L^0,=7CJ_HD_5XCY(%V&W0]#FT M<4-;QD=O?3NLX^*2\Q5R]%G%M,J'(5^N0(@J@XY)>6M3W:?V:UI!\ M>A2T3*:Y?KMZ<;/JBDDY&0U:%P.*Q0A>)0N<^Z \,V2K];D,OX.H)H6O-SS_ M-3%M_&&R2MU+WXYG83(/Z+JH M52G'TW=AF0&8'*EA[Q4D'PEJMK#*4@>EB)(+F<).=8RAQ0::X7G&\MU M!XF;3A:<*MKH&"183]Z9JIWJ@L ("8U.1K)H.^FD.RRXI]4BO:#U^'WO>@>F MK&)+.8,/TH/02$1A3B'T<5'OO0-[3+K.%YRYA5Y=*&0)F:B,D+6*1B2F)MXD4)Q:T/J$S=^!+%#DL";8NG[C)Z^O.MX M]Z>RDPIS!"?)F%-8/'B6&+!@K$'#LL7.+SZ9WEM_?SVG5I59Q3 M10,99%]6_1:4DMYJGD"R>E.I?>V.(!!2X)%GK0S]LI=9LR:-#28I)<2\]%#W MY_/36J!T4"X7.8Y\*3Q'7D Z4\OE$Z]I$1*2%4[[P UC?033_;0-295UPM4- MDY=:,JQ=$\WP;=G9_*!4&LXI6]VGI)1,)K,6I*\Q.,TL1",+A&)(Y&+,UO7) MD+J#J$$IN6UAIQ&/&F;&?[X@Z0J$LV0!72R *=0R2U$KJF-M"^N"4;H4[_J4 MIMY&T0/OU'\(N#3A3I=2YG>S,2WTKO\0J&G'IQZZ:5S7/LGSD=>281TU%RWB!88UF?[.)<># M1MLG8G$#,0\LL?DA8+(I3]I=:M!BKTTF.,3Y8C9."\SU%SN3?/4'ESXY*@$M M!IM(3X92$Y%)8]IL@;0FD6XLLDZ*:B.R-]?;EQ]\J8N<9BQGKA(8C.29$\/ M>11UZI&7,G&=.LT7NHVB(7D(VT/:]YJ\ ;\:6GV7J3EO@%%*$DID#6Y5(^X9 MV1,Z@+!66*Z,"KR/DW C.8.Z2Q@(;A[#J:9BND[-NGN&#"/[P5BF(!96RS67 M[5F07-^BT'#%A>W5W6$=\H:4F/MTH&K/R9:WFC?9/G5$R7QQU?;)F4D33:PY MHIDDIRW@.-DJG!RCF!.3,O;1=.O3V,IL/IXN)Y5BZN"^B4C5[_)H\1+ M\MHZ$%$S4-D[<(H%D%&BM2667/JD<#Z$RJ'EOO4 VVV&=G,N-G?/+BB\=;K\ M*-8K\R(-)"E]'9.8(=99&2('%T(BU2/Z)!JL3^-S""QVQU@;#G9 V"O\@B?3 MST?3LO@]S'"4M&8A2P6T7B*'(ZDTSPH8@1I-#MSZWF+K&DG/(=+8#S^;\*>W M&7!Q=7QIU3:**)"3+1QJU9$KHJ;/%_#."TETE^C[7(ZM3^/FEO>R/=/X?\@, MG'[Z?+K V3E[]C]]#N/9DG5\%",CU]%XP""1;$)FP-7!I5DRQXWF3,E>LS37 M(G!(H8!."/O>U&[/NO8#%G^;T6:]FOX^&=&!QEB$@)P#J_.R>:WL#.#(\K"* M2\ETK]SVZ[0,*0"P);1LR)"V\X8NUW;6^\I5G=[NQS#[0,M$IXQ*#J$H3FK! M24Z S0%83F2YJE*;Q_7+E;Z3MB$Y^5L"3F.&]9MOMYS>3?_NT@_'B_F(5FFS MSQ&TK]U\I:S%00JK"2-) -K(L(\3?Q]E0RK+W1*(FC*K9277K-YDOL+5O_N3 ML[FDY^3>.)]T5'1$*6@/R&"5I%#KX--H$Q3#BG-$=:_)T8^C]SE<0+;7=MTY MVZY["4E1?$E$+LTXHFK5\B!%IC$9"4FD LJ0GO:U$(23@UUB-BGP/OF)-],S MI-;M6P)1 \8T'&--:YW3ZU]/9Z^FIW%13D_.)R"-")U:>U1>"K2># MO]BH4R[*I3XUUG=1M0Y@[(\%F&9,ZJCAKHW-JHU6OIN:1)X!]XIY#H4M<_ = MJQ76M:6WU@&1NYB[E2$_@MYUH.9^+*AM@;%; .$A)AQ_J>2.1,TO#,Q!ML* MLJ*0'QI,G?9>@HU6,M.MW^F]U*T#,/_#FU ;6(+B7N/,?+"S]>#ZTFPQR);9YD0J]JIR1A7.T,H#1ON90YCK8 M31)"-6,H,3.;^JB7NZA:"R@_6!BZ&9>:X>:7,)Y4U!Y,7HWGGZ>K[H,'915* MXB->K\JY3$OPTF*S@)!MJ@%.A@1GKEB?\//==*V%G: 8>N!9A(2Z#B?LTS[\@82N!;!MS91Y,@.G'2_;M+-] M.YW4C5@6;EUTAU3>%18D"$$>G)*L]NHFHQUM3IG4L'7QVC3(6YK4WO#PM5#P M@\2+FVQP&S9?W/(?+?#S^\\CH24&)LB6: M4VJR!F_)<@]6EBB201/[W%IM=YU;+%NIPP^U28'LV#K/+M!?!%(-(L5 XLK+ MP/MT(WYLV!RK.A_Z M9'Z5P/4:;#[T%D@!F3$!A(:/,9H1)_:S?YK&Y)[_*,? MH ;HZC8&]M&+NN6RI]X"T5FB=I#.A@#!]"S.2 7BV.118L*A'*FSO(@=>EK)WPN1EFTS#4KF><^UYM;"<8^ M ;I?6>="WJYPPB:SC:=]>S)'S5D5FC'>>4%$]OWUQZD()Y6 MU)RU7;&.N1!"@13RLHJ8A"=F!44+\NL-Y^FZ83] *;-^LYW>ZG?0QZ"GX'D$ MG :I@?: 6RU!2=IVKV*!X(QU@9>" M9OM!VSM)_E$3"S8X!P/&S""5QD5Y\DCRZ(/3#J(CU:?H:W#!1E Z<'(>1#;/ M()GM8CD_:FK!P%3$X^ SR)-P^W"BE*RS=<:,=Y(S3 MY&LKR_M1,PT&=E+:P&N0)^>*2W76+OWF-ND^FLQ"TK34Z$ )M! 2+=4$(77V MQ(U.K:V>9+E#ZGS^ Y^L/O#;7MW9N\.]=SO[K_;^X]W>VZ.]HYVWKPZ._[%W MN/O^\'#O[?'.T='>\=$&-67SS>K-'KZU1K=E=<+@87%P;M5E"A4"70!5D M4%,QP!HR94C\"NPUH_1^XIH,3;KZGO-EVZAC43& E_6"701)IIL/M>HS,5IS MM*'/3=#M- TI!-H:.3=.1]J<,VV"+.?CW]Z,4R7D8H$AVYB$+J LQMKU78!+ M,==.AR9ZK('1]1)G;WG!D )YO1C>;(,;C@19KG1_,C^=A4G"D7(.>23?S=>_ ME!8>O'&DV"-*XWVQ1O0: W*5DB$%M'H+@(VXT*Z'W=Z2Q] M#/.:@Q6-3DX0)K54M=;,@F>.0PX*)?=9)].GX\Y=5 TILM,;(\VXTT9-[)Y, M3\]&AHXG'XY.XSS-QI^7>S_)^]48K0[M.B;AQ34Z*I8NK*D\>S.*RM&H:+BT@,3E8[:!S-@$!!3'>2G ME:,____V?O_=K^0OGL?0PJ7P MV4:>\<->T<$[WF"-S3SD6^*2-3$\DHH))7I(0I*-*FM[?$MPX\B,,BPQ)_MT M@[V+J@83\6Y^]B^SY2B)8+-*&L&+PFH'K001R06SD25GDE.T]NVN>4G7L'SC M1IBY80Y>*]:TLY!3.OU4][H6E_\QN8B^/L$S/7MYQ,3M<7XG+7=D#_\"3_)XTRFPW?!XOPLDR MX6'>6+^N\ZJMZ-D'K[FWOJ6O5PU/\:9,DYVR(+OM9FA>0^0H*BNM]KHT97# & M,F]<'I@*_M667[9)"\_67_Y9N]U9TX62J_ M'!R\^FW_S9O=,)M]&T\^_'LX.<5IN5Y=M8%]MOE+FUMJC?>AD8$J60#.(<&0G(ZBF!+Y'UNTN^F:U,Y?\?35^XXRU89 M46JZFN?DY01R<%C-A:Z5LSD9X7.?P7+W438D*Z4A=JX+RJ8,:F8>W$'5)1%] M12;+$MDREIUD+;@2OD 0,8#UF@LR99 V:=M NH7602GRI\%6"RYNLZO[[N'[ MO8L,M(V:M]_XI X]VN^GN)%B^[YM\_FED$Q!8M;F[%(H9ZR#RA"0'E*4,SGJ M/F;XK20UB./6![^<3DXO)> PX0K/B0':&E*V14+PZ, 9D:,L0;I.K=%N)&=( MBJL--FZ(KF[(A;:7TGMT\J??D*3+4J#=L-KH0DDD+B$92[0)FR!Z9< 8C=R4 M6AO<\:+Z7OJ&E$+7!S(=^-0,0T?A!.?51_V:QG,\#E_/VG2?$^6\+TF9"$QK M6VNA%(1ELTO"NPKH1'1]&A3=0]B0$NWZH*8E9]H-RCP;Z$RVS.D?I0P7S4:9 M4MSZ.MTYUXH*7S*X.B$'9> I))O(E.J"EKOI&E+&71^P-.1+PYF]"YSA?'$- MMSRF% 0CW&*I:)4*HI(,O) J*>V9[N1TWTS/D!+M^F"C 1]:YB+4%;Z;30O. MY[0CX>0U7E*!]%K!M8#,,JG ("3X$CB4)!3'9*T278W96^@:4GY=5ZNV!5\: MYUS>NMR4%(M<"3!6V4I3 A>B!5=,B!D52I$[YE^NY^7=C)5MC8?O:,ZVX4L[ MNV0Z6/_/$H?,9^>X+2\PKA)1N\ZCVT> MKWOP6AH%[]Y,)Q^.4@PWI5:#.* M [I&6L,9Z%88?JH_LM4 M;"J&+C_K[722SB%L$Q*/(PCG:VF<(U,K.4;J,V>EK)/)]RE#NIF>(07I'HV! MZQ*EP=8WTT:7:3D78R2JK%-9 &-&@$*29#!IN-<2%A4KQ/\*FE M!JG/V)_/3VN2T++>C?B"!V5WAGF\V)G-ZKSKFDJTO!_U* R7J78O+!*4U^2] M8XJ@"RING E6]5GQ0ZA\H+;I>^'\:,!VD(-K&'G4DES=( 4C<\4Y MK3%X$?N$M-8_E9OIZ#_V^A _AV]+ 7E0WLW&DS3^'$[V)_^)879,2\,1.D$+ MU@ZLE[69!%HR!6N?$2=)=!:,A?614(^C=T@^53.,W65B=V)E%Q_L7EK?TND^ M_AU/ON"OTPG)C1%/W JK I@Z2%0EVJJHHP5:1Y3!:IE2GY9:&Y$]) 4Z#!!N MQ-BGP6(]-Z^GI[-1$#E+)@NXU60S3<=&&3I 029D-O(L!X#!SXEUE?(11IMM\@5RP>7$\5+3D02(P*,Q@@[*]1&@ MVX??C90/*=MC"$CE4QSP6[ZW3J/JT M'7@,M4-*)QD"^!['QNWYNL>'.V^/=G:/]P_>'NZ]V3G>>[5[<+11N]I[GMC< MHWW("C9T8F^;3;'L;CP?UR_/TEMW)OD5%IS-,!\4^I=PM^K>E;*)$FL(/BI? M&TM$\"%HB#P$ETW(43UZ1LGZ9&S41.[=:3P9I]JR+$R^'6+(9W34Y1D>F)(Q:I\"UUN;Q' +C4-P(I\(7IT9NCVM=K3W2VT1L__V M]<'AKSM5-6R@T&Y_6'-=MB;=C6*Q^Q-Z,;Z9SN>O"7DU)6D\.24 G4U,(LI& MQ@6A6.! ^R% "87@LJLI3Y'KI(56-G9*5KZ/MLW3L^L;CL/7LU:-+W&"9;P8 M*9,TSW1P?*J7';F0WVJE X%)AYA3R*)/HL(M! WJ_K Q9+Y/U=Z<)PTO$.]O M'C;*/A5GDP34JY[/M0I%:"!MFU4T2B31ZR+Q?NH&5>O<&3K-N=6NQ.QCF.'+ M,,=EFU^"]8H6I83F*DH0+M1)C$& CP1L(H.EH*PWNH]HO9F>!\8OGS56&G"D M>970:LEG'18[7( M.43%')"2E"QGGG1.]YF\CWKS T-_SU*"]&=)MZ&[#_ =E4>%)D2PI79?-0DA M).&@,&4Q169COM=K:AVDNK?J[/GB:7O,:@.N53W_2BC.=W<.]XYV$HG&%'0J M-D'=!P)Y<;1\:R!(590IVH6TWJB(&Q__P+*RYPN&S3=WBQ)DB]D+3"(UE4T!K*A2.BQ&+!>MT0;33O1\=W['U@Y]GQAL@7V;-%^(8^_-FV^ MO>ECL2'&J#/DY&L17-;@G+.02)=M"3\1[]H63U?\ M+SN(+,%_,0A^Y$3"XE*!)%4"Q44 )PU]FQ@)6N,$UWU:,-Q%U5IQ/O;,95=S M]K014A?#N8X6^/G]YY$OGG,K#*1HR&!W(4 (2H,7R(L(.8OHUA(WUQZ\%H^? M>S!WXQUM)@16K8,(8LM>0DM!-2(]QX5-%JRL-Z2UEL$[0[Z8(TD4,[/*]#PHP1H-V7&]FX/:^_BO:,:&IQ.:CK/M"S;59_)J0UN$M=[L MIT6BS.56WU74CS@&$N"*T)-"[2G.+#@D0P S8]K)P-#'M:3J]2F&5DWBL52^DSEO8.HP62W=(/( M)ES8MHYY?;HXG>&OX\GXT^FG)?7OSE)(-]8R]S^ZDYYYX)K:=?B_0,!%"YV+ M%Y_B2*-T$DN&R*I3(6P&5U@!R:1&@I8JG=H>W4=92PETT_//\X^%9UP['<&P M3.< 5;VZ*@PD)IUS3&AXMQ[MZQ X!.75!4UW":M6#.NBS[XC[N9*"A^2-C9G M6KSAM8@[0C J@U(691$L)]LGI_/AM Y!^ST]QC9G8YNHRXU$'D]?DL(8Y^6P MHHL2,NM<$BE%.@9$H9)9D)67$J!45CKR$O%Z&^8U7(>[WSFD@KXN6.G)@^W( MHS-AN:1.2B.Y*@)X[>ZK3"@$WRA!>EW#B4*ZW&=HW[H4#BE]YLGUVX-9MC5 M?5_890]LXQX M#%%+1D:*"!"QV'KW'(/EEC/?Q\V_A: A>;5=T//=S6X#QFSGO+R?9/)^:C$X MUB$C]-&STO"8(KG>(4&P(9!=4J\I$U<@-=>A".^"ZI.9_RARA^33;@5A_9DZ MN##PX]JAKO_PIPH%=VJ+>J^)P(-6AN0.L)SKV.UE&XC 0,@0O/$Z<_TT-GT7 MH_/6,X&:!8Q"0C)8'3"-X(VQ@$+0(C)^%>GV["PXGHGK*M)AMCF%U*=D]D9RAJ00MX^7!S%C^XY)#B7) MR 6$(&LOL&PABA* U*_GB&0).O.L'9.UWG-S!#[)G'FT%G0*"LB9U!",,,#) M/+*1,>>PCU9Z/,U#DLU=,/@@X[,=>[=^,+^+F=7K'I><)\'D)*BH#6V7<_1M MXMD$=*S3>*G'4CPDL3\<*&[*VJT#\8\(6W(Y&TVG1/"HZZ43!Q^\!$.;$KA5 MROE.?>\>2NJ0K@H'!;W',?-I,/?[=)25\$:0U22,6MX.()!DYF Y'@Q-8#V;EML/32^I?AI,:;-@\,?G&IW4*0-]/>8M"EYLJ$T8\1L.0&&J7 M$D3E!-$@ ^3&&ZS=IL1Z/31N>GK'@I=1$:KPP!&R)JFGG%'@M25++;(0_#SS:<:.5F7LEUEPTV=DI6A R9E!6DIT=6092CR4KU#7# M;WTA=TL$OUERR*6QJ$[JC#PP*':9$28RQ.S)53!6^!C1&M\GY>I>TH8EZA[' MZC5S0A[)C[Z76>>C4X/B68500#-ER"#S#+SG'JS/C%?CSZ0M7A$/:'!M:W T MXT)?7%P&*]&!J3!@(O#:9!W!11U! ""2 0 %0 &-N=GDM,C R M,C S,S%?9&5F+GAM;.R]VW9;.9(F?#]/D7_.[1^=.!]Z3(#T!$(!#Q/_[7 M7Q?G/WW%T;@_'/SM9_YO[.>?<)"&N3_X]+>?__CX*[B?_]?__&__[7_\?P#_ M^]6'MS^]&:;+"QQ,?GH]PC#!_-.?_/'3/X>C?_6_!H#_ M.?U'KX=?OHWZGSY/?A),B,6_COX].'0A* <2G05EC0-?7(&2<]+T1RZ#^_\_ M_;MB7CHK!2#+ 13C!8(N"M#G$J*S7@4_?>AY?_"O?Z]?8ACC3S2XP7CZX]]^ M_CR9?/GW7W[Y\\\__^VO.#K_M^'HTR^",?G+_-,_SS[^UYW/_RFGG^;>^U^F M?[W^Z+A_WP?IL?R7__W[V[/T&2\"] ?C21BD[R^@U^?)]3^\B4;_DGZD\P_QC47P$7(/F__37./__/__;33U>2"Z,T M&I[C!RP_S;[]X\/)7:3]P>27W+_X9?:97\+Y.2&>/F'R[0O^[>=Q_^++.!%QU"746\^]@7,.?Q\/SRSK#Q_3;BU^F6%^?OGMS_.[L^ U]OO MQ^\^GIW^>OK^^,/1QQ/ZZ]$[^M#O[S\<_T;_X.0?QR?OZ,?CMZ=G9X^/,0V^ M?H.Z,C-YM1;\]VY>?$,(Q+;^H%^']Y9^G+V]CG''XL"_)CC(F'_^J9__]G-? MH](N2NNSB@JS"]('E,'GK"Q34O:Z@5#E,I?,^3#=0G1>%_KA-3//0\3SZ6][ MEV/X%,*7WMF$]MRZ_9(H\82^'?>B8,XEE8&A5:!H/X2 VM*7E#"ZS&*\A]?C M^3PI81RGS)Z]@A@N^"]X/AG/?U/IP8'QV6;QWY=CN=+ZTT?W ;_BX!+'1W$\ M&84TZ0F;?4S>0\BF@%("(:(T(*0Q,J,6PO,F8UM$##L4[97^: __S0<91S][6?6D:I_I7&_'@ZFD/Y)AN3KR_%D>(&C MX[_2^66U08_&8Z3_Y(_AKYZ42TH459 %X)F=3&2Q$8OIBDY$Q&6L8*\W(LAGV[=.J M&Q[<0ZXM*K$!#<_PG/[TZ>\XP%$XK^#R!>FBRF;2_XHS:?6X+(',[@2)TQ?% M P/( J ,A1U=BO\L(^51&5(>\]^IR3!OU>/QZ>!'[@RMX MZ;\N^^.ID#_@>8V\$N W6' TPGQ:Z'^)Y5,A];).KG ;03NTH!)]<2I%R,X* M+C6RY!;LY+M1@,UA/'.*;%D/=QFD-EU33K]@7>,&G^;RZ-DHK;1<@V7%D,U' M(HA9TDJ'S)NH,"@FFJPD=Z \=Z?QDD,A1>SL<$Z3@2RI$0R6R M!%5" N]H?S->)$LT]#&[MEK_#N;9NSZ;"KB![7 Z^8RC*SCW\3N0KY^9\GO:;TKXHO($[X8#T,^E9(55R M(4+0@L15"%%0*A)QBF&=EF];D%X]GK^NE"O:MALZF&C\-H0 O.^#V.SCZ'$;X* MXWZJT97^^66-L\RWZNBBFAYL%BYI(=*10_3!0I'DKJ.*O@C91/L(TN0,2LH$9-UIR#X[ZRJ3;9NLD26 ML^')@I\A"1/ MD7X#)^C>H?=BM;_1D^TBG ,E5(!0?!VR\\%)BR7&[2T9/P8AUI=\J^#8Z^'% MEQ%^KNFD7V>F[Z]D!/<_#5Y?CD8X2-\^CL)@3 *X.@>:_G1^%>[/_^=R/*E+ M*VV5IX6LHO?UC(C^,)F,^O%R$N(Y?AR^I_$.R$22+#D2&/#D$W$_T=X9I ?4 M)03') ^AC9^]U6$^^_UM?TEQ=P:XS9-B[HQSCIK6:NL,V7DT&RVMU?)Z-+_/[+ MX6""?TV.SZ5X\01E#CL4 M:H<6\0T\-S+IQF^FB^)*H'H+EY"ZTOA=.%TN^LNN4'U7>C>:NJOVCL2\-0XP M[5 JGB"A-J!R]! Q9'"22:,Q"R-7WKJ/M1/7K2+=)%NH4S>]3XZ?' M&$8R-Q$$^5UD>&0D'"X#.71"6%]2R&UB9K=@;,^VZU U=Q)*GRK7!M=H9D.< M@?&:2Z9CA"RLH&&I>MH8ZZX5(M?)H"EM,HIOP3@$)3]=KDMG\O_X94$>9(7^ M:SM71<]^._IP_-OIVS?''\Z._^./DX__>1MM1Q=#[WG-UJ^!/C;4Q4N?VBI6 M)".#3BA,/%B?# _"$4%*%/GQ2Y_WO+#S*YY&"4=D9N0KQGJS2DGPSB!P6^J- M+A48;W/8U?T53_*'1QC&^ :O_O=D<#89IG]]'I[37!D?_]=E?_+MP_#\_-?A MZ,\PRKTB16+.,]"U*(2RB8//) F63#9,1N<:Q?+7!+H748MU>'+/J6\SQ338 M^*81YO'IY:16UJ@7@WI)2S0Q>?#1T^!-K*D\R8+VQIC A(G6MIDDBU"VSX6F MRENT?S:2? M#]\Y0>P5]C$8D*!8=*(8"7#8!A(]HZL9O?9LK,W>Q'#@9-I-] M@P.?[['Y\-$CXWNZ95M!%<.L4C;/4:(D.$&MRJ\N,V%M"T75GG6'91&\X;7:>=0SAL6CU- MTLT31ID3GB%!,$E$4)ES"-'D::37,YO(=&V3 ;3CA-%MJO[I$F^037K73_$I MQ1)SJJ?ME93.@_,!P?* 3B8R3V6C2ED/>XB=N#S!E!RT%F!DJ7>/D-PQ4R^> M.JF3K,>9J';B\FRU)'L-:ZE[&G(W%WB+-]S:FV9'/*J#626I8/]WW/EC;36YHH+[%1-_.9+\U M8HC,?!3) @9)%HC.M)8:(:&(Z$SVF)5HLSMND1!+,AYVQ8=U1-ZD%MS%Q?#* MUIV=XEKI/=FS"J*ON9>%]E-7:FDP;HHOR>?4*-OQ#I0=Y/]OKJ*[6:X;R+?! MB="2F-X,7#:%&3+PP,)S%3"JNG0Y*"^.#3\YF7/ M!6TBZ0"<<*(&<2V$I -HI5F.G,21VFQF*X#;0>F_C5GQ@/';B0Y:)$C="NZ($R[/GVHIWF<7',AO/(%DH^%MEGK(3):S;T,SG 2DF]V M&6P]I(= H*;::>M-7QUF'%U./@]'_?^+F>2 (:DB(61&FS\M^1 4V6R!9Y6X MCMJG-L"-IH*=S-AP- MAWIO#E3A J)6!62T-MA0G!&-SF_60'D(A&FFE0;I2C>POA]=)57-MLTDT#C. M@%O':Q<11QR/";AC0ODDM,QMNG4L0W1@S'BZM!MDY=S 13O>N)]G5>H^8,+^ M5\RGMRG+LM/)$D13PJBM6]TAVT=F ?&EX[UTF&>S[1"^\TU M#R?O1\.$F,<]:0SF6HVY<(R@7 D0$1G$R(.S(D>3%]JX+"F!?__SG[..NQ); M@Y2=]Z-9'?W[C9X8HM:UGI0,TP*47($WY%O1@Z1'*Y5);8)O#^-ZSF1H(/D& MA=YNHUOJ<:,OPD4CP4[7H4S.MM.$EX C,SDS#&T.>5?#=W@\Z403#4H>U;;+ M^?)ZA7OU;2J(JXR88(KFP5O:G6I;ER0CK6XY0=D 9=R&E2-CJ(27.(/,DDO=:)->K6 MM0S2SE+,NM+Y(I,'YG!V"K(&R:>/8XQAUEH76CU 9)4CPPSYT#8R*KE7$9!(P),EE>$KG0:O%*VI)H MQ?W//QAE=B7##B?O'-(5EMITXYA6JMH(9OJ;V1'?G'K!B6PU(9.*W.@D-'AT M"GC..$QA53VO\L*#4WSG4FYQ-C;/L[[I;4VW+QE2!_GKP^>O?QZ/7KTS_>?3QY]_?WIV]/7I\< MG[V^'$^&%_4^Q"#1,GAUVKY!%GD';^TZQ;QK02SDG[NL8SVFYH%X$ (+&'2T M6F:4Y%>(TNO@_9OF4-YXY(?^^,813.&UP9I5-"%2J>52:&KP*$$')XU7RCG3 M9LE8CFGS"S1?<7")\S:4M;O0/_N3SW/Y'O^5SB]K*8RC\1CI/[EVQY YV.@< M!R]Y+124R0EP3("029J458BV3?N<)X#=10?[3OAS]_Y-6T4UV'SO2.(]N9[T MB_ )>0_)ZV?($Y@L0FVQ4L#;8&LB2\HAIBQTJ[L/RU$=#%LZ$WV;RY[#R\%D M?)6E5H,)[W!R5<9LTD/T6EHR-RH[:U2(L)FL@6,64J"QK%'%NH=0'0PM.A-] MB]C+XI"OXDPZ)NYK5V[M72U(1ZBBX0+0D67J/;=&MR'$_7BVE@.RI75A?2'O M2P[(G:&\^O8*!^GS11C-8A(Q^*3(XP@QY-K4/4Y["H#3CAPS MN.B51_"ECM053;ZXRQ +V=4^9HVFS?7;98@.C V="'XKF\BWC_1/IPLBM]9R M:22Y6-,%49,E'P.#XAFS+'"A6U6\6 [JL(W3)XE^*\XN_9O[^8\ MVP.KXZE*7"1'AQKHT!"MS39_#_]G.)KCNRH<:V4T/@<% ID#A<;1-"CUTE_D MPICLC5FI;-!*/83OOO\ K(H.!-MA@8Z*YBIU]Q:F>3OK%4!UWC5\*9SM=PW? M5$_#5D+N<"=X&)R*Q0FK&-#N%T$I79MH) M69&:2XR:ZE9*8]U'S#_0,WXKB MUY%MU]F))YEA>S;#0VZ3T(H)TF8&*(D$41$D3E#2AN$"&QUI*>W5@2GN* MH/8V:;!6S#V]K"V%?AN>YQCJI?X0^^>$I<8OZ1V)?MA.*N$3L.PFP7!3H2VD M'4;,B2>5C47_PZ548]\=_#(9QC*-I[/-D\.5R= %[99- MBIUQIFNWZZDC6C*@]^';M,5USYEHN'<2;*A]5YB.$&VQ$,@^4>@<%JM6\@0: M 7QA]IZ1H,%99,?#^CMIN3:6/1G4&PFUGO&\94@/A50^*81LBP3%4XV&T]X4K1445\^0,M/@LHJT4$@M$WT; M6)M3O"V823MUU>8U+(1/QA%)!'*NW$@[9_5J? M$OMR$^):"*^^77_[6Q]'A.SSM[?X%<^G!R$J<6]HD83,L-1#3TOK.*V5VA>K M>6&&89O.,:OAV]41\6XIM(S/W:FR0?+)?;O#^"[>^6G "F";YK.M!7QY3 J%"[(Q<%T84(.4?)L[$V\#;YM'O L$=2Y/:/8&OH MJB6QKJS8J03D[-116>V,("V3XU/S!+($G\@]1Z>D)@:8XAJ;A7=![="Q[%Z= MRXBSH2Y:1K]??;OV9:8UEH@A0>Z+^U1F*M>A5L!JVR2$SZ[!LU(WX0 MUHLAU:GB6D;<-I?4XO!FTW&5 6['YFHUQ)W;:9O2JITGVR$G6NZ\S0;*, ;/ M H)PM71MB1%\M 5T\CEA*4[Q-@UFGBGI5S<=GQWGUZ%"UV>&LV2A6V.;VC2F M%!4"6=6<:P;*U)9L21O(W$3-D6G%5COT6_:&9WT*T84FAUVKH>N,T'O2Q^9U M$H-WC*&$9&K-KL1"K:0J:C14*YU5MHMW0I>08^DK7MC1N2)VD'OZX?@?Q^_^ M./[UP^GOKT_???QP]/KCV3]//O[V^H^SCZ>_'W\X>Q=&]=K+5]P@J73]EW2= M+;KA,!?20%F4J: L04BOA' ^1JV,T)BL$\ZPWOJOV\P8>M,?AT^?1OAI2N[3 M,BMG\/UP1'KRG5D@'Z@844OX.8C9%P@2;6W\:BUO$XMX#-G&E7EGK8\_X)?A M:%)G^]G5:KL1?H. RU/*7 9:P6W,$;*U=:6F13HH@JPM5]*D(D1J,T>>13W2ID1JK:X& M_N?]*&L=_?<$T(1KW+^@CI^6,?CLN M5WUSZ!_TAYGW!(\^68]D* 9';D64X$36(#-SM0*Z#8O>7;>KT<8C.##*[42Q M#3+,[EM?KWVAZT&FX:?!M!KV5Q3 M=]7>D9BWQH&4HJ\IWY #;6Q*8KFZZ"=TR$%*YG+NKD+5EG7_0,6:+:E^'>EV M?1#Z)DS"T2"$UDJ(%,M$5(8@J]CM25[6;O6*+=:W9I['K[= M,B@=R7S8H<#:Q66?[D6?3<)H0@.[(K@KQ1F9.03MR0R*+H'':LI&Y$)88]"W MN=C4[3@.QES8 S4WB.G- 4Z[6Y=ZX/'WX3#?7FI-<)$Q9D#&NM1ZR0BB\*"E MX\$[JXMLRT?8J68!HM0>R*Z/SAFO6J++4P[BV'Y)M MH,Q%NG2GB:76^1XEB_46*NDT2A?KS=/D[AGXMA+&%H>ZD#)F$0VYW45C9"HY M&6W0G#D1M6&8K5\_98Q>^)(T]K21OR2-O22-O22-/7!7I+&7I+&7I+&7I+&7I+&7I+&7I+&7I+&7I+& M7I+&]B%I["7_9D\V]NWEW[3.V7K)OWG)O^F>3B_Y-WO*HI?\FY?\FQ\A_^;V MCC\LHZL=OV7IID=>N?6\G'5$L)"CDYVQGKNL%%IE97!&&Y,B,T$4C"D]GJ/S MR,L;Y^N@2DHQIZ#4OA?*Z=KC+ N:]<]'.:JC2=/:@H M<^V&E6E3\9$V%6%9+ 9YHS.HPTC,6(=+721FK*.N!B[F@ZZ2-8*6!:X(C*P5 M'A/)PBL/:#(RZ600>:7(\&&>*FS"E,[$ONM3A?F SB9A,GWBJ\LQ26@\GN>V MS8KW'P30-0-R"LYM 0X?J6B3"QK)N3@#,@AP,JR"B#*"LR+5K&0*34:>@N3:Z M3=K?%A3_2&A@6WI?1\1='S]\Q/1Y,#P??OIV/*CK6CZ;NS0SCY,+E[(4"$6: M6!N39'"(%@QWQ2>G='%EI;.(Q]ZT?1MS RT,6XFPZP+<1_EK?SP8I)U(N(.CX<>/C1=!=0/EPJREJ96R@=X MBIBWE@J"-AJ7T>Z#6SO M&;#YML,5TQHCN"A=111HVT$&P2H,5DME)3:QO6_!V)>,D;54,^Q*K@UB>;]- MSPY>A]'\5,=[ED/1 72N!B)9%#6V:"&Z;)V)UI,%V43/BT@.0=4;2;=K]^HU M>0&T2?0'G^:^@"V&HZLM>$1M]N@0@D,.,=)RI:+-:3'"ML3P7GSRLZ*[U+6'=XJ M6YIGF(((G.M2KV$*()_0@..B\E(SG:+7-JW6T6R/$S.?/($W%=C2.USM\A6. M7O_''R=G)Q]/3M]UTD?JP>=UG6FP.OC%-(*0P\^>;-5=1Y*/4K_==D?ST4P.ZG3G%D=A 3ALP65$@,O9=VX:>$G4TU9TR;/ MZ"%4&Y_<8IR<#,:3T64-4'W +Y>C]#F,\>AB>#F8]'RAC:Q@ F5*_4+[G:]A MPIA$O<:FHY)MXNL/X]I^!*\S9MPYP^U. 5U'9]_/H7P:(5ZANXIGD:;'GX?G MN6>+E(YI!VAKV]%ZSX%630G!YTR6K.6XF"6R9,=Y]%4'H/$&,FW@X]_FXZ\A MS9FH,LN\1 E)!,*5=;WZS#UMQ-9(U"SGT&;Y6X;H "C1J=!;M$BO(L6WM+_F MD\$D##[UXSG6O*/)'V,LE^=O^P5[DGM31"F0D9$9C(R<5^4S>*U2(*-8>]4F M/K *N@,B2>?*:%#IXI[!C\F8_[7>@Y^M=#W!R&"7,8,MO) ,= 2/-6O-)192 MC-S9-B[J"N .B"Y=JZ)!$8N'(+Y#6A')F\"WP_&8UL%DO:9-D1MO:Y2,:)TP M@F52JZ(SYZQ-K'EEB#\(919$6]4_:#FOK8+F#M2[<#&_>+4*KJ;) MJLN0[29O=5/-/4B$#<6^55J@TS0!R,$GZYSPH:O7-PUHSH7(/!0?VKA/VZ7# M(]FL6V/#&M+N^KCU3NQG?@R1M8DFT_ L(KGVND!(IH!1V26IR,^W"\475HVB M[2K?L1OQ/Q@W>X+L.L]>K1H@:W@T!13./^+HXNTP7&?6FJBUR"8#^D#[FL\, M8JX%4I-(GCL7\^*!P;(TUH=?= CZ[5*6#5;O>RR9Z1KE/0W6:@8IU=9** I$ MY0(DEPQ3)AB=VBS>2P#]$#9?%\IH$"R]#U;]EA:LV>Q8!6!3"_!1B+LQ!3M1 MZ HDV5P;6UI:;@-EOI;O+QE$0@:*BPB.\4)*9LJ&:$U,_)#H\HBIN!NVK*.$ MSJNP_7[VV_"\WOD>TQ8YVQ'1*:50"_@_P]'K\S"^NLNGHX]D225 46/SUC@(# ,( MEWPVOBBV>!VJ^0';'9 _A.'12FD-#N(>@/H=Z W#?16X34V3-0'OQE!I1H#5 MB=:9]AJ8,NO")@^=-NVB:"[2-%2!1XBH!4@KDK9!%\7+X9+M$3-G7[FVCM+: M%(/+6.%<1P:8LS':!-Y(#RK)>EV&OBM2UD1AG0NVJ0JRB&3[-E-3U=TM_?9T MN3#4&5%>WQB9"F2Y0].Q@!.).9-\$&4-FTO M'@!UV.SH2AM+%XSM9-E?22<,\KSQ2Q_',R\D=Y1XO\HK6N;BKSW$Q?3\Q%,M M516L\TIKVF%D\LJ'E%@,VJO>NB]KF+&?62PY) :B. 6J1 '>IPB9UBA?@HO1 MM^EGTC)C?_[LU\.+V!],9]OWMD0G&0>3?NF'ZZD^%_?1;26,QY<7],NKC\3Q MM,I<+V R7' '3-HZ4RT'+ZT!)#=)*IF#EVWLL79CVHM QM,8N2Q&M6/%-]C+ MNQS9ZS#^3'\XIH]\#>?3OJBYD)R+8^"RJ7?5)V\T\NPY^K^LN 83O08E1*H!,4.N9#1. M8>9JM>Y-NYTB2T;W,E'VE4H-3V&[&.,)6=4#>MVWGE"V!$T"MS;14)(OX"/S M8+DKQ7%KBF][SM_I<%XFQ-Z0I>$=G,YG^?L1?@G]7!ON#L9(GS^=?,;1U=]Z M$M$94ULDV1A!*2TA,N6@I""C+BP;_@R,K%6'^S*#G@W9&MY;ZF+0[T?#+SB: M?'M_'FCH5Y;GEYH#UV.!K,Q<&,1: DK5_NJQ. U)9V21Z9!CFZL$6QG>RPS: M6S)U>%-KFG_1Y0A/:7RAEF%ZBV&,'_J?/D].RQ_CJW_:LRDZ6P4?8ZBN6L[@ M@Y/ A2\Y&LQ!L)5R8K8&^8>?!GO,D+OSP.S3SC';"T-!4:$#8*&P4B)D M71N1U8H9SNE(]F%M1692'?+>SXE'A_DR7?:>7'=GDML;4^KV1TX&L[92U^-4 MNF8$T&*1E<#:MEB"U[Y +;.76!2049*]F'G-<@H(*<5:C=G5\I%[OY/<,["7<_$F%'@>YW^WLG%2+30V M?A^^3=/CH^(\9YM ^'K)0D4.@:8Q:&=53"6KU*BATE:'^;RWB8U)VCZ&VQ'# MNKY(U>G&F-+H\I8R>C8PX7@14$QMK-121$B8^!J@R_%HX:8G:ZMWCAM;-)RMO^'=O>/ M[67*[#&7.CSEWM:B\&XXF*\+SB9&NV$&J4J]C"T41,$32(9H2K28Q&H5D+8* M^V5"/ .Z-"@[VD@+/65"D(J<(JP5OY7! )[+#%P[E9ATRC6^KM+Q@%[FQ[ZQ M9L]/M-_AI!=\$BX6#UJF JJ$# %I@M/ODE)*8-1L[R?!NUTF=NQU@'5=%3?( M$+\^NI#6Y1(-@O.!MA'E#7BM/?VH$&,H2K(V=55V?UK5.4>>)-3MN'BU=5\_ M3VV*X>#C* S&5]8V[R59S]%X :X<$3$&#SX["\'J'*>.(RHVWD&!UDQ=$-#(]62MMJK\C[RXVM O>E MXF@S FQ8!?(IVMN#BJ.">T27(\3"&:AL&7@7:SS?Q(0R,J_:1)?W@FP=5AS= M)M?64=HV*HZ2T1=5*1:RD*+>I:TI[Q(A:1V-E::@;'-.]_PJCJZENL"88F<7",H6.>61H11&:2YM-L;V5W]*PJJ@F M+%EQ 2(48JVGM<@SEL&PJ$D1A;G8]DI0BZJB[\.W&K4>?QS.?.#YRW#\]U%M M]>1>""]--DU(\AVXO P=/8L;BF=:J$[=3II,E7 M4[4(]:UI>)VUUJDMH2.>R7M,I-:V/)?)HU]LO AAJQYDPV?JV=VN?Z]']6B18\>A^'67LY QV%8 O1_=/5.C:A[%/ MT<9NCNZ9\L6%""Y7(RY*#BX$/3H?AWQ+?6[VP44WW\X?7_\X>-_ M'KU[<_P??YR\__WXW<=Y*=!PHPKH!G'%=5_1=7AQHR$N1!EKYJD01 =#2HPE M>I^M4BIK+D2QN?36?=F&H;=E15N_F]Q!.:=]00A&5?YE(G+F'LCL-M.VQ\:U MJ?'X.+:- X_+WO#'&,OE^=M^(?O/*%F'2K,WJ5H(*Y$K:1)DD42PW"2.;7)> M5P"W_<6O8[[<"4)VK) &<.EN;G&2JQ\Z*>5 E%_!&N'H S='8J(OF3>C4U0@.CG@[46V#0.528/66 MI"LZ%%<*Z%#3185S-(Z@A?T M(T.;1"P%?6B4C;0K CT2Y]X'_JRCE :\^3VDS[3-C[[=A#<+X":FF- NTF*; M#2A.1EQPB:S]Z35T[J7 -A>:'@"U1[;T4Y4X;*.!!B&C:2VQS\/S?'+Q933\ M.C6=YNG".IDB%/E^3A4R\UD=L@P.9&22.\8PVC;)VP^ .CQR=*6!%K>(+D]#&'RZLJ<\3RHXY,!#X:!2D;1J>0L\9RVU\HX&NPH%Z*DW MU$\_+:K^UFL/TL]]NF [G/37(&8D6P7&.M[JZGKN?D(_[HENH()%)6X@OPYW M]T4X-F7.(F;@7@7:2FI;;BX3I&BEPNPS%_;YJ'&)/]B]%M<16\?:^YTD=7%Y M,0,2I>+<.@^\=EM3AB<(E@83B_=%"\&QK%2N<27]W7KU]G;6C80_[$)R'?I> M4R#AKQM LC'!H&.@19"@4!<"(AF80"/C&*)(*R4GKJ;"FZ]^ABI\LN1V<*7U MOHRIJXN_O^%Y_F- *%Z'+_U).)^Z@>..,]%6>=4V,M+6'O)"9IIDFKQ=H17+ M61E5@M?UOHP("3/7+MR;F;;*2YMGJ/DDC9%*0@G9@=)8??E ICE#R6*4EIDM MGPR];9ZA-O56!V&0\+Y6TZ^P#,FCO3]582%#H2=,SCD)"R&FVA2+!.FFP3+K M7,(45<0MQ[.[&]P>^:5/X^O*L? =$6*;&78/#W'5P7GN4DP%F&6TF=6ZKTX8 M#LD&Y1G2>B?:7(1J.JP7GCB'XG?!728&"((,6U:$GA)HI6MU;I.9 M:I-X^ RSR3:A7!.%/*=LLF1S1!\9.*=KH-@'F@LE@*F-=$(*VJ4V_3<.(9ML M+5(\(9ML'>7L* EH%8@OV62=*/@)V4!/T4\. X"Q 1 MM4=/IFBCP@S/.9NL-7_64C=W\_>?7V^.CL[/CCV=&[-W\_/7WSSY.W M;]^%4:V8]!4W"(&O\_BNP]Y/'MIBJ#N1TH2+9$$+I6-QBI'AHFPN//*@=&^= M%S4K(OW=TI4TS[!M]].AB>%GO24976W))R-P* M4#QY\%QYT([)'%@FY[=-LMO3,1\@D;:DP!9WL6_$P4[+HG1Z)01M@W#UL*.6 M-:W%Y'WAD")!CKJ@Y8UN6#^(ZP IU*$BFH8H'Q#$+/R1O"O>U.*DVH!"E0)5F'JR4#;1"D? SCML*4S4G32"W[$JH\FX3)](GSJE)G5\^]:G3! M8BS:92AIL9C,L,P]W M%3!-@Y"WX.PFW-BANA:)L+&LFQ- :,DE>>> N38!S#Y"Q!!JHFT6D7Q9M&V* M4VU!\8^$";>E]W5$W'4YQ:/\M3\>CKZ=X>AK/UW?2PI:.<]D EU#[\].UX4'>F M?#:/:LW J9@*]\1,K&:1LJ7:OTI %$HD:4HQZ%?2Y6-O>K9:[52$+2YPKM&Y MS)#S*Z7.X(6QH(*A[QAJ*#QDGVEIL>ELV->]:J:N!2[IN2ZM5X+YT MM6Q&@ T[#3Y%>]M=SNZ%[:1SV14-1G!1C]IJVC"96RS;DI.U-%57NMGV/,G6 M85?+;7)M':5U;=1.6RL.:FO%>]OH'0WR]QU_ML-+SGQ A< 84Z DU^ +"V!= M,5I[&[T-JQE):[][K^*PF^MRN#U%-#A%6GXG/]B MO56&JV@*B%B;:&3-P$O+:Z-!@][PS%BC>P7;4?MCP=*F6E]'N U"I/5^3*Z) M@$?Y@H0YGEQU!;PV6:)"# HL^FI6.S*K:_L4X877M.#EN-@Q=WFP],$W[2# MMIDFAJW$V'40]>SRRY>K<]=P_@H')%FB\7T@4?F@;(TQ2NVNKO4%:PLPG05' MYI!GO9*N5WWCL]9Y$[%V/;^GJ46OPACST2"^XEEKMQO!=1C5G*+Z;9K:>W811G-_ ;$4QF,&@S5+ M6Q@-3D@-VEI?R!#-=C&];XD:[SSZ6:MO,T$U*SM'GH UW!K VI%,J63!B[HH M"%N3J+TQ:J5DS.=6=JZ)\_1TT=[5K^JJ4MDJ, ZU\-Q:*EA2LNPI\FM8>,XD M6VJ"-RAI(^W=.4'T1@+RDE-$IE"LE-ZZ'VI$YKE6)2MG:]85<)Y2U MT1,7D*-+ 9D.WG57JG5/"L\]685/EMP."L\]<$ML?@5B:H4/[R2[M[E_M^)+ MMW@K[REB6+RKA\:Z+')@B:M@,1HA(G(O7!)2.//07;T57[^%&WRL7F#@ H%C M(2:GC! 0&4B5BE&T3)G%$\QG=(/O@7=<=6-$[:.;'C(5&KAR*D*,"<$$+)&C M\\6V.9U[#-E>'=(]C2UKI *LKXP&9[@/X+M1R^A6\2(=9%$F)3!&UMO^9-IY MVAG ..'():Z'SVVN:*V/]<Y+NG@S FR8POL4[>T!Z103*CJC(3I'L)&S>AG+0TDE2$F& M8<&MNX+/,EU\FUQ;1VD-.#9-5*YPYB?8D0"9$$/MXNBOS(M8+(=B$C.>2<]< MFVC*(I*]LMDW5]VP0[DW"!W[C6TU0:<40N/ 1T$K0PHR1PMA)'&KSAJXKAGH0UUGO%U MDTWHTHTFEF9%M3LB?/WA^,W)QU^/7I^\/?GXGUW4WWSDB5T?[JTS@(63.R6R MLU(FBYHI[VU$QYQFJ$WD)071>^39&S;=[@_PM+P>8>Y/?@VI?]Z??/L>H!*" M*Q36@S U0)6M!I=J GQ6%D5P&AMU@7D0UJ8+UAN,DY/!>#*ZK#.$'H^S$GP< MK;2<)>#),%I(:36-FMP&(XO32J%BC0[@EB':_G+5'1\6%Z=.I-[ 7+YOQ+/\ MBE?#T6CX9W_PZ77X0G^9?.LE(T1*VH%DBK!RQ2$DIZ$XKYPL6D71AB'KH#PD MUC333@-[^C;#/^+HHJ(!7I$HB'1M)(C4.B9?* T29ILF'( M&S5160[JD-C0E>P;W+"]7\TJ1LA1D M!$;3IB;(0Z@.B1B=2;_#BP33:RMW>'H3Z7L<]8>Y5YSD'KT FP(-W$^;=]3^ M"2Q(4:16MJQV2V^%EQV"TIL(]J[B]>960L$1C7O6LFZ*\BKE+'&K#8T3,I=D MOM1DWL!]!B8L!FU+)'HV,A:60#H$7G0K][N$,!NM!*^'@_'PO)]K6;FSLO#9\NCTYEL6^9!A9C(2TH2BD6M1=:8)%]I.5CUC8>@ M^W8BOLL#VXH'W]L(D)%K.'=,UI[RNC:J5^"-5,"%4&3]>F'8:I=Y5WK=C\" M)PKWKOI=M][CJS#NC\^^C##DT\$_PJA?4W0^T !X+Q(-@_,:DJKQDBPC>$8_ M%OHUNN1X*6TZ?:R*\!!XTU0K=]GC-S M[W!2(;T?#1-BKGV"<#0A64W/#,_".8Y/1_0!PC_Y=ORUQCUN[F'92,^#J54J MR*DU04#0J>YF6?',62EZM9KGFZ X&)IL317WD&BS B)WD->5[0:XH'-*Z!!8 M<=/%C(%CR0):)T/R]0QZM07CD1<=+A4V$.@]VGYRH/&>;>OHTZ<1?B*CY/VH M/TC]+^'\RK^9A4EO@);>Q.BD!:8"K7/((CAC _!,2L[,1E3V";;!R@ .AAW; M4, ]K'ER$/+^R/GQ7[5SW65__+G^\BI*ZISFMG8-8#H$XC4JB#(6P"P#LTI& M&=HD##X*[1#(TT8/]S!EXZCE'X-P%4G%?#/&>OS7%QR,L8=&YN"Y !T]$5E; M59M+T$)(&Z!6UBM$W80F#^,Z)(YTJ(%["/+D*.;UP(>#3_4@MF+[)_8_?:ZW M7:_\IY/!!$YKHPLC;7 M2]<$>D@4:JFC>SCUY(CH_<&7A7ZI+A0I#:\WU;RKI38M65Q.0#81"Z\!%]DF MN?0A5(?$ELZD?P\UGAPMG9I;-WE\,AKA5_IX/,>W."$2SX5Q'>+MU<9'V6E# MBA1U[^01 DL*+-,8!"\Z+?:N76+FKO?>0^!":W'?0XW-0J$K83VN&;CC[R?" MV?+$M>60M9SNF ZBLP:X-JB\MW4D7NF M%2/;.ZEPU9TH*%G DK/&4JFW_]K4X+F+95<5!SK2\8/&R-JR;I[M>[-AS JX MFA8,6(9L-Y4!-M7<@T384.S;I$51*EC'$7PB8UEI]. SE\"5M"%D[T5IE=VU M33H\P(UEUW4#CB"3.3@9I-.OV,,B3Y6YE+3_PHD-1R[/"&S55BY]3+./HT0KQQV3W)S&VT"C2F1'ZI21!K M(\XD4$C!BB&[8K4LV?L>?P@ZW5QN'=Z(N7DZ,9G%CS[2OYD:AXD9ZRSSY&>0 M7:@\EIJ*)4"+5&B0A7'7Z,+M/6@.RZ7>6-X-KE$N8IH1?15435WJ^W'MQJ'> M7&^/$&$#H3=PJ)>@,RF:8H4!:;F^2J_S5FAPDI"1$A-/VUD8=NA,;XL)Z\BZ M19]23)>CJZR'>=.2(CQW@G8Z[6I)9![J17\.AN7@BB#G0K=)'K@#90>G-QWH M:+%NT$8";ER38^Y.8.U71*,RJA9RU&@AZ&+ E%@22R9$VR;#Z"Z6@]#YAB)N MX98_Y&5P\C*LK=/ZU%F*Y7=9K%H4*6D1K1;U)XT'5&DYD@^8V$V[6E_\<@C\*?@]MI@?.NP,E+C> MC%Y5\\\M%H6:I9Q7LO(?>,DSUF>G\FM@V]^LB##=N8HF#R9X!2:K!(J9 M&7 M -PZ5R_!&N=+DTF\B.2P[/J-Y-S@Y.8FGOG1U J(FMKT=S'MQJ+?3%PZ>Y!EDN**9#9&B53-5%80,08:;LI/+&H=%C,JG]FJG_$DF^M^77DV^9< M)@\'TWMC,0S^=5H*TC)7\;T]>77Z81YM0A--\F16UMM!R@H+D9&!68IF&(T5 MKE'#D97@;=\6V%2/=P]L.E9""]L^C*?CG8>938F:K!M0,9+E4R^IAL(#E*!# M=F2BE-#FY.XVCF>O^PW$VF Y.+X<#?/P_#R,YIFALT M&$3T'AD&W>8JQ"*29Z_HC43;H9D_'DUZ'\+@T]5N)G.)Q"L%VAKR-8R)X!-M M;L6YP(H7PBUF6=VO7WKJ#=W23XMZO?7:PS#DGR[)#@O27H.89^6N &,=DWUU MQ78_3Q^WSS=0P:(2-Y!?APOQ(IPL-0M):!"AQGB,=Q P.A#"ZU1<*5:OU'I@ M/]2XQ-;N7HOKB*UC[?U.DKJXO)@'9+/3@MX*4M3]7(L(0=)*7TH.#(7F0J]T M*KJ2_FZ]>GL;YD;"'W8AN0[-W2F0JX+"<[M;)C*ZL@%A$FT-F2!Y)L@,SU() MHW/F7:KPYJN?H0J?++D6&6>7<=S/_3#Z5JO\G9:SR3#]:[K$>*M#BEA-+T'< M,U6"Y*-LX:@6UNA2^%=!@64;>2[[!*^S6P[W!J!OYI^3@*@W%(5=0S M&W\5A$UCGH]CW$T,M".E+E*EC49:+">/([6L(/#ISBBSCB(:4.7D_>EL"[0I",%Y!G2%G'RC \3:&\]R9Y6U/JK8 MYNSL&L+V R==ZV?8A7"7FHC;ZH?)E):58S1R,3 M25@$:\@84F@4>229O%-K5%0I:/)7FLSE1Z%U6?;QNWP_X)?KBJ;717 _8)W MN28M_-H?IW#^GQA&/9D\#Z*V90NB^NR60U0A@:Z7$47*V<4V8>)-D>_Z'NBF M/'NH.&1S3;:X,[(Z_I/!.UI-/OZ)YU_Q]^& UJD>SRR1S!A$7BLQ9T'>2U$& M9(A98^%H3+-SRJ?#_H$YN*$.&UU47!E\G3$?_QSV3)8U$:Q ]I9\Y: *>*6P MWOK()=H%^8MK;6&MS661OUK\/+$AJ>M1M:^$7CI8K MONK!<'NJ5;@_/-/6UEF#!-('2TTKC@I]YB"L)+LR8087:DDAQVP1Z(5SVZBI MN>M"WVUITYD&.DQ0>&SD5Z<-051V3=W>?2\TU( )Z\BZ==5>4Y*E10]!3,.9WBGR\[D"6O]*X2BL$ZLU MA=C7"B-K"?NAFKWK2&H'AVEGOQU]./[M].V;XP]GQ__QQ_0PZ,E'9\L?UO5! MV8JP%X[%E"S):(>QV*QJPEO!6-M_,6_]K/A&3\/GR;MOVX M-D"#%4(89!!E99=#!Z[P#"8FR1*CW^8V(U V>U$S;<*6;1 MD=P;G#[=@/8^C$Y'9Y,PP?R/<'Z)[W$T1=N+&7U)S($DGPN48+1.\I+ B9Q4 MIND:9)LLD"KHU4F!;45 M4LP '2H;GB+O!B_+X=CU2*;Q79VS#YID8HHO9-9H1B-0!J(R2I]*I^NHF7*WD"^6U"[],K6OA#@32"? M-WD-Q' .P>ODK8C&I\9S?)>]*)MI>QVQ=GV.=6/AZN=C&MFD/_@T=49J=W8< M79_:Q!0%[6TU5EJ3>KRI& T$309++@R973 !EIQOK?C"'=IX3]'*L+%(.XQ! MW\5X>CD93\(@UQ2N0?X'CB>83Z?9'+_= JR-3DDG#KQ$Q=&HS#I M?]WDNN&*3VYR@+KF@!9.4XUSCG:#7(SWJJ"G:/&%-K=P-4U&M>Q&M?M???O^D9D+>O1G&.7O_@U3!FU(!CR7F?P; MB_ ;GRT^6X]4) MU\EX?(GY9#X89(8+[\AY#:9>?_>TYV5I(HZ^HJC\ F/_\)1ZH_Q_:B?L*>$XUR6 +HFIBDI M)=EW04/)+%O' C/8)G]S2P-\F05[0)P&J0!/WKJF7ZH;0@/\4,;(,;FZW5RL( M[VFDC33+ "(;5?VM##%&!=E8#-X0]['-/?8N1_$R#;9%@0YS@:9G%G=1?A_# MN\NJ@]-2)VTX/Y_.VE[47/F"'!)3-/FF'Y4 MXFU5EWE:'M80F)!!["UKKG*6+V!X"$SGJR,F!-;[=Q\ M!^!?2+Y/[+@[&_S. H>+0Y[O/E>G!SW#$OG TH"[ZC)&WJ^K5QE(+]Q:1NYP MHTJMC0;TPTR$?2+&/0=)W9R-=C&NQ_U14R_2,TEF5Q$%E*@90RX8"(A>A;!S/'+G2."\,)*WX#39&_*^R9A^3.+OGA[W,'_CH]7CBR_GPV^(9SCZVD]X MOZ"O-[#IH,8?A^3=W_S[Z^%X\FXX^4^:>Z;&QD>JS49Y%1/[=3B:_:I^ MCO=B0NULB1!M+<+Y-E?VATSZQY\HGH-)@V M]_NO1M%CWJABB'%&8(US>0]!B 2.:6L-IMJD?*4HZ.WG_C 4VE2F]^AWXW(! M[=;^ZR==_:/%I(">XE$$)2UDD1THU(DXSA%T4(JU0#XVY!^&Z#N7 M]%KDNF=:;79H.I_B\]8,)X.:>-G_BK,YGR.A$ED"NMI\P04'42<'TAJ1"X_& M!;W6.KKD13\,WSJ7^CV4>/*AY>97DQ[+KSKZ]&F$G\)DP1N]GE@]P[#0;& @ ME1&@5-(D7;(D"EK+Q3U+ M]XS#\,]W:#??0 M?O,#T%GCYUGNPD.C'B\;]E4E, S%1JTR:.$*J#CU*&J]\<*9LBA=:%3GO;,A M;*OJWJZ7])VH?%]*^EW!G[=LL2H:%A5-.E%K7"GC(4H4D%(60HH02VIS6GD+ MQJY*^NV("<.N-+*+2_A+!?%]&(/\_CP,WH6+>6.95<;4M)9@BU'MIB#A!F19 MU[+=EJ:?"XM1V.+1.G"^EFRV1+-@O(>2C?*"E\)"_,'9^TA]Q3TG[SH*;D#: MZV#X]T/Q6:$X-$QHJ308*6IC-:[ ZUI04'D7!9J479LDTZ60]M A:J[Q96<7 M&ZFK066H#TC^5S]-9ND5?Y!FQA_._IB!$Q&+K[UN#,= #E?)X%@(A%"5I+FF MR=>F&?>#L%[XU*':6K0HPE$9CBZJ^WZ5XS^#Q8+6,L<(6I::R)DE..4L,!:M M%-)EUJB QA) +SSJ1%4=5B^:1I26'+G-U\MBBF.U92C3U1!@Y,RC1^ V6&EB M-.@7HN9+(H(/ON8'ID;'.FA0\6<^R*L^LK*@8]R#+Z7V(542O!0%2@AD$A;O MN6I35N0FBA\[)O%D?;1H@79[ JR"IFDP81_" $_7SQ)%;R#<%N;&0E1!!NZ+ M#_#_VKO6WC9S'?U]_XNPNE^^+.!VTMD"G7:0]F"QGPQ*HCI>I':/GU(F3][5?^9(:'732I+4H\A%%4KP8YVJT%Q,II^A929:3$VD@BS:98$?@ M,[>2=!^>#CV18%39_>'+=!)O%C^NH_M*KM*ZNIAJ1KASTC+G'#(MHV;@76)2 M1X=6 P33S3CHL>C^385=A#/; V>''DY =(IP^UQXCR+AC"N)3%0();$Z/8=Y MZR2YT*I8'5/R^&QO^_[",33S((KOX5K\1TS+[@LNAZO7CWM5_4#==O5^$3/N1P&*L3>5$2F3P M(C+'I0LQH2^IS27S!%&G'R;LA9)9&VDU""%M(.TNBMZ!N*9!Q"?).TQ,<3!A M=@/)#I+8.UP46>VE3F_42%I< S;^+?X!1;QN,S63ST:;?M^!E[7TD%&BC4VNOP\>L -899G5CQX@,5S4I_$<2:C=TQK M**1D?69UYI3TVI+9UG#4Y$$#+.W*D7Y4J%[.KJ[>S.;U'XV=59;4@V16@6%: MHFM/MN;_LID/^8950B M,59^"T9L+K_8[4%T(YI/&G?R6):DR[C MAC.,EKPHIPH+A5RIR+VK$R@SI$;NPYYV>#Y/!SE/.\"LU333?316D+E %I*S M9)2NI<*6A0"*1:G *VDC>8,G=IQ.MB?'2SI..\#LI$:FDA0*3NYOM62EM%>* ME :)@HQP4AJ0%%L^;N6(2*KCQ$[4@TV>#]5!#M5N8#O-.:LK\]:C,^"M82"- M8!I]I*\$++M]>A*2-?;4[JDG_:BCE,7S0YWN'2%E#&!&QY3'6E%52W%2 M'\6]=%P>J"!\OXPX(5UY,J&D9D <.A/X&'@Q^C*[F5Z/LY3<6R^8*3G6V0JD M2X,W=(H$*%=K(]9CY'OO+-9W3R=TM(X!V_OI8M84F*=S/G^.)W3EA21Q)AU3 M+4,DN],Z)'D2:U!Q#%'J*/RAV_]MM;'S23W"D]H>HD-7RN\K7M&5%TE 5)R< M+K'DA3>>@?#(5/8"(4:2K#OP<=UJ8^?C>H3'M3U$!XR\->;%*A)R,\=%5T8$ MR[D+)=LT.*MDRORD?=1#UCBYZ#-Y6(5%5, TF,""2YH);B4D M< K4N07S4030#B+R8ZEQ^KD-9O3:Z&(#PZA-'7M(*E*B8:Y8H:4&:72;JJ87 MUH*Y%Q*>;,'<1R*GTKRVRY[.+9@[U4GM )9]=+'=1M*G@F(L:$%DRTJM4-1H M"IUQSYD5/AENK?'V0+G91X/>7BV8CPZ\?03< +1/]V!5*6!*Q;!H%5D\LB#Y M8$C7C.3>0-(IVC8M''Z)UKE])-^K=6X?L1U-N=?#;IVM"KZ>76D_)5_]-KQ6 M]"4P8$0TSA=.6BO%$A(4&T7AT055-A1]/;OFP M&519.1>MC&TZO_\295]WF5=<12BSD'_+8+^O<"RC[CI-I(^ M%10KAZCJ8.@D.3(=HV, )C(9/&)QR?*0?W'T]@KZ'QUX^PAXZ/3XIZ#?Z=/';GZ/+ M3__]Z7+T_N/H];)M^PYQ^N<^48< 5A8M32+9J&"++-F4E)-+ M4/SXN0_?]<'NJO;P_A/FU]\_$7H7D%;,N'-8K+6N>,N@U-$86G(&,I#& PG* MV%QT:G-Y/$?93EIKPX>/IM,;N+JLG)WB_ WB6(42#8K$4+HZ@!2@VL>.9<^M MY'4"3#"=%%C7%?>ORP:%P$]ZJ0F7FPQ\?9S.97;FXD.Y]SUB1BC:E\*\#:2D M24NS@+8P[;,@>\#9G-K4+/<@\H5@J+5XAC:%-M!Y&QG\3[S*?Y*'3Q?T&+T( MQ7O/="[TF[+ 0@CD=(=4?-'"2F5W42H/5GPA@&C'Y:&KT#80N3($JZTVUM(K MQUUB(5>D@D:V[%[A08-RT0"!=Q<0W%OK%Q#_MIQMT$GH=V+0N]EB\6'Z>C:] MGA-]E:K)=.DBC&FKLHA2LV<2)R/?DH+*I.U3$>"31^-=FPR\)\EZ(0@97@0- M.N+\=H-OB!WW&##!Q>N;^7RIM)S/Q07.$JA(NT9/^[>2+*'DO,0(/K1)9G^* MJA>&CL$$\! ??_I)[>S9X02H+1C+A*I.DG+0BW< &EM MUH*;HFT3=;$5N?MZIVVJ/=H+ZEA>7+OM;QD2YTB'QM"F!&C2FCD0:VM5>Y-2D7^!<]JR!X%XJ:/KD^I.DP#Z:MI/@$ M6'80P7[ $4V..CNB#.L=#5ZQF&5F]8;V12!HU2:!.8=\G"8Z,/Y ;&P MF%^/1Z5,KB:5H(OI]>3Z^^I9BP,HZR R!\'+X@%Y1V5<]!=F-Y#L((G&AL5#(FT*B,%" M33T/3$>>ZC1&P6S]KC!>@6C31OH ,-G.W&B,DCX"&/H)[].?O_\!4[C-X1E- M\VM2I 3&R?3S&_PQ_E!FZPWGGI&-15=DL9[Y9&JW<>ZDCS(2(SK%X+JL=C11 MN&VD,VO)V@&MCSL":R#PW0RF]RA"Z3R/@"P94_.F:5X07 R9BAJ[ ? M?OQ+DNZ.S!OZ*%^\O:R;G.)\\2^HC3[/<0G %8$A<45V+BDP; M08Z<\1+H:A-!"]^MH5R/15\B$@9E],9G^89M)"Y^_^/B_:>W[]]\N/QCV=U@ METX1&S]L\&80W
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